data_2dnz_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dnz _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 N-CA-C 112.446 -0.262 . . . . 0.0 112.446 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.467 HD11 ' CE1' ' A' ' 277' ' ' PHE . 25.0 mt -121.09 146.99 46.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 110.922 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.558 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -111.9 139.65 47.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 14.2 p -124.44 131.29 72.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.114 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.23 165.38 27.43 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.498 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.2 m 72.82 44.67 0.35 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 0.0 110.883 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 79.5 mt -109.24 172.09 7.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -90.32 126.99 36.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -41.48 -42.46 2.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -51.09 -42.1 60.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.449 HG22 ' N ' ' A' ' 241' ' ' THR . 47.8 mm -44.66 152.2 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.161 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 241' ' ' THR . . . . . 0.449 ' N ' HG22 ' A' ' 240' ' ' ILE . 76.1 p -137.02 178.58 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.152 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . 0.427 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 12.1 mt-10 -61.67 -35.83 79.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -60.16 -34.87 74.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 244' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 240' ' ' ILE . 27.7 mtt -72.04 -41.17 67.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 59.8 mt -68.67 -42.24 78.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.919 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.41 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 6.1 ptm180 -67.3 -39.87 86.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.41 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.27 -34.75 86.51 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.464 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 92.2 mt -80.98 -42.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.854 0.359 . . . . 0.0 111.103 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.59 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.2 m-85 -83.48 -1.65 54.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.863 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.492 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.7 OUTLIER -70.29 -59.79 3.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.654 0.74 . . . . 0.0 110.883 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.81 2.88 3.16 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.419 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.7 m-85 -102.97 -30.41 10.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 176.62 149.01 7.38 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.453 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 7.4 ttpp -56.29 111.42 0.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 110.854 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 57.0 mt -80.62 124.97 39.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.161 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -82.28 -43.14 17.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -168.25 149.3 4.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 41.9 mt -128.25 132.72 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.158 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 4.9 m -134.99 127.02 47.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . 0.427 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 31.6 mt -92.11 136.29 33.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.42 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 29.9 mmm . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.87 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.42 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -148.63 163.32 37.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.868 0.366 . . . . 0.0 110.947 -179.814 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.32 175.56 39.58 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -120.37 137.74 54.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.859 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 30.1 mt -138.48 137.35 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.16 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.7 m -118.53 129.46 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.467 ' CE1' HD11 ' A' ' 231' ' ' LEU . 39.2 m-85 -97.76 -177.9 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.873 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.9 t -95.51 -41.55 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -116.59 141.23 48.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.1 m -63.87 -36.23 83.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -61.72 -43.65 98.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.94 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 99.2 m -62.06 -40.5 96.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.84 99.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . 0.414 ' HB2' ' NH1' ' A' ' 284' ' ' ARG . 13.0 ttm105 -60.73 -48.05 83.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 23.2 mtp180 -58.31 -50.88 72.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.419 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -58.49 -34.93 71.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.123 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.72 -40.81 95.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -68.96 -42.16 77.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.891 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -71.72 -38.43 70.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.924 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.59 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 56.7 mt -74.08 -47.04 39.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.931 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -44.51 110.16 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.71 37.19 40.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 28.1 t80 -104.83 91.79 3.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.849 0.357 . . . . 0.0 110.825 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -48.91 118.4 2.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 45.6 tp -103.85 -44.73 4.97 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -122.95 40.15 3.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.06 -27.75 18.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 29.6 mtp85 -118.32 148.46 43.9 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.558 0.694 . . . . 0.0 110.891 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 132.62 23.79 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.696 2.264 . . . . 0.0 112.336 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -86.88 170.93 11.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.898 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -108.64 127.82 54.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.897 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 16.4 t -132.47 127.6 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -152.47 163.87 30.44 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -71.13 146.41 49.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 0.0 110.863 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 95.3 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.133 179.977 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.375 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.475 HD12 ' CE1' ' A' ' 277' ' ' PHE . 53.7 mt -127.24 144.77 50.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.81 0.338 . . . . 0.0 110.93 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.482 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.5 t80 -109.69 136.29 49.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.8 p -122.87 137.77 55.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.089 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.65 164.32 28.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.466 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.3 t 74.12 47.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.891 0.376 . . . . 0.0 110.807 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 91.3 mt -109.28 170.29 8.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.586 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 8.0 t-80 -92.93 126.08 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.876 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.586 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 4.8 p90 -38.83 -48.36 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -46.31 -44.54 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.871 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.9 mm -40.07 154.47 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 14.4 t -137.42 173.72 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -60.69 -35.02 75.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.887 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -59.49 -34.53 72.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.7 mmt -71.77 -39.51 69.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.869 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 56.6 mt -68.89 -41.85 77.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 4.7 ptm180 -68.55 -36.15 78.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.42 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.06 -41.82 92.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.471 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.433 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 76.5 mt -75.18 -41.32 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.841 0.353 . . . . 0.0 111.097 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.536 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.2 m-85 -81.56 -4.03 54.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.498 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.0 tp10 -69.48 -59.7 4.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.643 0.735 . . . . 0.0 110.871 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.498 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.5 Cg_endo -69.79 3.02 3.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.665 2.243 . . . . 0.0 112.285 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.458 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.7 m-85 -103.16 -39.33 6.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.92 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -176.01 148.06 9.04 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -51.75 117.24 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.07 124.56 40.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -83.61 -44.7 14.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 11.7 t30 -167.51 150.01 5.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . 0.415 HG23 ' N ' ' A' ' 259' ' ' VAL . 34.6 mt -126.6 136.13 61.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . 0.415 ' N ' HG23 ' A' ' 258' ' ' ILE . 84.8 t -134.97 130.86 52.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.13 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.51 131.66 47.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 68.4 mmm . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.528 -0.229 . . . . 0.0 112.528 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.433 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.8 p90 -149.2 161.78 41.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 110.903 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -165.66 171.15 40.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.485 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -117.13 134.82 54.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.842 0.354 . . . . 0.0 110.856 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.479 HD13 ' CE2' ' A' ' 249' ' ' PHE . 97.2 mt -132.28 137.69 53.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.159 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.405 ' N ' HG22 ' A' ' 275' ' ' ILE . 96.4 m -117.22 129.51 55.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.209 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.475 ' CE1' HD12 ' A' ' 231' ' ' LEU . 43.6 m-85 -97.99 -177.27 3.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.9 t -101.48 -41.37 6.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -112.02 138.81 48.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.7 p -63.52 -40.93 98.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -61.3 -43.62 98.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 95.2 m -60.56 -42.96 97.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.67 -40.07 95.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -60.07 -48.91 79.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -58.96 -49.79 76.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.917 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.54 -35.79 70.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.9 tp -64.54 -43.36 94.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.891 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -68.8 -42.43 77.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 22.2 mm100 -69.1 -41.1 77.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.536 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 58.6 mt -73.12 -46.31 51.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.884 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -45.91 112.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.905 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.73 38.73 36.13 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 73.4 t80 -106.51 120.86 43.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.818 0.342 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -67.11 114.56 5.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.5 tp -98.17 -62.12 1.29 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.17 34.76 4.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.064 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 117.0 -35.42 4.17 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.502 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -120.42 156.51 55.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.627 0.727 . . . . 0.0 110.852 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 130.84 20.07 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.65 2.234 . . . . 0.0 112.334 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -79.54 170.92 15.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -105.99 119.08 38.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.11 132.38 71.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -154.65 163.9 31.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -70.13 135.99 49.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.809 0.337 . . . . 0.0 110.885 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.411 HG21 ' C ' ' A' ' 231' ' ' LEU . 94.9 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.499 -0.24 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 31.1 mt -111.8 147.03 36.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 110.881 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.514 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -107.23 137.11 45.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 9.4 p -123.76 131.86 72.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.077 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.0 165.66 27.27 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 72.71 43.67 0.43 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.853 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 30.3 mt -103.75 166.2 10.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.885 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.628 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 5.4 t-80 -86.42 128.47 34.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.628 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 36.9 p90 -37.88 -50.22 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.851 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.433 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 10.1 t-20 -47.53 -43.4 24.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.456 ' CD1' HD22 ' A' ' 295' ' ' LEU . 43.6 mm -38.64 147.9 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -138.88 178.42 7.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -60.65 -35.76 77.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . 0.453 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 1.3 m-20 -61.89 -32.86 73.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.9 mmt -71.98 -41.47 67.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 86.9 mt -69.88 -42.94 72.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.453 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 5.2 ptm180 -64.38 -37.74 88.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.445 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.56 -39.12 79.2 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.468 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.8 mt -75.86 -44.3 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.367 . . . . 0.0 111.11 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.486 ' CD2' HD13 ' A' ' 275' ' ' ILE . 3.1 m-85 -80.86 -2.77 48.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.5 tp10 -70.61 -59.86 3.52 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.595 0.712 . . . . 0.0 110.871 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.495 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.7 2.42 3.52 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.728 2.286 . . . . 0.0 112.339 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.8 m-85 -102.47 -31.42 10.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.76 149.86 7.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -54.77 113.32 1.28 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.759 0.314 . . . . 0.0 110.875 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 64.2 mt -83.35 122.65 37.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -78.83 -43.4 25.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -167.74 145.13 4.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.863 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 81.1 mt -120.24 135.29 61.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.74 128.87 51.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.0 mt -97.99 139.84 33.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.533 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 28.7 mmt . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.533 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.7 p90 -147.48 155.91 42.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.908 0.385 . . . . 0.0 110.93 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.54 -178.55 39.76 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.488 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.29 137.98 54.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.899 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.486 HD13 ' CD2' ' A' ' 249' ' ' PHE . 92.6 mt -132.03 140.87 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.077 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.3 m -118.83 129.94 55.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.147 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -98.63 -178.05 3.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.1 t -100.98 -39.47 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.812 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -112.84 135.62 53.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 4.5 m -60.54 -39.38 87.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -62.68 -42.74 99.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 75.4 m -61.96 -36.76 82.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.82 -41.8 86.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -61.84 -48.72 79.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -58.3 -50.91 71.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -56.89 -35.05 68.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.107 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.9 tp -64.65 -43.7 92.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.947 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -68.93 -42.77 76.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 25.7 mm100 -68.4 -41.85 79.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.447 HD12 ' CZ ' ' A' ' 249' ' ' PHE . 67.0 mt -72.93 -46.14 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -46.03 108.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.82 31.57 39.49 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.486 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -94.32 123.01 37.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.842 0.354 . . . . 0.0 110.881 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 71.2 mt-10 -70.83 96.1 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . 0.456 HD22 ' CD1' ' A' ' 240' ' ' ILE . 9.5 tp -78.87 -62.03 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -115.9 41.57 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.056 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.69 -21.44 43.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -124.31 149.58 61.47 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.581 0.705 . . . . 0.0 110.865 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.84 11.49 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -77.52 173.47 11.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.893 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -108.08 119.01 38.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.879 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 18.2 t -124.88 129.37 73.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.85 161.17 30.51 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 10.6 m170 -73.04 134.4 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.87 0.367 . . . . 0.0 110.838 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.7 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.168 179.957 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 31.4 mt -124.65 144.8 49.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.857 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.503 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.6 t80 -109.19 128.76 55.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.4 p -113.92 133.5 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.42 166.02 26.94 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 7.7 t 71.98 44.2 0.48 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.876 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 81.6 mt -106.76 167.39 9.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.909 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.409 ' O ' ' C ' ' A' ' 238' ' ' PHE . 5.7 t-80 -93.15 130.96 38.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.409 ' C ' ' O ' ' A' ' 237' ' ' HIS . 4.2 m-85 -36.79 -54.21 0.91 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -41.76 -43.48 2.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.405 ' CD1' HD22 ' A' ' 295' ' ' LEU . 31.1 mm -41.05 127.73 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 47.8 p -114.71 172.2 7.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 39.3 mp0 -60.27 -33.94 73.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -62.51 -32.46 73.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.848 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 52.0 mtt -72.01 -41.33 67.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.875 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 29.9 mt -66.91 -42.95 84.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.421 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 4.8 ptm180 -67.18 -39.69 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.421 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.12 -34.82 89.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.486 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.409 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 81.7 mt -81.56 -40.48 17.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.883 0.373 . . . . 0.0 111.141 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.538 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -84.72 -0.97 55.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.501 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.6 tp10 -70.77 -59.42 3.68 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.79 2.92 3.11 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.259 . . . . 0.0 112.36 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.409 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.9 m-85 -103.2 -31.08 10.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 178.28 157.31 18.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -63.2 108.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.707 0.289 . . . . 0.0 110.909 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 37.3 mt -77.15 125.01 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -86.39 -43.69 12.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.877 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -163.56 143.65 8.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 71.0 mt -123.13 127.53 74.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 2.7 m -134.04 129.35 54.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.12 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 33.3 mt -92.38 139.07 30.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.652 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 15.7 mmt . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.652 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.9 p90 -150.14 164.04 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.922 0.392 . . . . 0.0 110.922 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -172.57 176.38 45.49 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . 0.414 ' CE1' HG12 ' A' ' 305' ' ' VAL . 42.6 m-85 -117.11 136.1 53.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.886 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.422 HG23 ' N ' ' A' ' 276' ' ' THR . 96.3 mt -132.26 140.59 47.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.422 ' N ' HG23 ' A' ' 275' ' ' ILE . 56.1 m -120.98 127.7 52.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -97.43 -175.14 3.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.3 t -100.28 -40.5 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -115.22 140.05 49.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 13.0 p -62.51 -39.19 92.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -62.05 -42.93 99.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.3 m -60.38 -39.22 86.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.67 -40.69 88.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 32.6 ttp85 -59.07 -49.02 79.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -59.38 -48.94 79.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.6 71.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.0 tp -65.06 -43.58 91.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -68.96 -43.03 75.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 67.6 mm-40 -68.85 -41.21 78.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.538 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 66.2 mt -73.27 -45.02 58.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.901 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -45.15 98.16 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 96.01 24.46 14.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . 0.416 ' N ' ' O ' ' A' ' 290' ' ' LEU . 10.5 t80 -79.58 116.36 19.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.81 0.338 . . . . 0.0 110.901 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -80.25 89.06 5.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . 0.405 HD22 ' CD1' ' A' ' 240' ' ' ILE . 12.1 tp -86.66 -59.75 2.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.02 45.09 0.98 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.112 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 84.42 -27.75 4.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -113.23 143.93 30.21 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.573 0.702 . . . . 0.0 110.837 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 123.14 9.8 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.644 2.229 . . . . 0.0 112.367 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -73.96 169.71 16.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.852 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 40.3 mmt-85 -109.12 122.19 46.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 6.2 t -126.22 120.63 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.126 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -144.71 160.14 27.91 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 8.9 m170 -70.69 121.72 18.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.847 0.356 . . . . 0.0 110.832 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 232' ' ' TYR . 15.6 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 68.3 mt -124.41 145.69 49.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.773 0.32 . . . . 0.0 110.923 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.507 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.2 t80 -110.78 131.1 55.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 14.9 p -113.62 134.94 54.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.13 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.81 165.73 27.57 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.5 t 71.32 45.71 0.47 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.925 0.393 . . . . 0.0 110.823 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 86.8 mt -109.76 176.35 5.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -102.89 135.33 44.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 239' ' ' ASN . 0.6 OUTLIER -46.47 -51.37 15.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.902 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.407 ' N ' ' CD1' ' A' ' 238' ' ' PHE . 6.7 t-20 -42.15 -41.25 2.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.834 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.4 HG23 ' N ' ' A' ' 241' ' ' THR . 16.0 mm -47.94 139.91 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 241' ' ' THR . . . . . 0.4 ' N ' HG23 ' A' ' 240' ' ' ILE . 8.9 t -121.61 167.65 12.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.156 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -55.06 -33.71 62.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . 0.456 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 35.5 t0 -59.97 -36.9 78.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 4.8 mmt -71.38 -37.72 71.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 73.2 mt -69.98 -39.97 75.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.456 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 2.9 ptm180 -70.53 -35.3 73.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.449 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.79 -38.83 76.69 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.414 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 80.2 mt -75.72 -41.12 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.853 0.359 . . . . 0.0 111.113 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.533 ' CD2' HD11 ' A' ' 275' ' ' ILE . 4.5 m-85 -83.43 -4.19 58.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.523 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -69.47 -58.33 5.97 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.598 0.713 . . . . 0.0 110.901 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.523 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.76 2.52 3.46 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.736 2.291 . . . . 0.0 112.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.419 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.6 -26.93 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 172.87 162.05 24.32 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.504 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 20.4 ttpt -63.61 110.72 2.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.781 0.324 . . . . 0.0 110.936 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 25.2 mt -80.58 117.18 26.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -77.0 -46.4 23.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.828 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -168.89 142.46 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.903 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 46.0 mt -121.09 135.4 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.124 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.37 127.81 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.143 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 20.6 mt -98.15 136.54 38.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.506 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 20.2 mmt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.506 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 2.4 p90 -146.92 155.5 42.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.933 0.397 . . . . 0.0 110.962 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -160.39 170.17 36.34 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.51 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -113.52 138.74 49.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.855 0.359 . . . . 0.0 110.857 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.533 HD11 ' CD2' ' A' ' 249' ' ' PHE . 68.0 mt -136.01 134.16 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.0 m -118.19 129.01 55.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.166 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -99.15 -176.19 3.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.915 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 17.7 t -97.49 -41.85 7.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.414 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 26.1 t0 -115.42 142.59 46.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.858 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 29.2 t -63.99 -38.77 92.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . 0.465 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 10.7 pt-20 -61.52 -41.66 97.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . 0.465 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 84.0 m -61.35 -38.94 88.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.74 90.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 40.0 mtp180 -59.1 -48.89 79.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -58.78 -50.4 74.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.419 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -59.52 -34.99 73.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.083 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.49 HD23 ' CD2' ' A' ' 304' ' ' HIS . 15.3 tp -62.43 -45.26 93.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -68.83 -38.23 79.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -71.77 -36.62 70.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.497 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 62.6 mt -78.8 -39.97 34.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.917 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -55.09 103.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 87.91 30.89 16.35 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -98.49 109.79 22.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 110.842 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -56.7 99.31 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . 0.412 HD13 ' C ' ' A' ' 295' ' ' LEU . 0.9 OUTLIER -78.77 -65.52 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -119.5 39.62 3.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.08 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 112.44 -34.61 5.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.95 151.35 46.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.865 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 120.94 7.66 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.304 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -71.12 171.89 10.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -110.26 122.51 47.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.401 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 15.2 t -128.88 126.12 64.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.26 160.99 28.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.492 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.49 ' CD2' HD23 ' A' ' 287' ' ' LEU . 26.0 m-70 -70.46 128.04 34.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.766 0.317 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 59.5 t . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.143 179.949 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 277' ' ' PHE . 40.5 mt -131.56 144.78 51.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.806 0.336 . . . . 0.0 110.874 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.58 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.5 OUTLIER -110.3 137.17 48.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.956 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.42 133.12 70.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.79 165.65 27.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 m 72.29 45.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.86 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 37.3 mt -104.78 173.45 6.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -96.89 137.92 35.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.835 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -43.23 -49.41 6.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -47.78 -40.2 20.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 43.0 mm -43.71 145.73 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 33.5 p -143.07 173.65 11.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . 0.415 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 28.5 mp0 -54.97 -36.2 65.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -62.29 -35.5 79.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.847 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -72.01 -40.98 68.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 40.5 mt -68.17 -43.04 79.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 5.1 ptm180 -66.12 -37.62 86.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -68.85 -36.0 80.94 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.428 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.2 mt -80.36 -42.76 21.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.81 0.338 . . . . 0.0 111.117 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.552 ' CZ ' HD12 ' A' ' 290' ' ' LEU . 3.1 m-85 -81.45 -4.13 54.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.956 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.493 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tp10 -68.52 -59.93 5.31 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.646 0.736 . . . . 0.0 110.879 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.493 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.82 2.93 3.12 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.347 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.8 m-85 -103.31 -22.03 13.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 163.72 158.54 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -61.32 117.09 5.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.766 0.317 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.407 HD13 ' C ' ' A' ' 249' ' ' PHE . 57.2 mt -88.19 120.63 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -76.55 -49.03 17.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -158.17 155.45 29.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 44.6 mt -136.63 129.91 45.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.3 t -133.84 135.81 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.113 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . 0.415 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 27.8 mt -102.62 139.63 37.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.594 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 24.7 mmt . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.869 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.594 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 2.2 p90 -147.79 158.53 44.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.924 0.392 . . . . 0.0 110.905 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.6 172.28 39.48 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.494 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -118.35 136.28 53.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.884 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.484 HD11 ' CD2' ' A' ' 249' ' ' PHE . 78.1 mt -136.46 140.44 43.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 99.4 m -120.67 129.36 53.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.13 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.407 ' CE1' HD11 ' A' ' 231' ' ' LEU . 41.8 m-85 -98.46 -178.82 4.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 24.6 t -101.18 -33.97 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -117.6 136.28 53.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.7 p -64.04 -39.83 94.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.863 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -62.65 -43.83 97.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.889 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 32.7 m -62.89 -41.58 99.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.909 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.14 -41.46 97.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.036 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -59.78 -49.07 79.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -57.57 -48.99 77.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.411 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -54.8 -38.57 67.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.427 HD23 ' CD2' ' A' ' 304' ' ' HIS . 9.0 tp -65.18 -39.84 93.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.908 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -64.46 -34.94 79.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -83.91 -34.75 24.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.552 HD12 ' CZ ' ' A' ' 249' ' ' PHE . 76.3 mt -71.77 -47.07 56.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -55.02 118.31 4.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.24 23.2 63.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.456 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -93.87 111.63 23.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . 0.45 ' HG3' ' N ' ' A' ' 299' ' ' PRO . 2.4 mp0 -76.27 104.45 6.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -94.42 -57.44 2.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.7 41.02 1.45 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 102.66 -42.94 1.78 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 2.8 ptp180 -111.02 153.26 43.93 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.65 0.738 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . 0.45 ' N ' ' HG3' ' A' ' 294' ' ' GLU . 54.0 Cg_endo -69.76 135.42 30.43 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 3.4 ptp -82.85 162.91 21.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -106.28 121.28 43.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.43 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 22.1 t -130.81 125.47 58.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.14 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.26 161.36 26.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.427 ' CD2' HD23 ' A' ' 287' ' ' LEU . 22.1 m-70 -72.47 109.31 6.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.836 0.35 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.6 p . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.095 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.547 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.1 mt -125.77 143.62 50.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 110.93 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.17 130.58 56.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.903 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . 0.466 ' CG2' HD11 ' A' ' 236' ' ' LEU . 10.8 p -110.39 135.2 50.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -140.24 166.04 25.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.469 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.9 m 63.96 47.81 3.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.86 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . 0.466 HD11 ' CG2' ' A' ' 233' ' ' VAL . 72.5 mt -100.11 -175.94 3.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.484 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 4.0 t-80 -115.26 124.5 51.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.89 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.484 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 23.2 p90 -34.48 -54.13 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.414 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 2.1 t-20 -41.52 -46.76 3.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 51.7 mm -41.29 139.07 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.114 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 11.5 t -122.91 170.88 9.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.148 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 43.5 mp0 -57.69 -32.78 67.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -64.95 -32.51 74.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.86 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 17.5 mtt -71.98 -43.84 64.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.939 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 36.1 mt -65.51 -43.0 91.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.404 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.3 ptm180 -67.14 -38.36 85.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.404 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.34 -33.22 81.62 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.67 -45.48 23.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.87 0.367 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -80.47 -2.01 44.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.936 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.493 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.9 OUTLIER -69.8 -59.95 4.14 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.719 . . . . 0.0 110.891 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.493 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.27 3.69 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.69 2.26 . . . . 0.0 112.342 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.441 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.9 m-85 -102.47 -34.1 9.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 179.21 157.59 19.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.479 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -60.7 115.33 3.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.85 121.47 37.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.102 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -80.61 -40.55 25.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 16.5 t30 -168.61 148.03 4.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 52.5 mt -129.78 128.35 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 16.1 m -130.03 136.97 57.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.1 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.88 130.95 48.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.534 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 21.6 mmt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.866 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.534 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -147.16 162.93 37.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.911 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.23 173.71 39.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -119.91 134.09 55.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 88.1 mt -135.28 127.91 47.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.5 m -113.27 128.72 56.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.547 ' CE1' HD12 ' A' ' 231' ' ' LEU . 51.3 m-85 -95.65 -175.07 3.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.922 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 7.3 t -102.03 -39.37 7.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -112.61 139.15 48.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.88 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 76.9 p -63.27 -40.22 96.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -63.97 -42.58 97.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 93.3 m -62.04 -42.08 98.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.93 -40.28 97.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.07 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 12.2 ttt85 -61.77 -46.64 88.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.825 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 49.6 mtt180 -58.42 -51.01 71.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.441 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.14 -35.78 69.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.527 HD23 ' CE1' ' A' ' 304' ' ' HIS . 12.6 tp -63.85 -43.87 94.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.921 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -69.02 -35.01 76.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -73.55 -41.99 62.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.55 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 38.2 mt -74.88 -46.97 32.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -43.52 105.76 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.32 33.88 27.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.51 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -102.68 116.29 32.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.336 . . . . 0.0 110.882 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -61.59 114.22 3.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.886 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 13.4 tp -101.13 -55.92 2.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -123.04 42.23 3.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.115 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.79 -21.24 44.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -128.5 149.29 71.3 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.629 0.728 . . . . 0.0 110.837 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 125.5 12.25 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.622 2.214 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.5 ptp -76.09 172.99 11.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -110.58 122.21 47.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 16.2 t -129.27 123.58 58.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.099 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.24 26.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.487 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.527 ' CE1' HD23 ' A' ' 287' ' ' LEU . 10.2 m170 -74.12 100.94 3.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 4.8 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 179.969 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.421 -0.271 . . . . 0.0 112.421 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.476 HD12 ' CE2' ' A' ' 277' ' ' PHE . 29.7 mt -124.49 145.34 49.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.823 0.344 . . . . 0.0 110.886 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.529 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.8 OUTLIER -111.65 136.83 50.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.956 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . 0.442 ' CG2' HD23 ' A' ' 236' ' ' LEU . 7.3 p -121.96 133.63 67.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.106 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.15 166.03 26.83 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 4.7 t 73.05 43.2 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.903 0.382 . . . . 0.0 110.827 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . 0.442 HD23 ' CG2' ' A' ' 233' ' ' VAL . 49.4 mt -100.03 177.17 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.425 ' O ' ' C ' ' A' ' 238' ' ' PHE . 2.3 t-80 -102.09 133.04 47.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.844 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.425 ' C ' ' O ' ' A' ' 237' ' ' HIS . 59.3 m-85 -35.78 -52.51 0.71 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.43 ' O ' ' C ' ' A' ' 240' ' ' ILE . 16.5 m120 -45.14 -47.38 12.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.43 ' C ' ' O ' ' A' ' 239' ' ' ASN . 48.8 mm -35.38 150.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.179 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -147.13 179.96 7.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.181 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -60.19 -39.94 88.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -58.44 -36.88 74.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.845 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 18.9 mtt -72.09 -41.54 67.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.21 -41.72 80.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.422 ' CG ' ' N ' ' A' ' 247' ' ' GLY . 13.4 ptt180 -67.92 -42.95 80.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' CG ' ' A' ' 246' ' ' ARG . . . -63.3 -36.72 93.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.505 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.402 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.2 mt -76.23 -39.85 35.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.88 0.371 . . . . 0.0 111.13 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.634 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -88.42 -1.15 57.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.517 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.2 tp10 -70.34 -58.75 4.59 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 0.0 110.831 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.517 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.7 3.46 2.73 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.698 2.265 . . . . 0.0 112.332 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.2 m-85 -104.14 -37.99 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.883 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -174.77 160.14 29.14 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.476 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -65.48 109.08 2.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.735 0.302 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 36.7 mt -77.23 114.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.171 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -73.83 -43.99 57.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -162.54 152.09 15.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.2 mt -133.29 129.64 56.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.073 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 52.8 t -129.37 128.05 65.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.154 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 19.0 mt -97.13 127.72 43.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.943 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.559 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 40.6 mmm . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.559 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -149.39 154.39 38.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.885 0.374 . . . . 0.0 110.95 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.14 168.24 36.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -115.29 138.66 50.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.854 0.359 . . . . 0.0 110.865 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.566 HD13 ' CD2' ' A' ' 249' ' ' PHE . 70.2 mt -136.46 138.42 46.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.113 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 89.2 m -117.77 122.97 44.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.154 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.476 ' CE2' HD12 ' A' ' 231' ' ' LEU . 44.1 m-85 -91.62 -178.04 4.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.915 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 4.3 t -122.41 24.95 9.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.453 ' OD2' ' CG ' ' A' ' 281' ' ' GLU . 26.4 t0 -165.14 126.45 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.884 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 92.8 p -58.24 -40.98 83.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.891 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . 0.453 ' CG ' ' OD2' ' A' ' 279' ' ' ASP . 6.2 pt-20 -63.37 -40.96 98.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.868 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 36.1 m -64.14 -41.56 97.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -61.17 -44.05 97.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 48.9 mtm180 -63.09 -49.02 76.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 19.5 mmt-85 -59.67 -51.04 71.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -54.96 -36.36 65.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.061 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.42 HD21 ' CD2' ' A' ' 304' ' ' HIS . 15.0 tp -65.33 -43.59 90.45 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.923 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.57 -43.1 73.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.908 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 65.1 mm-40 -68.87 -42.14 77.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 84.1 mt -73.76 -47.02 42.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -46.2 103.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.02 36.47 13.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . 0.424 ' O ' ' N ' ' A' ' 295' ' ' LEU . 37.3 t80 -98.22 93.22 6.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -43.35 95.07 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . 0.427 HD22 ' N ' ' A' ' 296' ' ' ALA . 9.3 tt -82.39 -67.38 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . 0.427 ' N ' HD22 ' A' ' 295' ' ' LEU . . . -109.0 39.11 2.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 108.91 -41.42 2.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 22.6 ptt-85 -109.9 152.39 42.96 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.634 0.73 . . . . 0.0 110.834 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 118.38 5.64 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.5 ptt? -68.67 169.76 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.6 mmt180 -104.98 121.43 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 6.9 t -126.95 127.77 70.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.09 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.78 160.34 28.35 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.42 ' CD2' HD21 ' A' ' 287' ' ' LEU . 18.9 m-70 -71.66 125.03 26.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.343 . . . . 0.0 110.889 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.4 t . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.098 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 24.2 mt -126.22 146.63 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.551 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -109.92 136.74 48.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.1 p -120.37 138.13 51.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.105 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.96 165.25 28.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 t 71.27 46.59 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.945 0.402 . . . . 0.0 110.85 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 95.7 mt -109.7 154.02 23.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.956 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 31.9 t-80 -74.45 139.44 43.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -46.58 -45.22 18.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 240' ' ' ILE . 34.1 t-20 -49.88 -46.53 51.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.428 ' C ' ' O ' ' A' ' 239' ' ' ASN . 47.3 mm -35.55 131.67 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.9 p -120.2 177.23 5.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -62.42 -34.65 77.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.898 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -63.16 -33.86 76.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.873 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 38.1 mtt -71.9 -39.28 69.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . 0.461 ' CD1' HD23 ' A' ' 260' ' ' LEU . 34.0 mt -70.0 -42.91 72.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.449 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 17.8 ptt180 -66.77 -40.46 88.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.468 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.75 -36.39 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 90.4 mt -76.38 -42.6 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.832 0.349 . . . . 0.0 111.15 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.562 ' CE2' HD12 ' A' ' 290' ' ' LEU . 3.0 m-85 -85.47 -2.83 58.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.522 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -69.79 -58.35 5.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.855 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.522 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 0.84 5.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.659 2.24 . . . . 0.0 112.347 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.453 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.9 m-85 -101.55 -37.05 8.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -173.56 155.66 22.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -57.89 108.11 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.759 0.314 . . . . 0.0 110.891 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 43.4 mt -78.11 112.49 16.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -76.76 -41.71 43.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -165.23 149.99 9.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.891 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . 0.403 ' CD1' ' CB ' ' A' ' 246' ' ' ARG . 48.8 mt -132.41 126.19 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 2.5 m -133.12 129.93 57.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.138 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . 0.461 HD23 ' CD1' ' A' ' 245' ' ' LEU . 36.4 mt -91.2 137.7 32.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.496 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.2 mmt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.847 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.496 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.8 p90 -145.75 156.09 43.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.93 0.395 . . . . 0.0 110.944 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -158.06 176.17 35.13 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.29 134.02 55.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 0.0 110.836 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.45 HG23 ' N ' ' A' ' 276' ' ' THR . 97.3 mt -131.23 145.52 35.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.45 ' N ' HG23 ' A' ' 275' ' ' ILE . 56.2 m -120.98 129.66 53.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.124 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -104.24 175.9 5.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.899 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 3.1 t -120.19 24.87 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.898 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -165.13 127.61 2.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.862 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.5 p -64.05 -40.96 97.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.811 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.47 -43.02 82.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 43.6 m -63.22 -42.73 99.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -63.97 -42.44 97.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.049 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 21.4 mtm180 -60.14 -48.98 79.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.879 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.8 mmt85 -58.06 -47.73 82.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.841 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.453 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -58.03 -40.41 80.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.083 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 9.3 tp -61.66 -40.7 95.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -67.71 -35.0 77.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.938 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -84.11 -22.22 31.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.562 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.9 mt -86.54 -38.51 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . 0.409 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -60.02 119.98 8.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.891 179.893 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.53 20.82 78.2 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.507 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -84.78 105.13 15.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.807 0.337 . . . . 0.0 110.882 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -67.2 96.29 0.46 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.4 tt -91.12 -64.2 1.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.928 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -98.71 36.59 1.63 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.13 -35.22 4.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 40.6 mtp180 -113.68 154.11 45.77 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.626 0.727 . . . . 0.0 110.891 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 132.26 22.98 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.656 2.237 . . . . 0.0 112.345 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.9 ptp -83.44 165.89 18.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.875 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.8 122.74 47.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.404 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 47.7 t -131.41 135.44 59.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -153.06 163.58 30.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.534 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -71.97 112.34 7.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 64.5 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.999 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.507 HD12 ' CE1' ' A' ' 277' ' ' PHE . 38.3 mt -104.06 144.75 31.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.478 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.3 t80 -111.21 131.46 55.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.7 p -116.0 134.23 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.125 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.42 165.85 27.8 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 6.2 t 73.85 47.09 0.17 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 15.0 mt -109.53 166.08 11.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.907 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -94.31 140.59 29.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -45.44 -37.07 4.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -57.88 -37.86 74.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.935 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 36.7 mm -47.59 139.04 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.159 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.4 t -125.29 174.34 8.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.099 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -62.3 -36.55 82.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -58.37 -34.64 70.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.902 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 63.3 mtt -70.49 -37.07 74.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 81.9 mt -69.82 -42.34 73.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.479 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 20.5 ptt85 -69.65 -40.21 76.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -66.41 -35.16 89.75 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.5 mt -81.04 -44.22 20.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.844 0.354 . . . . 0.0 111.148 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.571 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -81.83 -2.43 50.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.498 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.0 tp10 -70.65 -59.66 3.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.677 0.751 . . . . 0.0 110.931 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.498 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.6 3.37 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.333 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.449 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.46 -44.17 5.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.903 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -171.21 139.03 5.22 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -44.61 119.0 1.74 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.744 0.307 . . . . 0.0 110.919 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.401 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 28.3 mt -88.85 133.31 31.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.149 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.27 -43.43 8.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -163.47 147.02 10.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.91 132.37 67.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.148 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 74.4 t -134.93 129.24 50.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.137 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 23.5 mt -94.01 129.55 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.616 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.3 mmt . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.861 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.491 -0.243 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.616 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 0.9 OUTLIER -150.5 157.42 43.0 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.919 0.39 . . . . 0.0 110.935 -179.832 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.56 169.37 38.56 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -113.58 137.97 50.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.363 . . . . 0.0 110.874 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.555 HD12 ' CD2' ' A' ' 249' ' ' PHE . 77.3 mt -136.43 132.61 49.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.9 m -113.51 129.23 56.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.507 ' CE1' HD12 ' A' ' 231' ' ' LEU . 42.6 m-85 -98.96 171.27 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 48.1 t -86.88 -40.08 15.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -116.2 141.13 48.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 40.6 p -63.99 -41.01 97.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . 0.411 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 13.3 pt-20 -60.97 -43.97 98.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . 0.411 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 73.9 m -60.01 -40.96 91.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.55 -37.84 88.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . 0.409 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 12.4 ttm105 -62.01 -48.73 79.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.6 mmt180 -58.02 -49.8 75.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.449 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.99 -35.54 71.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.091 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.417 HD23 ' CD2' ' A' ' 304' ' ' HIS . 8.4 tp -65.09 -40.83 95.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -68.34 -42.96 78.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -71.91 -38.2 69.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.571 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 82.4 mt -73.15 -47.03 47.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -44.47 107.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 77.82 39.3 24.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.462 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' LEU . 14.7 t80 -101.32 97.78 8.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.816 0.341 . . . . 0.0 110.871 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -43.96 93.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 293' ' ' PHE . 61.8 tp -81.03 -56.95 3.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -129.12 73.13 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.07 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 82.45 -35.53 2.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -125.77 154.85 73.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.579 0.705 . . . . 0.0 110.898 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 136.67 33.68 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.719 2.28 . . . . 0.0 112.336 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.3 ptt? -86.68 166.66 15.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 4.2 mmm180 -101.75 128.59 48.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 9.8 t -131.88 128.92 60.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -157.7 158.8 29.36 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.417 ' CD2' HD23 ' A' ' 287' ' ' LEU . 4.5 m170 -77.73 124.51 28.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 15.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.141 179.967 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.45 HD21 ' CD2' ' A' ' 304' ' ' HIS . 35.0 mt -115.1 145.62 42.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.848 0.356 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.463 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.5 t80 -111.53 133.69 53.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.921 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . 0.441 HG22 ' CD1' ' A' ' 236' ' ' LEU . 13.1 p -118.64 135.35 59.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.141 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.61 163.56 27.89 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 m 74.39 46.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.905 0.384 . . . . 0.0 110.81 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . 0.441 ' CD1' HG22 ' A' ' 233' ' ' VAL . 14.4 mt -108.98 170.19 8.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.408 ' O ' ' C ' ' A' ' 238' ' ' PHE . 13.7 t-80 -98.89 137.95 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.41 ' O ' ' C ' ' A' ' 239' ' ' ASN . 5.2 m-85 -37.82 -57.02 1.04 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.41 ' C ' ' O ' ' A' ' 238' ' ' PHE . 45.9 t30 -37.58 -42.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.901 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.7 mm -47.21 130.1 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 79.4 p -123.04 -175.63 3.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -62.38 -41.77 98.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -59.45 -29.75 68.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 20.0 mmt -71.87 -44.52 63.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 34.7 mt -68.25 -43.04 78.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.503 ' O ' ' N ' ' A' ' 250' ' ' GLU . 5.6 ptp180 -66.35 -44.55 82.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.499 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -61.08 -39.49 97.18 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.9 mt -76.17 -41.37 37.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.868 0.366 . . . . 0.0 111.147 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.0 m-85 -86.42 -5.55 59.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -67.36 -58.05 9.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.683 0.754 . . . . 0.0 110.894 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.72 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.471 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.7 m-85 -104.77 -25.32 12.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.88 159.04 15.91 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.53 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -62.22 117.82 6.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.724 0.297 . . . . 0.0 110.91 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.442 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 70.3 mt -90.99 114.06 27.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -69.77 -42.99 73.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -167.96 153.55 7.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 87.6 mt -132.94 128.43 56.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 75.8 t -127.42 129.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.093 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 35.9 mt -96.6 135.82 37.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.537 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 35.2 mmm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.893 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.537 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.4 p90 -149.38 160.32 43.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.914 -179.76 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.52 171.65 42.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.508 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -113.31 139.28 48.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.802 0.334 . . . . 0.0 110.887 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.488 HD12 ' CD2' ' A' ' 249' ' ' PHE . 54.1 mt -135.95 139.38 46.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.167 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 85.8 m -119.09 122.26 41.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.405 ' CE1' HD12 ' A' ' 231' ' ' LEU . 36.3 m-85 -91.08 -177.14 4.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.5 t -104.56 -22.14 13.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -133.62 134.94 43.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.8 p -61.7 -36.99 82.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -63.57 -44.0 95.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.875 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.4 m -61.94 -40.04 94.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.16 -41.7 97.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.079 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 11.8 mmt85 -60.0 -49.06 79.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -58.31 -50.6 73.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.885 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -56.55 -39.45 73.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.063 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.516 HD23 ' CD2' ' A' ' 304' ' ' HIS . 13.2 tp -62.08 -40.09 94.65 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -67.32 -34.96 78.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -84.6 -25.86 28.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.92 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.617 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 66.9 mt -81.87 -41.48 20.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . 0.435 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.6 OUTLIER -59.55 117.62 5.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.03 27.32 58.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -95.61 103.35 15.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.854 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -56.97 97.92 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.925 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -87.57 -54.31 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.04 55.01 1.01 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.85 -37.23 3.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -117.03 156.46 48.29 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.622 0.725 . . . . 0.0 110.864 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.56 40.44 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -91.25 162.8 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -99.71 122.06 42.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 5.1 t -129.26 128.77 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -151.19 162.09 29.35 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.484 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.516 ' CD2' HD23 ' A' ' 287' ' ' LEU . 7.0 m170 -75.51 123.32 25.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.826 0.346 . . . . 0.0 110.887 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 -179.982 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.569 HD12 ' CE1' ' A' ' 277' ' ' PHE . 33.4 mt -133.83 144.07 48.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.508 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -113.08 139.1 48.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 -179.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . 0.459 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.9 p -127.42 134.69 65.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.106 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.39 166.02 27.33 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.501 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 73.71 46.15 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.896 0.379 . . . . 0.0 110.842 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . 0.459 HD11 ' CG2' ' A' ' 233' ' ' VAL . 65.2 mt -108.5 174.55 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.426 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 4.5 t-80 -94.66 126.42 39.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.825 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.426 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 5.8 p90 -39.35 -50.28 2.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.864 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -43.53 -49.42 7.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 45.1 mm -38.73 139.59 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.119 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 30.8 p -120.09 175.15 6.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.156 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.12 -31.01 70.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . 0.443 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 2.2 m-20 -63.37 -35.84 81.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 8.2 mmt -72.08 -39.28 69.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 54.6 mt -68.23 -39.87 82.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.92 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.47 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 3.8 ptm180 -70.48 -37.31 74.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.47 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.45 -35.35 81.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.492 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.428 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 93.7 mt -77.5 -42.41 29.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.899 0.381 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.565 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.86 -4.12 58.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.524 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.8 OUTLIER -69.7 -58.29 5.76 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.637 0.732 . . . . 0.0 110.897 -179.901 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.3 Cg_endo -69.8 2.78 3.24 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.671 2.247 . . . . 0.0 112.34 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.43 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.96 -35.55 8.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -177.57 159.84 26.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 16.6 ttmt -60.24 120.15 9.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 64.5 mt -90.74 113.78 27.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.117 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' A' ' 256' ' ' ASP . 31.1 t0 -77.2 -40.61 44.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.826 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -168.33 147.76 4.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.89 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 53.3 mt -129.36 132.83 66.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.5 m -134.07 138.43 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.164 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 20.2 mt -104.16 132.6 50.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.492 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 26.3 mmt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.492 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 2.6 p90 -145.06 161.8 38.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.936 0.398 . . . . 0.0 110.907 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.72 171.55 37.7 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.477 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . 0.414 ' CE1' HG22 ' A' ' 305' ' ' VAL . 16.2 m-85 -118.86 136.76 53.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.859 0.362 . . . . 0.0 110.873 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.558 HD13 ' CD2' ' A' ' 249' ' ' PHE . 89.3 mt -135.73 138.7 47.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.134 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 61.0 m -113.03 128.77 56.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.569 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.1 m-85 -101.98 170.45 8.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 14.6 t -115.79 33.15 5.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -172.58 124.97 0.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 23.0 t -62.74 -40.52 97.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -66.8 -43.71 83.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.86 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 51.9 m -64.36 -42.58 96.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.913 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.74 -44.03 97.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -59.31 -48.56 81.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.87 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -57.96 -51.17 70.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.43 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -54.96 -39.62 69.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.098 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.551 HD21 ' CE1' ' A' ' 304' ' ' HIS . 11.7 tp -63.33 -39.99 96.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -68.49 -34.95 76.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 49.4 mm-40 -83.97 -26.77 28.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.565 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 62.2 mt -81.4 -47.02 13.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . 0.456 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.7 OUTLIER -53.07 114.71 1.54 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.18 34.99 35.39 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.488 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -105.04 122.53 46.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -77.17 112.02 13.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 40.7 tp -93.99 -60.47 1.74 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.964 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -102.93 -21.81 13.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.088 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 169.95 -33.94 0.17 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.79 152.5 45.63 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.67 0.747 . . . . 0.0 110.859 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 120.43 7.21 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.668 2.246 . . . . 0.0 112.344 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -72.41 168.54 18.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 41.7 mmt-85 -111.91 125.0 53.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.45 ' CG1' HD12 ' A' ' 287' ' ' LEU . 57.8 t -131.37 129.62 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.63 163.01 26.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.551 ' CE1' HD21 ' A' ' 287' ' ' LEU . 20.3 m170 -75.21 98.38 3.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 0.0 110.857 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.414 HG22 ' CE1' ' A' ' 274' ' ' PHE . 5.8 p . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.147 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.408 HD13 ' CE2' ' A' ' 277' ' ' PHE . 20.6 mt -128.29 146.97 50.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.92 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.463 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.7 t80 -114.39 136.53 52.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.4 p -121.12 134.53 64.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.099 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.47 165.05 27.97 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 3.8 t 74.58 46.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.933 0.397 . . . . 0.0 110.875 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 85.8 mt -111.49 170.69 7.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.934 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 18.4 t-80 -88.82 147.28 24.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.412 ' O ' ' C ' ' A' ' 239' ' ' ASN . 2.9 m-85 -52.91 -59.76 4.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.412 ' C ' ' O ' ' A' ' 238' ' ' PHE . 1.0 OUTLIER -36.17 -47.32 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 23.5 mm -38.42 136.7 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 7.8 t -123.03 179.55 4.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.158 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 45.7 mp0 -63.05 -35.23 79.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -58.78 -38.51 78.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -64.68 -45.98 84.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 56.0 mt -59.98 -39.24 85.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.501 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -40.8 68.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.472 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.91 -29.6 74.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.0 mt -87.51 -43.53 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 111.096 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.522 ' CE2' HD13 ' A' ' 275' ' ' ILE . 2.7 m-85 -85.17 -0.11 53.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 246' ' ' ARG . 4.0 tt0 -68.99 -59.88 4.87 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.652 0.739 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.4 Cg_endo -69.7 -9.45 26.15 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.256 . . . . 0.0 112.388 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.7 m-85 -88.78 -24.8 22.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.01 164.43 25.72 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.514 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -68.3 108.84 3.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.857 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.416 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 19.4 mt -77.23 113.63 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.094 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -72.19 -45.2 61.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.921 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -163.32 157.68 20.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 71.6 mt -138.6 131.85 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . 0.42 ' CG2' ' HB2' ' A' ' 274' ' ' PHE . 3.8 m -134.79 126.6 47.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 20.7 mt -93.58 129.33 39.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.559 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 17.8 mmm . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.559 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.3 p90 -150.36 162.21 40.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.951 0.405 . . . . 0.0 110.944 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.59 177.32 37.92 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.5 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . 0.42 ' HB2' ' CG2' ' A' ' 259' ' ' VAL . 29.1 m-85 -120.1 133.99 55.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.774 0.321 . . . . 0.0 110.925 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.522 HD13 ' CE2' ' A' ' 249' ' ' PHE . 67.9 mt -133.08 135.93 56.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 64.5 m -117.51 129.3 55.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.408 ' CE2' HD13 ' A' ' 231' ' ' LEU . 41.6 m-85 -100.68 178.74 4.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.6 t -114.98 12.84 16.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.858 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -155.66 128.5 8.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.4 t -64.0 -40.98 97.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 35.6 mm-40 -62.26 -43.93 97.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.897 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 98.7 m -64.51 -36.19 83.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.832 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.53 -43.7 89.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.087 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -61.11 -49.09 78.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 71.5 mtt180 -59.49 -44.32 93.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -62.61 -35.06 78.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.126 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.409 HD22 ' NE2' ' A' ' 304' ' ' HIS . 17.6 tp -64.74 -44.66 89.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -69.18 -35.02 75.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -73.59 -42.0 62.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.926 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.52 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 42.0 mt -75.25 -47.04 29.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.876 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -42.14 106.25 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.65 34.59 31.05 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -96.07 102.02 13.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.344 . . . . 0.0 110.891 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -56.22 90.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.909 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 25.6 tp -80.18 -58.53 3.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.76 40.34 2.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.53 -26.98 21.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 3.5 ptp85 -120.08 147.34 44.4 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 122.33 9.01 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.328 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -75.36 177.31 6.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 11.5 mmm-85 -110.85 122.68 48.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 15.0 t -128.99 123.51 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.113 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -156.47 161.25 30.78 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.409 ' NE2' HD22 ' A' ' 287' ' ' LEU . 90.4 m-70 -72.68 128.27 35.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.855 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.434 ' CG1' ' HB2' ' A' ' 232' ' ' TYR . 21.5 m . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.115 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.456 -0.257 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.558 HD13 ' CE1' ' A' ' 277' ' ' PHE . 34.3 mt -118.6 146.83 44.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.806 0.336 . . . . 0.0 110.929 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.581 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.4 OUTLIER -118.6 141.3 48.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.915 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . 0.455 ' CG2' HD13 ' A' ' 236' ' ' LEU . 12.0 p -123.08 131.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.14 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -136.91 165.9 25.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 58.5 m 62.54 49.87 3.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.884 0.373 . . . . 0.0 110.822 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . 0.455 HD13 ' CG2' ' A' ' 233' ' ' VAL . 61.8 mt -103.67 -175.13 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 16.8 t-80 -110.39 142.31 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -49.47 -44.31 45.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -52.44 -33.74 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 10.5 mm -57.21 125.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.144 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.1 p -117.28 178.64 4.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.162 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -60.83 -36.67 79.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . 0.431 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 6.9 t0 -60.88 -34.37 74.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.807 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 21.6 mtt -72.05 -42.71 65.97 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 63.1 mt -66.8 -42.97 85.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.939 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 4.0 ptm180 -66.38 -38.74 88.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.866 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.43 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.45 -36.82 92.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 86.8 mt -78.56 -43.91 26.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.912 0.387 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.549 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.4 m-85 -81.75 -4.72 57.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.924 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.488 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.5 OUTLIER -66.55 -60.13 7.06 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.677 0.751 . . . . 0.0 110.897 -179.908 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.34 3.61 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.706 2.271 . . . . 0.0 112.321 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.46 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.3 m-85 -103.39 -23.33 13.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.881 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 168.35 158.98 13.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.466 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.47 117.58 7.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.768 0.318 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.412 ' CG2' HG13 ' A' ' 258' ' ' ILE . 45.4 mt -86.33 120.89 36.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.103 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -79.51 -41.23 27.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.851 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 38.4 t30 -167.7 145.78 4.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . 0.412 HG13 ' CG2' ' A' ' 255' ' ' ILE . 93.9 mt -128.44 127.88 67.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.105 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . 0.462 ' CG2' ' HB2' ' A' ' 274' ' ' PHE . 18.3 m -129.51 139.15 52.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.096 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 28.9 mt -111.41 139.49 46.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.556 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 29.8 mmt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.556 ' CE1' ' HB2' ' A' ' 261' ' ' MET . 2.1 p90 -151.01 165.18 34.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.926 0.393 . . . . 0.0 110.94 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -157.89 168.01 34.37 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.492 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . 0.462 ' HB2' ' CG2' ' A' ' 259' ' ' VAL . 29.0 m-85 -114.44 137.79 51.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.864 0.364 . . . . 0.0 110.872 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.43 HD13 ' CE2' ' A' ' 249' ' ' PHE . 85.1 mt -137.24 134.45 47.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.114 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.6 m -117.76 129.18 55.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.191 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.558 ' CE1' HD13 ' A' ' 231' ' ' LEU . 45.4 m-85 -99.28 177.97 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 62.6 p -98.8 -36.28 9.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.819 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -115.97 129.19 56.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 32.8 p -57.48 -37.98 73.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . 0.414 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 11.1 pt-20 -62.32 -43.35 99.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . 0.414 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 68.1 m -62.25 -37.49 85.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -40.17 90.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 47.6 ttt85 -62.08 -48.94 77.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.862 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.8 mmt180 -58.66 -51.02 71.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.57 -35.07 69.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.459 ' HB2' ' CD2' ' A' ' 231' ' ' LEU . 10.7 tp -65.06 -41.96 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -68.99 -42.91 75.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.943 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.0 mm100 -71.98 -36.03 69.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.549 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 54.9 mt -75.3 -46.95 30.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -42.0 112.41 0.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.905 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 73.96 40.16 44.45 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 23.9 t80 -100.93 98.05 8.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.824 0.345 . . . . 0.0 110.861 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.19 105.83 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 5.7 tt -94.82 -53.68 3.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.926 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.14 40.64 2.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.2 -35.21 4.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.491 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 -110.23 149.1 39.66 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.576 0.703 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 119.16 6.15 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.724 2.283 . . . . 0.0 112.325 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptm -71.07 171.55 10.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -106.92 125.17 50.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.913 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.409 ' CG1' HD11 ' A' ' 287' ' ' LEU . 7.0 t -128.5 121.5 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.097 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.69 163.49 28.54 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.503 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.438 ' CE1' HD21 ' A' ' 287' ' ' LEU . 18.5 m170 -79.24 130.37 35.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.885 0.374 . . . . 0.0 110.82 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 83.9 t . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.134 179.959 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 37.0 mt -129.96 147.04 51.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.349 . . . . 0.0 110.873 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.492 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.4 t80 -110.13 131.81 54.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.74 136.46 55.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.18 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.56 165.47 27.53 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.448 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.5 t 74.28 46.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.9 0.381 . . . . 0.0 110.85 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.37 170.7 7.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 238' ' ' PHE . 31.4 t-80 -98.65 132.16 44.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.437 ' C ' ' O ' ' A' ' 237' ' ' HIS . 0.9 OUTLIER -34.46 -61.07 0.4 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.878 -179.91 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.533 ' ND2' ' N ' ' A' ' 240' ' ' ILE . 0.3 OUTLIER -36.95 -47.27 0.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.941 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.533 ' N ' ' ND2' ' A' ' 239' ' ' ASN . 40.3 mm -36.74 128.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.181 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.0 p -118.44 175.57 5.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -60.61 -31.07 70.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.844 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -64.89 -32.45 74.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 13.5 mmt -71.74 -40.88 69.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 45.1 mt -69.35 -43.0 74.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.436 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 6.2 ptm180 -66.02 -40.11 90.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -66.48 -38.25 93.32 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.507 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.0 mt -77.27 -41.84 30.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.902 0.382 . . . . 0.0 111.131 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -83.74 -3.88 58.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.847 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.524 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.94 -58.34 5.42 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.654 0.74 . . . . 0.0 110.853 -179.932 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.74 2.74 3.25 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.734 2.289 . . . . 0.0 112.347 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.441 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.62 -33.11 9.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 175.67 138.66 2.88 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.449 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -45.64 116.64 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.769 0.319 . . . . 0.0 110.924 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.421 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 55.5 mt -85.3 134.7 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.12 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -91.38 -46.47 8.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.874 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 33.8 t30 -160.92 145.82 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.1 mt -124.14 133.1 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.151 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 89.4 t -131.86 125.78 55.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.13 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 26.2 mt -96.93 131.32 43.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.933 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.7 mmt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.894 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.508 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 1.1 p90 -151.0 153.72 35.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 0.0 110.934 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.01 175.36 40.15 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -117.79 140.29 49.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.939 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.505 HD11 ' CE2' ' A' ' 249' ' ' PHE . 90.6 mt -138.25 128.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 83.5 m -110.02 130.0 55.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -96.37 179.51 5.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 27.8 t -92.03 -42.73 9.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.83 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -114.1 139.35 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.7 m -60.75 -39.74 89.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -61.62 -43.73 98.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 87.9 m -60.13 -38.93 84.55 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.37 -40.93 94.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -60.1 -48.31 82.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 47.7 mmt-85 -58.25 -51.01 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.441 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.24 -35.54 69.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.4 tp -65.01 -40.55 95.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.902 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -68.41 -42.63 78.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.855 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 24.7 mm-40 -71.88 -38.99 69.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.511 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 71.8 mt -72.62 -45.87 56.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.924 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -47.81 108.07 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.833 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.46 36.11 27.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.474 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -100.45 121.64 41.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.832 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -73.68 96.64 2.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 42.5 tp -88.52 -47.83 8.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.927 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -121.9 43.57 2.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.133 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 93.78 -25.17 22.73 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.507 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 55.2 mtp180 -122.94 148.69 54.75 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.605 0.717 . . . . 0.0 110.844 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 121.17 7.85 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.635 2.223 . . . . 0.0 112.357 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -74.46 171.8 13.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.2 mmm180 -108.8 123.51 49.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.431 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 15.4 t -129.46 126.6 63.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.126 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -147.78 158.97 27.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 6.3 m170 -71.65 120.58 17.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.812 0.339 . . . . 0.0 110.873 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.987 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.444 ' CD2' ' HB2' ' A' ' 287' ' ' LEU . 40.2 mt -122.18 144.82 48.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.358 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -109.52 141.97 41.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.948 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.92 135.75 63.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -142.59 166.06 26.61 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.8 m 64.03 49.82 2.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.892 0.377 . . . . 0.0 110.878 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 96.4 mt -103.06 -179.02 3.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.417 ' O ' ' C ' ' A' ' 238' ' ' PHE . 11.2 t-80 -109.85 133.11 53.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.434 ' O ' ' C ' ' A' ' 239' ' ' ASN . 71.7 m-85 -37.38 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.86 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.448 ' C ' ' ND2' ' A' ' 239' ' ' ASN . 0.2 OUTLIER -35.8 -40.86 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.908 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 37.4 mm -49.07 146.11 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 12.6 p -143.2 -179.86 6.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.171 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -60.52 -35.82 76.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.882 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.23 -41.23 88.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 19.3 mtt -69.28 -44.92 70.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 47.4 mt -60.25 -36.38 77.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.486 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -39.73 68.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.953 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.468 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.65 -36.34 93.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.438 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.45 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.4 mt -81.78 -44.1 20.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.871 0.367 . . . . 0.0 111.103 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.554 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.3 m-85 -79.07 -8.08 58.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.513 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.1 tp10 -67.96 -58.78 7.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.513 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.78 1.88 4.05 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.45 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.9 m-85 -103.0 -34.45 8.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -179.41 158.03 21.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 2.4 ttmp? -64.73 101.53 0.48 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.745 0.307 . . . . 0.0 110.932 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 38.4 mt -69.36 125.65 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.162 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -83.03 -42.53 17.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.823 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -168.82 146.77 3.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 95.9 mt -123.08 133.79 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.144 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 7.1 m -133.92 124.59 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 29.5 mt -92.04 138.05 31.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.546 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 10.5 mmm . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.546 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -146.89 153.29 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.926 0.393 . . . . 0.0 110.927 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -159.66 -178.15 33.4 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -129.71 140.11 51.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.554 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.5 mt -136.64 137.27 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.137 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.433 ' N ' HG23 ' A' ' 275' ' ' ILE . 87.5 m -116.13 127.25 54.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.125 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -96.92 -179.27 4.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.2 t -96.93 -41.85 8.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.863 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -112.52 138.12 49.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.1 p -61.51 -39.74 92.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.847 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -61.91 -44.04 97.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 72.2 m -60.4 -37.31 80.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.904 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -67.05 -41.44 86.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.4 ttt180 -59.96 -48.78 80.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.86 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -58.41 -51.02 71.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -57.15 -35.02 69.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.527 HD23 ' CE1' ' A' ' 304' ' ' HIS . 10.8 tp -63.88 -45.3 90.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -69.08 -39.01 79.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -69.46 -42.11 75.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.91 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . . . . . . . . . 56.7 mt -74.45 -47.03 35.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -43.59 114.53 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 71.22 38.2 63.17 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -104.57 109.57 21.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.923 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -55.29 95.05 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.913 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . 0.411 ' CD1' ' C ' ' A' ' 295' ' ' LEU . 0.5 OUTLIER -76.25 -64.78 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.6 37.41 3.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.62 -40.2 2.46 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 62.1 mtp180 -115.95 157.58 44.5 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 127.82 15.16 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.716 2.277 . . . . 0.0 112.356 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptp -79.51 179.53 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -110.73 123.36 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.89 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.411 HG11 ' CD1' ' A' ' 287' ' ' LEU . 14.8 t -132.75 125.35 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.56 160.83 28.3 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.436 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.527 ' CE1' HD23 ' A' ' 287' ' ' LEU . 9.6 m170 -75.55 111.6 11.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.834 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 304' ' ' HIS . 98.5 t . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 44.6 mt -116.85 144.66 44.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.847 0.356 . . . . 0.0 110.935 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.475 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.7 t80 -106.73 129.53 54.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 8.7 p -114.81 132.54 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.179 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.12 163.85 28.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.479 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 74.64 43.01 0.27 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.928 0.394 . . . . 0.0 110.881 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.1 mt -101.88 -177.41 3.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.891 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 240' ' ' ILE . 6.6 t-80 -103.75 126.77 51.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.865 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.49 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 4.2 p90 -35.89 -44.69 0.37 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.49 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 39.5 t30 -51.7 -46.15 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.44 ' N ' ' O ' ' A' ' 237' ' ' HIS . 40.3 mm -40.19 147.87 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.127 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.0 t -136.98 174.51 10.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.099 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 38.0 mp0 -56.89 -34.96 68.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -58.33 -44.18 88.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.4 mmt -65.08 -42.23 94.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 41.7 mt -61.19 -39.62 90.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.894 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.01 -37.97 69.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.462 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -63.37 -34.61 90.42 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . 0.437 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 68.1 mt -83.55 -44.81 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.571 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.7 m-85 -78.94 -5.97 55.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.523 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.58 -58.28 5.9 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 0.0 110.909 -179.919 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.523 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.78 -0.95 7.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.63 2.22 . . . . 0.0 112.388 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.437 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 11.7 m-85 -100.05 -23.87 14.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 167.57 167.33 28.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm -68.43 115.09 7.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.71 0.29 . . . . 0.0 110.872 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 27.3 mt -83.41 120.65 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.126 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -77.63 -49.37 14.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -163.25 145.64 10.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 84.8 mt -124.42 129.6 73.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 51.8 t -131.03 131.94 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.165 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 30.0 mt -101.08 133.7 45.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.457 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 57.6 mmm . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.888 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.457 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -148.19 159.09 44.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.904 0.383 . . . . 0.0 110.962 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -166.1 176.3 41.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -119.74 135.9 54.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.339 . . . . 0.0 110.886 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.56 HD13 ' CD2' ' A' ' 249' ' ' PHE . 75.8 mt -131.89 140.11 48.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.412 ' N ' HG22 ' A' ' 275' ' ' ILE . 69.5 m -120.97 128.23 52.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.181 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -96.8 -175.34 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.841 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.4 t -105.23 -28.79 10.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.893 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.66 135.56 55.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.3 p -63.54 -40.52 97.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -61.68 -43.63 98.49 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.861 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.9 m -62.5 -38.81 91.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.905 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -63.92 -43.17 96.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.128 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -61.65 -47.58 84.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -57.98 -49.8 75.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.418 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.25 -39.47 75.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 11.6 tp -61.68 -40.71 95.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -68.24 -35.04 77.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -82.58 -26.5 32.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.571 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 71.3 mt -81.71 -47.06 13.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . 0.444 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -51.36 117.17 2.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.25 32.45 55.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.446 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -97.49 106.89 19.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -59.73 102.53 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 39.7 tp -92.79 -63.36 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -107.88 39.79 1.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.109 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.88 -25.81 26.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -120.68 154.53 57.22 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.601 0.715 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.85 128.93 16.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.683 2.255 . . . . 0.0 112.333 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptt? -82.43 164.35 21.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 66.6 mmt-85 -102.28 121.19 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.4 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 15.9 t -130.28 121.32 51.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.15 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -140.78 163.98 26.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.514 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 305' ' ' VAL . 7.0 m170 -73.02 112.49 9.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 110.833 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' A' ' 304' ' ' HIS . 74.4 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.134 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.401 ' C ' HG22 ' A' ' 305' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 63.5 mt -129.03 145.7 51.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.942 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.498 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.0 t80 -105.54 135.0 47.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 9.6 p -121.73 129.39 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -138.65 162.55 25.84 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 73.47 46.73 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.891 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 64.2 mt -106.73 -176.14 2.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.959 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -113.6 130.26 56.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.418 ' O ' ' C ' ' A' ' 239' ' ' ASN . 1.2 m-85 -38.12 -58.29 0.98 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 238' ' ' PHE . 18.3 m-20 -36.19 -46.1 0.49 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.0 mm -47.43 128.92 3.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.7 p -113.1 174.88 5.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -58.53 -33.86 70.35 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.876 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -61.58 -46.02 91.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 30.6 mtt -60.23 -42.49 95.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 42.4 mt -60.42 -40.5 91.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.498 ' O ' ' N ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -63.51 -43.98 95.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.454 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -64.87 -32.01 82.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.485 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 87.0 mt -78.4 -40.99 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.881 0.372 . . . . 0.0 111.175 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.564 ' CZ ' HD11 ' A' ' 290' ' ' LEU . 3.2 m-85 -90.91 -8.65 48.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.886 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.502 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.6 tp10 -59.0 -59.28 14.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.636 0.731 . . . . 0.0 110.88 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 2.75 3.28 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.268 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . 0.458 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.6 m-85 -106.41 -9.67 16.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 152.7 168.25 16.5 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.45 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 31.6 tttp -72.46 122.03 20.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.75 0.309 . . . . 0.0 110.932 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.408 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 33.4 mt -93.8 111.65 25.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -70.14 -39.34 75.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.883 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -167.66 155.05 8.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 49.0 mt -131.57 131.99 62.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 8.1 t -128.4 137.8 56.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.161 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 48.3 mt -110.07 132.81 53.83 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.521 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 13.3 mmt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.521 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 0.5 OUTLIER -150.42 161.95 41.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.931 0.396 . . . . 0.0 110.879 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.9 -173.17 35.69 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.62 148.5 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' A' ' 249' ' ' PHE . 82.1 mt -138.58 139.66 40.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 275' ' ' ILE . 56.4 m -118.21 129.98 55.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -103.48 -175.11 2.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 22.8 t -100.15 -41.76 6.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -113.93 139.94 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.852 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 60.9 p -63.14 -40.16 96.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.847 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.15 -42.77 99.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.904 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.2 m -60.7 -35.98 77.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -68.07 -41.98 81.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.081 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 19.6 ttm180 -59.23 -49.11 79.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 28.4 mmt180 -58.91 -50.93 72.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.885 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.41 -34.9 69.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.09 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 15.0 tp -64.09 -45.29 89.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -69.01 -42.03 76.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -67.81 -42.02 82.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.916 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.564 HD11 ' CZ ' ' A' ' 249' ' ' PHE . 65.2 mt -73.72 -46.82 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 290' ' ' LEU . 0.7 OUTLIER -37.19 103.6 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 179.909 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.58 33.86 33.39 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 290' ' ' LEU . 22.6 t80 -87.42 105.48 17.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -57.67 96.75 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 8.5 tt -89.72 -69.54 0.71 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.946 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -99.3 32.05 2.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 107.68 -36.86 4.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.512 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -108.94 148.01 37.03 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.58 0.705 . . . . 0.0 110.885 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.03 7.73 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.716 2.277 . . . . 0.0 112.325 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptm -74.02 171.96 12.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.0 mmt85 -111.73 122.95 49.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.17 122.32 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.49 162.54 26.92 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.449 ' O ' ' C ' ' A' ' 305' ' ' VAL . 5.0 m170 -71.4 127.27 32.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.812 0.339 . . . . 0.0 110.826 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 304' ' ' HIS . 54.0 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.11 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . 0.429 HD11 ' CE2' ' A' ' 277' ' ' PHE . 51.8 mt -123.94 145.22 49.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -112.51 133.79 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.946 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 14.7 p -122.07 132.85 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.113 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.76 165.78 27.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.474 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.3 m 74.03 47.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 74.7 mt -110.03 178.78 4.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -97.53 132.08 43.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.468 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.1 t80 -42.62 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.85 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 238' ' ' PHE . 59.4 t-20 -34.62 -33.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.468 ' N ' ' O ' ' A' ' 238' ' ' PHE . 21.8 mm -54.85 147.98 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.109 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -134.98 175.8 9.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . 0.421 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 11.8 mt-10 -57.82 -32.65 67.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -60.26 -33.83 72.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.4 mmt -71.98 -37.87 69.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 39.1 mt -69.54 -42.89 74.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.959 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.489 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 14.9 ptt85 -67.53 -39.46 85.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.462 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.6 -35.63 86.58 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.492 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 73.3 mt -79.1 -45.19 24.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.815 0.341 . . . . 0.0 111.101 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' A' ' 275' ' ' ILE . 3.1 m-85 -80.6 -4.9 55.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.526 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.89 -58.19 5.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.69 0.757 . . . . 0.0 110.875 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.526 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.81 3.2 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -103.91 -25.84 12.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.841 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.93 166.14 29.33 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.464 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.2 ttmt -67.4 109.54 3.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 33.6 mt -81.06 123.68 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.141 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -79.31 -44.53 21.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -168.33 151.16 5.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.865 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 36.7 mt -128.19 134.02 65.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.16 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.7 m -134.51 134.76 54.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . 0.421 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 32.3 mt -97.48 134.62 40.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.934 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.553 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 26.9 mmm . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.553 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 3.7 p90 -148.69 155.92 41.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.931 0.396 . . . . 0.0 110.861 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.5 177.89 39.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -117.56 139.43 50.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.866 0.365 . . . . 0.0 110.92 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.564 HD11 ' CD2' ' A' ' 249' ' ' PHE . 71.0 mt -136.02 138.55 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.132 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.9 m -117.47 123.94 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . 0.429 ' CE2' HD11 ' A' ' 231' ' ' LEU . 41.4 m-85 -91.24 -175.69 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 38.9 t -100.02 -34.3 10.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.867 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -122.94 138.27 54.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.903 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.8 p -61.72 -35.88 79.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -63.66 -44.11 94.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.879 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 74.0 m -62.42 -37.8 87.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -67.22 -36.94 82.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.073 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . 0.428 ' HB2' ' NH1' ' A' ' 284' ' ' ARG . 0.1 OUTLIER -64.13 -48.98 73.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.864 -179.891 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -59.83 -43.22 94.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.83 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -63.15 -35.23 79.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.138 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 11.6 tp -65.07 -44.65 88.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.923 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -69.39 -38.98 78.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -71.5 -41.12 69.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.561 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 74.8 mt -74.29 -46.93 37.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -45.22 107.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.5 38.66 13.89 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.449 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -105.54 100.27 9.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.874 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -50.82 103.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 15.9 tp -94.67 -55.82 3.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.42 45.55 2.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.145 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.82 -37.19 3.65 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -117.03 150.45 46.01 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 123.36 10.01 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.64 2.226 . . . . 0.0 112.381 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -69.45 170.68 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 6.1 mmm180 -108.76 124.21 50.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 17.3 t -129.38 125.41 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.126 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -145.74 162.63 28.29 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.442 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -76.92 126.88 31.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.861 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 82.5 t . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.965 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 30.0 mt -121.78 139.12 53.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.948 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 232' ' ' TYR . . . . . 0.542 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.9 OUTLIER -106.47 137.79 43.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 233' ' ' VAL . . . . . 0.412 ' CG2' HD11 ' A' ' 236' ' ' LEU . 7.4 p -122.56 136.91 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.95 163.95 28.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.468 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 74.16 45.25 0.21 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.891 0.377 . . . . 0.0 110.902 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 236' ' ' LEU . . . . . 0.412 HD11 ' CG2' ' A' ' 233' ' ' VAL . 96.7 mt -104.9 -176.29 3.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 237' ' ' HIS . . . . . 0.438 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.2 t-80 -109.29 135.06 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.84 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 238' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 1.9 p90 -38.7 -44.14 0.97 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 239' ' ' ASN . . . . . 0.479 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 36.4 t30 -54.02 -42.18 68.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 240' ' ' ILE . . . . . 0.438 ' N ' ' O ' ' A' ' 237' ' ' HIS . 15.5 mm -50.63 106.25 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.152 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -95.25 179.49 5.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.096 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -61.16 -30.83 70.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -61.11 -43.55 98.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.8 mtt -62.68 -46.03 90.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 31.9 mt -60.07 -38.75 83.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.02 -42.4 66.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . 0.423 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -61.48 -30.61 74.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.468 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 88.4 mt -88.33 -43.59 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 111.171 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 249' ' ' PHE . . . . . 0.557 ' CD2' HD11 ' A' ' 275' ' ' ILE . 3.2 m-85 -82.23 -2.64 53.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.886 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 250' ' ' GLU . . . . . 0.514 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -70.34 -58.56 4.77 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.594 0.711 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 251' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.1 Cg_endo -69.72 2.03 3.88 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -103.27 -11.12 18.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 154.23 177.34 27.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.51 131.13 41.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.762 0.315 . . . . 0.0 110.921 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.447 HG22 ' CD1' ' A' ' 258' ' ' ILE . 94.6 mt -98.76 98.7 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -59.43 -44.72 92.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.825 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -167.2 153.55 8.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.938 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 258' ' ' ILE . . . . . 0.447 ' CD1' HG22 ' A' ' 255' ' ' ILE . 78.3 mt -130.27 133.01 64.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.6 m -134.41 134.28 54.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.6 mt -103.35 128.81 50.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 261' ' ' MET . . . . . 0.563 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 12.1 mmt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.831 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' TYR . . . . . 0.563 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -146.96 154.86 41.76 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.934 0.397 . . . . 0.0 110.929 -179.827 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -162.21 172.89 38.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' PHE . . . . . 0.441 ' CD2' HG13 ' A' ' 305' ' ' VAL . 33.1 m-85 -119.8 134.39 55.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 110.848 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' ILE . . . . . 0.557 HD11 ' CD2' ' A' ' 249' ' ' PHE . 96.3 mt -130.74 137.4 56.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' THR . . . . . 0.46 ' N ' HG21 ' A' ' 275' ' ' ILE . 90.9 m -110.42 129.77 55.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -103.68 170.83 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.845 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 1.1 t -115.38 24.79 11.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.843 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -162.59 113.09 1.49 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 95.2 p -53.12 -40.47 64.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 -179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -62.02 -43.99 97.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 85.6 m -64.56 -40.91 96.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -58.08 -46.35 85.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -61.91 -47.4 85.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -59.15 -50.93 72.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.87 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -56.71 -35.2 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.076 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 287' ' ' LEU . . . . . 0.449 HD21 ' CD2' ' A' ' 304' ' ' HIS . 7.6 tp -64.59 -44.66 89.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.14 -42.5 75.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.895 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 68.2 mm-40 -67.44 -41.95 83.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 290' ' ' LEU . . . . . 0.433 ' HB3' ' CG2' ' A' ' 302' ' ' VAL . 73.9 mt -73.73 -46.95 42.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -41.5 104.93 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.43 34.8 15.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.522 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -100.84 99.76 10.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -61.08 118.22 6.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.893 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 10.0 tp -108.1 -50.26 3.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.883 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -113.11 42.81 1.83 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.082 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.33 -35.53 4.54 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.479 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -115.92 152.51 47.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 130.47 19.36 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.357 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -78.24 174.78 10.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 16.6 mmt180 -111.38 120.6 42.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 302' ' ' VAL . . . . . 0.433 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 13.0 t -123.43 131.44 73.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.123 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.2 161.8 30.62 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.546 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 304' ' ' HIS . . . . . 0.449 ' CD2' HD21 ' A' ' 287' ' ' LEU . 34.2 m-70 -70.12 121.94 18.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.865 0.364 . . . . 0.0 110.864 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 305' ' ' VAL . . . . . 0.447 HG11 ' N ' ' A' ' 232' ' ' TYR . 17.2 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.099 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 80.7 p -96.17 -49.42 5.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.902 0.382 . . . . 0.0 110.919 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 56.5 p -99.09 88.19 3.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.89 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 228' ' ' SER . . . 179.51 -42.34 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 227' ' ' GLY . 18.1 m -37.13 120.3 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 0.0 110.865 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 77.7 p -85.39 87.36 7.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -127.96 140.67 11.97 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.467 HD11 ' CE1' ' A' ' 277' ' ' PHE . 25.0 mt -121.09 146.99 46.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 110.922 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.558 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -111.9 139.65 47.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 14.2 p -124.44 131.29 72.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.114 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.23 165.38 27.43 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.498 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.2 m 72.82 44.67 0.35 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 0.0 110.883 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 79.5 mt -109.24 172.09 7.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -90.32 126.99 36.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -41.48 -42.46 2.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -51.09 -42.1 60.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.449 HG22 ' N ' ' A' ' 241' ' ' THR . 47.8 mm -44.66 152.2 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.161 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' THR . . . . . 0.449 ' N ' HG22 ' A' ' 240' ' ' ILE . 76.1 p -137.02 178.58 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.152 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . 0.427 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 12.1 mt-10 -61.67 -35.83 79.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -60.16 -34.87 74.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 240' ' ' ILE . 27.7 mtt -72.04 -41.17 67.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 59.8 mt -68.67 -42.24 78.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.919 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.41 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 6.1 ptm180 -67.3 -39.87 86.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.41 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.27 -34.75 86.51 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.464 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 92.2 mt -80.98 -42.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.854 0.359 . . . . 0.0 111.103 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.59 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.2 m-85 -83.48 -1.65 54.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.863 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.492 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.7 OUTLIER -70.29 -59.79 3.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.654 0.74 . . . . 0.0 110.883 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.81 2.88 3.16 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.419 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.7 m-85 -102.97 -30.41 10.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 176.62 149.01 7.38 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.453 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 7.4 ttpp -56.29 111.42 0.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 110.854 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 57.0 mt -80.62 124.97 39.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.161 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -82.28 -43.14 17.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -168.25 149.3 4.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 41.9 mt -128.25 132.72 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.158 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 4.9 m -134.99 127.02 47.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . 0.427 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 31.6 mt -92.11 136.29 33.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.42 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 29.9 mmm -103.91 134.32 47.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.87 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.29 -175.85 4.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.9 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -102.79 -175.99 2.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 11.3 p -118.42 -47.42 2.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -68.45 -24.11 64.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 43.0 p -114.81 -38.1 4.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.142 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 62.3 24.86 65.99 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.468 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.404 ' O ' ' C ' ' A' ' 269' ' ' SER . 47.5 mmt-85 -113.95 110.69 20.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 110.847 -179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.404 ' C ' ' O ' ' A' ' 268' ' ' ARG . 5.3 p -38.18 103.78 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.414 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 20.5 mttm -52.2 -29.58 23.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 117.01 37.37 0.96 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.42 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -148.63 163.32 37.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.868 0.366 . . . . 0.0 110.947 -179.814 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.32 175.56 39.58 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -120.37 137.74 54.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.859 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 30.1 mt -138.48 137.35 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.16 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.7 m -118.53 129.46 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.467 ' CE1' HD11 ' A' ' 231' ' ' LEU . 39.2 m-85 -97.76 -177.9 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.873 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.9 t -95.51 -41.55 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -116.59 141.23 48.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.1 m -63.87 -36.23 83.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -61.72 -43.65 98.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.94 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 99.2 m -62.06 -40.5 96.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.84 99.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . 0.414 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 13.0 ttm105 -60.73 -48.05 83.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 23.2 mtp180 -58.31 -50.88 72.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.419 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -58.49 -34.93 71.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.123 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.72 -40.81 95.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -68.96 -42.16 77.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.891 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -71.72 -38.43 70.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.924 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.59 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 56.7 mt -74.08 -47.04 39.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.931 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -44.51 110.16 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.71 37.19 40.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 28.1 t80 -104.83 91.79 3.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.849 0.357 . . . . 0.0 110.825 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -48.91 118.4 2.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 45.6 tp -103.85 -44.73 4.97 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -122.95 40.15 3.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.06 -27.75 18.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 29.6 mtp85 -118.32 148.46 43.9 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.558 0.694 . . . . 0.0 110.891 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 132.62 23.79 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.696 2.264 . . . . 0.0 112.336 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -86.88 170.93 11.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.898 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -108.64 127.82 54.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.897 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 16.4 t -132.47 127.6 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -152.47 163.87 30.44 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -71.13 146.41 49.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 0.0 110.863 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 95.3 t -73.93 -41.04 53.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 10.8 t -79.55 -12.64 59.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.138 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 44.73 41.96 5.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 33.9 tpt85 -129.67 134.99 47.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.859 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.33 166.14 23.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.32 162.87 5.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 157.26 172.92 25.02 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.481 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -100.05 111.47 4.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.473 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 2.9 t -70.63 158.31 36.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.929 0.395 . . . . 0.0 110.847 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 152.27 76.44 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.481 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.12 20.25 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.702 2.268 . . . . 0.0 112.341 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 2.4 t -41.84 146.68 0.25 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 48.9 m 53.02 42.53 32.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.468 -179.977 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.6 m -131.57 146.47 52.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.915 0.388 . . . . 0.0 110.811 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 94.4 p -101.38 130.24 47.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.859 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 76.27 88.01 0.3 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.512 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 41.0 t -85.39 101.71 12.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 0.0 110.881 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 23.4 t -92.2 33.48 1.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -92.19 150.05 19.98 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.475 HD12 ' CE1' ' A' ' 277' ' ' PHE . 53.7 mt -127.24 144.77 50.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.81 0.338 . . . . 0.0 110.93 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.482 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.5 t80 -109.69 136.29 49.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.8 p -122.87 137.77 55.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.089 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.65 164.32 28.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.466 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.3 t 74.12 47.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.891 0.376 . . . . 0.0 110.807 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 91.3 mt -109.28 170.29 8.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.586 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 8.0 t-80 -92.93 126.08 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.876 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.586 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 4.8 p90 -38.83 -48.36 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -46.31 -44.54 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.871 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.9 mm -40.07 154.47 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 14.4 t -137.42 173.72 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -60.69 -35.02 75.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.887 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -59.49 -34.53 72.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.7 mmt -71.77 -39.51 69.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.869 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 56.6 mt -68.89 -41.85 77.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 4.7 ptm180 -68.55 -36.15 78.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.42 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.06 -41.82 92.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.471 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.433 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 76.5 mt -75.18 -41.32 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.841 0.353 . . . . 0.0 111.097 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.536 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.2 m-85 -81.56 -4.03 54.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.498 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.0 tp10 -69.48 -59.7 4.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.643 0.735 . . . . 0.0 110.871 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.498 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.5 Cg_endo -69.79 3.02 3.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.665 2.243 . . . . 0.0 112.285 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.458 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.7 m-85 -103.16 -39.33 6.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.92 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -176.01 148.06 9.04 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -51.75 117.24 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.07 124.56 40.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -83.61 -44.7 14.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 11.7 t30 -167.51 150.01 5.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . 0.415 HG23 ' N ' ' A' ' 259' ' ' VAL . 34.6 mt -126.6 136.13 61.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . 0.415 ' N ' HG23 ' A' ' 258' ' ' ILE . 84.8 t -134.97 130.86 52.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.13 179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.51 131.66 47.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 68.4 mmm -98.04 126.25 43.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.46 167.11 18.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.929 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.38 -178.9 4.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 28.0 p -111.94 -52.64 2.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -59.5 -38.65 81.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 61.6 p -101.58 -32.51 10.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.109 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 55.19 28.9 51.09 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.463 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.431 ' O ' ' C ' ' A' ' 269' ' ' SER . 14.9 ttt180 -120.98 109.02 14.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.833 0.349 . . . . 0.0 110.868 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 268' ' ' ARG . 12.0 p -35.34 103.32 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 47.1 mttt -48.96 -35.32 14.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.891 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 124.14 38.23 0.54 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.528 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.433 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.8 p90 -149.2 161.78 41.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 110.903 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -165.66 171.15 40.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.485 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -117.13 134.82 54.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.842 0.354 . . . . 0.0 110.856 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.479 HD13 ' CE2' ' A' ' 249' ' ' PHE . 97.2 mt -132.28 137.69 53.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.159 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.405 ' N ' HG22 ' A' ' 275' ' ' ILE . 96.4 m -117.22 129.51 55.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.209 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.475 ' CE1' HD12 ' A' ' 231' ' ' LEU . 43.6 m-85 -97.99 -177.27 3.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.9 t -101.48 -41.37 6.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -112.02 138.81 48.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.7 p -63.52 -40.93 98.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -61.3 -43.62 98.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 95.2 m -60.56 -42.96 97.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.67 -40.07 95.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -60.07 -48.91 79.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -58.96 -49.79 76.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.917 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.54 -35.79 70.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.9 tp -64.54 -43.36 94.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.891 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -68.8 -42.43 77.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 22.2 mm100 -69.1 -41.1 77.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.536 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 58.6 mt -73.12 -46.31 51.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.884 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -45.91 112.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.905 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.73 38.73 36.13 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 73.4 t80 -106.51 120.86 43.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.818 0.342 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -67.11 114.56 5.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.5 tp -98.17 -62.12 1.29 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.17 34.76 4.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.064 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 117.0 -35.42 4.17 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.502 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -120.42 156.51 55.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.627 0.727 . . . . 0.0 110.852 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 130.84 20.07 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.65 2.234 . . . . 0.0 112.334 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -79.54 170.92 15.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -105.99 119.08 38.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 6.2 t -124.11 132.38 71.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -154.65 163.9 31.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 16.5 m-70 -70.13 135.99 49.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.809 0.337 . . . . 0.0 110.885 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.411 HG21 ' C ' ' A' ' 231' ' ' LEU . 94.9 t -73.92 107.74 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 15.2 t -158.17 142.92 16.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.106 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . 0.408 ' O ' ' CG ' ' A' ' 307' ' ' GLU . 6.5 pt-20 -104.05 94.32 5.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 8.4 ttt85 -165.66 145.14 6.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 79.9 mt -96.27 168.56 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -115.52 154.47 29.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.887 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 167.84 114.65 0.3 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.479 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 158.96 105.43 0.21 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.455 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 48.8 m -144.2 149.25 36.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.946 0.403 . . . . 0.0 110.864 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 114.44 77.32 0.74 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -9.68 26.71 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.699 2.266 . . . . 0.0 112.376 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 51.7 p -129.44 166.9 18.67 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 78.3 p -69.15 99.93 1.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.89 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.446 -179.949 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.5 m -81.09 167.12 20.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 72.7 m -87.43 151.24 23.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.844 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -102.87 -82.44 1.64 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 83.8 p 44.0 39.09 2.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 97.0 p -123.41 -45.29 2.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -54.22 121.03 17.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.499 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 31.1 mt -111.8 147.03 36.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 110.881 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.514 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -107.23 137.11 45.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 9.4 p -123.76 131.86 72.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.077 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.0 165.66 27.27 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 72.71 43.67 0.43 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.853 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 30.3 mt -103.75 166.2 10.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.885 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.628 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 5.4 t-80 -86.42 128.47 34.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.628 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 36.9 p90 -37.88 -50.22 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.851 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.433 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 10.1 t-20 -47.53 -43.4 24.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.456 ' CD1' HD22 ' A' ' 295' ' ' LEU . 43.6 mm -38.64 147.9 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -138.88 178.42 7.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -60.65 -35.76 77.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . 0.453 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 1.3 m-20 -61.89 -32.86 73.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.9 mmt -71.98 -41.47 67.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 86.9 mt -69.88 -42.94 72.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.453 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 5.2 ptm180 -64.38 -37.74 88.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.445 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.56 -39.12 79.2 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.468 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.8 mt -75.86 -44.3 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.367 . . . . 0.0 111.11 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.486 ' CD2' HD13 ' A' ' 275' ' ' ILE . 3.1 m-85 -80.86 -2.77 48.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.495 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.5 tp10 -70.61 -59.86 3.52 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.595 0.712 . . . . 0.0 110.871 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.495 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.7 2.42 3.52 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.728 2.286 . . . . 0.0 112.339 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.8 m-85 -102.47 -31.42 10.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.76 149.86 7.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -54.77 113.32 1.28 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.759 0.314 . . . . 0.0 110.875 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 64.2 mt -83.35 122.65 37.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -78.83 -43.4 25.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -167.74 145.13 4.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.863 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 81.1 mt -120.24 135.29 61.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.74 128.87 51.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.0 mt -97.99 139.84 33.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.533 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 28.7 mmt -92.77 133.85 35.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -139.62 140.84 37.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -58.04 -179.4 0.05 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.848 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 20.2 m -111.48 -28.43 8.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.851 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -87.13 -51.12 6.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 82.4 p -90.69 -26.22 19.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.166 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 52.69 26.35 24.51 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.438 ' O ' ' C ' ' A' ' 269' ' ' SER . 3.6 ttp85 -109.82 107.34 17.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.815 0.34 . . . . 0.0 110.898 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.8 OUTLIER -34.94 118.63 0.44 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.774 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -75.82 -25.61 56.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.897 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 120.34 35.69 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.441 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.533 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.7 p90 -147.48 155.91 42.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.908 0.385 . . . . 0.0 110.93 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.54 -178.55 39.76 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.488 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.29 137.98 54.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.899 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.486 HD13 ' CD2' ' A' ' 249' ' ' PHE . 92.6 mt -132.03 140.87 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.077 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.3 m -118.83 129.94 55.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.147 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -98.63 -178.05 3.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.1 t -100.98 -39.47 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.812 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -112.84 135.62 53.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 4.5 m -60.54 -39.38 87.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -62.68 -42.74 99.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 75.4 m -61.96 -36.76 82.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.82 -41.8 86.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -61.84 -48.72 79.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -58.3 -50.91 71.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -56.89 -35.05 68.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.107 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.9 tp -64.65 -43.7 92.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.947 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -68.93 -42.77 76.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 25.7 mm100 -68.4 -41.85 79.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.447 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 67.0 mt -72.93 -46.14 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -46.03 108.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.82 31.57 39.49 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.486 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -94.32 123.01 37.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.842 0.354 . . . . 0.0 110.881 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 71.2 mt-10 -70.83 96.1 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . 0.456 HD22 ' CD1' ' A' ' 240' ' ' ILE . 9.5 tp -78.87 -62.03 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -115.9 41.57 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.056 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.69 -21.44 43.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -124.31 149.58 61.47 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.581 0.705 . . . . 0.0 110.865 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.84 11.49 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -77.52 173.47 11.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.893 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -108.08 119.01 38.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.879 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 18.2 t -124.88 129.37 73.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.85 161.17 30.51 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 10.6 m170 -73.04 134.4 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.87 0.367 . . . . 0.0 110.838 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.85 -66.62 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.168 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 40.2 p -56.35 132.57 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -105.82 78.5 1.34 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 16.5 ttt85 -105.08 147.74 27.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . 0.402 ' C ' HD12 ' A' ' 309' ' ' LEU . 0.3 OUTLIER -124.09 41.33 3.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.891 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.1 154.61 20.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 121.18 160.47 11.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 160.63 -55.77 0.32 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 42.5 m -68.15 -42.83 79.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.888 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 83.02 -158.18 36.2 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 130.03 18.64 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.323 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 p -72.58 176.09 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.825 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 67.5 m -118.51 132.11 56.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.464 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 37.5 m -123.14 154.86 38.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.877 0.37 . . . . 0.0 110.817 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 6.1 t -55.72 -52.23 64.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.828 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 142.42 -131.83 4.86 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 43.9 m -113.83 100.27 8.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.873 0.368 . . . . 0.0 110.849 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 3.3 t -65.43 91.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -131.83 140.42 11.78 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.474 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 31.4 mt -124.65 144.8 49.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.857 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.503 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.6 t80 -109.19 128.76 55.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.4 p -113.92 133.5 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.42 166.02 26.94 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 7.7 t 71.98 44.2 0.48 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.876 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 81.6 mt -106.76 167.39 9.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.909 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.409 ' O ' ' C ' ' A' ' 238' ' ' PHE . 5.7 t-80 -93.15 130.96 38.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.409 ' C ' ' O ' ' A' ' 237' ' ' HIS . 4.2 m-85 -36.79 -54.21 0.91 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -41.76 -43.48 2.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.405 ' CD1' HD22 ' A' ' 295' ' ' LEU . 31.1 mm -41.05 127.73 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 47.8 p -114.71 172.2 7.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 39.3 mp0 -60.27 -33.94 73.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -62.51 -32.46 73.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.848 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 52.0 mtt -72.01 -41.33 67.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.875 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 29.9 mt -66.91 -42.95 84.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.421 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 4.8 ptm180 -67.18 -39.69 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.421 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.12 -34.82 89.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.486 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.409 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 81.7 mt -81.56 -40.48 17.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.883 0.373 . . . . 0.0 111.141 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.538 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -84.72 -0.97 55.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.501 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.6 tp10 -70.77 -59.42 3.68 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.79 2.92 3.11 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.259 . . . . 0.0 112.36 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.409 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.9 m-85 -103.2 -31.08 10.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 178.28 157.31 18.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -63.2 108.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.707 0.289 . . . . 0.0 110.909 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 37.3 mt -77.15 125.01 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -86.39 -43.69 12.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.877 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -163.56 143.65 8.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 71.0 mt -123.13 127.53 74.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 2.7 m -134.04 129.35 54.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.12 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 33.3 mt -92.38 139.07 30.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.652 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 15.7 mmt -95.94 125.77 40.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.75 158.37 39.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.889 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -68.36 -179.26 1.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.857 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.3 m -111.27 -34.23 6.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -90.97 -55.34 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.882 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 72.5 p -74.19 -18.15 60.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 48.54 26.98 5.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -121.04 126.26 49.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.867 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 30.9 t -52.89 147.22 9.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.856 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.561 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 14.4 mmtp -104.34 16.41 26.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.889 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 76.86 40.01 26.99 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.514 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.652 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.9 p90 -150.14 164.04 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.922 0.392 . . . . 0.0 110.922 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -172.57 176.38 45.49 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . 0.414 ' CE1' HG12 ' A' ' 305' ' ' VAL . 42.6 m-85 -117.11 136.1 53.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.886 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.422 HG23 ' N ' ' A' ' 276' ' ' THR . 96.3 mt -132.26 140.59 47.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.422 ' N ' HG23 ' A' ' 275' ' ' ILE . 56.1 m -120.98 127.7 52.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -97.43 -175.14 3.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.3 t -100.28 -40.5 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -115.22 140.05 49.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 13.0 p -62.51 -39.19 92.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -62.05 -42.93 99.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.3 m -60.38 -39.22 86.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.67 -40.69 88.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 32.6 ttp85 -59.07 -49.02 79.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -59.38 -48.94 79.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.6 71.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.0 tp -65.06 -43.58 91.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -68.96 -43.03 75.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 67.6 mm-40 -68.85 -41.21 78.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.538 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 66.2 mt -73.27 -45.02 58.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.901 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -45.15 98.16 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 96.01 24.46 14.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . 0.416 ' N ' ' O ' ' A' ' 290' ' ' LEU . 10.5 t80 -79.58 116.36 19.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.81 0.338 . . . . 0.0 110.901 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -80.25 89.06 5.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . 0.405 HD22 ' CD1' ' A' ' 240' ' ' ILE . 12.1 tp -86.66 -59.75 2.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.02 45.09 0.98 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.112 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 84.42 -27.75 4.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -113.23 143.93 30.21 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.573 0.702 . . . . 0.0 110.837 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 123.14 9.8 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.644 2.229 . . . . 0.0 112.367 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -73.96 169.71 16.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.852 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 40.3 mmt-85 -109.12 122.19 46.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 6.2 t -126.22 120.63 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.126 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -144.71 160.14 27.91 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 8.9 m170 -70.69 121.72 18.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.847 0.356 . . . . 0.0 110.832 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 232' ' ' TYR . 15.6 m -60.99 -44.37 98.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' THR . . . . . 0.454 ' N ' HG22 ' A' ' 305' ' ' VAL . 96.3 m -152.81 113.54 4.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -129.49 153.19 48.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 20.2 ttp180 -156.55 133.42 10.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.843 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . 0.44 HD22 ' N ' ' A' ' 309' ' ' LEU . 0.7 OUTLIER -125.47 131.13 52.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.925 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -124.52 138.89 54.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -134.65 -129.89 2.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.446 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 170.1 -118.05 0.74 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 46.8 t -79.59 135.87 36.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 110.846 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -174.46 85.29 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.486 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -1.42 8.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.704 2.269 . . . . 0.0 112.328 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.4 m 72.33 52.34 0.18 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.83 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 3.2 m -104.3 160.8 14.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.485 -179.985 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 34.8 t -40.91 144.57 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.893 0.378 . . . . 0.0 110.883 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 29.1 t -117.78 88.78 2.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -63.32 128.95 39.79 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.523 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 25.4 m -107.7 98.46 8.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.876 0.37 . . . . 0.0 110.916 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 59.4 p -104.25 83.1 2.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.889 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -128.56 141.58 12.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 68.3 mt -124.41 145.69 49.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.773 0.32 . . . . 0.0 110.923 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.507 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.2 t80 -110.78 131.1 55.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 14.9 p -113.62 134.94 54.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.13 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.81 165.73 27.57 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.5 t 71.32 45.71 0.47 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.925 0.393 . . . . 0.0 110.823 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 86.8 mt -109.76 176.35 5.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -102.89 135.33 44.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 239' ' ' ASN . 0.6 OUTLIER -46.47 -51.37 15.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.902 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.407 ' N ' ' CD1' ' A' ' 238' ' ' PHE . 6.7 t-20 -42.15 -41.25 2.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.834 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.4 HG23 ' N ' ' A' ' 241' ' ' THR . 16.0 mm -47.94 139.91 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' THR . . . . . 0.4 ' N ' HG23 ' A' ' 240' ' ' ILE . 8.9 t -121.61 167.65 12.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.156 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -55.06 -33.71 62.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . 0.456 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 35.5 t0 -59.97 -36.9 78.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 4.8 mmt -71.38 -37.72 71.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 73.2 mt -69.98 -39.97 75.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.456 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 2.9 ptm180 -70.53 -35.3 73.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.449 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.79 -38.83 76.69 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.414 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 80.2 mt -75.72 -41.12 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.853 0.359 . . . . 0.0 111.113 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.533 ' CD2' HD11 ' A' ' 275' ' ' ILE . 4.5 m-85 -83.43 -4.19 58.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.523 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -69.47 -58.33 5.97 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.598 0.713 . . . . 0.0 110.901 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.523 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.76 2.52 3.46 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.736 2.291 . . . . 0.0 112.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.419 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.6 -26.93 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 172.87 162.05 24.32 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.504 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 20.4 ttpt -63.61 110.72 2.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.781 0.324 . . . . 0.0 110.936 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 25.2 mt -80.58 117.18 26.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -77.0 -46.4 23.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.828 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -168.89 142.46 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.903 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 46.0 mt -121.09 135.4 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.124 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.37 127.81 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.143 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 20.6 mt -98.15 136.54 38.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.506 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 20.2 mmt -96.29 134.06 39.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.91 136.04 30.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.43 177.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.1 t -110.35 -61.94 1.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -49.25 -47.22 46.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 30.3 p -94.07 -42.01 9.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.142 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 74.46 15.1 80.51 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 13.1 mtp85 -101.69 106.82 17.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 20.4 p -38.59 106.76 0.06 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.4 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 19.9 mmtm -50.21 -32.76 17.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 118.66 37.76 0.82 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.506 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 2.4 p90 -146.92 155.5 42.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.933 0.397 . . . . 0.0 110.962 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -160.39 170.17 36.34 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.51 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -113.52 138.74 49.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.855 0.359 . . . . 0.0 110.857 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.533 HD11 ' CD2' ' A' ' 249' ' ' PHE . 68.0 mt -136.01 134.16 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.0 m -118.19 129.01 55.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.166 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -99.15 -176.19 3.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.915 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 17.7 t -97.49 -41.85 7.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.414 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 26.1 t0 -115.42 142.59 46.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.858 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 29.2 t -63.99 -38.77 92.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.465 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 10.7 pt-20 -61.52 -41.66 97.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . 0.465 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 84.0 m -61.35 -38.94 88.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.74 90.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 40.0 mtp180 -59.1 -48.89 79.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -58.78 -50.4 74.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.419 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -59.52 -34.99 73.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.083 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.49 HD23 ' CD2' ' A' ' 304' ' ' HIS . 15.3 tp -62.43 -45.26 93.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -68.83 -38.23 79.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -71.77 -36.62 70.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.497 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 62.6 mt -78.8 -39.97 34.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.917 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -55.09 103.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 87.91 30.89 16.35 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -98.49 109.79 22.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 110.842 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -56.7 99.31 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . 0.412 HD13 ' C ' ' A' ' 295' ' ' LEU . 0.9 OUTLIER -78.77 -65.52 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -119.5 39.62 3.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.08 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 112.44 -34.61 5.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.95 151.35 46.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.865 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 120.94 7.66 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.304 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -71.12 171.89 10.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -110.26 122.51 47.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.401 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 15.2 t -128.88 126.12 64.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.26 160.99 28.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.492 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.49 ' CD2' HD23 ' A' ' 287' ' ' LEU . 26.0 m-70 -70.46 128.04 34.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.766 0.317 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 59.5 t -56.18 -58.57 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 6.4 t -68.33 151.68 46.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -99.67 85.14 3.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 16.3 mmm180 -96.13 152.35 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 5.2 mt -147.99 133.49 18.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -152.86 143.02 22.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 166.11 74.46 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 130.31 95.79 0.74 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.502 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 98.9 p -73.12 -43.13 62.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 0.0 110.86 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 157.3 -159.16 29.52 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 126.8 13.73 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.698 2.265 . . . . 0.0 112.346 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 317' ' ' SER . 11.8 t -85.04 -54.4 4.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.844 -179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 316' ' ' SER . 37.4 p 34.55 42.53 0.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.445 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 27.9 t -139.1 135.71 34.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.885 0.374 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 22.0 p -109.38 144.53 37.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 154.72 -76.25 0.22 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 58.9 m -157.55 141.75 16.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.903 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 80.3 p -84.7 86.72 7.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -99.2 142.54 16.09 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.486 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 277' ' ' PHE . 40.5 mt -131.56 144.78 51.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.806 0.336 . . . . 0.0 110.874 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.58 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.5 OUTLIER -110.3 137.17 48.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.956 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.42 133.12 70.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.79 165.65 27.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 m 72.29 45.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.86 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 37.3 mt -104.78 173.45 6.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -96.89 137.92 35.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.835 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -43.23 -49.41 6.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -47.78 -40.2 20.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 43.0 mm -43.71 145.73 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 33.5 p -143.07 173.65 11.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . 0.415 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 28.5 mp0 -54.97 -36.2 65.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -62.29 -35.5 79.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.847 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -72.01 -40.98 68.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 40.5 mt -68.17 -43.04 79.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 5.1 ptm180 -66.12 -37.62 86.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -68.85 -36.0 80.94 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.428 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.2 mt -80.36 -42.76 21.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.81 0.338 . . . . 0.0 111.117 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.552 ' CZ ' HD12 ' A' ' 290' ' ' LEU . 3.1 m-85 -81.45 -4.13 54.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.956 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.493 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tp10 -68.52 -59.93 5.31 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.646 0.736 . . . . 0.0 110.879 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.493 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.82 2.93 3.12 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.347 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.8 m-85 -103.31 -22.03 13.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 163.72 158.54 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -61.32 117.09 5.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.766 0.317 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.407 HD13 ' C ' ' A' ' 249' ' ' PHE . 57.2 mt -88.19 120.63 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -76.55 -49.03 17.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -158.17 155.45 29.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 44.6 mt -136.63 129.91 45.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.3 t -133.84 135.81 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.113 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . 0.415 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 27.8 mt -102.62 139.63 37.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.594 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 24.7 mmt -94.92 128.61 41.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.869 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.74 145.6 49.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -62.46 -178.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.88 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 17.6 t -112.59 -49.9 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.857 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -54.97 -40.31 69.87 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.845 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 267' ' ' GLY . 2.2 p -113.04 -57.95 2.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 266' ' ' THR . . . 94.22 26.87 13.03 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.452 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.436 ' O ' ' C ' ' A' ' 269' ' ' SER . 10.9 ttm180 -102.45 105.26 15.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 268' ' ' ARG . 19.9 m -34.98 110.15 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -61.04 -44.58 97.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.903 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 141.12 37.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.594 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 2.2 p90 -147.79 158.53 44.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.924 0.392 . . . . 0.0 110.905 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.6 172.28 39.48 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.494 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -118.35 136.28 53.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.884 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.484 HD11 ' CD2' ' A' ' 249' ' ' PHE . 78.1 mt -136.46 140.44 43.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 99.4 m -120.67 129.36 53.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.13 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.407 ' CE1' HD11 ' A' ' 231' ' ' LEU . 41.8 m-85 -98.46 -178.82 4.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 24.6 t -101.18 -33.97 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -117.6 136.28 53.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.7 p -64.04 -39.83 94.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.863 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -62.65 -43.83 97.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.889 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 32.7 m -62.89 -41.58 99.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.909 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.14 -41.46 97.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.036 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -59.78 -49.07 79.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -57.57 -48.99 77.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.411 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -54.8 -38.57 67.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.427 HD23 ' CD2' ' A' ' 304' ' ' HIS . 9.0 tp -65.18 -39.84 93.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.908 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -64.46 -34.94 79.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -83.91 -34.75 24.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.552 HD12 ' CZ ' ' A' ' 249' ' ' PHE . 76.3 mt -71.77 -47.07 56.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -55.02 118.31 4.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.24 23.2 63.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.456 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -93.87 111.63 23.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . 0.45 ' HG3' ' N ' ' A' ' 299' ' ' PRO . 2.4 mp0 -76.27 104.45 6.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -94.42 -57.44 2.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.7 41.02 1.45 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 102.66 -42.94 1.78 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 2.8 ptp180 -111.02 153.26 43.93 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.65 0.738 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . 0.45 ' N ' ' HG3' ' A' ' 294' ' ' GLU . 54.0 Cg_endo -69.76 135.42 30.43 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 3.4 ptp -82.85 162.91 21.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -106.28 121.28 43.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.43 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 22.1 t -130.81 125.47 58.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.14 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.26 161.36 26.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.427 ' CD2' HD23 ' A' ' 287' ' ' LEU . 22.1 m-70 -72.47 109.31 6.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.836 0.35 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.6 p -63.97 -41.04 91.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.095 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 28.4 m -66.91 97.16 0.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.143 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . 0.44 ' HG3' ' N ' ' A' ' 308' ' ' ARG . 13.3 tp10 -63.88 156.08 28.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.909 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.44 ' N ' ' HG3' ' A' ' 307' ' ' GLU . 3.0 ptt180 -131.03 156.38 45.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 63.2 mt -117.82 -44.37 2.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -94.95 136.12 35.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -158.47 76.01 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.452 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 313' ' ' SER . . . 88.81 68.09 1.27 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.494 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 312' ' ' GLY . 16.3 t -36.84 123.66 0.85 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.853 0.359 . . . . 0.0 110.886 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 82.39 177.61 51.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.504 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 316' ' ' SER . 54.0 Cg_endo -69.78 2.46 3.52 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 315' ' ' PRO . 21.5 p -34.58 144.27 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 1.7 t -43.05 137.53 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.902 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 -179.949 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.5 t -121.48 162.17 20.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.919 0.39 . . . . 0.0 110.845 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 2.4 m -100.76 91.31 4.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.851 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -104.49 149.24 16.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.526 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 35.1 t -119.42 95.99 5.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.868 0.366 . . . . 0.0 110.809 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 32.1 t -67.59 -47.67 69.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.885 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -38.68 137.85 0.89 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.472 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.547 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.1 mt -125.77 143.62 50.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 110.93 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.17 130.58 56.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.903 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . 0.466 ' CG2' HD11 ' A' ' 236' ' ' LEU . 10.8 p -110.39 135.2 50.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -140.24 166.04 25.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.469 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.9 m 63.96 47.81 3.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.86 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . 0.466 HD11 ' CG2' ' A' ' 233' ' ' VAL . 72.5 mt -100.11 -175.94 3.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.484 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 4.0 t-80 -115.26 124.5 51.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.89 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.484 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 23.2 p90 -34.48 -54.13 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.414 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 2.1 t-20 -41.52 -46.76 3.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 51.7 mm -41.29 139.07 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.114 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 11.5 t -122.91 170.88 9.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.148 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 43.5 mp0 -57.69 -32.78 67.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -64.95 -32.51 74.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.86 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 17.5 mtt -71.98 -43.84 64.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.939 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 36.1 mt -65.51 -43.0 91.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.404 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.3 ptm180 -67.14 -38.36 85.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.404 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.34 -33.22 81.62 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.67 -45.48 23.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.87 0.367 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -80.47 -2.01 44.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.936 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.493 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.9 OUTLIER -69.8 -59.95 4.14 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.719 . . . . 0.0 110.891 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.493 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.27 3.69 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.69 2.26 . . . . 0.0 112.342 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.441 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.9 m-85 -102.47 -34.1 9.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 179.21 157.59 19.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.479 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -60.7 115.33 3.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.0 mt -85.85 121.47 37.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.102 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -80.61 -40.55 25.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 16.5 t30 -168.61 148.03 4.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 52.5 mt -129.78 128.35 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 16.1 m -130.03 136.97 57.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.1 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.88 130.95 48.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.534 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 21.6 mmt -88.62 131.36 35.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.866 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.03 158.51 42.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.882 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -88.37 179.19 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.8 t -107.82 -45.4 4.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.44 -45.37 80.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 78.1 p -91.61 -44.72 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.161 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 73.65 24.78 73.83 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.46 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.434 ' O ' ' C ' ' A' ' 269' ' ' SER . 47.7 mtp180 -128.12 114.1 16.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.823 0.344 . . . . 0.0 110.851 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 268' ' ' ARG . 29.7 t -34.94 106.67 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.85 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 33.7 mttt -51.3 -28.69 12.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.884 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.79 37.01 0.46 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.534 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -147.16 162.93 37.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.911 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.23 173.71 39.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -119.91 134.09 55.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 88.1 mt -135.28 127.91 47.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.5 m -113.27 128.72 56.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.547 ' CE1' HD12 ' A' ' 231' ' ' LEU . 51.3 m-85 -95.65 -175.07 3.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.922 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 7.3 t -102.03 -39.37 7.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -112.61 139.15 48.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.88 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 76.9 p -63.27 -40.22 96.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -63.97 -42.58 97.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 93.3 m -62.04 -42.08 98.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.93 -40.28 97.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.07 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 12.2 ttt85 -61.77 -46.64 88.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.825 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 49.6 mtt180 -58.42 -51.01 71.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.441 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.14 -35.78 69.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.527 HD23 ' CE1' ' A' ' 304' ' ' HIS . 12.6 tp -63.85 -43.87 94.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.921 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -69.02 -35.01 76.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -73.55 -41.99 62.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.55 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 38.2 mt -74.88 -46.97 32.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -43.52 105.76 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.32 33.88 27.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.51 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -102.68 116.29 32.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.336 . . . . 0.0 110.882 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -61.59 114.22 3.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.886 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 13.4 tp -101.13 -55.92 2.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -123.04 42.23 3.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.115 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.79 -21.24 44.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -128.5 149.29 71.3 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.629 0.728 . . . . 0.0 110.837 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 125.5 12.25 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.622 2.214 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.5 ptp -76.09 172.99 11.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -110.58 122.21 47.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 16.2 t -129.27 123.58 58.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.099 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.24 26.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.487 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.527 ' CE1' HD23 ' A' ' 287' ' ' LEU . 10.2 m170 -74.12 100.94 3.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 4.8 p -39.3 125.06 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 3.1 t -80.06 141.02 36.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 10.1 tm-20 -173.87 156.87 2.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 11.9 tpt85 -156.51 159.41 38.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . 0.419 HD11 ' C ' ' A' ' 309' ' ' LEU . 2.8 pp -90.98 -38.86 12.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.898 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -117.53 -69.87 0.83 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.832 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 95.99 117.97 3.34 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.503 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 148.55 -171.05 28.99 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.4 t 53.68 36.24 23.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.937 0.399 . . . . 0.0 110.861 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -97.11 -95.07 1.88 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.495 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 176.09 7.28 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.711 2.274 . . . . 0.0 112.347 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 55.3 p -147.19 174.47 11.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.865 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 8.5 t -123.57 -49.24 1.9 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.496 -179.975 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 8.0 t -46.74 -48.49 20.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.354 . . . . 0.0 110.885 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 93.6 p -76.24 163.36 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 97.4 -142.97 16.45 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.499 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 5.7 m 56.41 43.1 26.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.857 0.361 . . . . 0.0 110.852 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 59.6 p -128.32 -49.92 1.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.872 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -66.21 141.36 41.06 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.421 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.476 HD12 ' CE2' ' A' ' 277' ' ' PHE . 29.7 mt -124.49 145.34 49.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.823 0.344 . . . . 0.0 110.886 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.529 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.8 OUTLIER -111.65 136.83 50.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.956 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . 0.442 ' CG2' HD23 ' A' ' 236' ' ' LEU . 7.3 p -121.96 133.63 67.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.106 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.15 166.03 26.83 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 4.7 t 73.05 43.2 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.903 0.382 . . . . 0.0 110.827 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . 0.442 HD23 ' CG2' ' A' ' 233' ' ' VAL . 49.4 mt -100.03 177.17 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.425 ' O ' ' C ' ' A' ' 238' ' ' PHE . 2.3 t-80 -102.09 133.04 47.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.844 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 269' ' ' SER . 59.3 m-85 -35.78 -52.51 0.71 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.43 ' O ' ' C ' ' A' ' 240' ' ' ILE . 16.5 m120 -45.14 -47.38 12.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.43 ' C ' ' O ' ' A' ' 239' ' ' ASN . 48.8 mm -35.38 150.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.179 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -147.13 179.96 7.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.181 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -60.19 -39.94 88.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -58.44 -36.88 74.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.845 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 18.9 mtt -72.09 -41.54 67.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.21 -41.72 80.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.422 ' CG ' ' N ' ' A' ' 247' ' ' GLY . 13.4 ptt180 -67.92 -42.95 80.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' CG ' ' A' ' 246' ' ' ARG . . . -63.3 -36.72 93.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.505 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.402 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.2 mt -76.23 -39.85 35.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.88 0.371 . . . . 0.0 111.13 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.634 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -88.42 -1.15 57.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.517 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.2 tp10 -70.34 -58.75 4.59 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 0.0 110.831 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.517 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.7 3.46 2.73 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.698 2.265 . . . . 0.0 112.332 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.2 m-85 -104.14 -37.99 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.883 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -174.77 160.14 29.14 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.476 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -65.48 109.08 2.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.735 0.302 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 36.7 mt -77.23 114.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.171 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -73.83 -43.99 57.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -162.54 152.09 15.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.2 mt -133.29 129.64 56.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.073 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 52.8 t -129.37 128.05 65.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.154 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 19.0 mt -97.13 127.72 43.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.943 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.559 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 40.6 mmm -89.71 118.38 29.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.93 143.67 51.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.903 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.11 173.26 3.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.897 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 5.7 t -107.17 -41.08 5.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -71.5 -44.76 64.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 33.2 p -96.65 -34.77 11.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 58.59 25.66 58.71 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.481 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.465 ' O ' ' N ' ' A' ' 270' ' ' LYS . 12.0 mmt180 -109.27 109.71 20.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.578 ' O ' ' CD1' ' A' ' 238' ' ' PHE . 19.4 m -39.21 94.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.465 ' N ' ' O ' ' A' ' 268' ' ' ARG . 18.2 mttp -47.12 -40.67 15.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.866 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 129.66 41.32 0.25 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.559 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -149.39 154.39 38.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.885 0.374 . . . . 0.0 110.95 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.14 168.24 36.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -115.29 138.66 50.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.854 0.359 . . . . 0.0 110.865 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.566 HD13 ' CD2' ' A' ' 249' ' ' PHE . 70.2 mt -136.46 138.42 46.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.113 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 89.2 m -117.77 122.97 44.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.154 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.476 ' CE2' HD12 ' A' ' 231' ' ' LEU . 44.1 m-85 -91.62 -178.04 4.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.915 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 4.3 t -122.41 24.95 9.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.453 ' OD2' ' CG ' ' A' ' 281' ' ' GLU . 26.4 t0 -165.14 126.45 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.884 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 92.8 p -58.24 -40.98 83.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.891 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.453 ' CG ' ' OD2' ' A' ' 279' ' ' ASP . 6.2 pt-20 -63.37 -40.96 98.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.868 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 36.1 m -64.14 -41.56 97.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -61.17 -44.05 97.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 48.9 mtm180 -63.09 -49.02 76.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 19.5 mmt-85 -59.67 -51.04 71.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -54.96 -36.36 65.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.061 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.42 HD21 ' CD2' ' A' ' 304' ' ' HIS . 15.0 tp -65.33 -43.59 90.45 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.923 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.57 -43.1 73.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.908 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 65.1 mm-40 -68.87 -42.14 77.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 84.1 mt -73.76 -47.02 42.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -46.2 103.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.02 36.47 13.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . 0.424 ' O ' ' N ' ' A' ' 295' ' ' LEU . 37.3 t80 -98.22 93.22 6.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -43.35 95.07 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . 0.427 HD22 ' N ' ' A' ' 296' ' ' ALA . 9.3 tt -82.39 -67.38 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . 0.427 ' N ' HD22 ' A' ' 295' ' ' LEU . . . -109.0 39.11 2.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 108.91 -41.42 2.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 22.6 ptt-85 -109.9 152.39 42.96 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.634 0.73 . . . . 0.0 110.834 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 118.38 5.64 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.5 ptt? -68.67 169.76 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.6 mmt180 -104.98 121.43 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 6.9 t -126.95 127.77 70.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.09 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.78 160.34 28.35 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.42 ' CD2' HD21 ' A' ' 287' ' ' LEU . 18.9 m-70 -71.66 125.03 26.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.343 . . . . 0.0 110.889 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.4 t -50.49 118.7 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 11.8 t -121.51 147.53 45.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.163 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -105.19 -43.57 4.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.865 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -151.16 139.04 19.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 6.1 mp -72.65 119.45 16.89 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.934 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.11 139.2 46.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.849 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -56.1 -168.71 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.479 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -150.95 158.04 27.48 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.531 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 65.0 p -43.91 141.41 1.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.959 0.409 . . . . 0.0 110.861 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -120.57 176.45 16.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.503 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -23.09 31.1 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.657 2.238 . . . . 0.0 112.353 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -118.06 142.23 47.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.822 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 4.8 m -67.11 -58.8 4.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 21.8 m 37.35 51.33 1.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 92.7 p -101.53 178.91 4.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.838 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -138.45 81.49 0.27 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.482 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 74.9 m -113.07 121.97 46.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.873 0.368 . . . . 0.0 110.909 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 87.4 p -76.59 -45.45 30.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -39.5 141.85 0.59 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.502 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 24.2 mt -126.22 146.63 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.551 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -109.92 136.74 48.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.1 p -120.37 138.13 51.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.105 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.96 165.25 28.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 t 71.27 46.59 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.945 0.402 . . . . 0.0 110.85 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 95.7 mt -109.7 154.02 23.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.956 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 31.9 t-80 -74.45 139.44 43.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -46.58 -45.22 18.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 240' ' ' ILE . 34.1 t-20 -49.88 -46.53 51.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.428 ' C ' ' O ' ' A' ' 239' ' ' ASN . 47.3 mm -35.55 131.67 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.9 p -120.2 177.23 5.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -62.42 -34.65 77.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.898 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -63.16 -33.86 76.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.873 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 38.1 mtt -71.9 -39.28 69.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . 0.461 ' CD1' HD23 ' A' ' 260' ' ' LEU . 34.0 mt -70.0 -42.91 72.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.449 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 17.8 ptt180 -66.77 -40.46 88.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.468 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.75 -36.39 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 90.4 mt -76.38 -42.6 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.832 0.349 . . . . 0.0 111.15 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.562 ' CE2' HD12 ' A' ' 290' ' ' LEU . 3.0 m-85 -85.47 -2.83 58.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.522 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -69.79 -58.35 5.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.855 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.522 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 0.84 5.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.659 2.24 . . . . 0.0 112.347 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.453 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.9 m-85 -101.55 -37.05 8.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -173.56 155.66 22.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -57.89 108.11 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.759 0.314 . . . . 0.0 110.891 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 43.4 mt -78.11 112.49 16.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -76.76 -41.71 43.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -165.23 149.99 9.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.891 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . 0.403 ' CD1' ' CB ' ' A' ' 246' ' ' ARG . 48.8 mt -132.41 126.19 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 2.5 m -133.12 129.93 57.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.138 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . 0.461 HD23 ' CD1' ' A' ' 245' ' ' LEU . 36.4 mt -91.2 137.7 32.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.496 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.2 mmt -93.82 112.23 24.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.847 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . 0.465 ' N ' ' HD3' ' A' ' 262' ' ' LYS . 0.0 OUTLIER -125.18 146.75 49.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.877 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -67.83 178.61 1.68 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.856 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 t -106.04 -48.26 3.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.83 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -62.34 -61.23 2.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 11.7 p -82.77 -31.3 28.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.134 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 60.01 14.36 31.15 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.474 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 -97.56 119.3 35.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 16.1 m -49.21 123.09 6.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 -179.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -74.36 -31.63 62.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 125.63 33.75 0.69 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.496 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.8 p90 -145.75 156.09 43.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.93 0.395 . . . . 0.0 110.944 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -158.06 176.17 35.13 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -121.29 134.02 55.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 0.0 110.836 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.45 HG23 ' N ' ' A' ' 276' ' ' THR . 97.3 mt -131.23 145.52 35.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.45 ' N ' HG23 ' A' ' 275' ' ' ILE . 56.2 m -120.98 129.66 53.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.124 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -104.24 175.9 5.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.899 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 3.1 t -120.19 24.87 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.898 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -165.13 127.61 2.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.862 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.5 p -64.05 -40.96 97.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.811 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.47 -43.02 82.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 43.6 m -63.22 -42.73 99.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -63.97 -42.44 97.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.049 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 21.4 mtm180 -60.14 -48.98 79.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.879 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.8 mmt85 -58.06 -47.73 82.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.841 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.453 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -58.03 -40.41 80.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.083 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 9.3 tp -61.66 -40.7 95.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -67.71 -35.0 77.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.938 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -84.11 -22.22 31.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.562 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.9 mt -86.54 -38.51 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . 0.409 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -60.02 119.98 8.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.891 179.893 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.53 20.82 78.2 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.507 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -84.78 105.13 15.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.807 0.337 . . . . 0.0 110.882 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -67.2 96.29 0.46 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.4 tt -91.12 -64.2 1.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.928 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -98.71 36.59 1.63 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.13 -35.22 4.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 40.6 mtp180 -113.68 154.11 45.77 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.626 0.727 . . . . 0.0 110.891 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 132.26 22.98 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.656 2.237 . . . . 0.0 112.345 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.9 ptp -83.44 165.89 18.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.875 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.8 122.74 47.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.404 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 47.7 t -131.41 135.44 59.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -153.06 163.58 30.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.534 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -71.97 112.34 7.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 64.5 t -46.26 97.46 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 14.9 m -95.99 141.59 29.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.162 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -118.84 -48.5 2.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 76.9 mtt180 -150.09 138.51 20.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . 0.523 ' N ' ' CD2' ' A' ' 309' ' ' LEU . 0.3 OUTLIER -82.0 155.34 25.23 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -119.76 91.61 3.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -45.91 97.66 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -89.8 81.91 1.42 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.474 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 8.5 t -141.52 108.82 5.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.88 0.371 . . . . 0.0 110.858 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -159.21 64.79 0.29 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -176.83 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.362 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 54.2 p -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' SER . . . . . 0.422 ' O ' ' C ' ' A' ' 318' ' ' GLY . 84.0 p -85.55 88.36 7.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 317' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.523 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 87.4 p -144.0 175.22 10.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.872 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 73.2 m -146.45 132.04 18.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -47.58 109.56 0.46 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 52.5 p -68.17 143.26 55.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.87 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 10.0 t -82.41 161.87 22.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.869 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 159.4 109.76 0.27 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.481 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.507 HD12 ' CE1' ' A' ' 277' ' ' PHE . 38.3 mt -104.06 144.75 31.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.478 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.3 t80 -111.21 131.46 55.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.7 p -116.0 134.23 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.125 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.42 165.85 27.8 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 6.2 t 73.85 47.09 0.17 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 15.0 mt -109.53 166.08 11.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.907 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -94.31 140.59 29.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -45.44 -37.07 4.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -57.88 -37.86 74.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.935 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 36.7 mm -47.59 139.04 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.159 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.4 t -125.29 174.34 8.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.099 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -62.3 -36.55 82.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -58.37 -34.64 70.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.902 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 63.3 mtt -70.49 -37.07 74.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 81.9 mt -69.82 -42.34 73.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.479 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 20.5 ptt85 -69.65 -40.21 76.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -66.41 -35.16 89.75 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.5 mt -81.04 -44.22 20.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.844 0.354 . . . . 0.0 111.148 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.571 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -81.83 -2.43 50.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.498 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.0 tp10 -70.65 -59.66 3.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.677 0.751 . . . . 0.0 110.931 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.498 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.6 3.37 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.333 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.449 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.46 -44.17 5.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.903 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -171.21 139.03 5.22 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -44.61 119.0 1.74 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.744 0.307 . . . . 0.0 110.919 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.401 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 28.3 mt -88.85 133.31 31.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.149 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.27 -43.43 8.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -163.47 147.02 10.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.91 132.37 67.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.148 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 74.4 t -134.93 129.24 50.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.137 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 23.5 mt -94.01 129.55 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.616 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.3 mmt -91.88 135.26 34.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.95 149.96 51.28 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -50.63 -177.43 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 34.6 p -105.32 -58.15 1.93 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.818 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -62.71 -58.59 6.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 25.4 p -72.57 -41.36 65.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 73.63 18.45 79.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.498 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 4.3 ptt180 -98.01 162.35 13.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.86 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 15.5 m -78.21 100.83 6.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.821 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -58.99 -35.43 73.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.917 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.93 40.1 0.33 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.491 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.616 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 0.9 OUTLIER -150.5 157.42 43.0 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.919 0.39 . . . . 0.0 110.935 -179.832 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.56 169.37 38.56 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -113.58 137.97 50.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.363 . . . . 0.0 110.874 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.555 HD12 ' CD2' ' A' ' 249' ' ' PHE . 77.3 mt -136.43 132.61 49.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.9 m -113.51 129.23 56.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.507 ' CE1' HD12 ' A' ' 231' ' ' LEU . 42.6 m-85 -98.96 171.27 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 48.1 t -86.88 -40.08 15.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -116.2 141.13 48.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 40.6 p -63.99 -41.01 97.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.411 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 13.3 pt-20 -60.97 -43.97 98.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . 0.411 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 73.9 m -60.01 -40.96 91.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.55 -37.84 88.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . 0.409 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 12.4 ttm105 -62.01 -48.73 79.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.6 mmt180 -58.02 -49.8 75.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.449 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.99 -35.54 71.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.091 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.417 HD23 ' CD2' ' A' ' 304' ' ' HIS . 8.4 tp -65.09 -40.83 95.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -68.34 -42.96 78.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -71.91 -38.2 69.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.571 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 82.4 mt -73.15 -47.03 47.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -44.47 107.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 77.82 39.3 24.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.462 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' LEU . 14.7 t80 -101.32 97.78 8.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.816 0.341 . . . . 0.0 110.871 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -43.96 93.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 293' ' ' PHE . 61.8 tp -81.03 -56.95 3.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -129.12 73.13 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.07 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 82.45 -35.53 2.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -125.77 154.85 73.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.579 0.705 . . . . 0.0 110.898 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 136.67 33.68 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.719 2.28 . . . . 0.0 112.336 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.3 ptt? -86.68 166.66 15.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 4.2 mmm180 -101.75 128.59 48.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 9.8 t -131.88 128.92 60.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -157.7 158.8 29.36 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.417 ' CD2' HD23 ' A' ' 287' ' ' LEU . 4.5 m170 -77.73 124.51 28.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 15.3 m -53.29 -47.76 56.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.141 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' THR . . . . . 0.404 HG21 ' N ' ' A' ' 307' ' ' GLU . 23.8 m -113.72 141.12 47.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . 0.404 ' N ' HG21 ' A' ' 306' ' ' THR . 2.7 pp20? -159.45 149.23 18.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 13.5 mtp85 -91.42 -57.46 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.866 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -138.66 127.07 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.951 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -50.15 121.05 5.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.864 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 134.35 -77.47 0.37 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.485 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 68.47 143.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.484 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 80.8 p -123.85 169.64 11.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.946 0.403 . . . . 0.0 110.82 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -78.89 141.19 24.08 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 2.47 3.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.654 2.236 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.8 m 63.89 34.76 11.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 3.0 t -53.97 -53.43 52.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.48 -179.986 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 8.5 t 49.6 42.95 23.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.86 -179.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 4.2 m -77.49 140.67 39.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -171.31 173.01 44.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.464 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 34.6 m -74.56 150.51 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 96.7 p -106.96 94.25 5.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.871 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -133.87 133.6 7.0 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.475 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.45 HD21 ' CD2' ' A' ' 304' ' ' HIS . 35.0 mt -115.1 145.62 42.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.848 0.356 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.463 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.5 t80 -111.53 133.69 53.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.921 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . 0.441 HG22 ' CD1' ' A' ' 236' ' ' LEU . 13.1 p -118.64 135.35 59.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.141 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.61 163.56 27.89 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 m 74.39 46.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.905 0.384 . . . . 0.0 110.81 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . 0.441 ' CD1' HG22 ' A' ' 233' ' ' VAL . 14.4 mt -108.98 170.19 8.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.408 ' O ' ' C ' ' A' ' 238' ' ' PHE . 13.7 t-80 -98.89 137.95 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.41 ' O ' ' C ' ' A' ' 239' ' ' ASN . 5.2 m-85 -37.82 -57.02 1.04 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.41 ' C ' ' O ' ' A' ' 238' ' ' PHE . 45.9 t30 -37.58 -42.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.901 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.7 mm -47.21 130.1 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 79.4 p -123.04 -175.63 3.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -62.38 -41.77 98.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -59.45 -29.75 68.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 20.0 mmt -71.87 -44.52 63.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 34.7 mt -68.25 -43.04 78.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.503 ' O ' ' N ' ' A' ' 250' ' ' GLU . 5.6 ptp180 -66.35 -44.55 82.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.499 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -61.08 -39.49 97.18 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.9 mt -76.17 -41.37 37.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.868 0.366 . . . . 0.0 111.147 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.0 m-85 -86.42 -5.55 59.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -67.36 -58.05 9.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.683 0.754 . . . . 0.0 110.894 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.72 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.471 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.7 m-85 -104.77 -25.32 12.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.88 159.04 15.91 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.53 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -62.22 117.82 6.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.724 0.297 . . . . 0.0 110.91 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.442 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 70.3 mt -90.99 114.06 27.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -69.77 -42.99 73.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -167.96 153.55 7.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 87.6 mt -132.94 128.43 56.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 75.8 t -127.42 129.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.093 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 35.9 mt -96.6 135.82 37.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.537 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 35.2 mmm -96.09 133.0 40.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.893 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.83 152.21 51.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -66.35 170.49 5.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.857 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 60.7 p -103.78 -41.01 6.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.819 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -61.2 -41.97 97.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 267' ' ' GLY . 2.2 p -111.94 -58.61 2.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.143 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 266' ' ' THR . . . 99.03 18.46 24.57 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.547 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 89.2 mmt-85 -95.64 113.4 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.804 0.335 . . . . 0.0 110.83 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 1.8 m -41.34 107.87 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 33.4 mmtt -60.05 -39.31 85.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.943 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 133.12 38.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.482 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.537 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.4 p90 -149.38 160.32 43.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.914 -179.76 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.52 171.65 42.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.508 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -113.31 139.28 48.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.802 0.334 . . . . 0.0 110.887 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.488 HD12 ' CD2' ' A' ' 249' ' ' PHE . 54.1 mt -135.95 139.38 46.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.167 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 85.8 m -119.09 122.26 41.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.405 ' CE1' HD12 ' A' ' 231' ' ' LEU . 36.3 m-85 -91.08 -177.14 4.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.5 t -104.56 -22.14 13.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -133.62 134.94 43.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.8 p -61.7 -36.99 82.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -63.57 -44.0 95.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.875 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.4 m -61.94 -40.04 94.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.16 -41.7 97.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.079 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 11.8 mmt85 -60.0 -49.06 79.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -58.31 -50.6 73.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.885 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -56.55 -39.45 73.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.063 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.516 HD23 ' CD2' ' A' ' 304' ' ' HIS . 13.2 tp -62.08 -40.09 94.65 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -67.32 -34.96 78.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -84.6 -25.86 28.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.92 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.617 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 66.9 mt -81.87 -41.48 20.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . 0.435 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.6 OUTLIER -59.55 117.62 5.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.03 27.32 58.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -95.61 103.35 15.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.854 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -56.97 97.92 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.925 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -87.57 -54.31 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.04 55.01 1.01 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.85 -37.23 3.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -117.03 156.46 48.29 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.622 0.725 . . . . 0.0 110.864 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.56 40.44 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -91.25 162.8 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -99.71 122.06 42.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 5.1 t -129.26 128.77 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -151.19 162.09 29.35 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.484 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.516 ' CD2' HD23 ' A' ' 287' ' ' LEU . 7.0 m170 -75.51 123.32 25.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.826 0.346 . . . . 0.0 110.887 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 87.1 t -52.32 94.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 81.3 p -72.67 135.71 45.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.159 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -109.33 118.31 36.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.414 ' C ' HD22 ' A' ' 309' ' ' LEU . 10.6 ttm-85 -110.61 110.29 20.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.849 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . 0.469 HD22 ' N ' ' A' ' 309' ' ' LEU . 1.0 OUTLIER -157.97 173.47 16.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 -179.937 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.68 119.64 32.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 139.43 115.1 1.24 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.448 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -82.58 106.09 2.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.458 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 78.5 p -65.89 -48.78 70.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.851 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -79.95 146.32 28.03 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.516 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 94.45 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.7 2.267 . . . . 0.0 112.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 317' ' ' SER . 40.6 m -165.79 170.73 13.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.893 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 316' ' ' SER . 93.0 p -37.43 139.49 0.26 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.489 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 48.9 m -119.27 124.43 46.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.879 0.371 . . . . 0.0 110.825 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 53.1 p -59.87 175.48 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.854 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 175.29 85.17 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.479 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 2.1 m -84.84 115.61 22.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.886 0.374 . . . . 0.0 110.835 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 39.2 p 44.36 40.62 3.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -68.97 154.34 53.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.498 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.569 HD12 ' CE1' ' A' ' 277' ' ' PHE . 33.4 mt -133.83 144.07 48.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.508 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -113.08 139.1 48.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 -179.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . 0.459 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.9 p -127.42 134.69 65.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.106 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.39 166.02 27.33 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.501 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 73.71 46.15 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.896 0.379 . . . . 0.0 110.842 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . 0.459 HD11 ' CG2' ' A' ' 233' ' ' VAL . 65.2 mt -108.5 174.55 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.426 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 4.5 t-80 -94.66 126.42 39.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.825 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.426 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 5.8 p90 -39.35 -50.28 2.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.864 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -43.53 -49.42 7.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 45.1 mm -38.73 139.59 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.119 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 30.8 p -120.09 175.15 6.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.156 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.12 -31.01 70.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . 0.443 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 2.2 m-20 -63.37 -35.84 81.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 8.2 mmt -72.08 -39.28 69.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 54.6 mt -68.23 -39.87 82.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.92 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.47 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 3.8 ptm180 -70.48 -37.31 74.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.47 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.45 -35.35 81.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.492 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.428 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 93.7 mt -77.5 -42.41 29.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.899 0.381 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.565 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.86 -4.12 58.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.524 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.8 OUTLIER -69.7 -58.29 5.76 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.637 0.732 . . . . 0.0 110.897 -179.901 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.3 Cg_endo -69.8 2.78 3.24 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.671 2.247 . . . . 0.0 112.34 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.43 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.96 -35.55 8.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -177.57 159.84 26.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 16.6 ttmt -60.24 120.15 9.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 64.5 mt -90.74 113.78 27.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.117 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' A' ' 256' ' ' ASP . 31.1 t0 -77.2 -40.61 44.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.826 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -168.33 147.76 4.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.89 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 53.3 mt -129.36 132.83 66.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.5 m -134.07 138.43 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.164 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 20.2 mt -104.16 132.6 50.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.492 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 26.3 mmt -90.8 121.08 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.27 142.44 51.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -68.2 179.03 1.68 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.842 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 30.4 t -112.82 -53.33 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.832 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -61.94 -41.6 98.16 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.915 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 76.3 p -94.34 -42.07 9.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 67.47 24.15 73.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.445 ' O ' ' C ' ' A' ' 269' ' ' SER . 57.7 mtp180 -115.17 103.49 10.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.861 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.7 OUTLIER -34.62 108.93 0.07 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.773 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 22.6 mmtp -53.52 -42.39 67.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.901 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 130.99 35.93 0.37 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.481 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.492 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 2.6 p90 -145.06 161.8 38.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.936 0.398 . . . . 0.0 110.907 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.72 171.55 37.7 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.477 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . 0.414 ' CE1' HG22 ' A' ' 305' ' ' VAL . 16.2 m-85 -118.86 136.76 53.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.859 0.362 . . . . 0.0 110.873 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.558 HD13 ' CD2' ' A' ' 249' ' ' PHE . 89.3 mt -135.73 138.7 47.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.134 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 61.0 m -113.03 128.77 56.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.569 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.1 m-85 -101.98 170.45 8.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 14.6 t -115.79 33.15 5.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -172.58 124.97 0.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 23.0 t -62.74 -40.52 97.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -66.8 -43.71 83.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.86 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 51.9 m -64.36 -42.58 96.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.913 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.74 -44.03 97.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -59.31 -48.56 81.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.87 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -57.96 -51.17 70.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.43 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -54.96 -39.62 69.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.098 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.551 HD21 ' CE1' ' A' ' 304' ' ' HIS . 11.7 tp -63.33 -39.99 96.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -68.49 -34.95 76.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 49.4 mm-40 -83.97 -26.77 28.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.565 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 62.2 mt -81.4 -47.02 13.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . 0.456 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.7 OUTLIER -53.07 114.71 1.54 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.18 34.99 35.39 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.488 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -105.04 122.53 46.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -77.17 112.02 13.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 40.7 tp -93.99 -60.47 1.74 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.964 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -102.93 -21.81 13.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.088 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 169.95 -33.94 0.17 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.79 152.5 45.63 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.67 0.747 . . . . 0.0 110.859 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 120.43 7.21 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.668 2.246 . . . . 0.0 112.344 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -72.41 168.54 18.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 41.7 mmt-85 -111.91 125.0 53.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.45 ' CG1' HD12 ' A' ' 287' ' ' LEU . 57.8 t -131.37 129.62 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.63 163.01 26.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.551 ' CE1' HD21 ' A' ' 287' ' ' LEU . 20.3 m170 -75.21 98.38 3.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 0.0 110.857 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.414 HG22 ' CE1' ' A' ' 274' ' ' PHE . 5.8 p -40.18 -28.87 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.147 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 49.8 p -77.24 120.36 22.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -104.29 140.57 37.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 56.5 mtt180 -113.79 132.23 55.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 7.0 mp -123.51 121.55 35.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.913 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.66 141.25 37.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -132.92 104.79 0.56 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 176.69 120.65 0.63 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.491 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.0 t -83.12 160.96 21.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.911 0.386 . . . . 0.0 110.859 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -143.59 78.46 0.26 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.494 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.71 127.5 14.73 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.8 t -98.31 136.8 37.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 23.5 m -88.51 156.73 18.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.834 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.462 -179.984 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 N-CA-C 112.45 -0.26 . . . . 0.0 112.45 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 3.2 m -41.71 108.6 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.927 0.394 . . . . 0.0 110.857 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 36.6 t -115.05 127.96 55.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 61.6 -106.73 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 73.0 m -142.52 -179.77 6.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.898 0.38 . . . . 0.0 110.841 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 95.8 p -107.16 85.49 2.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.817 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -104.9 143.24 15.62 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.466 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.408 HD13 ' CE2' ' A' ' 277' ' ' PHE . 20.6 mt -128.29 146.97 50.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.92 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.463 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.7 t80 -114.39 136.53 52.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.4 p -121.12 134.53 64.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.099 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.47 165.05 27.97 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 3.8 t 74.58 46.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.933 0.397 . . . . 0.0 110.875 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 85.8 mt -111.49 170.69 7.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.934 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 18.4 t-80 -88.82 147.28 24.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.412 ' O ' ' C ' ' A' ' 239' ' ' ASN . 2.9 m-85 -52.91 -59.76 4.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.412 ' C ' ' O ' ' A' ' 238' ' ' PHE . 1.0 OUTLIER -36.17 -47.32 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 23.5 mm -38.42 136.7 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 7.8 t -123.03 179.55 4.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.158 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 45.7 mp0 -63.05 -35.23 79.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -58.78 -38.51 78.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -64.68 -45.98 84.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 56.0 mt -59.98 -39.24 85.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.501 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -40.8 68.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.472 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.91 -29.6 74.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.0 mt -87.51 -43.53 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 111.096 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.522 ' CE2' HD13 ' A' ' 275' ' ' ILE . 2.7 m-85 -85.17 -0.11 53.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 246' ' ' ARG . 4.0 tt0 -68.99 -59.88 4.87 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.652 0.739 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.4 Cg_endo -69.7 -9.45 26.15 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.256 . . . . 0.0 112.388 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.7 m-85 -88.78 -24.8 22.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.01 164.43 25.72 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.514 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -68.3 108.84 3.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.857 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.416 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 19.4 mt -77.23 113.63 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.094 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -72.19 -45.2 61.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.921 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -163.32 157.68 20.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 71.6 mt -138.6 131.85 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . 0.42 ' CG2' ' HB2' ' A' ' 274' ' ' PHE . 3.8 m -134.79 126.6 47.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 20.7 mt -93.58 129.33 39.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.559 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 17.8 mmm -89.85 128.49 36.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.85 165.42 18.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -85.57 170.21 12.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 27.4 p -106.54 -42.63 4.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.872 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.9 -46.62 71.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 36.3 p -93.95 -41.73 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.164 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 74.58 24.83 71.61 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.513 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 61.0 mtp180 -119.95 114.23 21.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.787 0.327 . . . . 0.0 110.927 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 24.9 m -38.94 112.06 0.22 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.86 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -58.91 -50.3 74.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 145.72 40.32 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.506 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.559 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.3 p90 -150.36 162.21 40.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.951 0.405 . . . . 0.0 110.944 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.59 177.32 37.92 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.5 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . 0.42 ' HB2' ' CG2' ' A' ' 259' ' ' VAL . 29.1 m-85 -120.1 133.99 55.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.774 0.321 . . . . 0.0 110.925 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.522 HD13 ' CE2' ' A' ' 249' ' ' PHE . 67.9 mt -133.08 135.93 56.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 64.5 m -117.51 129.3 55.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.408 ' CE2' HD13 ' A' ' 231' ' ' LEU . 41.6 m-85 -100.68 178.74 4.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.6 t -114.98 12.84 16.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.858 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -155.66 128.5 8.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.4 t -64.0 -40.98 97.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 35.6 mm-40 -62.26 -43.93 97.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.897 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 98.7 m -64.51 -36.19 83.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.832 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.53 -43.7 89.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.087 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -61.11 -49.09 78.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 71.5 mtt180 -59.49 -44.32 93.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -62.61 -35.06 78.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.126 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.409 HD22 ' NE2' ' A' ' 304' ' ' HIS . 17.6 tp -64.74 -44.66 89.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -69.18 -35.02 75.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -73.59 -42.0 62.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.926 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.52 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 42.0 mt -75.25 -47.04 29.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.876 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -42.14 106.25 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.65 34.59 31.05 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -96.07 102.02 13.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.344 . . . . 0.0 110.891 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -56.22 90.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.909 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 25.6 tp -80.18 -58.53 3.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.76 40.34 2.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.53 -26.98 21.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 3.5 ptp85 -120.08 147.34 44.4 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 122.33 9.01 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.328 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -75.36 177.31 6.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 11.5 mmm-85 -110.85 122.68 48.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 15.0 t -128.99 123.51 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.113 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -156.47 161.25 30.78 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.409 ' NE2' HD22 ' A' ' 287' ' ' LEU . 90.4 m-70 -72.68 128.27 35.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.855 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.434 ' CG1' ' HB2' ' A' ' 232' ' ' TYR . 21.5 m -59.5 -43.33 90.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 10.5 t -78.52 131.18 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.123 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -52.29 125.66 16.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.411 ' HD2' ' C ' ' A' ' 308' ' ' ARG . 3.4 ppt_? -91.33 1.07 57.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 29.7 tp -57.76 -58.81 6.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -94.11 137.73 32.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.892 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 115.93 88.87 1.5 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 116.66 163.28 13.2 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 88.7 p -147.5 157.21 43.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.93 0.395 . . . . 0.0 110.864 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -116.45 179.53 17.73 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.468 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 172.94 11.68 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.652 2.235 . . . . 0.0 112.38 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 6.6 t -119.23 135.79 54.52 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.837 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 87.9 p -131.23 152.74 50.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.986 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 49.3 m -116.88 102.88 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 110.851 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 32.2 m -127.51 163.65 23.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.868 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -47.58 114.32 1.68 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.501 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 21.3 t -86.09 60.62 6.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 110.889 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 4.8 t -72.41 121.48 19.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -168.41 131.19 2.25 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.456 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.558 HD13 ' CE1' ' A' ' 277' ' ' PHE . 34.3 mt -118.6 146.83 44.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.806 0.336 . . . . 0.0 110.929 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.581 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.4 OUTLIER -118.6 141.3 48.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.915 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . 0.455 ' CG2' HD13 ' A' ' 236' ' ' LEU . 12.0 p -123.08 131.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.14 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -136.91 165.9 25.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 58.5 m 62.54 49.87 3.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.884 0.373 . . . . 0.0 110.822 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . 0.455 HD13 ' CG2' ' A' ' 233' ' ' VAL . 61.8 mt -103.67 -175.13 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 16.8 t-80 -110.39 142.31 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.47 ' CD1' ' HD2' ' A' ' 268' ' ' ARG . 3.2 t80 -49.47 -44.31 45.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -52.44 -33.74 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 10.5 mm -57.21 125.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.144 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.1 p -117.28 178.64 4.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.162 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -60.83 -36.67 79.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . 0.431 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 6.9 t0 -60.88 -34.37 74.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.807 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 21.6 mtt -72.05 -42.71 65.97 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 63.1 mt -66.8 -42.97 85.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.939 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 4.0 ptm180 -66.38 -38.74 88.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.866 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.43 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.45 -36.82 92.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 86.8 mt -78.56 -43.91 26.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.912 0.387 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.549 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.4 m-85 -81.75 -4.72 57.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.924 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.488 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.5 OUTLIER -66.55 -60.13 7.06 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.677 0.751 . . . . 0.0 110.897 -179.908 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.34 3.61 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.706 2.271 . . . . 0.0 112.321 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.46 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.3 m-85 -103.39 -23.33 13.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.881 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 168.35 158.98 13.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.466 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.47 117.58 7.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.768 0.318 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.412 ' CG2' HG13 ' A' ' 258' ' ' ILE . 45.4 mt -86.33 120.89 36.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.103 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -79.51 -41.23 27.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.851 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 38.4 t30 -167.7 145.78 4.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . 0.412 HG13 ' CG2' ' A' ' 255' ' ' ILE . 93.9 mt -128.44 127.88 67.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.105 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . 0.462 ' CG2' ' HB2' ' A' ' 274' ' ' PHE . 18.3 m -129.51 139.15 52.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.096 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 28.9 mt -111.41 139.49 46.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.556 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 29.8 mmt -97.78 120.34 37.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.53 131.06 39.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -51.5 -175.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.881 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 31.0 t -114.81 -66.12 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 -179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -49.55 -40.84 39.63 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 18.1 p -91.62 -44.81 8.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 77.47 8.44 87.1 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.47 ' HD2' ' CD1' ' A' ' 238' ' ' PHE . 3.0 tpt180 -103.61 112.75 25.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.344 . . . . 0.0 110.877 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.403 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.7 OUTLIER -37.37 132.31 0.8 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 -179.856 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.09 -36.07 82.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.858 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.92 29.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.506 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.556 ' CE1' ' HB2' ' A' ' 261' ' ' MET . 2.1 p90 -151.01 165.18 34.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.926 0.393 . . . . 0.0 110.94 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -157.89 168.01 34.37 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.492 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . 0.462 ' HB2' ' CG2' ' A' ' 259' ' ' VAL . 29.0 m-85 -114.44 137.79 51.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.864 0.364 . . . . 0.0 110.872 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.43 HD13 ' CE2' ' A' ' 249' ' ' PHE . 85.1 mt -137.24 134.45 47.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.114 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.6 m -117.76 129.18 55.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.191 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.558 ' CE1' HD13 ' A' ' 231' ' ' LEU . 45.4 m-85 -99.28 177.97 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 62.6 p -98.8 -36.28 9.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.819 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -115.97 129.19 56.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 32.8 p -57.48 -37.98 73.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.414 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 11.1 pt-20 -62.32 -43.35 99.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . 0.414 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 68.1 m -62.25 -37.49 85.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -40.17 90.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 47.6 ttt85 -62.08 -48.94 77.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.862 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.8 mmt180 -58.66 -51.02 71.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.57 -35.07 69.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.459 ' HB2' ' CD2' ' A' ' 231' ' ' LEU . 10.7 tp -65.06 -41.96 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -68.99 -42.91 75.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.943 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.0 mm100 -71.98 -36.03 69.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.549 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 54.9 mt -75.3 -46.95 30.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -42.0 112.41 0.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.905 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 73.96 40.16 44.45 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 23.9 t80 -100.93 98.05 8.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.824 0.345 . . . . 0.0 110.861 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.19 105.83 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 5.7 tt -94.82 -53.68 3.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.926 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.14 40.64 2.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.2 -35.21 4.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.491 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 -110.23 149.1 39.66 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.576 0.703 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 119.16 6.15 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.724 2.283 . . . . 0.0 112.325 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptm -71.07 171.55 10.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -106.92 125.17 50.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.913 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.409 ' CG1' HD11 ' A' ' 287' ' ' LEU . 7.0 t -128.5 121.5 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.097 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.69 163.49 28.54 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.503 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.438 ' CE1' HD21 ' A' ' 287' ' ' LEU . 18.5 m170 -79.24 130.37 35.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.885 0.374 . . . . 0.0 110.82 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 83.9 t -53.4 -63.4 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.134 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 12.4 t -46.0 151.68 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -122.71 112.93 18.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.858 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.421 ' C ' ' HD3' ' A' ' 308' ' ' ARG . 0.4 OUTLIER -95.23 173.07 7.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.893 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 1.7 tt -128.43 121.67 29.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.889 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -54.22 179.78 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 148.0 150.56 5.23 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -162.13 41.96 0.37 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.504 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 14.7 m -79.76 158.34 26.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.957 0.408 . . . . 0.0 110.819 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -147.27 -100.88 0.26 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 108.56 2.1 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.697 2.265 . . . . 0.0 112.313 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 5.2 m -73.2 -50.56 21.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 2.1 m -75.63 91.59 2.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.812 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.488 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 51.8 p -103.12 155.83 18.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.872 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 59.7 p -90.52 -45.89 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.853 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -66.96 133.41 31.55 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.471 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 19.8 m -126.34 120.57 30.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.932 0.396 . . . . 0.0 110.795 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 23.1 t -132.1 -178.77 5.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 140.08 131.25 2.75 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.514 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 37.0 mt -129.96 147.04 51.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.349 . . . . 0.0 110.873 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.492 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.4 t80 -110.13 131.81 54.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.74 136.46 55.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.18 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.56 165.47 27.53 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.448 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.5 t 74.28 46.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.9 0.381 . . . . 0.0 110.85 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.37 170.7 7.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 238' ' ' PHE . 31.4 t-80 -98.65 132.16 44.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.437 ' C ' ' O ' ' A' ' 237' ' ' HIS . 0.9 OUTLIER -34.46 -61.07 0.4 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.878 -179.91 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.533 ' ND2' ' N ' ' A' ' 240' ' ' ILE . 0.3 OUTLIER -36.95 -47.27 0.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.941 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.533 ' N ' ' ND2' ' A' ' 239' ' ' ASN . 40.3 mm -36.74 128.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.181 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.0 p -118.44 175.57 5.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -60.61 -31.07 70.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.844 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -64.89 -32.45 74.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 13.5 mmt -71.74 -40.88 69.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 45.1 mt -69.35 -43.0 74.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.436 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 6.2 ptm180 -66.02 -40.11 90.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -66.48 -38.25 93.32 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.507 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.0 mt -77.27 -41.84 30.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.902 0.382 . . . . 0.0 111.131 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -83.74 -3.88 58.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.847 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.524 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.94 -58.34 5.42 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.654 0.74 . . . . 0.0 110.853 -179.932 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.74 2.74 3.25 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.734 2.289 . . . . 0.0 112.347 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.441 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.62 -33.11 9.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 175.67 138.66 2.88 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.449 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -45.64 116.64 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.769 0.319 . . . . 0.0 110.924 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.421 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 55.5 mt -85.3 134.7 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.12 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -91.38 -46.47 8.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.874 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 33.8 t30 -160.92 145.82 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.1 mt -124.14 133.1 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.151 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 89.4 t -131.86 125.78 55.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.13 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 26.2 mt -96.93 131.32 43.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.933 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.7 mmt -90.54 140.92 29.28 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.894 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . 0.423 ' HD2' ' C ' ' A' ' 261' ' ' MET . 0.0 OUTLIER -140.44 135.13 31.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.946 179.939 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -51.6 176.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 37.5 p -106.42 -58.8 1.88 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.899 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -55.79 -58.81 6.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.865 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 63.1 p -78.78 -39.69 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.131 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 71.77 14.7 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -100.95 134.56 43.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.859 0.361 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 1.5 p -50.18 111.59 0.55 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.492 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 1.1 mmmp? -69.34 -28.54 66.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.905 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 114.4 40.5 0.94 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.497 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.508 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 1.1 p90 -151.0 153.72 35.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 0.0 110.934 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.01 175.36 40.15 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -117.79 140.29 49.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.939 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.505 HD11 ' CE2' ' A' ' 249' ' ' PHE . 90.6 mt -138.25 128.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 83.5 m -110.02 130.0 55.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -96.37 179.51 5.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 27.8 t -92.03 -42.73 9.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.83 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -114.1 139.35 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.7 m -60.75 -39.74 89.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -61.62 -43.73 98.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 87.9 m -60.13 -38.93 84.55 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.37 -40.93 94.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -60.1 -48.31 82.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 47.7 mmt-85 -58.25 -51.01 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.441 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.24 -35.54 69.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 12.4 tp -65.01 -40.55 95.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.902 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -68.41 -42.63 78.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.855 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 24.7 mm-40 -71.88 -38.99 69.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.511 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 71.8 mt -72.62 -45.87 56.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.924 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -47.81 108.07 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.833 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.46 36.11 27.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.474 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -100.45 121.64 41.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.832 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -73.68 96.64 2.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 42.5 tp -88.52 -47.83 8.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.927 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -121.9 43.57 2.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.133 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 93.78 -25.17 22.73 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.507 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 55.2 mtp180 -122.94 148.69 54.75 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.605 0.717 . . . . 0.0 110.844 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 121.17 7.85 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.635 2.223 . . . . 0.0 112.357 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -74.46 171.8 13.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.2 mmm180 -108.8 123.51 49.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.431 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 15.4 t -129.46 126.6 63.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.126 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -147.78 158.97 27.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 6.3 m170 -71.65 120.58 17.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.812 0.339 . . . . 0.0 110.873 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 96.4 t -42.87 -55.59 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 90.3 m -140.77 115.7 9.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -101.17 79.62 2.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.835 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.438 ' HB2' ' NH1' ' A' ' 308' ' ' ARG . 0.5 OUTLIER -100.13 100.88 11.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.944 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 1.4 pp -119.93 140.3 51.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.927 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -128.97 98.39 4.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 58.73 -113.07 4.6 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.516 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -84.91 113.02 3.72 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -47.37 -64.75 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.889 0.376 . . . . 0.0 110.877 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -164.24 -162.89 16.04 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.488 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -0.02 6.27 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.736 2.291 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 4.0 t -118.37 -43.93 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 -179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 2.6 m -102.57 108.37 19.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.999 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 83.7 p -162.28 153.81 18.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.86 0.362 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.5 p -66.11 95.48 0.28 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.889 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -74.84 -98.31 0.11 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 10.3 t -130.44 161.41 31.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 110.864 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 76.7 p -96.64 79.6 3.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -126.21 144.59 15.2 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.444 ' CD2' ' HB2' ' A' ' 287' ' ' LEU . 40.2 mt -122.18 144.82 48.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.358 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -109.52 141.97 41.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.948 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.92 135.75 63.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -142.59 166.06 26.61 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.8 m 64.03 49.82 2.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.892 0.377 . . . . 0.0 110.878 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 96.4 mt -103.06 -179.02 3.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.417 ' O ' ' C ' ' A' ' 238' ' ' PHE . 11.2 t-80 -109.85 133.11 53.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.528 ' CD1' ' O ' ' A' ' 269' ' ' SER . 71.7 m-85 -37.38 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.86 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.448 ' C ' ' ND2' ' A' ' 239' ' ' ASN . 0.2 OUTLIER -35.8 -40.86 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.908 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 37.4 mm -49.07 146.11 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 12.6 p -143.2 -179.86 6.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.171 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -60.52 -35.82 76.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.882 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.23 -41.23 88.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 19.3 mtt -69.28 -44.92 70.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 47.4 mt -60.25 -36.38 77.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.486 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -39.73 68.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.953 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.468 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.65 -36.34 93.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.438 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.45 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.4 mt -81.78 -44.1 20.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.871 0.367 . . . . 0.0 111.103 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.554 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.3 m-85 -79.07 -8.08 58.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.513 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.1 tp10 -67.96 -58.78 7.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.513 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.78 1.88 4.05 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.45 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.9 m-85 -103.0 -34.45 8.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -179.41 158.03 21.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 2.4 ttmp? -64.73 101.53 0.48 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.745 0.307 . . . . 0.0 110.932 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 38.4 mt -69.36 125.65 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.162 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -83.03 -42.53 17.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.823 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -168.82 146.77 3.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 95.9 mt -123.08 133.79 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.144 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 7.1 m -133.92 124.59 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 29.5 mt -92.04 138.05 31.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.546 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 10.5 mmm -102.63 122.36 44.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 262' ' ' LYS . 1.0 OUTLIER -131.88 150.9 52.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.886 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 13.1 t0 -69.54 169.31 12.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.846 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 31.0 t -105.2 -31.76 8.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -65.94 -63.13 1.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.825 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 15.4 p -86.42 -39.6 16.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.098 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 76.89 28.15 59.34 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 31.8 mmt180 -110.26 132.27 54.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 0.0 110.897 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.528 ' O ' ' CD1' ' A' ' 238' ' ' PHE . 1.6 m -61.26 92.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.885 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 24.0 mttm -46.14 -42.17 13.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 131.81 39.34 0.24 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.526 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.546 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -146.89 153.29 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.926 0.393 . . . . 0.0 110.927 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -159.66 -178.15 33.4 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -129.71 140.11 51.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.554 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.5 mt -136.64 137.27 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.137 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.433 ' N ' HG23 ' A' ' 275' ' ' ILE . 87.5 m -116.13 127.25 54.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.125 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -96.92 -179.27 4.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.2 t -96.93 -41.85 8.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.863 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -112.52 138.12 49.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.1 p -61.51 -39.74 92.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.847 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -61.91 -44.04 97.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 72.2 m -60.4 -37.31 80.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.904 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -67.05 -41.44 86.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.4 ttt180 -59.96 -48.78 80.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.86 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -58.41 -51.02 71.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -57.15 -35.02 69.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.527 HD23 ' CE1' ' A' ' 304' ' ' HIS . 10.8 tp -63.88 -45.3 90.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -69.08 -39.01 79.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -69.46 -42.11 75.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.91 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . . . . . . . . . 56.7 mt -74.45 -47.03 35.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -43.59 114.53 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 71.22 38.2 63.17 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -104.57 109.57 21.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.923 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -55.29 95.05 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.913 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . 0.411 ' CD1' ' C ' ' A' ' 295' ' ' LEU . 0.5 OUTLIER -76.25 -64.78 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.6 37.41 3.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.62 -40.2 2.46 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 62.1 mtp180 -115.95 157.58 44.5 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 127.82 15.16 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.716 2.277 . . . . 0.0 112.356 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptp -79.51 179.53 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -110.73 123.36 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.89 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.411 HG11 ' CD1' ' A' ' 287' ' ' LEU . 14.8 t -132.75 125.35 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.56 160.83 28.3 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.436 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.527 ' CE1' HD23 ' A' ' 287' ' ' LEU . 9.6 m170 -75.55 111.6 11.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.834 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 304' ' ' HIS . 98.5 t -35.59 133.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 10.2 t -59.22 137.73 57.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.178 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -116.66 99.81 7.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 26.9 ttt85 -89.96 91.59 8.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.859 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 5.8 tp -148.76 125.5 11.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -94.27 157.31 16.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.873 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -156.72 129.45 2.42 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.454 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -116.5 173.43 14.71 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.2 t -127.73 -59.72 1.19 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.894 0.378 . . . . 0.0 110.827 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 148.81 -159.1 27.91 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.501 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 173.34 11.13 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.631 2.221 . . . . 0.0 112.332 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 7.4 t -97.63 138.61 34.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 8.0 t -45.32 -47.18 13.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.46 -179.951 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 16.5 t -163.39 157.19 19.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.873 0.368 . . . . 0.0 110.817 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 2.3 t -89.94 168.01 12.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.879 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 157.64 -112.25 0.52 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.478 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 5.2 t 41.69 40.21 1.38 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.91 0.385 . . . . 0.0 110.851 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 14.8 m -93.8 -41.14 9.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.888 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -51.17 138.52 26.97 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 44.6 mt -116.85 144.66 44.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.847 0.356 . . . . 0.0 110.935 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.475 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.7 t80 -106.73 129.53 54.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 8.7 p -114.81 132.54 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.179 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.12 163.85 28.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.479 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 74.64 43.01 0.27 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.928 0.394 . . . . 0.0 110.881 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.1 mt -101.88 -177.41 3.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.891 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 240' ' ' ILE . 6.6 t-80 -103.75 126.77 51.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.865 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.49 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 4.2 p90 -35.89 -44.69 0.37 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.49 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 39.5 t30 -51.7 -46.15 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.44 ' N ' ' O ' ' A' ' 237' ' ' HIS . 40.3 mm -40.19 147.87 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.127 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.0 t -136.98 174.51 10.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.099 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 38.0 mp0 -56.89 -34.96 68.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -58.33 -44.18 88.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.4 mmt -65.08 -42.23 94.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 41.7 mt -61.19 -39.62 90.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.894 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.01 -37.97 69.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.462 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -63.37 -34.61 90.42 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . 0.437 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 68.1 mt -83.55 -44.81 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.571 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.7 m-85 -78.94 -5.97 55.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.523 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.58 -58.28 5.9 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 0.0 110.909 -179.919 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.523 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.78 -0.95 7.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.63 2.22 . . . . 0.0 112.388 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.437 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 11.7 m-85 -100.05 -23.87 14.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 167.57 167.33 28.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm -68.43 115.09 7.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.71 0.29 . . . . 0.0 110.872 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 27.3 mt -83.41 120.65 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.126 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -77.63 -49.37 14.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -163.25 145.64 10.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 84.8 mt -124.42 129.6 73.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 51.8 t -131.03 131.94 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.165 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 30.0 mt -101.08 133.7 45.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.457 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 57.6 mmm -94.62 125.97 39.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.888 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.67 157.91 40.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.868 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -65.53 172.67 3.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 19.1 t -106.85 -41.8 5.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.844 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -75.5 -54.42 7.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.895 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 72.2 p -78.04 -41.2 36.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.177 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 72.53 21.05 79.72 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.458 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 23.2 mmm-85 -109.89 131.2 55.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.813 0.339 . . . . 0.0 110.874 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 14.9 m -61.18 125.97 25.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.846 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 52.4 mmtt -77.32 -39.5 47.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 131.25 37.92 0.29 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.481 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.457 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -148.19 159.09 44.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.904 0.383 . . . . 0.0 110.962 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -166.1 176.3 41.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -119.74 135.9 54.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.339 . . . . 0.0 110.886 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.56 HD13 ' CD2' ' A' ' 249' ' ' PHE . 75.8 mt -131.89 140.11 48.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.412 ' N ' HG22 ' A' ' 275' ' ' ILE . 69.5 m -120.97 128.23 52.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.181 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -96.8 -175.34 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.841 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.4 t -105.23 -28.79 10.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.893 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.66 135.56 55.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.3 p -63.54 -40.52 97.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -61.68 -43.63 98.49 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.861 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.9 m -62.5 -38.81 91.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.905 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -63.92 -43.17 96.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.128 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -61.65 -47.58 84.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -57.98 -49.8 75.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.418 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.25 -39.47 75.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 11.6 tp -61.68 -40.71 95.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -68.24 -35.04 77.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -82.58 -26.5 32.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.571 ' CD1' ' CZ ' ' A' ' 249' ' ' PHE . 71.3 mt -81.71 -47.06 13.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . 0.444 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -51.36 117.17 2.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.25 32.45 55.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.446 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -97.49 106.89 19.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -59.73 102.53 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 39.7 tp -92.79 -63.36 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -107.88 39.79 1.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.109 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.88 -25.81 26.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -120.68 154.53 57.22 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.601 0.715 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.85 128.93 16.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.683 2.255 . . . . 0.0 112.333 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptt? -82.43 164.35 21.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 66.6 mmt-85 -102.28 121.19 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.4 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 15.9 t -130.28 121.32 51.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.15 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -140.78 163.98 26.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.514 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 305' ' ' VAL . 7.0 m170 -73.02 112.49 9.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 110.833 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' A' ' 304' ' ' HIS . 74.4 t -34.27 136.1 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.134 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 9.8 t -102.41 142.44 33.61 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.15 -175.49 2.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.29 153.55 46.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.894 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.47 99.23 5.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.944 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -108.61 108.66 19.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -159.82 130.09 2.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -161.31 111.86 0.5 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 6.9 t -70.83 -41.01 72.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.918 0.39 . . . . 0.0 110.891 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 113.19 145.55 9.38 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 126.2 13.07 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.719 2.279 . . . . 0.0 112.373 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.1 t -172.46 159.33 4.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 26.4 t -110.75 -54.76 2.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.824 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.493 -179.986 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 24.6 m -139.06 166.49 24.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 96.4 p -57.29 -46.92 82.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 103.98 164.55 24.93 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.48 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 47.7 t -68.06 139.72 56.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.882 0.373 . . . . 0.0 110.874 -179.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 36.9 p -69.05 101.54 1.43 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.401 ' C ' HG22 ' A' ' 305' ' ' VAL . . . -128.34 149.97 18.39 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.444 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 63.5 mt -129.03 145.7 51.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.942 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.498 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.0 t80 -105.54 135.0 47.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 9.6 p -121.73 129.39 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -138.65 162.55 25.84 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 73.47 46.73 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.891 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 64.2 mt -106.73 -176.14 2.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.959 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -113.6 130.26 56.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.418 ' O ' ' C ' ' A' ' 239' ' ' ASN . 1.2 m-85 -38.12 -58.29 0.98 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 238' ' ' PHE . 18.3 m-20 -36.19 -46.1 0.49 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.0 mm -47.43 128.92 3.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.7 p -113.1 174.88 5.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -58.53 -33.86 70.35 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.876 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -61.58 -46.02 91.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 30.6 mtt -60.23 -42.49 95.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 42.4 mt -60.42 -40.5 91.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.498 ' O ' ' N ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -63.51 -43.98 95.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.454 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -64.87 -32.01 82.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.485 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 87.0 mt -78.4 -40.99 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.881 0.372 . . . . 0.0 111.175 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.564 ' CZ ' HD11 ' A' ' 290' ' ' LEU . 3.2 m-85 -90.91 -8.65 48.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.886 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.502 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.6 tp10 -59.0 -59.28 14.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.636 0.731 . . . . 0.0 110.88 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 2.75 3.28 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.268 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . 0.458 ' HB3' ' CB ' ' A' ' 286' ' ' ALA . 9.6 m-85 -106.41 -9.67 16.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 152.7 168.25 16.5 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.45 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 31.6 tttp -72.46 122.03 20.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.75 0.309 . . . . 0.0 110.932 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.408 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 33.4 mt -93.8 111.65 25.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -70.14 -39.34 75.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.883 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -167.66 155.05 8.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 49.0 mt -131.57 131.99 62.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 8.1 t -128.4 137.8 56.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.161 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 48.3 mt -110.07 132.81 53.83 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.521 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 13.3 mmt -84.34 141.82 30.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . 0.402 ' HD2' ' C ' ' A' ' 261' ' ' MET . 0.0 OUTLIER -140.85 151.79 44.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -61.92 -176.97 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.903 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 3.2 m -124.83 -11.25 7.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.834 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 32.8 p-10 -87.4 -41.3 13.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.88 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 1.3 p -119.67 -53.6 2.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 116.74 14.07 7.58 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -89.93 123.04 33.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.76 143.89 1.29 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.831 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.46 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 6.5 mmmm -91.02 -8.2 49.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.897 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 96.98 27.81 9.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.496 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.521 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 0.5 OUTLIER -150.42 161.95 41.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.931 0.396 . . . . 0.0 110.879 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.9 -173.17 35.69 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.62 148.5 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' A' ' 249' ' ' PHE . 82.1 mt -138.58 139.66 40.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 275' ' ' ILE . 56.4 m -118.21 129.98 55.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.16 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -103.48 -175.11 2.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 22.8 t -100.15 -41.76 6.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -113.93 139.94 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.852 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 60.9 p -63.14 -40.16 96.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.847 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.15 -42.77 99.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.904 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.2 m -60.7 -35.98 77.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -68.07 -41.98 81.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.081 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 19.6 ttm180 -59.23 -49.11 79.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 28.4 mmt180 -58.91 -50.93 72.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.885 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 252' ' ' PHE . . . -57.41 -34.9 69.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.09 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 15.0 tp -64.09 -45.29 89.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -69.01 -42.03 76.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -67.81 -42.02 82.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.916 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.564 HD11 ' CZ ' ' A' ' 249' ' ' PHE . 65.2 mt -73.72 -46.82 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 290' ' ' LEU . 0.7 OUTLIER -37.19 103.6 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 179.909 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.58 33.86 33.39 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 290' ' ' LEU . 22.6 t80 -87.42 105.48 17.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -57.67 96.75 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 8.5 tt -89.72 -69.54 0.71 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.946 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -99.3 32.05 2.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 107.68 -36.86 4.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.512 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -108.94 148.01 37.03 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.58 0.705 . . . . 0.0 110.885 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.03 7.73 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.716 2.277 . . . . 0.0 112.325 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptm -74.02 171.96 12.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.0 mmt85 -111.73 122.95 49.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.17 122.32 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.49 162.54 26.92 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.449 ' O ' ' C ' ' A' ' 305' ' ' VAL . 5.0 m170 -71.4 127.27 32.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.812 0.339 . . . . 0.0 110.826 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 304' ' ' HIS . 54.0 t -34.17 123.35 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 38.7 p -79.2 -51.96 8.79 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.146 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -41.69 133.45 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -53.91 133.84 42.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.884 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 32.5 mt -115.09 44.96 1.71 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.927 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -165.32 166.73 18.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.905 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -164.82 -100.34 0.15 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.47 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 44.93 66.38 1.48 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.507 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 69.2 m -41.55 123.91 2.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 0.0 110.877 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -160.65 82.9 0.13 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 128.42 16.0 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.64 2.227 . . . . 0.0 112.334 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.3 t -135.57 145.6 47.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 60.8 p -93.62 142.82 26.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.89 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.496 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 1.8 m -169.19 134.77 1.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 110.88 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 34.3 p -108.06 176.05 5.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 134.29 -167.01 23.97 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.523 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 10.6 t -72.79 127.99 34.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 0.0 110.853 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 20.7 m -52.73 109.03 0.36 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.851 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -138.87 134.37 6.74 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.482 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . 0.429 HD11 ' CE2' ' A' ' 277' ' ' PHE . 51.8 mt -123.94 145.22 49.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -112.51 133.79 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.946 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 14.7 p -122.07 132.85 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.113 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.76 165.78 27.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.474 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.3 m 74.03 47.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 74.7 mt -110.03 178.78 4.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -97.53 132.08 43.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.468 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.1 t80 -42.62 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.85 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 238' ' ' PHE . 59.4 t-20 -34.62 -33.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.468 ' N ' ' O ' ' A' ' 238' ' ' PHE . 21.8 mm -54.85 147.98 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.109 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -134.98 175.8 9.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.137 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . 0.421 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 11.8 mt-10 -57.82 -32.65 67.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -60.26 -33.83 72.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.4 mmt -71.98 -37.87 69.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 39.1 mt -69.54 -42.89 74.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.959 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.489 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 14.9 ptt85 -67.53 -39.46 85.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.462 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.6 -35.63 86.58 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.492 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 73.3 mt -79.1 -45.19 24.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.815 0.341 . . . . 0.0 111.101 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' A' ' 275' ' ' ILE . 3.1 m-85 -80.6 -4.9 55.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.526 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.89 -58.19 5.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.69 0.757 . . . . 0.0 110.875 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.526 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.81 3.2 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -103.91 -25.84 12.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.841 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.93 166.14 29.33 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.464 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.2 ttmt -67.4 109.54 3.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 33.6 mt -81.06 123.68 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.141 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -79.31 -44.53 21.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -168.33 151.16 5.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.865 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 36.7 mt -128.19 134.02 65.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.16 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.7 m -134.51 134.76 54.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . 0.421 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 32.3 mt -97.48 134.62 40.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.934 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.553 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 26.9 mmm -98.16 129.31 44.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.33 146.34 51.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.883 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.4 t0 -61.4 -176.69 0.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.868 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 72.6 m -118.35 -47.81 2.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -57.93 -38.33 75.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.825 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 5.4 p -107.31 -54.5 2.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.106 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 93.13 15.84 49.91 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.474 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 84.8 mtt-85 -105.88 117.55 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.854 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 6.5 t -43.81 128.83 5.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.567 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 32.5 mttm -86.89 8.87 21.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 83.12 40.28 9.38 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.477 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.567 ' CE1' ' HB2' ' A' ' 270' ' ' LYS . 3.7 p90 -148.69 155.92 41.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.931 0.396 . . . . 0.0 110.861 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.5 177.89 39.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -117.56 139.43 50.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.866 0.365 . . . . 0.0 110.92 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.564 HD11 ' CD2' ' A' ' 249' ' ' PHE . 71.0 mt -136.02 138.55 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.132 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.9 m -117.47 123.94 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . 0.429 ' CE2' HD11 ' A' ' 231' ' ' LEU . 41.4 m-85 -91.24 -175.69 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 38.9 t -100.02 -34.3 10.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.867 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -122.94 138.27 54.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.903 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.8 p -61.72 -35.88 79.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -63.66 -44.11 94.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.879 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 74.0 m -62.42 -37.8 87.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -67.22 -36.94 82.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.073 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . 0.428 ' HB2' ' NH1' ' A' ' 284' ' ' ARG . 0.1 OUTLIER -64.13 -48.98 73.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.864 -179.891 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -59.83 -43.22 94.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.83 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -63.15 -35.23 79.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.138 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 11.6 tp -65.07 -44.65 88.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.923 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -69.39 -38.98 78.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -71.5 -41.12 69.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.561 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 74.8 mt -74.29 -46.93 37.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -45.22 107.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.5 38.66 13.89 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.449 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -105.54 100.27 9.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.874 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -50.82 103.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 15.9 tp -94.67 -55.82 3.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.42 45.55 2.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.145 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.82 -37.19 3.65 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -117.03 150.45 46.01 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 123.36 10.01 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.64 2.226 . . . . 0.0 112.381 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -69.45 170.68 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 6.1 mmm180 -108.76 124.21 50.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . . . . . . . . . 17.3 t -129.38 125.41 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.126 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -145.74 162.63 28.29 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.442 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.419 ' O ' ' N ' ' A' ' 306' ' ' THR . 39.9 m-70 -76.92 126.88 31.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.861 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 82.5 t -45.1 94.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 304' ' ' HIS . 15.2 t -116.7 134.8 54.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -92.65 147.82 22.56 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.93 -2.08 53.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.67 -67.03 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.13 93.02 6.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.848 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -102.28 -78.81 1.34 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.431 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 142.64 179.35 19.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.531 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 91.9 p -170.6 121.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.901 0.382 . . . . 0.0 110.939 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -135.38 92.63 0.23 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 153.6 68.92 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.708 2.272 . . . . 0.0 112.345 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 26.3 m -121.92 179.1 4.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 35.5 t -88.11 135.09 33.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.519 179.987 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 68.9 m -101.58 43.58 1.06 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.861 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 3.1 m -71.68 90.14 1.04 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.856 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -168.57 158.24 30.81 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 15.9 t -157.85 162.26 38.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 13.3 p -89.26 90.57 8.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -150.86 147.34 17.25 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.493 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 30.0 mt -121.78 139.12 53.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.948 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' TYR . . . . . 0.542 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.9 OUTLIER -106.47 137.79 43.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' VAL . . . . . 0.412 ' CG2' HD11 ' A' ' 236' ' ' LEU . 7.4 p -122.56 136.91 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.95 163.95 28.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.468 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 74.16 45.25 0.21 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.891 0.377 . . . . 0.0 110.902 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' LEU . . . . . 0.412 HD11 ' CG2' ' A' ' 233' ' ' VAL . 96.7 mt -104.9 -176.29 3.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' HIS . . . . . 0.438 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.2 t-80 -109.29 135.06 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.84 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 1.9 p90 -38.7 -44.14 0.97 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' ASN . . . . . 0.479 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 36.4 t30 -54.02 -42.18 68.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' ILE . . . . . 0.438 ' N ' ' O ' ' A' ' 237' ' ' HIS . 15.5 mm -50.63 106.25 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.152 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -95.25 179.49 5.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.096 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -61.16 -30.83 70.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -61.11 -43.55 98.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.8 mtt -62.68 -46.03 90.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 31.9 mt -60.07 -38.75 83.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.02 -42.4 66.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . 0.423 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -61.48 -30.61 74.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.468 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 88.4 mt -88.33 -43.59 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 111.171 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' PHE . . . . . 0.557 ' CD2' HD11 ' A' ' 275' ' ' ILE . 3.2 m-85 -82.23 -2.64 53.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.886 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' GLU . . . . . 0.514 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -70.34 -58.56 4.77 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.594 0.711 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.1 Cg_endo -69.72 2.03 3.88 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -103.27 -11.12 18.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 154.23 177.34 27.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.51 131.13 41.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.762 0.315 . . . . 0.0 110.921 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.447 HG22 ' CD1' ' A' ' 258' ' ' ILE . 94.6 mt -98.76 98.7 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -59.43 -44.72 92.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.825 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -167.2 153.55 8.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.938 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' ILE . . . . . 0.447 ' CD1' HG22 ' A' ' 255' ' ' ILE . 78.3 mt -130.27 133.01 64.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.6 m -134.41 134.28 54.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.6 mt -103.35 128.81 50.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' MET . . . . . 0.563 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 12.1 mmt -86.04 135.59 33.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.831 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.52 154.64 51.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.931 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -67.13 177.58 1.73 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.0 m -110.93 -35.15 6.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.845 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -67.62 -45.71 74.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.866 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 1.3 p -105.51 -54.63 2.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.094 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 96.18 26.67 10.93 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.531 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 269' ' ' SER . 6.5 ttm105 -110.2 124.17 51.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 0.0 110.846 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' SER . . . . . 0.402 ' C ' ' O ' ' A' ' 268' ' ' ARG . 6.4 m -38.06 124.79 1.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.888 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.34 -29.3 31.09 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 124.87 31.43 0.87 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.501 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' TYR . . . . . 0.563 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -146.96 154.86 41.76 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.934 0.397 . . . . 0.0 110.929 -179.827 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -162.21 172.89 38.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' PHE . . . . . 0.441 ' CD2' HG13 ' A' ' 305' ' ' VAL . 33.1 m-85 -119.8 134.39 55.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 110.848 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' ILE . . . . . 0.557 HD11 ' CD2' ' A' ' 249' ' ' PHE . 96.3 mt -130.74 137.4 56.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' THR . . . . . 0.46 ' N ' HG21 ' A' ' 275' ' ' ILE . 90.9 m -110.42 129.77 55.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -103.68 170.83 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.845 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 1.1 t -115.38 24.79 11.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.843 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -162.59 113.09 1.49 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 95.2 p -53.12 -40.47 64.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 -179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -62.02 -43.99 97.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 85.6 m -64.56 -40.91 96.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -58.08 -46.35 85.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -61.91 -47.4 85.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -59.15 -50.93 72.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.87 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -56.71 -35.2 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.076 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.449 HD21 ' CD2' ' A' ' 304' ' ' HIS . 7.6 tp -64.59 -44.66 89.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.14 -42.5 75.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.895 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 68.2 mm-40 -67.44 -41.95 83.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 290' ' ' LEU . . . . . 0.433 ' HB3' ' CG2' ' A' ' 302' ' ' VAL . 73.9 mt -73.73 -46.95 42.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -41.5 104.93 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.43 34.8 15.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.522 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -100.84 99.76 10.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -61.08 118.22 6.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.893 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 10.0 tp -108.1 -50.26 3.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.883 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -113.11 42.81 1.83 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.082 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.33 -35.53 4.54 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.479 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -115.92 152.51 47.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 130.47 19.36 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.357 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -78.24 174.78 10.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 16.6 mmt180 -111.38 120.6 42.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' VAL . . . . . 0.433 ' CG2' ' HB3' ' A' ' 290' ' ' LEU . 13.0 t -123.43 131.44 73.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.123 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.2 161.8 30.62 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.546 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' HIS . . . . . 0.449 ' CD2' HD21 ' A' ' 287' ' ' LEU . 34.2 m-70 -70.12 121.94 18.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.865 0.364 . . . . 0.0 110.864 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' VAL . . . . . 0.447 HG11 ' N ' ' A' ' 232' ' ' TYR . 17.2 m -63.11 -32.17 55.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 7.0 t -60.0 147.65 38.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.154 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 308' ' ' ARG . 6.7 tt0 67.48 40.24 2.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.87 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' ARG . . . . . 0.422 ' C ' ' O ' ' A' ' 307' ' ' GLU . 22.8 mtp180 -35.81 -62.38 0.42 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' LEU . . . . . 0.409 ' N ' HD11 ' A' ' 309' ' ' LEU . 7.6 mp -85.99 103.87 15.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -123.12 127.88 49.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -74.91 -66.81 1.85 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.503 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 124.52 78.94 0.37 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.48 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 34.2 p -104.49 86.24 2.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.89 0.376 . . . . 0.0 110.844 -179.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 60.03 68.56 1.62 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 123.36 10.02 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.363 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.7 p -57.75 169.96 0.65 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 7.3 t -113.32 167.05 10.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.848 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.53 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 N-CA-C 112.446 -0.262 . . . . 0.0 112.446 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.452 HD12 ' CE1' ' A' ' 277' ' ' PHE . 25.0 mt -121.09 146.99 46.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 110.922 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.558 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -111.9 139.65 47.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.676 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.2 p -124.44 131.29 72.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.114 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.23 165.38 27.43 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.498 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.2 m 72.82 44.67 0.35 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 0.0 110.883 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.676 HD11 ' CG2' ' A' ' 233' ' ' VAL . 79.5 mt -109.24 172.09 7.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.914 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -90.32 126.99 36.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -41.48 -42.46 2.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -51.09 -42.1 60.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.545 ' CD1' HD21 ' A' ' 295' ' ' LEU . 47.8 mm -44.66 152.2 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.161 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 240' ' ' ILE . 76.1 p -137.02 178.58 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.152 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 242' ' ' GLU . . . . . 0.437 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 12.1 mt-10 -61.67 -35.83 79.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -60.16 -34.87 74.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 244' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 240' ' ' ILE . 27.7 mtt -72.04 -41.17 67.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 59.8 mt -68.67 -42.24 78.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.919 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.428 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 6.1 ptm180 -67.3 -39.87 86.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.428 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.27 -34.75 86.51 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.464 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 92.2 mt -80.98 -42.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.854 0.359 . . . . 0.0 111.103 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.788 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.48 -1.65 54.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.863 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.7 OUTLIER -70.29 -59.79 3.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.654 0.74 . . . . 0.0 110.883 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.81 2.88 3.16 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -102.97 -30.41 10.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 176.62 149.01 7.38 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.453 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 7.4 ttpp -56.29 111.42 0.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 110.854 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.495 HG21 HD11 ' A' ' 258' ' ' ILE . 57.0 mt -80.62 124.97 39.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.161 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -82.28 -43.14 17.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -168.25 149.3 4.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.495 HD11 HG21 ' A' ' 255' ' ' ILE . 41.9 mt -128.25 132.72 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.158 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.552 HG23 ' HB2' ' A' ' 274' ' ' PHE . 4.9 m -134.99 127.02 47.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.437 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 31.6 mt -92.11 136.29 33.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 29.9 mmm . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.87 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -148.63 163.32 37.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.868 0.366 . . . . 0.0 110.947 -179.814 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.32 175.56 39.58 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.552 ' HB2' HG23 ' A' ' 259' ' ' VAL . 31.4 m-85 -120.37 137.74 54.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.859 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 30.1 mt -138.48 137.35 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.16 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.7 m -118.53 129.46 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.452 ' CE1' HD12 ' A' ' 231' ' ' LEU . 39.2 m-85 -97.76 -177.9 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.873 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.9 t -95.51 -41.55 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -116.59 141.23 48.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.1 m -63.87 -36.23 83.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -61.72 -43.65 98.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.94 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 99.2 m -62.06 -40.5 96.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.8 -42.84 99.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 284' ' ' ARG . . . . . 0.427 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 13.0 ttm105 -60.73 -48.05 83.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 23.2 mtp180 -58.31 -50.88 72.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.49 -34.93 71.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.123 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.454 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -64.72 -40.81 95.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -68.96 -42.16 77.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.891 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -71.72 -38.43 70.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.924 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.788 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 56.7 mt -74.08 -47.04 39.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.931 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -44.51 110.16 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.71 37.19 40.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 28.1 t80 -104.83 91.79 3.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.849 0.357 . . . . 0.0 110.825 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -48.91 118.4 2.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.545 HD21 ' CD1' ' A' ' 240' ' ' ILE . 45.6 tp -103.85 -44.73 4.97 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -122.95 40.15 3.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.06 -27.75 18.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 29.6 mtp85 -118.32 148.46 43.9 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.558 0.694 . . . . 0.0 110.891 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 132.62 23.79 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.696 2.264 . . . . 0.0 112.336 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 300' ' ' MET . . . . . 0.431 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -86.88 170.93 11.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.898 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -108.64 127.82 54.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.897 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.784 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.4 t -132.47 127.6 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -152.47 163.87 30.44 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -71.13 146.41 49.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 0.0 110.863 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 95.3 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.133 179.977 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.375 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.495 ' CA ' HG23 ' A' ' 305' ' ' VAL . 53.7 mt -127.24 144.77 50.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.81 0.338 . . . . 0.0 110.93 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.482 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.5 t80 -109.69 136.29 49.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.8 p -122.87 137.77 55.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.089 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.65 164.32 28.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.466 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.3 t 74.12 47.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.891 0.376 . . . . 0.0 110.807 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 91.3 mt -109.28 170.29 8.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -92.93 126.08 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.876 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -38.83 -48.36 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -46.31 -44.54 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.871 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.44 HG22 ' N ' ' A' ' 241' ' ' THR . 47.9 mm -40.07 154.47 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 240' ' ' ILE . 14.4 t -137.42 173.72 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -60.69 -35.02 75.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.887 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -59.49 -34.53 72.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.7 mmt -71.77 -39.51 69.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.869 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.453 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.6 mt -68.89 -41.85 77.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.554 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.7 ptm180 -68.55 -36.15 78.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.42 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.06 -41.82 92.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.471 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.433 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 76.5 mt -75.18 -41.32 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.841 0.353 . . . . 0.0 111.097 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.676 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -81.56 -4.03 54.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.51 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.0 tp10 -69.48 -59.7 4.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.643 0.735 . . . . 0.0 110.871 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.5 Cg_endo -69.79 3.02 3.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.665 2.243 . . . . 0.0 112.285 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.823 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -103.16 -39.33 6.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.92 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -176.01 148.06 9.04 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -51.75 117.24 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 246' ' ' ARG . 31.2 mt -87.07 124.56 40.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -83.61 -44.7 14.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 11.7 t30 -167.51 150.01 5.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.412 HD11 HG21 ' A' ' 255' ' ' ILE . 34.6 mt -126.6 136.13 61.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 84.8 t -134.97 130.86 52.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.13 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.51 131.66 47.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.455 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 68.4 mmm . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.528 -0.229 . . . . 0.0 112.528 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.8 p90 -149.2 161.78 41.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 110.903 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -165.66 171.15 40.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.485 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -117.13 134.82 54.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.842 0.354 . . . . 0.0 110.856 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.453 HD11 ' HB3' ' A' ' 245' ' ' LEU . 97.2 mt -132.28 137.69 53.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.159 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 96.4 m -117.22 129.51 55.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.209 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.485 ' CE1' HD12 ' A' ' 231' ' ' LEU . 43.6 m-85 -97.99 -177.27 3.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.9 t -101.48 -41.37 6.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -112.02 138.81 48.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.7 p -63.52 -40.93 98.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -61.3 -43.62 98.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 95.2 m -60.56 -42.96 97.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.67 -40.07 95.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -60.07 -48.91 79.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -58.96 -49.79 76.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.917 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.823 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.54 -35.79 70.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.404 HD22 ' CD2' ' A' ' 304' ' ' HIS . 12.9 tp -64.54 -43.36 94.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.891 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -68.8 -42.43 77.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 22.2 mm100 -69.1 -41.1 77.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 58.6 mt -73.12 -46.31 51.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.884 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -45.91 112.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.905 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.73 38.73 36.13 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 73.4 t80 -106.51 120.86 43.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.818 0.342 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -67.11 114.56 5.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.5 tp -98.17 -62.12 1.29 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.17 34.76 4.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.064 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 117.0 -35.42 4.17 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.502 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -120.42 156.51 55.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.627 0.727 . . . . 0.0 110.852 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 130.84 20.07 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.65 2.234 . . . . 0.0 112.334 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -79.54 170.92 15.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -105.99 119.08 38.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -124.11 132.38 71.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -154.65 163.9 31.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.404 ' CD2' HD22 ' A' ' 287' ' ' LEU . 16.5 m-70 -70.13 135.99 49.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.809 0.337 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.495 HG23 ' CA ' ' A' ' 231' ' ' LEU . 94.9 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.499 -0.24 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.441 HD11 ' O ' ' A' ' 283' ' ' ALA . 31.1 mt -111.8 147.03 36.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 110.881 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.514 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -107.23 137.11 45.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.506 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.4 p -123.76 131.86 72.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.077 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.0 165.66 27.27 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 72.71 43.67 0.43 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.853 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.506 HD11 ' CG2' ' A' ' 233' ' ' VAL . 30.3 mt -103.75 166.2 10.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.427 ' NE2' ' CE1' ' A' ' 238' ' ' PHE . 6.9 t60 -86.42 128.47 34.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 239' ' ' ASN . 36.9 p90 -37.88 -50.22 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.851 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.433 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 10.1 t-20 -47.53 -43.4 24.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' A' ' 237' ' ' HIS . 43.6 mm -38.64 147.9 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -138.88 178.42 7.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -60.65 -35.76 77.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 243' ' ' ASP . . . . . 0.464 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 1.3 m-20 -61.89 -32.86 73.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.9 mmt -71.98 -41.47 67.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.454 ' HB3' HD11 ' A' ' 275' ' ' ILE . 86.9 mt -69.88 -42.94 72.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.464 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 5.2 ptm180 -64.38 -37.74 88.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.445 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.56 -39.12 79.2 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.468 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.8 mt -75.86 -44.3 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.367 . . . . 0.0 111.11 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.61 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.86 -2.77 48.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.5 tp10 -70.61 -59.86 3.52 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.595 0.712 . . . . 0.0 110.871 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.7 2.42 3.52 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.728 2.286 . . . . 0.0 112.339 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.687 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.47 -31.42 10.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.76 149.86 7.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -54.77 113.32 1.28 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.759 0.314 . . . . 0.0 110.875 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.45 HD13 HD11 ' A' ' 258' ' ' ILE . 64.2 mt -83.35 122.65 37.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -78.83 -43.4 25.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -167.74 145.13 4.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.863 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.45 HD11 HD13 ' A' ' 255' ' ' ILE . 81.1 mt -120.24 135.29 61.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.74 128.87 51.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.0 mt -97.99 139.84 33.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.533 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 28.7 mmt . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.533 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.7 p90 -147.48 155.91 42.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.908 0.385 . . . . 0.0 110.93 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.54 -178.55 39.76 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.488 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.29 137.98 54.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.899 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.454 HD11 ' HB3' ' A' ' 245' ' ' LEU . 92.6 mt -132.03 140.87 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.077 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.3 m -118.83 129.94 55.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.147 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -98.63 -178.05 3.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.1 t -100.98 -39.47 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.812 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -112.84 135.62 53.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 4.5 m -60.54 -39.38 87.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -62.68 -42.74 99.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 75.4 m -61.96 -36.76 82.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.82 -41.8 86.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -61.84 -48.72 79.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -58.3 -50.91 71.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.687 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.89 -35.05 68.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.107 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.703 HD12 HG12 ' A' ' 302' ' ' VAL . 12.9 tp -64.65 -43.7 92.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.947 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -68.93 -42.77 76.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 25.7 mm100 -68.4 -41.85 79.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.704 ' HB3' HG21 ' A' ' 302' ' ' VAL . 67.0 mt -72.93 -46.14 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -46.03 108.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.82 31.57 39.49 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.486 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -94.32 123.01 37.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.842 0.354 . . . . 0.0 110.881 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 71.2 mt-10 -70.83 96.1 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.402 HD21 ' CD1' ' A' ' 240' ' ' ILE . 9.5 tp -78.87 -62.03 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -115.9 41.57 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.056 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.69 -21.44 43.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -124.31 149.58 61.47 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.581 0.705 . . . . 0.0 110.865 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.84 11.49 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -77.52 173.47 11.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.893 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -108.08 119.01 38.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.879 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' A' ' 290' ' ' LEU . 18.2 t -124.88 129.37 73.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.85 161.17 30.51 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.04 134.4 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.87 0.367 . . . . 0.0 110.838 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.7 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.168 179.957 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.463 HD11 ' O ' ' A' ' 283' ' ' ALA . 31.4 mt -124.65 144.8 49.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.857 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.905 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.6 t80 -109.19 128.76 55.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.616 ' CG2' HD11 ' A' ' 236' ' ' LEU . 10.4 p -113.92 133.5 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.42 166.02 26.94 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 7.7 t 71.98 44.2 0.48 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.876 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.616 HD11 ' CG2' ' A' ' 233' ' ' VAL . 81.6 mt -106.76 167.39 9.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.909 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.409 ' O ' ' C ' ' A' ' 238' ' ' PHE . 5.7 t-80 -93.15 130.96 38.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.409 ' C ' ' O ' ' A' ' 237' ' ' HIS . 4.2 m-85 -36.79 -54.21 0.91 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -41.76 -43.48 2.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.415 HD13 ' SD ' ' A' ' 244' ' ' MET . 31.1 mm -41.05 127.73 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 47.8 p -114.71 172.2 7.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 39.3 mp0 -60.27 -33.94 73.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -62.51 -32.46 73.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.848 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 244' ' ' MET . . . . . 0.415 ' SD ' HD13 ' A' ' 240' ' ' ILE . 52.0 mtt -72.01 -41.33 67.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 29.9 mt -66.91 -42.95 84.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.454 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.8 ptm180 -67.18 -39.69 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.44 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.12 -34.82 89.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.486 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.409 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 81.7 mt -81.56 -40.48 17.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.883 0.373 . . . . 0.0 111.141 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.703 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -84.72 -0.97 55.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.514 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.6 tp10 -70.77 -59.42 3.68 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.79 2.92 3.11 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.259 . . . . 0.0 112.36 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.647 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.2 -31.08 10.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 178.28 157.31 18.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -63.2 108.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.707 0.289 . . . . 0.0 110.909 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.454 HD13 ' HA ' ' A' ' 246' ' ' ARG . 37.3 mt -77.15 125.01 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.125 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -86.39 -43.69 12.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.877 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -163.56 143.65 8.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.449 HD11 HD13 ' A' ' 255' ' ' ILE . 71.0 mt -123.13 127.53 74.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.7 m -134.04 129.35 54.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.12 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 33.3 mt -92.38 139.07 30.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.652 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 15.7 mmt . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.652 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.9 p90 -150.14 164.04 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.922 0.392 . . . . 0.0 110.922 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -172.57 176.38 45.49 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.407 ' HB2' HG23 ' A' ' 259' ' ' VAL . 42.6 m-85 -117.11 136.1 53.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.886 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -132.26 140.59 47.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.1 m -120.98 127.7 52.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -97.43 -175.14 3.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.3 t -100.28 -40.5 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -115.22 140.05 49.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 13.0 p -62.51 -39.19 92.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -62.05 -42.93 99.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.3 m -60.38 -39.22 86.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.463 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.67 -40.69 88.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 32.6 ttp85 -59.07 -49.02 79.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -59.38 -48.94 79.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.647 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.04 -35.6 71.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.444 HD12 HG12 ' A' ' 302' ' ' VAL . 12.0 tp -65.06 -43.58 91.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -68.96 -43.03 75.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 67.6 mm-40 -68.85 -41.21 78.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.818 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.2 mt -73.27 -45.02 58.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.901 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -45.15 98.16 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 96.01 24.46 14.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 293' ' ' PHE . . . . . 0.416 ' N ' ' O ' ' A' ' 290' ' ' LEU . 10.5 t80 -79.58 116.36 19.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.81 0.338 . . . . 0.0 110.901 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -80.25 89.06 5.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 12.1 tp -86.66 -59.75 2.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.02 45.09 0.98 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.112 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 84.42 -27.75 4.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -113.23 143.93 30.21 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.573 0.702 . . . . 0.0 110.837 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 123.14 9.8 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.644 2.229 . . . . 0.0 112.367 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -73.96 169.71 16.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.852 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 40.3 mmt-85 -109.12 122.19 46.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -126.22 120.63 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -144.71 160.14 27.91 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 8.9 m170 -70.69 121.72 18.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.847 0.356 . . . . 0.0 110.832 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.905 HG12 ' HB2' ' A' ' 232' ' ' TYR . 15.6 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 68.3 mt -124.41 145.69 49.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.773 0.32 . . . . 0.0 110.923 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.507 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.2 t80 -110.78 131.1 55.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.662 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.9 p -113.62 134.94 54.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.13 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.81 165.73 27.57 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.5 t 71.32 45.71 0.47 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.925 0.393 . . . . 0.0 110.823 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.662 HD11 ' CG2' ' A' ' 233' ' ' VAL . 86.8 mt -109.76 176.35 5.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -102.89 135.33 44.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 239' ' ' ASN . 0.6 OUTLIER -46.47 -51.37 15.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.902 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.407 ' N ' ' CD1' ' A' ' 238' ' ' PHE . 6.7 t-20 -42.15 -41.25 2.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.834 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 16.0 mm -47.94 139.91 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -121.61 167.65 12.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.156 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -55.06 -33.71 62.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 243' ' ' ASP . . . . . 0.467 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 35.5 t0 -59.97 -36.9 78.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 4.8 mmt -71.38 -37.72 71.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.664 ' CD1' HD21 ' A' ' 260' ' ' LEU . 73.2 mt -69.98 -39.97 75.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.511 ' HA ' HD13 ' A' ' 255' ' ' ILE . 2.9 ptm180 -70.53 -35.3 73.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.456 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -69.79 -38.83 76.69 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.414 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 80.2 mt -75.72 -41.12 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.853 0.359 . . . . 0.0 111.113 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.622 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 4.5 m-85 -83.43 -4.19 58.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -69.47 -58.33 5.97 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.598 0.713 . . . . 0.0 110.901 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.76 2.52 3.46 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.736 2.291 . . . . 0.0 112.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.783 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.6 -26.93 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 172.87 162.05 24.32 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.504 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 20.4 ttpt -63.61 110.72 2.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.781 0.324 . . . . 0.0 110.936 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.622 HG21 HD11 ' A' ' 258' ' ' ILE . 25.2 mt -80.58 117.18 26.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -77.0 -46.4 23.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.828 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -168.89 142.46 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.903 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.622 HD11 HG21 ' A' ' 255' ' ' ILE . 46.0 mt -121.09 135.4 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.124 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.37 127.81 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.143 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.664 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.6 mt -98.15 136.54 38.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.523 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 20.2 mmt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.523 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 2.4 p90 -146.92 155.5 42.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.933 0.397 . . . . 0.0 110.962 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -160.39 170.17 36.34 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.51 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -113.52 138.74 49.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.855 0.359 . . . . 0.0 110.857 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 68.0 mt -136.01 134.16 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.0 m -118.19 129.01 55.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.166 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -99.15 -176.19 3.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.915 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 17.7 t -97.49 -41.85 7.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.426 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 26.1 t0 -115.42 142.59 46.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.858 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 29.2 t -63.99 -38.77 92.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 281' ' ' GLU . . . . . 0.478 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 10.7 pt-20 -61.52 -41.66 97.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 282' ' ' CYS . . . . . 0.478 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 84.0 m -61.35 -38.94 88.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.74 90.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 40.0 mtp180 -59.1 -48.89 79.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -58.78 -50.4 74.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.783 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -59.52 -34.99 73.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.083 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.531 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.3 tp -62.43 -45.26 93.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -68.83 -38.23 79.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -71.77 -36.62 70.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.6 mt -78.8 -39.97 34.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.917 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -55.09 103.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 87.91 30.89 16.35 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -98.49 109.79 22.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 110.842 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -56.7 99.31 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.431 HD13 ' C ' ' A' ' 295' ' ' LEU . 0.9 OUTLIER -78.77 -65.52 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -119.5 39.62 3.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.08 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 112.44 -34.61 5.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.95 151.35 46.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.865 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 120.94 7.66 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.304 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -71.12 171.89 10.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -110.26 122.51 47.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.2 t -128.88 126.12 64.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.26 160.99 28.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.492 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.531 ' CD2' HD22 ' A' ' 287' ' ' LEU . 26.0 m-70 -70.46 128.04 34.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.766 0.317 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 59.5 t . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.143 179.949 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.432 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.5 mt -131.56 144.78 51.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.806 0.336 . . . . 0.0 110.874 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.58 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.5 OUTLIER -110.3 137.17 48.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.956 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.42 133.12 70.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.79 165.65 27.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 m 72.29 45.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.86 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 37.3 mt -104.78 173.45 6.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -96.89 137.92 35.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.835 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -43.23 -49.41 6.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.516 ' O ' HG23 ' A' ' 241' ' ' THR . 16.0 t-20 -47.78 -40.2 20.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 43.0 mm -43.71 145.73 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.516 HG23 ' O ' ' A' ' 239' ' ' ASN . 33.5 p -143.07 173.65 11.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 242' ' ' GLU . . . . . 0.413 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 28.5 mp0 -54.97 -36.2 65.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -62.29 -35.5 79.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.847 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -72.01 -40.98 68.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 40.5 mt -68.17 -43.04 79.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.403 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.1 ptm180 -66.12 -37.62 86.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.403 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.85 -36.0 80.94 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.428 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.2 mt -80.36 -42.76 21.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.81 0.338 . . . . 0.0 111.117 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.516 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -81.45 -4.13 54.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.956 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tp10 -68.52 -59.93 5.31 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.646 0.736 . . . . 0.0 110.879 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.82 2.93 3.12 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.347 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.748 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -103.31 -22.03 13.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 163.72 158.54 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -61.32 117.09 5.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.766 0.317 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.66 HG21 HD11 ' A' ' 258' ' ' ILE . 57.2 mt -88.19 120.63 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -76.55 -49.03 17.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -158.17 155.45 29.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.66 HD11 HG21 ' A' ' 255' ' ' ILE . 44.6 mt -136.63 129.91 45.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.3 t -133.84 135.81 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.113 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.413 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 27.8 mt -102.62 139.63 37.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.594 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 24.7 mmt . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.869 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.594 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 2.2 p90 -147.79 158.53 44.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.924 0.392 . . . . 0.0 110.905 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.6 172.28 39.48 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.494 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -118.35 136.28 53.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.884 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.567 HG12 HG23 ' A' ' 258' ' ' ILE . 78.1 mt -136.46 140.44 43.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 99.4 m -120.67 129.36 53.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.13 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.432 ' CE1' HD12 ' A' ' 231' ' ' LEU . 41.8 m-85 -98.46 -178.82 4.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 24.6 t -101.18 -33.97 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -117.6 136.28 53.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.7 p -64.04 -39.83 94.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.863 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -62.65 -43.83 97.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.889 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 32.7 m -62.89 -41.58 99.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.909 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.424 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.14 -41.46 97.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.036 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -59.78 -49.07 79.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -57.57 -48.99 77.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.748 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.8 -38.57 67.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 9.0 tp -65.18 -39.84 93.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.908 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -64.46 -34.94 79.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -83.91 -34.75 24.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.943 ' HB3' HG21 ' A' ' 302' ' ' VAL . 76.3 mt -71.77 -47.07 56.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 291' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -55.02 118.31 4.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.24 23.2 63.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.456 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -93.87 111.63 23.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 294' ' ' GLU . . . . . 0.46 ' HG3' ' N ' ' A' ' 299' ' ' PRO . 2.4 mp0 -76.27 104.45 6.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -94.42 -57.44 2.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.7 41.02 1.45 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 102.66 -42.94 1.78 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 2.8 ptp180 -111.02 153.26 43.93 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.65 0.738 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 299' ' ' PRO . . . . . 0.46 ' N ' ' HG3' ' A' ' 294' ' ' GLU . 54.0 Cg_endo -69.76 135.42 30.43 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 3.4 ptp -82.85 162.91 21.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -106.28 121.28 43.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.943 HG21 ' HB3' ' A' ' 290' ' ' LEU . 22.1 t -130.81 125.47 58.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.14 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.26 161.36 26.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 9.0 m80 -72.47 109.31 6.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.836 0.35 . . . . 0.0 110.83 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.6 p . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.095 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.509 ' O ' HG12 ' A' ' 305' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.853 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.1 mt -125.77 143.62 50.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 110.93 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.17 130.58 56.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.903 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.493 HG21 HD11 ' A' ' 236' ' ' LEU . 10.8 p -110.39 135.2 50.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -140.24 166.04 25.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.469 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.9 m 63.96 47.81 3.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.86 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 233' ' ' VAL . 72.5 mt -100.11 -175.94 3.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.433 ' O ' ' C ' ' A' ' 238' ' ' PHE . 9.2 t60 -115.26 124.5 51.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.89 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.433 ' C ' ' O ' ' A' ' 237' ' ' HIS . 23.2 p90 -34.48 -54.13 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.414 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 2.1 t-20 -41.52 -46.76 3.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 51.7 mm -41.29 139.07 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.114 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 11.5 t -122.91 170.88 9.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.148 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 43.5 mp0 -57.69 -32.78 67.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -64.95 -32.51 74.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.86 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 17.5 mtt -71.98 -43.84 64.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.939 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.446 HD22 HD11 ' A' ' 275' ' ' ILE . 36.1 mt -65.51 -43.0 91.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.422 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.3 ptm180 -67.14 -38.36 85.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.34 -33.22 81.62 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.67 -45.48 23.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.87 0.367 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.47 -2.01 44.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.936 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.504 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.9 OUTLIER -69.8 -59.95 4.14 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.719 . . . . 0.0 110.891 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.27 3.69 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.69 2.26 . . . . 0.0 112.342 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.802 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.9 m-85 -102.47 -34.1 9.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 179.21 157.59 19.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.479 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -60.7 115.33 3.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.677 HD13 HD11 ' A' ' 258' ' ' ILE . 66.0 mt -85.85 121.47 37.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -80.61 -40.55 25.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 16.5 t30 -168.61 148.03 4.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.677 HD11 HD13 ' A' ' 255' ' ' ILE . 52.5 mt -129.78 128.35 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.585 HG23 ' HB2' ' A' ' 274' ' ' PHE . 16.1 m -130.03 136.97 57.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.88 130.95 48.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.534 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 21.6 mmt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.866 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.534 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -147.16 162.93 37.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.911 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.23 173.71 39.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.585 ' HB2' HG23 ' A' ' 259' ' ' VAL . 18.7 m-85 -119.91 134.09 55.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.446 HD11 HD22 ' A' ' 245' ' ' LEU . 88.1 mt -135.28 127.91 47.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.5 m -113.27 128.72 56.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.853 ' CE1' HD12 ' A' ' 231' ' ' LEU . 51.3 m-85 -95.65 -175.07 3.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.922 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 7.3 t -102.03 -39.37 7.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -112.61 139.15 48.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.88 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 76.9 p -63.27 -40.22 96.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -63.97 -42.58 97.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 93.3 m -62.04 -42.08 98.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.555 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -62.93 -40.28 97.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.07 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 12.2 ttt85 -61.77 -46.64 88.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.825 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 49.6 mtt180 -58.42 -51.01 71.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.802 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.14 -35.78 69.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.64 HD12 HG12 ' A' ' 302' ' ' VAL . 12.6 tp -63.85 -43.87 94.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.921 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -69.02 -35.01 76.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -73.55 -41.99 62.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.775 ' HB3' HG21 ' A' ' 302' ' ' VAL . 38.2 mt -74.88 -46.97 32.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -43.52 105.76 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.32 33.88 27.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.51 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -102.68 116.29 32.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.336 . . . . 0.0 110.882 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -61.59 114.22 3.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.886 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 13.4 tp -101.13 -55.92 2.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -123.04 42.23 3.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.115 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.79 -21.24 44.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -128.5 149.29 71.3 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.629 0.728 . . . . 0.0 110.837 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 125.5 12.25 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.622 2.214 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.5 ptp -76.09 172.99 11.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -110.58 122.21 47.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.775 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.2 t -129.27 123.58 58.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.24 26.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.487 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.479 ' CE1' HD22 ' A' ' 287' ' ' LEU . 10.2 m170 -74.12 100.94 3.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 230' ' ' GLY . 4.8 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.421 -0.271 . . . . 0.0 112.421 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 277' ' ' PHE . 29.7 mt -124.49 145.34 49.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.823 0.344 . . . . 0.0 110.886 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.529 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.8 OUTLIER -111.65 136.83 50.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.956 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.456 ' CG2' HD21 ' A' ' 236' ' ' LEU . 7.3 p -121.96 133.63 67.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.106 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.15 166.03 26.83 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 4.7 t 73.05 43.2 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.903 0.382 . . . . 0.0 110.827 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.456 HD21 ' CG2' ' A' ' 233' ' ' VAL . 49.4 mt -100.03 177.17 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.425 ' O ' ' C ' ' A' ' 238' ' ' PHE . 2.3 t-80 -102.09 133.04 47.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.844 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.425 ' C ' ' O ' ' A' ' 237' ' ' HIS . 59.3 m-85 -35.78 -52.51 0.71 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.43 ' O ' ' C ' ' A' ' 240' ' ' ILE . 16.5 m120 -45.14 -47.38 12.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.613 HD11 HD21 ' A' ' 295' ' ' LEU . 48.8 mm -35.38 150.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.179 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -147.13 179.96 7.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.181 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -60.19 -39.94 88.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -58.44 -36.88 74.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.845 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 244' ' ' MET . . . . . 0.477 ' SD ' HD13 ' A' ' 240' ' ' ILE . 18.9 mtt -72.09 -41.54 67.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.521 ' CD1' HD21 ' A' ' 260' ' ' LEU . 75.0 mt -68.21 -41.72 80.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.479 ' HA ' HD13 ' A' ' 255' ' ' ILE . 13.4 ptt180 -67.92 -42.95 80.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' CG ' ' A' ' 246' ' ' ARG . . . -63.3 -36.72 93.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.505 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.402 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.2 mt -76.23 -39.85 35.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.88 0.371 . . . . 0.0 111.13 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.755 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -88.42 -1.15 57.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.2 tp10 -70.34 -58.75 4.59 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 0.0 110.831 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.7 3.46 2.73 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.698 2.265 . . . . 0.0 112.332 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.2 m-85 -104.14 -37.99 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.883 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -174.77 160.14 29.14 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.476 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -65.48 109.08 2.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.735 0.302 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.708 HG21 HD11 ' A' ' 258' ' ' ILE . 36.7 mt -77.23 114.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.171 179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -73.83 -43.99 57.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -162.54 152.09 15.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 255' ' ' ILE . 63.2 mt -133.29 129.64 56.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.073 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 52.8 t -129.37 128.05 65.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.154 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.521 HD21 ' CD1' ' A' ' 245' ' ' LEU . 19.0 mt -97.13 127.72 43.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.573 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 40.6 mmm . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.573 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -149.39 154.39 38.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.885 0.374 . . . . 0.0 110.95 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.14 168.24 36.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -115.29 138.66 50.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.854 0.359 . . . . 0.0 110.865 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 70.2 mt -136.46 138.42 46.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.113 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 89.2 m -117.77 122.97 44.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.154 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 231' ' ' LEU . 44.1 m-85 -91.62 -178.04 4.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.915 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 4.3 t -122.41 24.95 9.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.453 ' OD2' ' CG ' ' A' ' 281' ' ' GLU . 26.4 t0 -165.14 126.45 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.884 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 92.8 p -58.24 -40.98 83.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.891 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 281' ' ' GLU . . . . . 0.453 ' CG ' ' OD2' ' A' ' 279' ' ' ASP . 6.2 pt-20 -63.37 -40.96 98.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.868 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 36.1 m -64.14 -41.56 97.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.486 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.17 -44.05 97.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.125 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 48.9 mtm180 -63.09 -49.02 76.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 19.5 mmt-85 -59.67 -51.04 71.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -54.96 -36.36 65.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.061 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.421 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.0 tp -65.33 -43.59 90.45 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.923 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.57 -43.1 73.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.908 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 65.1 mm-40 -68.87 -42.14 77.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.755 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 84.1 mt -73.76 -47.02 42.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -46.2 103.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.02 36.47 13.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 293' ' ' PHE . . . . . 0.424 ' O ' ' N ' ' A' ' 295' ' ' LEU . 37.3 t80 -98.22 93.22 6.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -43.35 95.07 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.613 HD21 HD11 ' A' ' 240' ' ' ILE . 9.3 tt -82.39 -67.38 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -109.0 39.11 2.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 108.91 -41.42 2.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 22.6 ptt-85 -109.9 152.39 42.96 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.634 0.73 . . . . 0.0 110.834 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 118.38 5.64 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.5 ptt? -68.67 169.76 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.6 mmt180 -104.98 121.43 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.9 t -126.95 127.77 70.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.09 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.78 160.34 28.35 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.421 ' CD2' HD22 ' A' ' 287' ' ' LEU . 18.9 m-70 -71.66 125.03 26.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.343 . . . . 0.0 110.889 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.4 t . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.098 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.691 HD12 ' CE2' ' A' ' 277' ' ' PHE . 24.2 mt -126.22 146.63 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.551 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -109.92 136.74 48.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.648 HG21 HD11 ' A' ' 236' ' ' LEU . 7.1 p -120.37 138.13 51.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.96 165.25 28.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 t 71.27 46.59 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.945 0.402 . . . . 0.0 110.85 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.648 HD11 HG21 ' A' ' 233' ' ' VAL . 95.7 mt -109.7 154.02 23.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.956 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 31.9 t-80 -74.45 139.44 43.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -46.58 -45.22 18.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 240' ' ' ILE . 34.1 t-20 -49.88 -46.53 51.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.428 ' C ' ' O ' ' A' ' 239' ' ' ASN . 47.3 mm -35.55 131.67 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.9 p -120.2 177.23 5.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -62.42 -34.65 77.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.898 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -63.16 -33.86 76.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.873 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 244' ' ' MET . . . . . 0.401 ' SD ' HD13 ' A' ' 240' ' ' ILE . 38.1 mtt -71.9 -39.28 69.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.0 -42.91 72.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.624 ' HA ' HD13 ' A' ' 255' ' ' ILE . 17.8 ptt180 -66.77 -40.46 88.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.468 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.75 -36.39 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 90.4 mt -76.38 -42.6 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.832 0.349 . . . . 0.0 111.15 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.583 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -85.47 -2.83 58.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.534 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -69.79 -58.35 5.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.855 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.534 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 0.84 5.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.659 2.24 . . . . 0.0 112.347 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.831 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -101.55 -37.05 8.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -173.56 155.66 22.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -57.89 108.11 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.759 0.314 . . . . 0.0 110.891 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 258' ' ' ILE . 43.4 mt -78.11 112.49 16.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -76.76 -41.71 43.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -165.23 149.99 9.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.891 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 255' ' ' ILE . 48.8 mt -132.41 126.19 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.426 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.5 m -133.12 129.93 57.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.138 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 36.4 mt -91.2 137.7 32.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.496 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.2 mmt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.847 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.496 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.8 p90 -145.75 156.09 43.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.93 0.395 . . . . 0.0 110.944 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -158.06 176.17 35.13 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.426 ' HB2' HG23 ' A' ' 259' ' ' VAL . 22.3 m-85 -121.29 134.02 55.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 0.0 110.836 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.421 HD12 ' CE2' ' A' ' 249' ' ' PHE . 97.3 mt -131.23 145.52 35.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.2 m -120.98 129.66 53.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.691 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.7 m-85 -104.24 175.9 5.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.899 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 3.1 t -120.19 24.87 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.898 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -165.13 127.61 2.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.862 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.5 p -64.05 -40.96 97.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.811 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.47 -43.02 82.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 43.6 m -63.22 -42.73 99.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.438 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.97 -42.44 97.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.049 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 21.4 mtm180 -60.14 -48.98 79.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.879 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.8 mmt85 -58.06 -47.73 82.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.841 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.831 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.03 -40.41 80.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.083 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.496 ' CD1' HG12 ' A' ' 302' ' ' VAL . 9.3 tp -61.66 -40.7 95.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -67.71 -35.0 77.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.938 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -84.11 -22.22 31.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.922 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.9 mt -86.54 -38.51 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 291' ' ' ASN . . . . . 0.409 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -60.02 119.98 8.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.891 179.893 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.53 20.82 78.2 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.507 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -84.78 105.13 15.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.807 0.337 . . . . 0.0 110.882 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -67.2 96.29 0.46 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.4 tt -91.12 -64.2 1.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.928 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -98.71 36.59 1.63 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.13 -35.22 4.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 40.6 mtp180 -113.68 154.11 45.77 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.626 0.727 . . . . 0.0 110.891 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 132.26 22.98 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.656 2.237 . . . . 0.0 112.345 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.9 ptp -83.44 165.89 18.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.875 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.8 122.74 47.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' A' ' 290' ' ' LEU . 47.7 t -131.41 135.44 59.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -153.06 163.58 30.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.534 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -71.97 112.34 7.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.482 HG23 ' CA ' ' A' ' 231' ' ' LEU . 64.5 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.842 HD12 ' CE1' ' A' ' 277' ' ' PHE . 38.3 mt -104.06 144.75 31.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.478 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.3 t80 -111.21 131.46 55.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.507 HG22 HD11 ' A' ' 236' ' ' LEU . 7.7 p -116.0 134.23 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.125 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.42 165.85 27.8 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 6.2 t 73.85 47.09 0.17 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.507 HD11 HG22 ' A' ' 233' ' ' VAL . 15.0 mt -109.53 166.08 11.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.907 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -94.31 140.59 29.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -45.44 -37.07 4.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -57.88 -37.86 74.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.935 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 36.7 mm -47.59 139.04 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.159 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.4 t -125.29 174.34 8.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.099 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -62.3 -36.55 82.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -58.37 -34.64 70.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.902 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 63.3 mtt -70.49 -37.07 74.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 81.9 mt -69.82 -42.34 73.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.505 ' HA ' HD13 ' A' ' 255' ' ' ILE . 20.5 ptt85 -69.65 -40.21 76.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -66.41 -35.16 89.75 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.5 mt -81.04 -44.22 20.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.844 0.354 . . . . 0.0 111.148 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.69 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -81.83 -2.43 50.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.508 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.0 tp10 -70.65 -59.66 3.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.677 0.751 . . . . 0.0 110.931 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.6 3.37 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.333 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.834 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.46 -44.17 5.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.903 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -171.21 139.03 5.22 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -44.61 119.0 1.74 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.744 0.307 . . . . 0.0 110.919 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.505 HD13 ' HA ' ' A' ' 246' ' ' ARG . 28.3 mt -88.85 133.31 31.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.149 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.27 -43.43 8.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -163.47 147.02 10.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 255' ' ' ILE . 61.1 mt -128.91 132.37 67.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 74.4 t -134.93 129.24 50.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.137 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 23.5 mt -94.01 129.55 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.616 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.3 mmt . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.861 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.491 -0.243 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.616 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 0.9 OUTLIER -150.5 157.42 43.0 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.919 0.39 . . . . 0.0 110.935 -179.832 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.56 169.37 38.56 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -113.58 137.97 50.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.363 . . . . 0.0 110.874 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 77.3 mt -136.43 132.61 49.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.9 m -113.51 129.23 56.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.842 ' CE1' HD12 ' A' ' 231' ' ' LEU . 42.6 m-85 -98.96 171.27 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 48.1 t -86.88 -40.08 15.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -116.2 141.13 48.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 40.6 p -63.99 -41.01 97.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 281' ' ' GLU . . . . . 0.423 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 13.3 pt-20 -60.97 -43.97 98.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 282' ' ' CYS . . . . . 0.423 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 73.9 m -60.01 -40.96 91.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.585 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.55 -37.84 88.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 284' ' ' ARG . . . . . 0.418 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 12.4 ttm105 -62.01 -48.73 79.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.6 mmt180 -58.02 -49.8 75.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.834 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.99 -35.54 71.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.091 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 8.4 tp -65.09 -40.83 95.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -68.34 -42.96 78.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -71.91 -38.2 69.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.854 ' HB3' HG21 ' A' ' 302' ' ' VAL . 82.4 mt -73.15 -47.03 47.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -44.47 107.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 77.82 39.3 24.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.462 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 293' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' LEU . 14.7 t80 -101.32 97.78 8.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.816 0.341 . . . . 0.0 110.871 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -43.96 93.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 293' ' ' PHE . 61.8 tp -81.03 -56.95 3.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -129.12 73.13 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.07 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 82.45 -35.53 2.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -125.77 154.85 73.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.579 0.705 . . . . 0.0 110.898 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 136.67 33.68 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.719 2.28 . . . . 0.0 112.336 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 300' ' ' MET . . . . . 0.596 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.3 ptt? -86.68 166.66 15.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 4.2 mmm180 -101.75 128.59 48.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' A' ' 290' ' ' LEU . 9.8 t -131.88 128.92 60.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -157.7 158.8 29.36 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -77.73 124.51 28.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 15.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.141 179.967 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.434 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.0 mt -115.1 145.62 42.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.848 0.356 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.573 ' HB2' HG22 ' A' ' 305' ' ' VAL . 1.5 t80 -111.53 133.69 53.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.921 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 13.1 p -118.64 135.35 59.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.141 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.61 163.56 27.89 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 m 74.39 46.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.905 0.384 . . . . 0.0 110.81 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 14.4 mt -108.98 170.19 8.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.408 ' O ' ' C ' ' A' ' 238' ' ' PHE . 13.7 t-80 -98.89 137.95 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.41 ' O ' ' C ' ' A' ' 239' ' ' ASN . 5.2 m-85 -37.82 -57.02 1.04 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 241' ' ' THR . 45.9 t30 -37.58 -42.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.901 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.7 mm -47.21 130.1 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.463 HG23 ' O ' ' A' ' 239' ' ' ASN . 79.4 p -123.04 -175.63 3.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.145 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -62.38 -41.77 98.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -59.45 -29.75 68.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 20.0 mmt -71.87 -44.52 63.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.465 HD22 HD11 ' A' ' 275' ' ' ILE . 34.7 mt -68.25 -43.04 78.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.503 ' O ' ' N ' ' A' ' 250' ' ' GLU . 5.6 ptp180 -66.35 -44.55 82.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.499 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -61.08 -39.49 97.18 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.9 mt -76.17 -41.37 37.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.868 0.366 . . . . 0.0 111.147 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.762 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -86.42 -5.55 59.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.541 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -67.36 -58.05 9.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.683 0.754 . . . . 0.0 110.894 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.541 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.72 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.856 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -104.77 -25.32 12.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.88 159.04 15.91 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.53 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -62.22 117.82 6.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.724 0.297 . . . . 0.0 110.91 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.645 HD13 HD11 ' A' ' 258' ' ' ILE . 70.3 mt -90.99 114.06 27.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -69.77 -42.99 73.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -167.96 153.55 7.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.645 HD11 HD13 ' A' ' 255' ' ' ILE . 87.6 mt -132.94 128.43 56.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 75.8 t -127.42 129.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.093 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 35.9 mt -96.6 135.82 37.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.549 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 35.2 mmm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.893 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.549 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.4 p90 -149.38 160.32 43.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.914 -179.76 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.52 171.65 42.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.508 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -113.31 139.28 48.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.802 0.334 . . . . 0.0 110.887 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.465 HD11 HD22 ' A' ' 245' ' ' LEU . 54.1 mt -135.95 139.38 46.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.167 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 85.8 m -119.09 122.26 41.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.434 ' CE1' HD12 ' A' ' 231' ' ' LEU . 36.3 m-85 -91.08 -177.14 4.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.5 t -104.56 -22.14 13.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -133.62 134.94 43.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.8 p -61.7 -36.99 82.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -63.57 -44.0 95.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.875 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.4 m -61.94 -40.04 94.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.16 -41.7 97.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.079 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 284' ' ' ARG . . . . . 0.423 ' HD3' ' CE1' ' A' ' 304' ' ' HIS . 11.8 mmt85 -60.0 -49.06 79.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -58.31 -50.6 73.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.885 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.856 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.55 -39.45 73.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.063 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.45 HD12 HG12 ' A' ' 302' ' ' VAL . 13.2 tp -62.08 -40.09 94.65 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -67.32 -34.96 78.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -84.6 -25.86 28.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.92 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.763 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.9 mt -81.87 -41.48 20.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 291' ' ' ASN . . . . . 0.435 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.6 OUTLIER -59.55 117.62 5.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.03 27.32 58.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -95.61 103.35 15.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.854 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -56.97 97.92 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.925 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -87.57 -54.31 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.04 55.01 1.01 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.85 -37.23 3.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -117.03 156.46 48.29 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.622 0.725 . . . . 0.0 110.864 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.56 40.44 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 300' ' ' MET . . . . . 0.549 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.0 ptt? -91.25 162.8 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -99.71 122.06 42.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.763 HG21 ' HB3' ' A' ' 290' ' ' LEU . 5.1 t -129.26 128.77 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -151.19 162.09 29.35 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.484 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.423 ' CE1' ' HD3' ' A' ' 284' ' ' ARG . 0.2 OUTLIER -75.51 123.32 25.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.826 0.346 . . . . 0.0 110.887 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.573 HG22 ' HB2' ' A' ' 232' ' ' TYR . 87.1 t . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.843 HD12 ' CE1' ' A' ' 277' ' ' PHE . 33.4 mt -133.83 144.07 48.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.508 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -113.08 139.1 48.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 -179.975 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.449 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.9 p -127.42 134.69 65.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.106 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.39 166.02 27.33 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.501 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 73.71 46.15 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.896 0.379 . . . . 0.0 110.842 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 233' ' ' VAL . 65.2 mt -108.5 174.55 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.426 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 4.5 t-80 -94.66 126.42 39.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.825 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.426 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 5.8 p90 -39.35 -50.28 2.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.864 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -43.53 -49.42 7.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 45.1 mm -38.73 139.59 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.119 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 30.8 p -120.09 175.15 6.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.156 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.12 -31.01 70.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 243' ' ' ASP . . . . . 0.454 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 2.2 m-20 -63.37 -35.84 81.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 8.2 mmt -72.08 -39.28 69.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.59 ' CD1' HD21 ' A' ' 260' ' ' LEU . 54.6 mt -68.23 -39.87 82.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.92 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.487 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 3.8 ptm180 -70.48 -37.31 74.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.45 -35.35 81.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.492 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.428 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 93.7 mt -77.5 -42.41 29.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.899 0.381 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.602 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.86 -4.12 58.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.8 OUTLIER -69.7 -58.29 5.76 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.637 0.732 . . . . 0.0 110.897 -179.901 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.3 Cg_endo -69.8 2.78 3.24 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.671 2.247 . . . . 0.0 112.34 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.96 -35.55 8.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -177.57 159.84 26.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 16.6 ttmt -60.24 120.15 9.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.732 HG21 HD11 ' A' ' 258' ' ' ILE . 64.5 mt -90.74 113.78 27.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.117 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 256' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' A' ' 256' ' ' ASP . 31.1 t0 -77.2 -40.61 44.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.826 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -168.33 147.76 4.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.89 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 255' ' ' ILE . 53.3 mt -129.36 132.83 66.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.485 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.5 m -134.07 138.43 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.164 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.59 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.2 mt -104.16 132.6 50.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 26.3 mmt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 2.6 p90 -145.06 161.8 38.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.936 0.398 . . . . 0.0 110.907 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.72 171.55 37.7 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.477 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.485 ' HB2' HG23 ' A' ' 259' ' ' VAL . 16.2 m-85 -118.86 136.76 53.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.859 0.362 . . . . 0.0 110.873 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.421 HG12 HG23 ' A' ' 258' ' ' ILE . 89.3 mt -135.73 138.7 47.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.134 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 61.0 m -113.03 128.77 56.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.843 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.1 m-85 -101.98 170.45 8.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 14.6 t -115.79 33.15 5.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -172.58 124.97 0.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 23.0 t -62.74 -40.52 97.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -66.8 -43.71 83.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.86 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 51.9 m -64.36 -42.58 96.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.913 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.74 -44.03 97.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -59.31 -48.56 81.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.87 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -57.96 -51.17 70.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.96 -39.62 69.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.098 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.645 HD22 ' CE1' ' A' ' 304' ' ' HIS . 11.7 tp -63.33 -39.99 96.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -68.49 -34.95 76.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 49.4 mm-40 -83.97 -26.77 28.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.771 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.2 mt -81.4 -47.02 13.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 291' ' ' ASN . . . . . 0.456 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.7 OUTLIER -53.07 114.71 1.54 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.18 34.99 35.39 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.488 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -105.04 122.53 46.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -77.17 112.02 13.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 40.7 tp -93.99 -60.47 1.74 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.964 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -102.93 -21.81 13.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.088 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 169.95 -33.94 0.17 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.79 152.5 45.63 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.67 0.747 . . . . 0.0 110.859 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 120.43 7.21 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.668 2.246 . . . . 0.0 112.344 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 300' ' ' MET . . . . . 0.643 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -72.41 168.54 18.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 41.7 mmt-85 -111.91 125.0 53.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 290' ' ' LEU . 57.8 t -131.37 129.62 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.63 163.01 26.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.645 ' CE1' HD22 ' A' ' 287' ' ' LEU . 20.3 m170 -75.21 98.38 3.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 0.0 110.857 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.147 179.984 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.539 HD12 ' CE2' ' A' ' 277' ' ' PHE . 20.6 mt -128.29 146.97 50.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.92 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.683 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.7 t80 -114.39 136.53 52.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.604 ' CG2' HD11 ' A' ' 236' ' ' LEU . 7.4 p -121.12 134.53 64.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.099 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.47 165.05 27.97 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 3.8 t 74.58 46.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.933 0.397 . . . . 0.0 110.875 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.604 HD11 ' CG2' ' A' ' 233' ' ' VAL . 85.8 mt -111.49 170.69 7.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.934 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 18.4 t-80 -88.82 147.28 24.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.412 ' O ' ' C ' ' A' ' 239' ' ' ASN . 2.9 m-85 -52.91 -59.76 4.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.412 ' C ' ' O ' ' A' ' 238' ' ' PHE . 20.1 t-20 -36.17 -47.32 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 23.5 mm -38.42 136.7 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 7.8 t -123.03 179.55 4.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.158 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 45.7 mp0 -63.05 -35.23 79.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -58.78 -38.51 78.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -64.68 -45.98 84.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.529 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.0 mt -59.98 -39.24 85.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.536 ' HA ' HD13 ' A' ' 255' ' ' ILE . 0.0 OUTLIER -72.05 -40.8 68.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.46 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.91 -29.6 74.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.0 mt -87.51 -43.53 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 111.096 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.557 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 2.7 m-85 -85.17 -0.11 53.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.502 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 4.0 tt0 -68.99 -59.88 4.87 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.652 0.739 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.4 Cg_endo -69.7 -9.45 26.15 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.256 . . . . 0.0 112.388 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.7 m-85 -88.78 -24.8 22.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.01 164.43 25.72 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.514 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -68.3 108.84 3.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.857 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.74 HG21 HD11 ' A' ' 258' ' ' ILE . 19.4 mt -77.23 113.63 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.094 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -72.19 -45.2 61.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.921 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -163.32 157.68 20.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.74 HD11 HG21 ' A' ' 255' ' ' ILE . 71.6 mt -138.6 131.85 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 274' ' ' PHE . 3.8 m -134.79 126.6 47.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.486 HD21 HD11 ' A' ' 245' ' ' LEU . 20.7 mt -93.58 129.33 39.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.936 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.574 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 17.8 mmm . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.574 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.3 p90 -150.36 162.21 40.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.951 0.405 . . . . 0.0 110.944 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.59 177.32 37.92 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.5 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.771 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.1 m-85 -120.1 133.99 55.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.774 0.321 . . . . 0.0 110.925 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.529 HD11 ' HB3' ' A' ' 245' ' ' LEU . 67.9 mt -133.08 135.93 56.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 64.5 m -117.51 129.3 55.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.539 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.6 m-85 -100.68 178.74 4.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.6 t -114.98 12.84 16.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.858 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -155.66 128.5 8.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.4 t -64.0 -40.98 97.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 35.6 mm-40 -62.26 -43.93 97.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.897 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 98.7 m -64.51 -36.19 83.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.832 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.53 -43.7 89.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.087 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -61.11 -49.09 78.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 71.5 mtt180 -59.49 -44.32 93.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.407 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -62.61 -35.06 78.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.126 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.607 HD12 HG12 ' A' ' 302' ' ' VAL . 17.6 tp -64.74 -44.66 89.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -69.18 -35.02 75.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -73.59 -42.0 62.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.926 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.823 ' HB3' HG21 ' A' ' 302' ' ' VAL . 42.0 mt -75.25 -47.04 29.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.876 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -42.14 106.25 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.65 34.59 31.05 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -96.07 102.02 13.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.344 . . . . 0.0 110.891 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -56.22 90.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.909 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 25.6 tp -80.18 -58.53 3.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.76 40.34 2.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.53 -26.98 21.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 3.5 ptp85 -120.08 147.34 44.4 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 122.33 9.01 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.328 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -75.36 177.31 6.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 11.5 mmm-85 -110.85 122.68 48.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.823 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.0 t -128.99 123.51 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.113 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -156.47 161.25 30.78 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.444 ' CD2' HD22 ' A' ' 287' ' ' LEU . 90.4 m-70 -72.68 128.27 35.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.855 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 232' ' ' TYR . 21.5 m . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.115 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.456 -0.257 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.97 HD12 ' CE1' ' A' ' 277' ' ' PHE . 34.3 mt -118.6 146.83 44.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.806 0.336 . . . . 0.0 110.929 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.581 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.4 OUTLIER -118.6 141.3 48.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.915 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.64 ' CG2' HD11 ' A' ' 236' ' ' LEU . 12.0 p -123.08 131.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.14 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -136.91 165.9 25.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 58.5 m 62.54 49.87 3.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.884 0.373 . . . . 0.0 110.822 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.64 HD11 ' CG2' ' A' ' 233' ' ' VAL . 61.8 mt -103.67 -175.13 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 16.8 t-80 -110.39 142.31 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -49.47 -44.31 45.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -52.44 -33.74 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 10.5 mm -57.21 125.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.144 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.1 p -117.28 178.64 4.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.162 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -60.83 -36.67 79.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 243' ' ' ASP . . . . . 0.443 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 6.9 t0 -60.88 -34.37 74.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.807 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 21.6 mtt -72.05 -42.71 65.97 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 63.1 mt -66.8 -42.97 85.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.939 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.448 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 4.0 ptm180 -66.38 -38.74 88.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.866 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.448 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.45 -36.82 92.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 86.8 mt -78.56 -43.91 26.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.912 0.387 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.4 m-85 -81.75 -4.72 57.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.924 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.501 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.5 OUTLIER -66.55 -60.13 7.06 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.677 0.751 . . . . 0.0 110.897 -179.908 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.34 3.61 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.706 2.271 . . . . 0.0 112.321 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.824 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.3 m-85 -103.39 -23.33 13.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.881 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 168.35 158.98 13.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.466 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.47 117.58 7.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.768 0.318 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.68 HD13 HD11 ' A' ' 258' ' ' ILE . 45.4 mt -86.33 120.89 36.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.103 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -79.51 -41.23 27.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.851 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 38.4 t30 -167.7 145.78 4.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.68 HD11 HD13 ' A' ' 255' ' ' ILE . 93.9 mt -128.44 127.88 67.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.105 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.635 HG23 ' HB2' ' A' ' 274' ' ' PHE . 18.3 m -129.51 139.15 52.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.096 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 28.9 mt -111.41 139.49 46.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.572 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 29.8 mmt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.572 ' CE1' ' HB2' ' A' ' 261' ' ' MET . 2.1 p90 -151.01 165.18 34.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.926 0.393 . . . . 0.0 110.94 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -157.89 168.01 34.37 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.492 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.635 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.0 m-85 -114.44 137.79 51.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.864 0.364 . . . . 0.0 110.872 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 85.1 mt -137.24 134.45 47.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.6 m -117.76 129.18 55.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.191 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.97 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.4 m-85 -99.28 177.97 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 62.6 p -98.8 -36.28 9.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.819 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -115.97 129.19 56.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 32.8 p -57.48 -37.98 73.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 281' ' ' GLU . . . . . 0.419 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 11.1 pt-20 -62.32 -43.35 99.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 282' ' ' CYS . . . . . 0.419 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 68.1 m -62.25 -37.49 85.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -40.17 90.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 47.6 ttt85 -62.08 -48.94 77.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.862 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.8 mmt180 -58.66 -51.02 71.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.57 -35.07 69.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.7 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -65.06 -41.96 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -68.99 -42.91 75.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.943 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.0 mm100 -71.98 -36.03 69.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.664 ' HB3' HG21 ' A' ' 302' ' ' VAL . 54.9 mt -75.3 -46.95 30.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -42.0 112.41 0.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.905 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 73.96 40.16 44.45 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 23.9 t80 -100.93 98.05 8.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.824 0.345 . . . . 0.0 110.861 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.19 105.83 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 5.7 tt -94.82 -53.68 3.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.926 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.14 40.64 2.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.2 -35.21 4.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.491 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 -110.23 149.1 39.66 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.576 0.703 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 119.16 6.15 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.724 2.283 . . . . 0.0 112.325 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptm -71.07 171.55 10.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -106.92 125.17 50.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.913 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.7 HG12 HD12 ' A' ' 287' ' ' LEU . 7.0 t -128.5 121.5 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.097 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.69 163.49 28.54 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.503 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.478 ' CE1' HD22 ' A' ' 287' ' ' LEU . 18.5 m170 -79.24 130.37 35.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.885 0.374 . . . . 0.0 110.82 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 83.9 t . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.134 179.959 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.465 HD11 ' O ' ' A' ' 283' ' ' ALA . 37.0 mt -129.96 147.04 51.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.349 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.492 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.4 t80 -110.13 131.81 54.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.74 136.46 55.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.18 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.56 165.47 27.53 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.448 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.5 t 74.28 46.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.9 0.381 . . . . 0.0 110.85 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.37 170.7 7.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 238' ' ' PHE . 31.4 t-80 -98.65 132.16 44.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.437 ' C ' ' O ' ' A' ' 237' ' ' HIS . 0.9 OUTLIER -34.46 -61.07 0.4 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.878 -179.91 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 238' ' ' PHE . 4.5 p30 -36.95 -47.27 0.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.411 ' C ' ' O ' ' A' ' 239' ' ' ASN . 40.3 mm -36.74 128.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.181 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.0 p -118.44 175.57 5.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -60.61 -31.07 70.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.844 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -64.89 -32.45 74.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 13.5 mmt -71.74 -40.88 69.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.476 ' CD1' HD21 ' A' ' 260' ' ' LEU . 45.1 mt -69.35 -43.0 74.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.436 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 6.2 ptm180 -66.02 -40.11 90.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -66.48 -38.25 93.32 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.507 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.0 mt -77.27 -41.84 30.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.902 0.382 . . . . 0.0 111.131 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.591 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -83.74 -3.88 58.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.847 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.535 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.94 -58.34 5.42 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.654 0.74 . . . . 0.0 110.853 -179.932 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.74 2.74 3.25 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.734 2.289 . . . . 0.0 112.347 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.816 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.62 -33.11 9.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 175.67 138.66 2.88 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.449 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -45.64 116.64 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.769 0.319 . . . . 0.0 110.924 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 55.5 mt -85.3 134.7 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.12 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -91.38 -46.47 8.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.874 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 33.8 t30 -160.92 145.82 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.1 mt -124.14 133.1 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.151 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 89.4 t -131.86 125.78 55.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.13 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.476 HD21 ' CD1' ' A' ' 245' ' ' LEU . 26.2 mt -96.93 131.32 43.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.53 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.7 mmt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.894 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.53 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 1.1 p90 -151.0 153.72 35.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 0.0 110.934 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.01 175.36 40.15 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -117.79 140.29 49.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.939 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.437 HD11 ' HB3' ' A' ' 245' ' ' LEU . 90.6 mt -138.25 128.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 83.5 m -110.02 130.0 55.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.444 ' CE1' HD12 ' A' ' 231' ' ' LEU . 32.7 m-85 -96.37 179.51 5.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 27.8 t -92.03 -42.73 9.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.83 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.41 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 10.9 t0 -114.1 139.35 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.7 m -60.75 -39.74 89.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 281' ' ' GLU . . . . . 0.41 ' HG2' ' CG ' ' A' ' 279' ' ' ASP . 11.6 pt-20 -61.62 -43.73 98.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 87.9 m -60.13 -38.93 84.55 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.465 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -65.37 -40.93 94.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -60.1 -48.31 82.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 47.7 mmt-85 -58.25 -51.01 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.816 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.24 -35.54 69.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.593 HD12 HG12 ' A' ' 302' ' ' VAL . 12.4 tp -65.01 -40.55 95.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.902 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -68.41 -42.63 78.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.855 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 24.7 mm-40 -71.88 -38.99 69.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.997 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.8 mt -72.62 -45.87 56.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.924 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -47.81 108.07 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.833 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.46 36.11 27.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.474 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -100.45 121.64 41.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.832 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -73.68 96.64 2.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 42.5 tp -88.52 -47.83 8.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.927 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -121.9 43.57 2.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.133 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 93.78 -25.17 22.73 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.507 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 55.2 mtp180 -122.94 148.69 54.75 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.605 0.717 . . . . 0.0 110.844 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 121.17 7.85 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.635 2.223 . . . . 0.0 112.357 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -74.46 171.8 13.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.2 mmm180 -108.8 123.51 49.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.997 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.4 t -129.46 126.6 63.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.126 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -147.78 158.97 27.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -71.65 120.58 17.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.812 0.339 . . . . 0.0 110.873 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.987 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.694 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.2 mt -122.18 144.82 48.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.358 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -109.52 141.97 41.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.948 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.92 135.75 63.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -142.59 166.06 26.61 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.8 m 64.03 49.82 2.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.892 0.377 . . . . 0.0 110.878 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 96.4 mt -103.06 -179.02 3.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.417 ' O ' ' C ' ' A' ' 238' ' ' PHE . 11.2 t-80 -109.85 133.11 53.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.434 ' O ' ' C ' ' A' ' 239' ' ' ASN . 71.7 m-85 -37.38 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.86 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.434 ' C ' ' O ' ' A' ' 238' ' ' PHE . 2.3 p30 -35.8 -40.86 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.908 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 37.4 mm -49.07 146.11 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 239' ' ' ASN . 12.6 p -143.2 -179.86 6.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.171 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -60.52 -35.82 76.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.882 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.23 -41.23 88.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 19.3 mtt -69.28 -44.92 70.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.464 HD22 HD11 ' A' ' 275' ' ' ILE . 47.4 mt -60.25 -36.38 77.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.486 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -39.73 68.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.953 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.482 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.65 -36.34 93.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.438 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.612 ' CG2' HD21 ' A' ' 290' ' ' LEU . 95.4 mt -81.78 -44.1 20.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.871 0.367 . . . . 0.0 111.103 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.628 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.3 m-85 -79.07 -8.08 58.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.525 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.1 tp10 -67.96 -58.78 7.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.525 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.78 1.88 4.05 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.779 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.0 -34.45 8.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -179.41 158.03 21.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 2.4 ttmp? -64.73 101.53 0.48 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.745 0.307 . . . . 0.0 110.932 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 38.4 mt -69.36 125.65 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.162 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -83.03 -42.53 17.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.823 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -168.82 146.77 3.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 95.9 mt -123.08 133.79 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.144 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.517 HG23 ' HB2' ' A' ' 274' ' ' PHE . 7.1 m -133.92 124.59 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 29.5 mt -92.04 138.05 31.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.562 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 10.5 mmm . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.562 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -146.89 153.29 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.926 0.393 . . . . 0.0 110.927 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -159.66 -178.15 33.4 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.517 ' HB2' HG23 ' A' ' 259' ' ' VAL . 32.7 m-85 -129.71 140.11 51.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.5 mt -136.64 137.27 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.137 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.5 m -116.13 127.25 54.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.125 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.694 ' CE1' HD12 ' A' ' 231' ' ' LEU . 48.9 m-85 -96.92 -179.27 4.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.2 t -96.93 -41.85 8.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.863 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -112.52 138.12 49.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.1 p -61.51 -39.74 92.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.847 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -61.91 -44.04 97.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 72.2 m -60.4 -37.31 80.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.904 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.05 -41.44 86.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.4 ttt180 -59.96 -48.78 80.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.86 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -58.41 -51.02 71.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.779 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.15 -35.02 69.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.664 HD12 HG12 ' A' ' 302' ' ' VAL . 10.8 tp -63.88 -45.3 90.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -69.08 -39.01 79.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -69.46 -42.11 75.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.91 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 56.7 mt -74.45 -47.03 35.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -43.59 114.53 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 71.22 38.2 63.17 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -104.57 109.57 21.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.923 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -55.29 95.05 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.913 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.454 HD13 ' C ' ' A' ' 295' ' ' LEU . 0.5 OUTLIER -76.25 -64.78 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.6 37.41 3.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.62 -40.2 2.46 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 62.1 mtp180 -115.95 157.58 44.5 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 127.82 15.16 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.716 2.277 . . . . 0.0 112.356 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 300' ' ' MET . . . . . 0.41 ' HE2' HD23 ' A' ' 295' ' ' LEU . 2.1 ptp -79.51 179.53 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.875 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -110.73 123.36 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.89 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 14.8 t -132.75 125.35 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.56 160.83 28.3 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.436 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.534 ' CE1' HD22 ' A' ' 287' ' ' LEU . 9.6 m170 -75.55 111.6 11.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.834 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 304' ' ' HIS . 98.5 t . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.611 HD11 ' O ' ' A' ' 283' ' ' ALA . 44.6 mt -116.85 144.66 44.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.847 0.356 . . . . 0.0 110.935 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.475 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.7 t80 -106.73 129.53 54.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.7 p -114.81 132.54 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.179 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.12 163.85 28.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.479 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 74.64 43.01 0.27 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.928 0.394 . . . . 0.0 110.881 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.428 HD11 ' CG2' ' A' ' 233' ' ' VAL . 23.1 mt -101.88 -177.41 3.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 240' ' ' ILE . 6.6 t-80 -103.75 126.77 51.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.865 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.49 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 4.2 p90 -35.89 -44.69 0.37 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.49 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 39.5 t30 -51.7 -46.15 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.44 ' N ' ' O ' ' A' ' 237' ' ' HIS . 40.3 mm -40.19 147.87 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.127 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.0 t -136.98 174.51 10.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.099 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 38.0 mp0 -56.89 -34.96 68.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -58.33 -44.18 88.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.4 mmt -65.08 -42.23 94.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.694 HD11 HD21 ' A' ' 260' ' ' LEU . 41.7 mt -61.19 -39.62 90.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.894 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.01 -37.97 69.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.454 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -63.37 -34.61 90.42 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 248' ' ' ILE . . . . . 0.437 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 68.1 mt -83.55 -44.81 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.618 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.7 m-85 -78.94 -5.97 55.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.58 -58.28 5.9 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 0.0 110.909 -179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.78 -0.95 7.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.63 2.22 . . . . 0.0 112.388 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.793 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 11.7 m-85 -100.05 -23.87 14.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 167.57 167.33 28.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm -68.43 115.09 7.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.71 0.29 . . . . 0.0 110.872 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.441 HG21 HD11 ' A' ' 258' ' ' ILE . 27.3 mt -83.41 120.65 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.126 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -77.63 -49.37 14.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -163.25 145.64 10.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.441 HD11 HG21 ' A' ' 255' ' ' ILE . 84.8 mt -124.42 129.6 73.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 51.8 t -131.03 131.94 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.165 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.694 HD21 HD11 ' A' ' 245' ' ' LEU . 30.0 mt -101.08 133.7 45.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.473 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 57.6 mmm . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.888 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.473 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -148.19 159.09 44.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.904 0.383 . . . . 0.0 110.962 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -166.1 176.3 41.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -119.74 135.9 54.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.339 . . . . 0.0 110.886 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.428 HD12 ' CE2' ' A' ' 249' ' ' PHE . 75.8 mt -131.89 140.11 48.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 69.5 m -120.97 128.23 52.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.181 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -96.8 -175.34 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.841 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.4 t -105.23 -28.79 10.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.893 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.66 135.56 55.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.3 p -63.54 -40.52 97.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -61.68 -43.63 98.49 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.861 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.9 m -62.5 -38.81 91.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.905 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.611 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.92 -43.17 96.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.128 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -61.65 -47.58 84.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -57.98 -49.8 75.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.793 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.25 -39.47 75.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.683 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -61.68 -40.71 95.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -68.24 -35.04 77.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -82.58 -26.5 32.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.952 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.3 mt -81.71 -47.06 13.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 291' ' ' ASN . . . . . 0.444 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -51.36 117.17 2.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.25 32.45 55.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.446 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -97.49 106.89 19.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -59.73 102.53 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 39.7 tp -92.79 -63.36 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -107.88 39.79 1.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.109 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.88 -25.81 26.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -120.68 154.53 57.22 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.601 0.715 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.85 128.93 16.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.683 2.255 . . . . 0.0 112.333 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 300' ' ' MET . . . . . 0.605 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.9 ptt? -82.43 164.35 21.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 66.6 mmt-85 -102.28 121.19 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.952 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.9 t -130.28 121.32 51.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.15 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -140.78 163.98 26.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.514 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 305' ' ' VAL . 7.0 m170 -73.02 112.49 9.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 110.833 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' A' ' 304' ' ' HIS . 74.4 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.134 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 63.5 mt -129.03 145.7 51.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.942 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.498 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.0 t80 -105.54 135.0 47.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.597 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.6 p -121.73 129.39 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -138.65 162.55 25.84 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 73.47 46.73 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.891 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.597 HD11 ' CG2' ' A' ' 233' ' ' VAL . 64.2 mt -106.73 -176.14 2.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.959 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -113.6 130.26 56.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.418 ' O ' ' C ' ' A' ' 239' ' ' ASN . 1.2 m-85 -38.12 -58.29 0.98 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 238' ' ' PHE . 18.3 m-20 -36.19 -46.1 0.49 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.0 mm -47.43 128.92 3.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.7 p -113.1 174.88 5.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -58.53 -33.86 70.35 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.876 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -61.58 -46.02 91.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 30.6 mtt -60.23 -42.49 95.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.735 HD11 HD21 ' A' ' 260' ' ' LEU . 42.4 mt -60.42 -40.5 91.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.498 ' O ' ' N ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -63.51 -43.98 95.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.467 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -64.87 -32.01 82.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.485 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 87.0 mt -78.4 -40.99 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.881 0.372 . . . . 0.0 111.175 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.701 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.2 m-85 -90.91 -8.65 48.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.886 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.515 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.6 tp10 -59.0 -59.28 14.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.636 0.731 . . . . 0.0 110.88 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.515 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 2.75 3.28 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.268 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.725 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.6 m-85 -106.41 -9.67 16.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 152.7 168.25 16.5 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.45 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 31.6 tttp -72.46 122.03 20.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.75 0.309 . . . . 0.0 110.932 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.468 HG21 HD11 ' A' ' 258' ' ' ILE . 33.4 mt -93.8 111.65 25.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -70.14 -39.34 75.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.883 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -167.66 155.05 8.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 255' ' ' ILE . 49.0 mt -131.57 131.99 62.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 8.1 t -128.4 137.8 56.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.161 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.735 HD21 HD11 ' A' ' 245' ' ' LEU . 48.3 mt -110.07 132.81 53.83 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.525 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.3 mmt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.525 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 0.5 OUTLIER -150.42 161.95 41.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.931 0.396 . . . . 0.0 110.879 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.9 -173.17 35.69 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.62 148.5 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.701 HD12 ' CE2' ' A' ' 249' ' ' PHE . 82.1 mt -138.58 139.66 40.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.4 m -118.21 129.98 55.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.16 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -103.48 -175.11 2.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 22.8 t -100.15 -41.76 6.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -113.93 139.94 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.852 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 60.9 p -63.14 -40.16 96.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.847 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.15 -42.77 99.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.904 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.2 m -60.7 -35.98 77.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -68.07 -41.98 81.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.081 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 19.6 ttm180 -59.23 -49.11 79.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 28.4 mmt180 -58.91 -50.93 72.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.885 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.725 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.41 -34.9 69.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.09 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.759 HD12 HG12 ' A' ' 302' ' ' VAL . 15.0 tp -64.09 -45.29 89.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -69.01 -42.03 76.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -67.81 -42.02 82.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.916 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.675 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 65.2 mt -73.72 -46.82 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 291' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 290' ' ' LEU . 0.7 OUTLIER -37.19 103.6 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 179.909 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.58 33.86 33.39 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 293' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 290' ' ' LEU . 22.6 t80 -87.42 105.48 17.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -57.67 96.75 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.404 HD23 ' C ' ' A' ' 295' ' ' LEU . 8.5 tt -89.72 -69.54 0.71 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.946 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -99.3 32.05 2.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 107.68 -36.86 4.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.512 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -108.94 148.01 37.03 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.58 0.705 . . . . 0.0 110.885 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.03 7.73 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.716 2.277 . . . . 0.0 112.325 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptm -74.02 171.96 12.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.0 mmt85 -111.73 122.95 49.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.759 HG12 HD12 ' A' ' 287' ' ' LEU . 4.2 t -124.17 122.32 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.49 162.54 26.92 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.449 ' O ' ' C ' ' A' ' 305' ' ' VAL . 5.0 m170 -71.4 127.27 32.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.812 0.339 . . . . 0.0 110.826 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 304' ' ' HIS . 54.0 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.11 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.752 HD12 ' CE2' ' A' ' 277' ' ' PHE . 51.8 mt -123.94 145.22 49.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -112.51 133.79 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.946 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.415 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.7 p -122.07 132.85 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.113 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.76 165.78 27.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.474 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.3 m 74.03 47.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.415 HD11 ' CG2' ' A' ' 233' ' ' VAL . 74.7 mt -110.03 178.78 4.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.919 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -97.53 132.08 43.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.468 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.1 t80 -42.62 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.85 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 238' ' ' PHE . 59.4 t-20 -34.62 -33.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.468 ' N ' ' O ' ' A' ' 238' ' ' PHE . 21.8 mm -54.85 147.98 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.109 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.407 HG23 ' HB3' ' A' ' 243' ' ' ASP . 8.9 t -134.98 175.8 9.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.137 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 242' ' ' GLU . . . . . 0.431 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 11.8 mt-10 -57.82 -32.65 67.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 243' ' ' ASP . . . . . 0.407 ' HB3' HG23 ' A' ' 241' ' ' THR . 4.1 t70 -60.26 -33.83 72.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.89 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.4 mmt -71.98 -37.87 69.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 245' ' ' LEU . . . . . 0.666 ' HB3' HD11 ' A' ' 275' ' ' ILE . 39.1 mt -69.54 -42.89 74.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.959 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.489 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 14.9 ptt85 -67.53 -39.46 85.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.462 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.6 -35.63 86.58 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.492 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 73.3 mt -79.1 -45.19 24.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.815 0.341 . . . . 0.0 111.101 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 255' ' ' ILE . 3.1 m-85 -80.6 -4.9 55.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.537 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.89 -58.19 5.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.69 0.757 . . . . 0.0 110.875 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.537 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.81 3.2 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.479 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.6 m-85 -103.91 -25.84 12.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.93 166.14 29.33 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.464 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.2 ttmt -67.4 109.54 3.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 249' ' ' PHE . 33.6 mt -81.06 123.68 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.141 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -79.31 -44.53 21.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -168.33 151.16 5.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.865 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.513 HG23 HG12 ' A' ' 275' ' ' ILE . 36.7 mt -128.19 134.02 65.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.16 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.7 m -134.51 134.76 54.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 260' ' ' LEU . . . . . 0.431 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 32.3 mt -97.48 134.62 40.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.934 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.571 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 26.9 mmm . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.571 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 3.7 p90 -148.69 155.92 41.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.931 0.396 . . . . 0.0 110.861 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.5 177.89 39.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.553 ' HE1' HG22 ' A' ' 305' ' ' VAL . 18.1 m-85 -117.56 139.43 50.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.866 0.365 . . . . 0.0 110.92 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 275' ' ' ILE . . . . . 0.666 HD11 ' HB3' ' A' ' 245' ' ' LEU . 71.0 mt -136.02 138.55 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.132 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.9 m -117.47 123.94 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.752 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.4 m-85 -91.24 -175.69 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 38.9 t -100.02 -34.3 10.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.867 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -122.94 138.27 54.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.903 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.8 p -61.72 -35.88 79.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -63.66 -44.11 94.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.879 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 74.0 m -62.42 -37.8 87.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.588 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.22 -36.94 82.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.073 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 284' ' ' ARG . . . . . 0.42 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 0.1 OUTLIER -64.13 -48.98 73.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.864 -179.891 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -59.83 -43.22 94.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.83 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.479 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -63.15 -35.23 79.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.138 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.816 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -65.07 -44.65 88.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.923 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -69.39 -38.98 78.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -71.5 -41.12 69.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.565 ' HB3' HG21 ' A' ' 302' ' ' VAL . 74.8 mt -74.29 -46.93 37.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -45.22 107.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.5 38.66 13.89 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.449 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -105.54 100.27 9.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.874 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -50.82 103.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 15.9 tp -94.67 -55.82 3.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.42 45.55 2.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.145 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.82 -37.19 3.65 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -117.03 150.45 46.01 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 123.36 10.01 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.64 2.226 . . . . 0.0 112.381 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -69.45 170.68 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 6.1 mmm180 -108.76 124.21 50.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.816 HG12 HD12 ' A' ' 287' ' ' LEU . 17.3 t -129.38 125.41 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.126 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -145.74 162.63 28.29 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.442 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.483 ' NE2' HD22 ' A' ' 287' ' ' LEU . 39.9 m-70 -76.92 126.88 31.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.861 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.553 HG22 ' HE1' ' A' ' 274' ' ' PHE . 82.5 t . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.413 ' O ' HG22 ' A' ' 305' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 231' ' ' LEU . . . . . 0.639 HD11 ' O ' ' A' ' 283' ' ' ALA . 30.0 mt -121.78 139.12 53.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.948 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 232' ' ' TYR . . . . . 0.948 ' HB2' HG12 ' A' ' 305' ' ' VAL . 0.9 OUTLIER -106.47 137.79 43.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 233' ' ' VAL . . . . . 0.4 HG21 HD11 ' A' ' 236' ' ' LEU . 7.4 p -122.56 136.91 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.95 163.95 28.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.468 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 74.16 45.25 0.21 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.891 0.377 . . . . 0.0 110.902 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 236' ' ' LEU . . . . . 0.4 HD11 HG21 ' A' ' 233' ' ' VAL . 96.7 mt -104.9 -176.29 3.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 237' ' ' HIS . . . . . 0.438 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.2 t-80 -109.29 135.06 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.84 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 238' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 1.9 p90 -38.7 -44.14 0.97 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 239' ' ' ASN . . . . . 0.479 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 36.4 t30 -54.02 -42.18 68.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 240' ' ' ILE . . . . . 0.503 ' CD1' HD21 ' A' ' 295' ' ' LEU . 15.5 mm -50.63 106.25 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.152 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 241' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 243' ' ' ASP . 10.9 t -95.25 179.49 5.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.096 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -61.16 -30.83 70.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 243' ' ' ASP . . . . . 0.447 ' H ' HG23 ' A' ' 241' ' ' THR . 5.1 m-20 -61.11 -43.55 98.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.8 mtt -62.68 -46.03 90.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 31.9 mt -60.07 -38.75 83.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.02 -42.4 66.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 247' ' ' GLY . . . . . 0.435 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -61.48 -30.61 74.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.468 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 88.4 mt -88.33 -43.59 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 111.171 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 249' ' ' PHE . . . . . 0.534 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -82.23 -2.64 53.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.886 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 250' ' ' GLU . . . . . 0.528 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -70.34 -58.56 4.77 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.594 0.711 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 251' ' ' PRO . . . . . 0.528 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.1 Cg_endo -69.72 2.03 3.88 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 252' ' ' PHE . . . . . 0.496 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.5 m-85 -103.27 -11.12 18.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 154.23 177.34 27.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.51 131.13 41.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.762 0.315 . . . . 0.0 110.921 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.641 HG21 HD11 ' A' ' 258' ' ' ILE . 94.6 mt -98.76 98.7 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -59.43 -44.72 92.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.825 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -167.2 153.55 8.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.938 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 258' ' ' ILE . . . . . 0.641 HD11 HG21 ' A' ' 255' ' ' ILE . 78.3 mt -130.27 133.01 64.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 259' ' ' VAL . . . . . 0.476 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.6 m -134.41 134.28 54.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.6 mt -103.35 128.81 50.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 261' ' ' MET . . . . . 0.563 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 12.1 mmt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.831 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 272' ' ' TYR . . . . . 0.563 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -146.96 154.86 41.76 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.934 0.397 . . . . 0.0 110.929 -179.827 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -162.21 172.89 38.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 274' ' ' PHE . . . . . 0.476 ' HB2' HG23 ' A' ' 259' ' ' VAL . 33.1 m-85 -119.8 134.39 55.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 110.848 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.74 137.4 56.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 90.9 m -110.42 129.77 55.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 277' ' ' PHE . . . . . 0.499 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.3 m-85 -103.68 170.83 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.845 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 1.1 t -115.38 24.79 11.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.843 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -162.59 113.09 1.49 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 95.2 p -53.12 -40.47 64.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 -179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -62.02 -43.99 97.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 85.6 m -64.56 -40.91 96.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 283' ' ' ALA . . . . . 0.639 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -58.08 -46.35 85.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -61.91 -47.4 85.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -59.15 -50.93 72.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.87 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 286' ' ' ALA . . . . . 0.496 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.71 -35.2 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.076 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 287' ' ' LEU . . . . . 0.437 HD22 ' CD2' ' A' ' 304' ' ' HIS . 7.6 tp -64.59 -44.66 89.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.14 -42.5 75.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.895 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 68.2 mm-40 -67.44 -41.95 83.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 73.9 mt -73.73 -46.95 42.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -41.5 104.93 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.43 34.8 15.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.522 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -100.84 99.76 10.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -61.08 118.22 6.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.893 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 295' ' ' LEU . . . . . 0.503 HD21 ' CD1' ' A' ' 240' ' ' ILE . 10.0 tp -108.1 -50.26 3.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.883 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -113.11 42.81 1.83 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.082 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.33 -35.53 4.54 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.479 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -115.92 152.51 47.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 130.47 19.36 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.357 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -78.24 174.78 10.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 16.6 mmt180 -111.38 120.6 42.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 13.0 t -123.43 131.44 73.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.123 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.2 161.8 30.62 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.546 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 304' ' ' HIS . . . . . 0.437 ' CD2' HD22 ' A' ' 287' ' ' LEU . 34.2 m-70 -70.12 121.94 18.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.865 0.364 . . . . 0.0 110.864 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 305' ' ' VAL . . . . . 0.948 HG12 ' HB2' ' A' ' 232' ' ' TYR . 17.2 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.099 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 80.7 p -96.17 -49.42 5.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.902 0.382 . . . . 0.0 110.919 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 56.5 p -99.09 88.19 3.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.89 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 227' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 228' ' ' SER . . . 179.51 -42.34 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 228' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 227' ' ' GLY . 18.1 m -37.13 120.3 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 0.0 110.865 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 77.7 p -85.39 87.36 7.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -127.96 140.67 11.97 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.452 HD12 ' CE1' ' A' ' 277' ' ' PHE . 25.0 mt -121.09 146.99 46.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 110.922 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.558 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -111.9 139.65 47.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.676 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.2 p -124.44 131.29 72.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.114 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.23 165.38 27.43 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.498 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.2 m 72.82 44.67 0.35 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 0.0 110.883 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.676 HD11 ' CG2' ' A' ' 233' ' ' VAL . 79.5 mt -109.24 172.09 7.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.914 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -90.32 126.99 36.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -41.48 -42.46 2.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -51.09 -42.1 60.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.545 ' CD1' HD21 ' A' ' 295' ' ' LEU . 47.8 mm -44.66 152.2 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.161 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 240' ' ' ILE . 76.1 p -137.02 178.58 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.152 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 242' ' ' GLU . . . . . 0.437 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 12.1 mt-10 -61.67 -35.83 79.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -60.16 -34.87 74.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 244' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 240' ' ' ILE . 27.7 mtt -72.04 -41.17 67.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 59.8 mt -68.67 -42.24 78.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.919 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.428 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 6.1 ptm180 -67.3 -39.87 86.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.428 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.27 -34.75 86.51 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.464 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 92.2 mt -80.98 -42.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.854 0.359 . . . . 0.0 111.103 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.788 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.48 -1.65 54.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.863 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.7 OUTLIER -70.29 -59.79 3.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.654 0.74 . . . . 0.0 110.883 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.81 2.88 3.16 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -102.97 -30.41 10.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 176.62 149.01 7.38 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.453 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 7.4 ttpp -56.29 111.42 0.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 110.854 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.495 HG21 HD11 ' A' ' 258' ' ' ILE . 57.0 mt -80.62 124.97 39.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.161 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -82.28 -43.14 17.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -168.25 149.3 4.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.495 HD11 HG21 ' A' ' 255' ' ' ILE . 41.9 mt -128.25 132.72 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.158 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.552 HG23 ' HB2' ' A' ' 274' ' ' PHE . 4.9 m -134.99 127.02 47.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.437 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 31.6 mt -92.11 136.29 33.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 29.9 mmm -103.91 134.32 47.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.87 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.29 -175.85 4.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.9 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -102.79 -175.99 2.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 11.3 p -118.42 -47.42 2.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -68.45 -24.11 64.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 43.0 p -114.81 -38.1 4.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.142 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 62.3 24.86 65.99 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.468 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.404 ' O ' ' C ' ' A' ' 269' ' ' SER . 47.5 mmt-85 -113.95 110.69 20.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 110.847 -179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.404 ' C ' ' O ' ' A' ' 268' ' ' ARG . 5.3 p -38.18 103.78 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 20.5 mttm -52.2 -29.58 23.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 117.01 37.37 0.96 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -148.63 163.32 37.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.868 0.366 . . . . 0.0 110.947 -179.814 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.32 175.56 39.58 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.552 ' HB2' HG23 ' A' ' 259' ' ' VAL . 31.4 m-85 -120.37 137.74 54.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.859 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 30.1 mt -138.48 137.35 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.16 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.7 m -118.53 129.46 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.452 ' CE1' HD12 ' A' ' 231' ' ' LEU . 39.2 m-85 -97.76 -177.9 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.873 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.9 t -95.51 -41.55 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -116.59 141.23 48.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.1 m -63.87 -36.23 83.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -61.72 -43.65 98.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.94 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 99.2 m -62.06 -40.5 96.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.8 -42.84 99.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 284' ' ' ARG . . . . . 0.427 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 13.0 ttm105 -60.73 -48.05 83.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 23.2 mtp180 -58.31 -50.88 72.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.49 -34.93 71.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.123 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.454 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -64.72 -40.81 95.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -68.96 -42.16 77.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.891 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -71.72 -38.43 70.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.924 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.788 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 56.7 mt -74.08 -47.04 39.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.931 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -44.51 110.16 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.71 37.19 40.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 28.1 t80 -104.83 91.79 3.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.849 0.357 . . . . 0.0 110.825 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -48.91 118.4 2.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.545 HD21 ' CD1' ' A' ' 240' ' ' ILE . 45.6 tp -103.85 -44.73 4.97 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -122.95 40.15 3.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.06 -27.75 18.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 29.6 mtp85 -118.32 148.46 43.9 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.558 0.694 . . . . 0.0 110.891 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 132.62 23.79 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.696 2.264 . . . . 0.0 112.336 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 300' ' ' MET . . . . . 0.431 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -86.88 170.93 11.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.898 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -108.64 127.82 54.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.897 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.784 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.4 t -132.47 127.6 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -152.47 163.87 30.44 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -71.13 146.41 49.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 0.0 110.863 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 95.3 t -73.93 -41.04 53.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 306' ' ' THR . . . . . 0.456 HG23 ' H ' ' A' ' 308' ' ' ARG . 10.8 t -79.55 -12.64 59.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.138 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 44.73 41.96 5.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.456 ' H ' HG23 ' A' ' 306' ' ' THR . 33.9 tpt85 -129.67 134.99 47.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.33 166.14 23.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.32 162.87 5.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 157.26 172.92 25.02 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.481 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -100.05 111.47 4.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.473 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 2.9 t -70.63 158.31 36.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.929 0.395 . . . . 0.0 110.847 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 152.27 76.44 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.481 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.12 20.25 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.702 2.268 . . . . 0.0 112.341 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 2.4 t -41.84 146.68 0.25 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 48.9 m 53.02 42.53 32.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.468 -179.977 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.6 m -131.57 146.47 52.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.915 0.388 . . . . 0.0 110.811 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 94.4 p -101.38 130.24 47.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.859 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 76.27 88.01 0.3 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.512 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 41.0 t -85.39 101.71 12.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 0.0 110.881 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 23.4 t -92.2 33.48 1.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -92.19 150.05 19.98 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.495 ' CA ' HG23 ' A' ' 305' ' ' VAL . 53.7 mt -127.24 144.77 50.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.81 0.338 . . . . 0.0 110.93 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.482 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.5 t80 -109.69 136.29 49.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.8 p -122.87 137.77 55.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.089 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.65 164.32 28.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.466 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.3 t 74.12 47.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.891 0.376 . . . . 0.0 110.807 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 91.3 mt -109.28 170.29 8.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.2 t60 -92.93 126.08 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.876 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -38.83 -48.36 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -46.31 -44.54 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.871 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.44 HG22 ' N ' ' A' ' 241' ' ' THR . 47.9 mm -40.07 154.47 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 240' ' ' ILE . 14.4 t -137.42 173.72 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -60.69 -35.02 75.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.887 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -59.49 -34.53 72.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.7 mmt -71.77 -39.51 69.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.869 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.453 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.6 mt -68.89 -41.85 77.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.554 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.7 ptm180 -68.55 -36.15 78.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.42 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.06 -41.82 92.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.471 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.433 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 76.5 mt -75.18 -41.32 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.841 0.353 . . . . 0.0 111.097 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.676 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -81.56 -4.03 54.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.51 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.0 tp10 -69.48 -59.7 4.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.643 0.735 . . . . 0.0 110.871 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.5 Cg_endo -69.79 3.02 3.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.665 2.243 . . . . 0.0 112.285 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.823 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -103.16 -39.33 6.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.92 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -176.01 148.06 9.04 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -51.75 117.24 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 246' ' ' ARG . 31.2 mt -87.07 124.56 40.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -83.61 -44.7 14.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 11.7 t30 -167.51 150.01 5.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.412 HD11 HG21 ' A' ' 255' ' ' ILE . 34.6 mt -126.6 136.13 61.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 84.8 t -134.97 130.86 52.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.13 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.51 131.66 47.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.455 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 68.4 mmm -98.04 126.25 43.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.46 167.11 18.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.929 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.38 -178.9 4.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 28.0 p -111.94 -52.64 2.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -59.5 -38.65 81.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 61.6 p -101.58 -32.51 10.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.109 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 55.19 28.9 51.09 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.463 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.431 ' O ' ' C ' ' A' ' 269' ' ' SER . 14.9 ttt180 -120.98 109.02 14.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.833 0.349 . . . . 0.0 110.868 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 268' ' ' ARG . 12.0 p -35.34 103.32 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 47.1 mttt -48.96 -35.32 14.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.891 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 124.14 38.23 0.54 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.528 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.8 p90 -149.2 161.78 41.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 110.903 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -165.66 171.15 40.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.485 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -117.13 134.82 54.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.842 0.354 . . . . 0.0 110.856 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.453 HD11 ' HB3' ' A' ' 245' ' ' LEU . 97.2 mt -132.28 137.69 53.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.159 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 96.4 m -117.22 129.51 55.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.209 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.485 ' CE1' HD12 ' A' ' 231' ' ' LEU . 43.6 m-85 -97.99 -177.27 3.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.9 t -101.48 -41.37 6.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -112.02 138.81 48.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.7 p -63.52 -40.93 98.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -61.3 -43.62 98.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 95.2 m -60.56 -42.96 97.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.67 -40.07 95.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -60.07 -48.91 79.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -58.96 -49.79 76.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.917 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.823 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.54 -35.79 70.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.404 HD22 ' CD2' ' A' ' 304' ' ' HIS . 12.9 tp -64.54 -43.36 94.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.891 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -68.8 -42.43 77.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 22.2 mm100 -69.1 -41.1 77.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 58.6 mt -73.12 -46.31 51.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.884 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -45.91 112.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.905 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.73 38.73 36.13 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 73.4 t80 -106.51 120.86 43.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.818 0.342 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -67.11 114.56 5.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.5 tp -98.17 -62.12 1.29 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.17 34.76 4.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.064 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 117.0 -35.42 4.17 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.502 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -120.42 156.51 55.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.627 0.727 . . . . 0.0 110.852 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 130.84 20.07 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.65 2.234 . . . . 0.0 112.334 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -79.54 170.92 15.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -105.99 119.08 38.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -124.11 132.38 71.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -154.65 163.9 31.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.404 ' CD2' HD22 ' A' ' 287' ' ' LEU . 16.5 m-70 -70.13 135.99 49.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.809 0.337 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.495 HG23 ' CA ' ' A' ' 231' ' ' LEU . 94.9 t -73.92 107.74 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 15.2 t -158.17 142.92 16.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.106 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 307' ' ' GLU . . . . . 0.408 ' CG ' ' O ' ' A' ' 307' ' ' GLU . 6.5 pt-20 -104.05 94.32 5.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 8.4 ttt85 -165.66 145.14 6.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 79.9 mt -96.27 168.56 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -115.52 154.47 29.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.887 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 167.84 114.65 0.3 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.479 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 158.96 105.43 0.21 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.455 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 48.8 m -144.2 149.25 36.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.946 0.403 . . . . 0.0 110.864 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 114.44 77.32 0.74 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -9.68 26.71 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.699 2.266 . . . . 0.0 112.376 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 51.7 p -129.44 166.9 18.67 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 78.3 p -69.15 99.93 1.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.89 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.446 -179.949 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.5 m -81.09 167.12 20.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 72.7 m -87.43 151.24 23.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.844 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -102.87 -82.44 1.64 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 83.8 p 44.0 39.09 2.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 97.0 p -123.41 -45.29 2.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -54.22 121.03 17.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.499 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.441 HD11 ' O ' ' A' ' 283' ' ' ALA . 31.1 mt -111.8 147.03 36.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 110.881 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.514 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -107.23 137.11 45.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.506 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.4 p -123.76 131.86 72.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.077 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.0 165.66 27.27 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 72.71 43.67 0.43 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.853 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.506 HD11 ' CG2' ' A' ' 233' ' ' VAL . 30.3 mt -103.75 166.2 10.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.427 ' NE2' ' CE1' ' A' ' 238' ' ' PHE . 6.9 t60 -86.42 128.47 34.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.433 ' CD2' ' N ' ' A' ' 239' ' ' ASN . 36.9 p90 -37.88 -50.22 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.851 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.433 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 10.1 t-20 -47.53 -43.4 24.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' A' ' 237' ' ' HIS . 43.6 mm -38.64 147.9 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -138.88 178.42 7.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -60.65 -35.76 77.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 243' ' ' ASP . . . . . 0.464 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 1.3 m-20 -61.89 -32.86 73.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.9 mmt -71.98 -41.47 67.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.454 ' HB3' HD11 ' A' ' 275' ' ' ILE . 86.9 mt -69.88 -42.94 72.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.464 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 5.2 ptm180 -64.38 -37.74 88.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.445 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.56 -39.12 79.2 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.468 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.8 mt -75.86 -44.3 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.367 . . . . 0.0 111.11 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.61 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.86 -2.77 48.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.5 tp10 -70.61 -59.86 3.52 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.595 0.712 . . . . 0.0 110.871 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.7 2.42 3.52 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.728 2.286 . . . . 0.0 112.339 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.687 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.47 -31.42 10.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.76 149.86 7.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -54.77 113.32 1.28 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.759 0.314 . . . . 0.0 110.875 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.45 HD13 HD11 ' A' ' 258' ' ' ILE . 64.2 mt -83.35 122.65 37.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -78.83 -43.4 25.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -167.74 145.13 4.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.863 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.45 HD11 HD13 ' A' ' 255' ' ' ILE . 81.1 mt -120.24 135.29 61.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.74 128.87 51.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.0 mt -97.99 139.84 33.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.533 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 28.7 mmt -92.77 133.85 35.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -139.62 140.84 37.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -58.04 -179.4 0.05 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.848 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 20.2 m -111.48 -28.43 8.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.851 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -87.13 -51.12 6.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 82.4 p -90.69 -26.22 19.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.166 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 52.69 26.35 24.51 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.438 ' O ' ' C ' ' A' ' 269' ' ' SER . 3.6 ttp85 -109.82 107.34 17.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.815 0.34 . . . . 0.0 110.898 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.8 OUTLIER -34.94 118.63 0.44 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.774 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -75.82 -25.61 56.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.897 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 120.34 35.69 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.441 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.533 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.7 p90 -147.48 155.91 42.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.908 0.385 . . . . 0.0 110.93 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.54 -178.55 39.76 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.488 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.29 137.98 54.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.899 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.454 HD11 ' HB3' ' A' ' 245' ' ' LEU . 92.6 mt -132.03 140.87 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.077 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.3 m -118.83 129.94 55.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.147 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -98.63 -178.05 3.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.1 t -100.98 -39.47 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.812 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -112.84 135.62 53.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 4.5 m -60.54 -39.38 87.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -62.68 -42.74 99.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 75.4 m -61.96 -36.76 82.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.82 -41.8 86.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -61.84 -48.72 79.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -58.3 -50.91 71.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.687 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.89 -35.05 68.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.107 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.703 HD12 HG12 ' A' ' 302' ' ' VAL . 12.9 tp -64.65 -43.7 92.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.947 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -68.93 -42.77 76.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 25.7 mm100 -68.4 -41.85 79.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.704 ' HB3' HG21 ' A' ' 302' ' ' VAL . 67.0 mt -72.93 -46.14 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -46.03 108.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.82 31.57 39.49 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.486 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -94.32 123.01 37.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.842 0.354 . . . . 0.0 110.881 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 71.2 mt-10 -70.83 96.1 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.402 HD21 ' CD1' ' A' ' 240' ' ' ILE . 9.5 tp -78.87 -62.03 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -115.9 41.57 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.056 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.69 -21.44 43.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -124.31 149.58 61.47 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.581 0.705 . . . . 0.0 110.865 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.84 11.49 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -77.52 173.47 11.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.893 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -108.08 119.01 38.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.879 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' A' ' 290' ' ' LEU . 18.2 t -124.88 129.37 73.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.85 161.17 30.51 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -73.04 134.4 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.87 0.367 . . . . 0.0 110.838 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.85 -66.62 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.168 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 40.2 p -56.35 132.57 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -105.82 78.5 1.34 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 16.5 ttt85 -105.08 147.74 27.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.09 41.33 3.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.891 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.1 154.61 20.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 121.18 160.47 11.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 160.63 -55.77 0.32 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 42.5 m -68.15 -42.83 79.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.888 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 83.02 -158.18 36.2 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 130.03 18.64 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.323 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 p -72.58 176.09 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.825 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 67.5 m -118.51 132.11 56.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.464 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 37.5 m -123.14 154.86 38.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.877 0.37 . . . . 0.0 110.817 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 6.1 t -55.72 -52.23 64.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.828 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 142.42 -131.83 4.86 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 43.9 m -113.83 100.27 8.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.873 0.368 . . . . 0.0 110.849 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 3.3 t -65.43 91.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -131.83 140.42 11.78 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.474 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.463 HD11 ' O ' ' A' ' 283' ' ' ALA . 31.4 mt -124.65 144.8 49.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.857 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.905 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.6 t80 -109.19 128.76 55.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.616 ' CG2' HD11 ' A' ' 236' ' ' LEU . 10.4 p -113.92 133.5 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.42 166.02 26.94 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 7.7 t 71.98 44.2 0.48 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.876 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.616 HD11 ' CG2' ' A' ' 233' ' ' VAL . 81.6 mt -106.76 167.39 9.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.909 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.409 ' O ' ' C ' ' A' ' 238' ' ' PHE . 5.7 t-80 -93.15 130.96 38.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.409 ' C ' ' O ' ' A' ' 237' ' ' HIS . 4.2 m-85 -36.79 -54.21 0.91 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -41.76 -43.48 2.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.415 HD13 ' SD ' ' A' ' 244' ' ' MET . 31.1 mm -41.05 127.73 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 47.8 p -114.71 172.2 7.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 39.3 mp0 -60.27 -33.94 73.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -62.51 -32.46 73.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.848 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 244' ' ' MET . . . . . 0.415 ' SD ' HD13 ' A' ' 240' ' ' ILE . 52.0 mtt -72.01 -41.33 67.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 29.9 mt -66.91 -42.95 84.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.454 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.8 ptm180 -67.18 -39.69 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.44 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.12 -34.82 89.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.486 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.409 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 81.7 mt -81.56 -40.48 17.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.883 0.373 . . . . 0.0 111.141 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.703 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -84.72 -0.97 55.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.514 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.6 tp10 -70.77 -59.42 3.68 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.79 2.92 3.11 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.259 . . . . 0.0 112.36 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.647 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.2 -31.08 10.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 178.28 157.31 18.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -63.2 108.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.707 0.289 . . . . 0.0 110.909 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.454 HD13 ' HA ' ' A' ' 246' ' ' ARG . 37.3 mt -77.15 125.01 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.125 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -86.39 -43.69 12.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.877 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -163.56 143.65 8.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.449 HD11 HD13 ' A' ' 255' ' ' ILE . 71.0 mt -123.13 127.53 74.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.7 m -134.04 129.35 54.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.12 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 33.3 mt -92.38 139.07 30.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.652 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 15.7 mmt -95.94 125.77 40.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.75 158.37 39.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.889 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -68.36 -179.26 1.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.857 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.3 m -111.27 -34.23 6.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -90.97 -55.34 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.882 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 72.5 p -74.19 -18.15 60.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 48.54 26.98 5.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -121.04 126.26 49.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.867 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 30.9 t -52.89 147.22 9.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.856 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.561 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 14.4 mmtp -104.34 16.41 26.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.889 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 76.86 40.01 26.99 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.514 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.652 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.9 p90 -150.14 164.04 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.922 0.392 . . . . 0.0 110.922 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -172.57 176.38 45.49 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.407 ' HB2' HG23 ' A' ' 259' ' ' VAL . 42.6 m-85 -117.11 136.1 53.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.886 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -132.26 140.59 47.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.1 m -120.98 127.7 52.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -97.43 -175.14 3.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.3 t -100.28 -40.5 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -115.22 140.05 49.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 13.0 p -62.51 -39.19 92.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -62.05 -42.93 99.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.3 m -60.38 -39.22 86.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.463 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.67 -40.69 88.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 32.6 ttp85 -59.07 -49.02 79.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -59.38 -48.94 79.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.647 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.04 -35.6 71.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.444 HD12 HG12 ' A' ' 302' ' ' VAL . 12.0 tp -65.06 -43.58 91.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -68.96 -43.03 75.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 67.6 mm-40 -68.85 -41.21 78.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.818 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.2 mt -73.27 -45.02 58.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.901 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -45.15 98.16 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 96.01 24.46 14.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 293' ' ' PHE . . . . . 0.416 ' N ' ' O ' ' A' ' 290' ' ' LEU . 10.5 t80 -79.58 116.36 19.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.81 0.338 . . . . 0.0 110.901 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -80.25 89.06 5.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 12.1 tp -86.66 -59.75 2.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.02 45.09 0.98 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.112 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 84.42 -27.75 4.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -113.23 143.93 30.21 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.573 0.702 . . . . 0.0 110.837 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 123.14 9.8 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.644 2.229 . . . . 0.0 112.367 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -73.96 169.71 16.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.852 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 40.3 mmt-85 -109.12 122.19 46.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -126.22 120.63 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -144.71 160.14 27.91 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 8.9 m170 -70.69 121.72 18.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.847 0.356 . . . . 0.0 110.832 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.905 HG12 ' HB2' ' A' ' 232' ' ' TYR . 15.6 m -60.99 -44.37 98.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 306' ' ' THR . . . . . 0.512 ' N ' HG23 ' A' ' 305' ' ' VAL . 96.3 m -152.81 113.54 4.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -129.49 153.19 48.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 20.2 ttp180 -156.55 133.42 10.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.843 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.503 ' N ' HD23 ' A' ' 309' ' ' LEU . 0.7 OUTLIER -125.47 131.13 52.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.925 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -124.52 138.89 54.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -134.65 -129.89 2.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.446 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 170.1 -118.05 0.74 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 46.8 t -79.59 135.87 36.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 110.846 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -174.46 85.29 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.486 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -1.42 8.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.704 2.269 . . . . 0.0 112.328 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.4 m 72.33 52.34 0.18 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.83 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 3.2 m -104.3 160.8 14.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.485 -179.985 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 34.8 t -40.91 144.57 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.893 0.378 . . . . 0.0 110.883 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 29.1 t -117.78 88.78 2.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -63.32 128.95 39.79 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.523 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 25.4 m -107.7 98.46 8.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.876 0.37 . . . . 0.0 110.916 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 59.4 p -104.25 83.1 2.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.889 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -128.56 141.58 12.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 68.3 mt -124.41 145.69 49.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.773 0.32 . . . . 0.0 110.923 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.507 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.2 t80 -110.78 131.1 55.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.662 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.9 p -113.62 134.94 54.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.13 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.81 165.73 27.57 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.5 t 71.32 45.71 0.47 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.925 0.393 . . . . 0.0 110.823 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.662 HD11 ' CG2' ' A' ' 233' ' ' VAL . 86.8 mt -109.76 176.35 5.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -102.89 135.33 44.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 239' ' ' ASN . 0.6 OUTLIER -46.47 -51.37 15.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.902 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.407 ' N ' ' CD1' ' A' ' 238' ' ' PHE . 6.7 t-20 -42.15 -41.25 2.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.834 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 16.0 mm -47.94 139.91 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -121.61 167.65 12.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.156 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -55.06 -33.71 62.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 243' ' ' ASP . . . . . 0.467 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 35.5 t0 -59.97 -36.9 78.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 4.8 mmt -71.38 -37.72 71.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.664 ' CD1' HD21 ' A' ' 260' ' ' LEU . 73.2 mt -69.98 -39.97 75.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.511 ' HA ' HD13 ' A' ' 255' ' ' ILE . 2.9 ptm180 -70.53 -35.3 73.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.456 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -69.79 -38.83 76.69 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.414 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 80.2 mt -75.72 -41.12 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.853 0.359 . . . . 0.0 111.113 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.622 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 4.5 m-85 -83.43 -4.19 58.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -69.47 -58.33 5.97 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.598 0.713 . . . . 0.0 110.901 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.76 2.52 3.46 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.736 2.291 . . . . 0.0 112.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.783 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.6 -26.93 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 172.87 162.05 24.32 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.504 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 20.4 ttpt -63.61 110.72 2.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.781 0.324 . . . . 0.0 110.936 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.622 HG21 HD11 ' A' ' 258' ' ' ILE . 25.2 mt -80.58 117.18 26.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -77.0 -46.4 23.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.828 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -168.89 142.46 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.903 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.622 HD11 HG21 ' A' ' 255' ' ' ILE . 46.0 mt -121.09 135.4 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.124 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.37 127.81 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.143 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.664 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.6 mt -98.15 136.54 38.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.523 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 20.2 mmt -96.29 134.06 39.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.91 136.04 30.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.43 177.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.1 t -110.35 -61.94 1.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -49.25 -47.22 46.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 30.3 p -94.07 -42.01 9.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.142 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 74.46 15.1 80.51 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 13.1 mtp85 -101.69 106.82 17.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 20.4 p -38.59 106.76 0.06 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.408 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 19.9 mmtm -50.21 -32.76 17.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 118.66 37.76 0.82 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.523 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 2.4 p90 -146.92 155.5 42.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.933 0.397 . . . . 0.0 110.962 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -160.39 170.17 36.34 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.51 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -113.52 138.74 49.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.855 0.359 . . . . 0.0 110.857 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 68.0 mt -136.01 134.16 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.0 m -118.19 129.01 55.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.166 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -99.15 -176.19 3.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.915 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 17.7 t -97.49 -41.85 7.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.426 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 26.1 t0 -115.42 142.59 46.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.858 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 29.2 t -63.99 -38.77 92.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.478 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 10.7 pt-20 -61.52 -41.66 97.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 282' ' ' CYS . . . . . 0.478 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 84.0 m -61.35 -38.94 88.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.74 90.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 40.0 mtp180 -59.1 -48.89 79.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -58.78 -50.4 74.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.783 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -59.52 -34.99 73.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.083 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.531 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.3 tp -62.43 -45.26 93.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -68.83 -38.23 79.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -71.77 -36.62 70.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.6 mt -78.8 -39.97 34.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.917 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -55.09 103.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 87.91 30.89 16.35 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -98.49 109.79 22.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 110.842 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -56.7 99.31 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.431 HD13 ' C ' ' A' ' 295' ' ' LEU . 0.9 OUTLIER -78.77 -65.52 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -119.5 39.62 3.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.08 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 112.44 -34.61 5.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.95 151.35 46.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.865 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 120.94 7.66 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.304 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -71.12 171.89 10.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -110.26 122.51 47.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.2 t -128.88 126.12 64.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.26 160.99 28.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.492 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.531 ' CD2' HD22 ' A' ' 287' ' ' LEU . 26.0 m-70 -70.46 128.04 34.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.766 0.317 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 59.5 t -56.18 -58.57 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 6.4 t -68.33 151.68 46.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -99.67 85.14 3.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 16.3 mmm180 -96.13 152.35 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 5.2 mt -147.99 133.49 18.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -152.86 143.02 22.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 166.11 74.46 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 130.31 95.79 0.74 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.502 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 98.9 p -73.12 -43.13 62.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 0.0 110.86 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 157.3 -159.16 29.52 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 126.8 13.73 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.698 2.265 . . . . 0.0 112.346 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 317' ' ' SER . 11.8 t -85.04 -54.4 4.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.844 -179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 317' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 316' ' ' SER . 37.4 p 34.55 42.53 0.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.445 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 27.9 t -139.1 135.71 34.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.885 0.374 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 22.0 p -109.38 144.53 37.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 154.72 -76.25 0.22 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 58.9 m -157.55 141.75 16.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.903 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 80.3 p -84.7 86.72 7.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -99.2 142.54 16.09 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.486 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.432 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.5 mt -131.56 144.78 51.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.806 0.336 . . . . 0.0 110.874 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.58 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.5 OUTLIER -110.3 137.17 48.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.956 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.42 133.12 70.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.79 165.65 27.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 m 72.29 45.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.86 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 37.3 mt -104.78 173.45 6.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -96.89 137.92 35.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.835 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -43.23 -49.41 6.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.516 ' O ' HG23 ' A' ' 241' ' ' THR . 16.0 t-20 -47.78 -40.2 20.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 43.0 mm -43.71 145.73 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.516 HG23 ' O ' ' A' ' 239' ' ' ASN . 33.5 p -143.07 173.65 11.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 242' ' ' GLU . . . . . 0.413 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 28.5 mp0 -54.97 -36.2 65.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -62.29 -35.5 79.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.847 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -72.01 -40.98 68.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 40.5 mt -68.17 -43.04 79.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.403 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.1 ptm180 -66.12 -37.62 86.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.403 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.85 -36.0 80.94 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.428 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.2 mt -80.36 -42.76 21.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.81 0.338 . . . . 0.0 111.117 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.516 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -81.45 -4.13 54.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.956 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tp10 -68.52 -59.93 5.31 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.646 0.736 . . . . 0.0 110.879 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.82 2.93 3.12 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.347 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.748 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -103.31 -22.03 13.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 163.72 158.54 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -61.32 117.09 5.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.766 0.317 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.66 HG21 HD11 ' A' ' 258' ' ' ILE . 57.2 mt -88.19 120.63 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -76.55 -49.03 17.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -158.17 155.45 29.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.66 HD11 HG21 ' A' ' 255' ' ' ILE . 44.6 mt -136.63 129.91 45.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.3 t -133.84 135.81 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.113 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.413 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 27.8 mt -102.62 139.63 37.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.594 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 24.7 mmt -94.92 128.61 41.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.869 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.74 145.6 49.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -62.46 -178.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.88 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 17.6 t -112.59 -49.9 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.857 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -54.97 -40.31 69.87 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.845 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 266' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 267' ' ' GLY . 2.2 p -113.04 -57.95 2.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 267' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 266' ' ' THR . . . 94.22 26.87 13.03 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.452 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.436 ' O ' ' C ' ' A' ' 269' ' ' SER . 10.9 ttm180 -102.45 105.26 15.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 268' ' ' ARG . 19.9 m -34.98 110.15 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -61.04 -44.58 97.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.903 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 141.12 37.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.594 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 2.2 p90 -147.79 158.53 44.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.924 0.392 . . . . 0.0 110.905 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.6 172.28 39.48 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.494 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -118.35 136.28 53.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.884 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.567 HG12 HG23 ' A' ' 258' ' ' ILE . 78.1 mt -136.46 140.44 43.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 99.4 m -120.67 129.36 53.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.13 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.432 ' CE1' HD12 ' A' ' 231' ' ' LEU . 41.8 m-85 -98.46 -178.82 4.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 24.6 t -101.18 -33.97 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -117.6 136.28 53.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.7 p -64.04 -39.83 94.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.863 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -62.65 -43.83 97.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.889 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 32.7 m -62.89 -41.58 99.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.909 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.424 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.14 -41.46 97.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.036 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -59.78 -49.07 79.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -57.57 -48.99 77.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.748 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.8 -38.57 67.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 9.0 tp -65.18 -39.84 93.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.908 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -64.46 -34.94 79.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -83.91 -34.75 24.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.943 ' HB3' HG21 ' A' ' 302' ' ' VAL . 76.3 mt -71.77 -47.07 56.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -55.02 118.31 4.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.24 23.2 63.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.456 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -93.87 111.63 23.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 294' ' ' GLU . . . . . 0.46 ' HG3' ' N ' ' A' ' 299' ' ' PRO . 2.4 mp0 -76.27 104.45 6.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -94.42 -57.44 2.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.7 41.02 1.45 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 102.66 -42.94 1.78 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 2.8 ptp180 -111.02 153.26 43.93 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.65 0.738 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 299' ' ' PRO . . . . . 0.46 ' N ' ' HG3' ' A' ' 294' ' ' GLU . 54.0 Cg_endo -69.76 135.42 30.43 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 3.4 ptp -82.85 162.91 21.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -106.28 121.28 43.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.943 HG21 ' HB3' ' A' ' 290' ' ' LEU . 22.1 t -130.81 125.47 58.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.14 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.26 161.36 26.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 9.0 m80 -72.47 109.31 6.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.836 0.35 . . . . 0.0 110.83 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.6 p -63.97 -41.04 91.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.095 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 28.4 m -66.91 97.16 0.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.143 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 307' ' ' GLU . . . . . 0.431 ' HG3' ' N ' ' A' ' 308' ' ' ARG . 13.3 tp10 -63.88 156.08 28.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.909 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.431 ' N ' ' HG3' ' A' ' 307' ' ' GLU . 3.0 ptt180 -131.03 156.38 45.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 63.2 mt -117.82 -44.37 2.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -94.95 136.12 35.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -158.47 76.01 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.452 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 312' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 313' ' ' SER . . . 88.81 68.09 1.27 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.494 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 313' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 312' ' ' GLY . 16.3 t -36.84 123.66 0.85 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.853 0.359 . . . . 0.0 110.886 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 82.39 177.61 51.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.504 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 315' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 316' ' ' SER . 54.0 Cg_endo -69.78 2.46 3.52 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 315' ' ' PRO . 21.5 p -34.58 144.27 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 1.7 t -43.05 137.53 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.902 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 -179.949 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.5 t -121.48 162.17 20.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.919 0.39 . . . . 0.0 110.845 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 2.4 m -100.76 91.31 4.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.851 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -104.49 149.24 16.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.526 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 35.1 t -119.42 95.99 5.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.868 0.366 . . . . 0.0 110.809 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 229' ' ' SER . . . . . 0.405 ' O ' ' HB1' ' A' ' 283' ' ' ALA . 32.1 t -67.59 -47.67 69.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.885 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.509 ' O ' HG12 ' A' ' 305' ' ' VAL . . . -38.68 137.85 0.89 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.472 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.853 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.1 mt -125.77 143.62 50.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 110.93 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.17 130.58 56.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.903 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.493 HG21 HD11 ' A' ' 236' ' ' LEU . 10.8 p -110.39 135.2 50.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -140.24 166.04 25.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.469 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.9 m 63.96 47.81 3.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.86 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 233' ' ' VAL . 72.5 mt -100.11 -175.94 3.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.433 ' O ' ' C ' ' A' ' 238' ' ' PHE . 9.2 t60 -115.26 124.5 51.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.89 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.433 ' C ' ' O ' ' A' ' 237' ' ' HIS . 23.2 p90 -34.48 -54.13 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.414 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 2.1 t-20 -41.52 -46.76 3.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 51.7 mm -41.29 139.07 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.114 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 11.5 t -122.91 170.88 9.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.148 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 43.5 mp0 -57.69 -32.78 67.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -64.95 -32.51 74.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.86 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 17.5 mtt -71.98 -43.84 64.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.939 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.446 HD22 HD11 ' A' ' 275' ' ' ILE . 36.1 mt -65.51 -43.0 91.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.422 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.3 ptm180 -67.14 -38.36 85.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.34 -33.22 81.62 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.67 -45.48 23.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.87 0.367 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.47 -2.01 44.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.936 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.504 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.9 OUTLIER -69.8 -59.95 4.14 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.719 . . . . 0.0 110.891 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.27 3.69 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.69 2.26 . . . . 0.0 112.342 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.802 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.9 m-85 -102.47 -34.1 9.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 179.21 157.59 19.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.479 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -60.7 115.33 3.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.677 HD13 HD11 ' A' ' 258' ' ' ILE . 66.0 mt -85.85 121.47 37.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -80.61 -40.55 25.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 16.5 t30 -168.61 148.03 4.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.677 HD11 HD13 ' A' ' 255' ' ' ILE . 52.5 mt -129.78 128.35 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.585 HG23 ' HB2' ' A' ' 274' ' ' PHE . 16.1 m -130.03 136.97 57.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.88 130.95 48.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.534 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 21.6 mmt -88.62 131.36 35.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.866 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.03 158.51 42.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.882 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -88.37 179.19 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.8 t -107.82 -45.4 4.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.44 -45.37 80.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 78.1 p -91.61 -44.72 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.161 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 73.65 24.78 73.83 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.46 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.434 ' O ' ' C ' ' A' ' 269' ' ' SER . 47.7 mtp180 -128.12 114.1 16.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.823 0.344 . . . . 0.0 110.851 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 268' ' ' ARG . 29.7 t -34.94 106.67 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.85 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 33.7 mttt -51.3 -28.69 12.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.884 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.79 37.01 0.46 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.534 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -147.16 162.93 37.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.911 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.23 173.71 39.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.585 ' HB2' HG23 ' A' ' 259' ' ' VAL . 18.7 m-85 -119.91 134.09 55.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.446 HD11 HD22 ' A' ' 245' ' ' LEU . 88.1 mt -135.28 127.91 47.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.5 m -113.27 128.72 56.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.853 ' CE1' HD12 ' A' ' 231' ' ' LEU . 51.3 m-85 -95.65 -175.07 3.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.922 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 7.3 t -102.03 -39.37 7.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -112.61 139.15 48.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.88 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 76.9 p -63.27 -40.22 96.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -63.97 -42.58 97.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 93.3 m -62.04 -42.08 98.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.555 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -62.93 -40.28 97.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.07 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 12.2 ttt85 -61.77 -46.64 88.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.825 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 49.6 mtt180 -58.42 -51.01 71.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.802 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.14 -35.78 69.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.64 HD12 HG12 ' A' ' 302' ' ' VAL . 12.6 tp -63.85 -43.87 94.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.921 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -69.02 -35.01 76.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -73.55 -41.99 62.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.775 ' HB3' HG21 ' A' ' 302' ' ' VAL . 38.2 mt -74.88 -46.97 32.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -43.52 105.76 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.32 33.88 27.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.51 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -102.68 116.29 32.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.336 . . . . 0.0 110.882 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -61.59 114.22 3.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.886 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 13.4 tp -101.13 -55.92 2.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -123.04 42.23 3.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.115 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.79 -21.24 44.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -128.5 149.29 71.3 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.629 0.728 . . . . 0.0 110.837 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 125.5 12.25 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.622 2.214 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.5 ptp -76.09 172.99 11.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -110.58 122.21 47.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.775 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.2 t -129.27 123.58 58.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.24 26.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.487 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.479 ' CE1' HD22 ' A' ' 287' ' ' LEU . 10.2 m170 -74.12 100.94 3.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 230' ' ' GLY . 4.8 p -39.3 125.06 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 3.1 t -80.06 141.02 36.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 10.1 tm-20 -173.87 156.87 2.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 11.9 tpt85 -156.51 159.41 38.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.508 ' C ' HD12 ' A' ' 309' ' ' LEU . 2.8 pp -90.98 -38.86 12.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.898 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 310' ' ' ASP . . . . . 0.458 ' N ' HD12 ' A' ' 309' ' ' LEU . 1.0 OUTLIER -117.53 -69.87 0.83 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.832 179.87 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 95.99 117.97 3.34 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.503 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 148.55 -171.05 28.99 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.4 t 53.68 36.24 23.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.937 0.399 . . . . 0.0 110.861 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -97.11 -95.07 1.88 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.495 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 176.09 7.28 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.711 2.274 . . . . 0.0 112.347 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 55.3 p -147.19 174.47 11.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.865 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 8.5 t -123.57 -49.24 1.9 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.496 -179.975 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 8.0 t -46.74 -48.49 20.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.354 . . . . 0.0 110.885 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 93.6 p -76.24 163.36 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 97.4 -142.97 16.45 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.499 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 5.7 m 56.41 43.1 26.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.857 0.361 . . . . 0.0 110.852 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 59.6 p -128.32 -49.92 1.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.872 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -66.21 141.36 41.06 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.421 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 277' ' ' PHE . 29.7 mt -124.49 145.34 49.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.823 0.344 . . . . 0.0 110.886 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.529 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.8 OUTLIER -111.65 136.83 50.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.956 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.456 ' CG2' HD21 ' A' ' 236' ' ' LEU . 7.3 p -121.96 133.63 67.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.106 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.15 166.03 26.83 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 4.7 t 73.05 43.2 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.903 0.382 . . . . 0.0 110.827 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.456 HD21 ' CG2' ' A' ' 233' ' ' VAL . 49.4 mt -100.03 177.17 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.425 ' O ' ' C ' ' A' ' 238' ' ' PHE . 2.3 t-80 -102.09 133.04 47.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.844 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 269' ' ' SER . 59.3 m-85 -35.78 -52.51 0.71 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.43 ' O ' ' C ' ' A' ' 240' ' ' ILE . 16.5 m120 -45.14 -47.38 12.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.613 HD11 HD21 ' A' ' 295' ' ' LEU . 48.8 mm -35.38 150.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.179 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -147.13 179.96 7.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.181 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -60.19 -39.94 88.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -58.44 -36.88 74.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.845 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 244' ' ' MET . . . . . 0.477 ' SD ' HD13 ' A' ' 240' ' ' ILE . 18.9 mtt -72.09 -41.54 67.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.521 ' CD1' HD21 ' A' ' 260' ' ' LEU . 75.0 mt -68.21 -41.72 80.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.479 ' HA ' HD13 ' A' ' 255' ' ' ILE . 13.4 ptt180 -67.92 -42.95 80.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' CG ' ' A' ' 246' ' ' ARG . . . -63.3 -36.72 93.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.505 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.402 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.2 mt -76.23 -39.85 35.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.88 0.371 . . . . 0.0 111.13 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.755 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -88.42 -1.15 57.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.2 tp10 -70.34 -58.75 4.59 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 0.0 110.831 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.7 3.46 2.73 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.698 2.265 . . . . 0.0 112.332 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.2 m-85 -104.14 -37.99 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.883 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -174.77 160.14 29.14 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.476 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -65.48 109.08 2.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.735 0.302 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.708 HG21 HD11 ' A' ' 258' ' ' ILE . 36.7 mt -77.23 114.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.171 179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -73.83 -43.99 57.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -162.54 152.09 15.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 255' ' ' ILE . 63.2 mt -133.29 129.64 56.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.073 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 52.8 t -129.37 128.05 65.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.154 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.521 HD21 ' CD1' ' A' ' 245' ' ' LEU . 19.0 mt -97.13 127.72 43.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.573 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 40.6 mmm -89.71 118.38 29.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.93 143.67 51.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.903 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.11 173.26 3.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.897 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 5.7 t -107.17 -41.08 5.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -71.5 -44.76 64.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 33.2 p -96.65 -34.77 11.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 58.59 25.66 58.71 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.481 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.465 ' O ' ' N ' ' A' ' 270' ' ' LYS . 12.0 mmt180 -109.27 109.71 20.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.578 ' O ' ' CD1' ' A' ' 238' ' ' PHE . 19.4 m -39.21 94.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.465 ' N ' ' O ' ' A' ' 268' ' ' ARG . 18.2 mttp -47.12 -40.67 15.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.866 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 129.66 41.32 0.25 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.573 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -149.39 154.39 38.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.885 0.374 . . . . 0.0 110.95 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.14 168.24 36.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -115.29 138.66 50.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.854 0.359 . . . . 0.0 110.865 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 70.2 mt -136.46 138.42 46.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.113 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 89.2 m -117.77 122.97 44.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.154 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 231' ' ' LEU . 44.1 m-85 -91.62 -178.04 4.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.915 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 4.3 t -122.41 24.95 9.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.453 ' OD2' ' CG ' ' A' ' 281' ' ' GLU . 26.4 t0 -165.14 126.45 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.884 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 92.8 p -58.24 -40.98 83.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.891 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.453 ' CG ' ' OD2' ' A' ' 279' ' ' ASP . 6.2 pt-20 -63.37 -40.96 98.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.868 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 36.1 m -64.14 -41.56 97.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.486 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.17 -44.05 97.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.125 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 48.9 mtm180 -63.09 -49.02 76.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 19.5 mmt-85 -59.67 -51.04 71.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -54.96 -36.36 65.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.061 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.421 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.0 tp -65.33 -43.59 90.45 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.923 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.57 -43.1 73.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.908 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 65.1 mm-40 -68.87 -42.14 77.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.755 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 84.1 mt -73.76 -47.02 42.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -46.2 103.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.02 36.47 13.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 293' ' ' PHE . . . . . 0.424 ' O ' ' N ' ' A' ' 295' ' ' LEU . 37.3 t80 -98.22 93.22 6.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -43.35 95.07 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.613 HD21 HD11 ' A' ' 240' ' ' ILE . 9.3 tt -82.39 -67.38 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -109.0 39.11 2.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 108.91 -41.42 2.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 22.6 ptt-85 -109.9 152.39 42.96 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.634 0.73 . . . . 0.0 110.834 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 118.38 5.64 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.5 ptt? -68.67 169.76 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.6 mmt180 -104.98 121.43 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.9 t -126.95 127.77 70.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.09 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.78 160.34 28.35 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.421 ' CD2' HD22 ' A' ' 287' ' ' LEU . 18.9 m-70 -71.66 125.03 26.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.343 . . . . 0.0 110.889 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.4 t -50.49 118.7 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 11.8 t -121.51 147.53 45.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.163 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -105.19 -43.57 4.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.865 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -151.16 139.04 19.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 6.1 mp -72.65 119.45 16.89 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.934 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.11 139.2 46.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.849 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -56.1 -168.71 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.479 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -150.95 158.04 27.48 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.531 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 65.0 p -43.91 141.41 1.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.959 0.409 . . . . 0.0 110.861 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -120.57 176.45 16.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.503 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -23.09 31.1 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.657 2.238 . . . . 0.0 112.353 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -118.06 142.23 47.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.822 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 4.8 m -67.11 -58.8 4.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 21.8 m 37.35 51.33 1.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 92.7 p -101.53 178.91 4.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.838 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -138.45 81.49 0.27 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.482 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 74.9 m -113.07 121.97 46.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.873 0.368 . . . . 0.0 110.909 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 87.4 p -76.59 -45.45 30.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -39.5 141.85 0.59 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.502 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.691 HD12 ' CE2' ' A' ' 277' ' ' PHE . 24.2 mt -126.22 146.63 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.551 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -109.92 136.74 48.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.648 HG21 HD11 ' A' ' 236' ' ' LEU . 7.1 p -120.37 138.13 51.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.96 165.25 28.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 t 71.27 46.59 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.945 0.402 . . . . 0.0 110.85 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.648 HD11 HG21 ' A' ' 233' ' ' VAL . 95.7 mt -109.7 154.02 23.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.956 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 31.9 t-80 -74.45 139.44 43.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -46.58 -45.22 18.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 240' ' ' ILE . 34.1 t-20 -49.88 -46.53 51.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.428 ' C ' ' O ' ' A' ' 239' ' ' ASN . 47.3 mm -35.55 131.67 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.9 p -120.2 177.23 5.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -62.42 -34.65 77.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.898 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -63.16 -33.86 76.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.873 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 244' ' ' MET . . . . . 0.401 ' SD ' HD13 ' A' ' 240' ' ' ILE . 38.1 mtt -71.9 -39.28 69.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.0 -42.91 72.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.624 ' HA ' HD13 ' A' ' 255' ' ' ILE . 17.8 ptt180 -66.77 -40.46 88.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.468 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.75 -36.39 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 90.4 mt -76.38 -42.6 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.832 0.349 . . . . 0.0 111.15 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.583 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -85.47 -2.83 58.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.534 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -69.79 -58.35 5.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.855 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.534 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 0.84 5.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.659 2.24 . . . . 0.0 112.347 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.831 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -101.55 -37.05 8.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -173.56 155.66 22.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -57.89 108.11 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.759 0.314 . . . . 0.0 110.891 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 258' ' ' ILE . 43.4 mt -78.11 112.49 16.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -76.76 -41.71 43.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -165.23 149.99 9.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.891 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 255' ' ' ILE . 48.8 mt -132.41 126.19 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.426 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.5 m -133.12 129.93 57.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.138 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 36.4 mt -91.2 137.7 32.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.496 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.2 mmt -93.82 112.23 24.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.847 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 262' ' ' LYS . . . . . 0.463 ' N ' ' HD3' ' A' ' 262' ' ' LYS . 0.0 OUTLIER -125.18 146.75 49.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.877 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -67.83 178.61 1.68 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.856 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 t -106.04 -48.26 3.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.83 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -62.34 -61.23 2.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 11.7 p -82.77 -31.3 28.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.134 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 60.01 14.36 31.15 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.474 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 -97.56 119.3 35.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 16.1 m -49.21 123.09 6.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 -179.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -74.36 -31.63 62.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 125.63 33.75 0.69 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.496 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.8 p90 -145.75 156.09 43.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.93 0.395 . . . . 0.0 110.944 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -158.06 176.17 35.13 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.426 ' HB2' HG23 ' A' ' 259' ' ' VAL . 22.3 m-85 -121.29 134.02 55.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 0.0 110.836 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.421 HD12 ' CE2' ' A' ' 249' ' ' PHE . 97.3 mt -131.23 145.52 35.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.2 m -120.98 129.66 53.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.691 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.7 m-85 -104.24 175.9 5.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.899 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 3.1 t -120.19 24.87 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.898 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -165.13 127.61 2.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.862 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.5 p -64.05 -40.96 97.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.811 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.47 -43.02 82.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 43.6 m -63.22 -42.73 99.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.438 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.97 -42.44 97.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.049 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 21.4 mtm180 -60.14 -48.98 79.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.879 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.8 mmt85 -58.06 -47.73 82.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.841 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.831 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.03 -40.41 80.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.083 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.496 ' CD1' HG12 ' A' ' 302' ' ' VAL . 9.3 tp -61.66 -40.7 95.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -67.71 -35.0 77.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.938 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -84.11 -22.22 31.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.922 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.9 mt -86.54 -38.51 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ASN . . . . . 0.409 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -60.02 119.98 8.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.891 179.893 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.53 20.82 78.2 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.507 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -84.78 105.13 15.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.807 0.337 . . . . 0.0 110.882 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -67.2 96.29 0.46 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.4 tt -91.12 -64.2 1.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.928 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -98.71 36.59 1.63 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.13 -35.22 4.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 40.6 mtp180 -113.68 154.11 45.77 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.626 0.727 . . . . 0.0 110.891 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 132.26 22.98 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.656 2.237 . . . . 0.0 112.345 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.9 ptp -83.44 165.89 18.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.875 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.8 122.74 47.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' A' ' 290' ' ' LEU . 47.7 t -131.41 135.44 59.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -153.06 163.58 30.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.534 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -71.97 112.34 7.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.482 HG23 ' CA ' ' A' ' 231' ' ' LEU . 64.5 t -46.26 97.46 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 14.9 m -95.99 141.59 29.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.162 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -118.84 -48.5 2.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 76.9 mtt180 -150.09 138.51 20.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.523 ' N ' ' CD2' ' A' ' 309' ' ' LEU . 0.3 OUTLIER -82.0 155.34 25.23 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -119.76 91.61 3.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -45.91 97.66 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -89.8 81.91 1.42 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.474 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 8.5 t -141.52 108.82 5.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.88 0.371 . . . . 0.0 110.858 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -159.21 64.79 0.29 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -176.83 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.362 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 54.2 p -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 317' ' ' SER . . . . . 0.422 ' O ' ' C ' ' A' ' 318' ' ' GLY . 84.0 p -85.55 88.36 7.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 318' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 317' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.523 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 87.4 p -144.0 175.22 10.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.872 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 73.2 m -146.45 132.04 18.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -47.58 109.56 0.46 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 52.5 p -68.17 143.26 55.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.87 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 10.0 t -82.41 161.87 22.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.869 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 159.4 109.76 0.27 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.481 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.842 HD12 ' CE1' ' A' ' 277' ' ' PHE . 38.3 mt -104.06 144.75 31.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.478 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.3 t80 -111.21 131.46 55.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.507 HG22 HD11 ' A' ' 236' ' ' LEU . 7.7 p -116.0 134.23 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.125 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.42 165.85 27.8 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 6.2 t 73.85 47.09 0.17 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.507 HD11 HG22 ' A' ' 233' ' ' VAL . 15.0 mt -109.53 166.08 11.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.907 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -94.31 140.59 29.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -45.44 -37.07 4.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -57.88 -37.86 74.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.935 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 36.7 mm -47.59 139.04 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.159 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.4 t -125.29 174.34 8.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.099 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -62.3 -36.55 82.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -58.37 -34.64 70.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.902 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 63.3 mtt -70.49 -37.07 74.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 81.9 mt -69.82 -42.34 73.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.505 ' HA ' HD13 ' A' ' 255' ' ' ILE . 20.5 ptt85 -69.65 -40.21 76.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -66.41 -35.16 89.75 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.5 mt -81.04 -44.22 20.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.844 0.354 . . . . 0.0 111.148 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.69 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -81.83 -2.43 50.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.508 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.0 tp10 -70.65 -59.66 3.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.677 0.751 . . . . 0.0 110.931 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.6 3.37 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.333 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.834 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.46 -44.17 5.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.903 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -171.21 139.03 5.22 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -44.61 119.0 1.74 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.744 0.307 . . . . 0.0 110.919 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.505 HD13 ' HA ' ' A' ' 246' ' ' ARG . 28.3 mt -88.85 133.31 31.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.149 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.27 -43.43 8.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -163.47 147.02 10.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 255' ' ' ILE . 61.1 mt -128.91 132.37 67.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 74.4 t -134.93 129.24 50.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.137 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 23.5 mt -94.01 129.55 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.616 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.3 mmt -91.88 135.26 34.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.95 149.96 51.28 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -50.63 -177.43 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 34.6 p -105.32 -58.15 1.93 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.818 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -62.71 -58.59 6.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 25.4 p -72.57 -41.36 65.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 73.63 18.45 79.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.498 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 4.3 ptt180 -98.01 162.35 13.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.86 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 15.5 m -78.21 100.83 6.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.821 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -58.99 -35.43 73.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.917 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.93 40.1 0.33 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.491 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.616 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 0.9 OUTLIER -150.5 157.42 43.0 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.919 0.39 . . . . 0.0 110.935 -179.832 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.56 169.37 38.56 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -113.58 137.97 50.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.363 . . . . 0.0 110.874 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 77.3 mt -136.43 132.61 49.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.9 m -113.51 129.23 56.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.842 ' CE1' HD12 ' A' ' 231' ' ' LEU . 42.6 m-85 -98.96 171.27 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 48.1 t -86.88 -40.08 15.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -116.2 141.13 48.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 40.6 p -63.99 -41.01 97.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.423 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 13.3 pt-20 -60.97 -43.97 98.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 282' ' ' CYS . . . . . 0.423 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 73.9 m -60.01 -40.96 91.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.585 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.55 -37.84 88.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 284' ' ' ARG . . . . . 0.418 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 12.4 ttm105 -62.01 -48.73 79.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.6 mmt180 -58.02 -49.8 75.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.834 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.99 -35.54 71.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.091 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 8.4 tp -65.09 -40.83 95.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -68.34 -42.96 78.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -71.91 -38.2 69.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.854 ' HB3' HG21 ' A' ' 302' ' ' VAL . 82.4 mt -73.15 -47.03 47.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -44.47 107.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 77.82 39.3 24.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.462 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 293' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' LEU . 14.7 t80 -101.32 97.78 8.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.816 0.341 . . . . 0.0 110.871 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -43.96 93.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 293' ' ' PHE . 61.8 tp -81.03 -56.95 3.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -129.12 73.13 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.07 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 82.45 -35.53 2.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -125.77 154.85 73.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.579 0.705 . . . . 0.0 110.898 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 136.67 33.68 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.719 2.28 . . . . 0.0 112.336 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 300' ' ' MET . . . . . 0.596 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.3 ptt? -86.68 166.66 15.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 4.2 mmm180 -101.75 128.59 48.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' A' ' 290' ' ' LEU . 9.8 t -131.88 128.92 60.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -157.7 158.8 29.36 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -77.73 124.51 28.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 306' ' ' THR . 15.3 m -53.29 -47.76 56.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.141 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 306' ' ' THR . . . . . 0.473 ' N ' HG23 ' A' ' 305' ' ' VAL . 23.8 m -113.72 141.12 47.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -159.45 149.23 18.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 13.5 mtp85 -91.42 -57.46 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.866 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.559 HD13 ' N ' ' A' ' 310' ' ' ASP . 0.4 OUTLIER -138.66 127.07 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.951 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 310' ' ' ASP . . . . . 0.559 ' N ' HD13 ' A' ' 309' ' ' LEU . 2.9 p30 -50.15 121.05 5.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.864 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 134.35 -77.47 0.37 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.485 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 68.47 143.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.484 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 80.8 p -123.85 169.64 11.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.946 0.403 . . . . 0.0 110.82 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -78.89 141.19 24.08 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 2.47 3.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.654 2.236 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.8 m 63.89 34.76 11.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 3.0 t -53.97 -53.43 52.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.48 -179.986 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 8.5 t 49.6 42.95 23.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.86 -179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 4.2 m -77.49 140.67 39.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -171.31 173.01 44.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.464 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 34.6 m -74.56 150.51 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 96.7 p -106.96 94.25 5.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.871 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -133.87 133.6 7.0 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.475 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.434 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.0 mt -115.1 145.62 42.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.848 0.356 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.573 ' HB2' HG22 ' A' ' 305' ' ' VAL . 1.5 t80 -111.53 133.69 53.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.921 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 13.1 p -118.64 135.35 59.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.141 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.61 163.56 27.89 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 m 74.39 46.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.905 0.384 . . . . 0.0 110.81 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 14.4 mt -108.98 170.19 8.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.408 ' O ' ' C ' ' A' ' 238' ' ' PHE . 13.7 t-80 -98.89 137.95 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.41 ' O ' ' C ' ' A' ' 239' ' ' ASN . 5.2 m-85 -37.82 -57.02 1.04 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 241' ' ' THR . 45.9 t30 -37.58 -42.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.901 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.7 mm -47.21 130.1 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.463 HG23 ' O ' ' A' ' 239' ' ' ASN . 79.4 p -123.04 -175.63 3.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.145 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -62.38 -41.77 98.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -59.45 -29.75 68.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 20.0 mmt -71.87 -44.52 63.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.465 HD22 HD11 ' A' ' 275' ' ' ILE . 34.7 mt -68.25 -43.04 78.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.503 ' O ' ' N ' ' A' ' 250' ' ' GLU . 5.6 ptp180 -66.35 -44.55 82.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.499 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -61.08 -39.49 97.18 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.9 mt -76.17 -41.37 37.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.868 0.366 . . . . 0.0 111.147 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.762 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -86.42 -5.55 59.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.541 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -67.36 -58.05 9.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.683 0.754 . . . . 0.0 110.894 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.541 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.72 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.856 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -104.77 -25.32 12.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.88 159.04 15.91 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.53 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -62.22 117.82 6.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.724 0.297 . . . . 0.0 110.91 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.645 HD13 HD11 ' A' ' 258' ' ' ILE . 70.3 mt -90.99 114.06 27.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -69.77 -42.99 73.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -167.96 153.55 7.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.645 HD11 HD13 ' A' ' 255' ' ' ILE . 87.6 mt -132.94 128.43 56.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 75.8 t -127.42 129.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.093 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 35.9 mt -96.6 135.82 37.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.549 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 35.2 mmm -96.09 133.0 40.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.893 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.83 152.21 51.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -66.35 170.49 5.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.857 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 60.7 p -103.78 -41.01 6.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.819 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -61.2 -41.97 97.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 266' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 267' ' ' GLY . 2.2 p -111.94 -58.61 2.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.143 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 267' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 266' ' ' THR . . . 99.03 18.46 24.57 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.547 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 89.2 mmt-85 -95.64 113.4 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.804 0.335 . . . . 0.0 110.83 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 1.8 m -41.34 107.87 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 33.4 mmtt -60.05 -39.31 85.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.943 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 133.12 38.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.482 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.549 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.4 p90 -149.38 160.32 43.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.914 -179.76 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.52 171.65 42.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.508 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -113.31 139.28 48.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.802 0.334 . . . . 0.0 110.887 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.465 HD11 HD22 ' A' ' 245' ' ' LEU . 54.1 mt -135.95 139.38 46.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.167 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 85.8 m -119.09 122.26 41.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.434 ' CE1' HD12 ' A' ' 231' ' ' LEU . 36.3 m-85 -91.08 -177.14 4.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.5 t -104.56 -22.14 13.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -133.62 134.94 43.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.8 p -61.7 -36.99 82.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -63.57 -44.0 95.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.875 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.4 m -61.94 -40.04 94.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.16 -41.7 97.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.079 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 284' ' ' ARG . . . . . 0.423 ' HD3' ' CE1' ' A' ' 304' ' ' HIS . 11.8 mmt85 -60.0 -49.06 79.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -58.31 -50.6 73.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.885 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.856 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.55 -39.45 73.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.063 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.45 HD12 HG12 ' A' ' 302' ' ' VAL . 13.2 tp -62.08 -40.09 94.65 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -67.32 -34.96 78.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -84.6 -25.86 28.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.92 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.763 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.9 mt -81.87 -41.48 20.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 291' ' ' ASN . . . . . 0.435 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.6 OUTLIER -59.55 117.62 5.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.03 27.32 58.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -95.61 103.35 15.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.854 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -56.97 97.92 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.925 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -87.57 -54.31 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.04 55.01 1.01 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.85 -37.23 3.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -117.03 156.46 48.29 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.622 0.725 . . . . 0.0 110.864 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.56 40.44 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 300' ' ' MET . . . . . 0.549 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.0 ptt? -91.25 162.8 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -99.71 122.06 42.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.763 HG21 ' HB3' ' A' ' 290' ' ' LEU . 5.1 t -129.26 128.77 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -151.19 162.09 29.35 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.484 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.423 ' CE1' ' HD3' ' A' ' 284' ' ' ARG . 0.2 OUTLIER -75.51 123.32 25.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.826 0.346 . . . . 0.0 110.887 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.573 HG22 ' HB2' ' A' ' 232' ' ' TYR . 87.1 t -52.32 94.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 81.3 p -72.67 135.71 45.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.159 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -109.33 118.31 36.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 10.6 ttm-85 -110.61 110.29 20.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.849 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.515 ' N ' HD23 ' A' ' 309' ' ' LEU . 1.0 OUTLIER -157.97 173.47 16.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 -179.937 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.68 119.64 32.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 139.43 115.1 1.24 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.448 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -82.58 106.09 2.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.458 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 78.5 p -65.89 -48.78 70.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.851 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -79.95 146.32 28.03 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.516 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 94.45 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.7 2.267 . . . . 0.0 112.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 317' ' ' SER . 40.6 m -165.79 170.73 13.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.893 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 317' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 316' ' ' SER . 93.0 p -37.43 139.49 0.26 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.489 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 48.9 m -119.27 124.43 46.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.879 0.371 . . . . 0.0 110.825 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 53.1 p -59.87 175.48 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.854 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 175.29 85.17 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.479 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 2.1 m -84.84 115.61 22.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.886 0.374 . . . . 0.0 110.835 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 39.2 p 44.36 40.62 3.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -68.97 154.34 53.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.498 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.843 HD12 ' CE1' ' A' ' 277' ' ' PHE . 33.4 mt -133.83 144.07 48.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.508 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -113.08 139.1 48.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 -179.975 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.449 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.9 p -127.42 134.69 65.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.106 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.39 166.02 27.33 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.501 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 73.71 46.15 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.896 0.379 . . . . 0.0 110.842 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 233' ' ' VAL . 65.2 mt -108.5 174.55 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.426 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 4.5 t-80 -94.66 126.42 39.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.825 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.426 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 5.8 p90 -39.35 -50.28 2.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.864 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -43.53 -49.42 7.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 45.1 mm -38.73 139.59 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.119 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 30.8 p -120.09 175.15 6.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.156 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.12 -31.01 70.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 243' ' ' ASP . . . . . 0.454 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 2.2 m-20 -63.37 -35.84 81.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 8.2 mmt -72.08 -39.28 69.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.59 ' CD1' HD21 ' A' ' 260' ' ' LEU . 54.6 mt -68.23 -39.87 82.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.92 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.487 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 3.8 ptm180 -70.48 -37.31 74.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.45 -35.35 81.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.492 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.428 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 93.7 mt -77.5 -42.41 29.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.899 0.381 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.602 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.86 -4.12 58.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.8 OUTLIER -69.7 -58.29 5.76 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.637 0.732 . . . . 0.0 110.897 -179.901 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.3 Cg_endo -69.8 2.78 3.24 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.671 2.247 . . . . 0.0 112.34 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.96 -35.55 8.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -177.57 159.84 26.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 16.6 ttmt -60.24 120.15 9.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.732 HG21 HD11 ' A' ' 258' ' ' ILE . 64.5 mt -90.74 113.78 27.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.117 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 256' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' A' ' 256' ' ' ASP . 31.1 t0 -77.2 -40.61 44.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.826 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -168.33 147.76 4.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.89 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 255' ' ' ILE . 53.3 mt -129.36 132.83 66.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.485 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.5 m -134.07 138.43 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.164 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.59 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.2 mt -104.16 132.6 50.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 26.3 mmt -90.8 121.08 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.27 142.44 51.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -68.2 179.03 1.68 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.842 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 30.4 t -112.82 -53.33 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.832 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -61.94 -41.6 98.16 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.915 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 76.3 p -94.34 -42.07 9.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 67.47 24.15 73.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.445 ' O ' ' C ' ' A' ' 269' ' ' SER . 57.7 mtp180 -115.17 103.49 10.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.861 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.7 OUTLIER -34.62 108.93 0.07 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.773 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 22.6 mmtp -53.52 -42.39 67.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.901 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 130.99 35.93 0.37 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.481 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 2.6 p90 -145.06 161.8 38.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.936 0.398 . . . . 0.0 110.907 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.72 171.55 37.7 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.477 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.485 ' HB2' HG23 ' A' ' 259' ' ' VAL . 16.2 m-85 -118.86 136.76 53.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.859 0.362 . . . . 0.0 110.873 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.421 HG12 HG23 ' A' ' 258' ' ' ILE . 89.3 mt -135.73 138.7 47.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.134 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 61.0 m -113.03 128.77 56.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.843 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.1 m-85 -101.98 170.45 8.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 14.6 t -115.79 33.15 5.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -172.58 124.97 0.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 23.0 t -62.74 -40.52 97.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -66.8 -43.71 83.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.86 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 51.9 m -64.36 -42.58 96.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.913 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.74 -44.03 97.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -59.31 -48.56 81.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.87 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -57.96 -51.17 70.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.96 -39.62 69.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.098 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.645 HD22 ' CE1' ' A' ' 304' ' ' HIS . 11.7 tp -63.33 -39.99 96.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -68.49 -34.95 76.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 49.4 mm-40 -83.97 -26.77 28.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.771 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.2 mt -81.4 -47.02 13.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 291' ' ' ASN . . . . . 0.456 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.7 OUTLIER -53.07 114.71 1.54 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.18 34.99 35.39 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.488 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -105.04 122.53 46.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -77.17 112.02 13.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 40.7 tp -93.99 -60.47 1.74 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.964 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -102.93 -21.81 13.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.088 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 169.95 -33.94 0.17 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.79 152.5 45.63 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.67 0.747 . . . . 0.0 110.859 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 120.43 7.21 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.668 2.246 . . . . 0.0 112.344 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 300' ' ' MET . . . . . 0.643 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -72.41 168.54 18.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 41.7 mmt-85 -111.91 125.0 53.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 290' ' ' LEU . 57.8 t -131.37 129.62 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.63 163.01 26.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.645 ' CE1' HD22 ' A' ' 287' ' ' LEU . 20.3 m170 -75.21 98.38 3.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 0.0 110.857 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.8 p -40.18 -28.87 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.147 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 49.8 p -77.24 120.36 22.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -104.29 140.57 37.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 56.5 mtt180 -113.79 132.23 55.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 7.0 mp -123.51 121.55 35.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.913 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.66 141.25 37.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -132.92 104.79 0.56 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 176.69 120.65 0.63 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.491 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.0 t -83.12 160.96 21.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.911 0.386 . . . . 0.0 110.859 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -143.59 78.46 0.26 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.494 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.71 127.5 14.73 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.8 t -98.31 136.8 37.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 23.5 m -88.51 156.73 18.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.834 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.462 -179.984 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 N-CA-C 112.45 -0.26 . . . . 0.0 112.45 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 3.2 m -41.71 108.6 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.927 0.394 . . . . 0.0 110.857 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 36.6 t -115.05 127.96 55.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 61.6 -106.73 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 73.0 m -142.52 -179.77 6.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.898 0.38 . . . . 0.0 110.841 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 95.8 p -107.16 85.49 2.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.817 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -104.9 143.24 15.62 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.466 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.539 HD12 ' CE2' ' A' ' 277' ' ' PHE . 20.6 mt -128.29 146.97 50.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.92 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.683 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.7 t80 -114.39 136.53 52.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.604 ' CG2' HD11 ' A' ' 236' ' ' LEU . 7.4 p -121.12 134.53 64.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.099 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.47 165.05 27.97 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 3.8 t 74.58 46.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.933 0.397 . . . . 0.0 110.875 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.604 HD11 ' CG2' ' A' ' 233' ' ' VAL . 85.8 mt -111.49 170.69 7.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.934 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 18.4 t-80 -88.82 147.28 24.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.412 ' O ' ' C ' ' A' ' 239' ' ' ASN . 2.9 m-85 -52.91 -59.76 4.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.412 ' C ' ' O ' ' A' ' 238' ' ' PHE . 20.1 t-20 -36.17 -47.32 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 23.5 mm -38.42 136.7 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 7.8 t -123.03 179.55 4.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.158 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 45.7 mp0 -63.05 -35.23 79.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -58.78 -38.51 78.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -64.68 -45.98 84.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.529 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.0 mt -59.98 -39.24 85.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.536 ' HA ' HD13 ' A' ' 255' ' ' ILE . 0.0 OUTLIER -72.05 -40.8 68.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.46 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.91 -29.6 74.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.0 mt -87.51 -43.53 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 111.096 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.557 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 2.7 m-85 -85.17 -0.11 53.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.502 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 4.0 tt0 -68.99 -59.88 4.87 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.652 0.739 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.4 Cg_endo -69.7 -9.45 26.15 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.256 . . . . 0.0 112.388 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.7 m-85 -88.78 -24.8 22.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.01 164.43 25.72 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.514 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -68.3 108.84 3.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.857 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.74 HG21 HD11 ' A' ' 258' ' ' ILE . 19.4 mt -77.23 113.63 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.094 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -72.19 -45.2 61.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.921 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -163.32 157.68 20.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.74 HD11 HG21 ' A' ' 255' ' ' ILE . 71.6 mt -138.6 131.85 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 274' ' ' PHE . 3.8 m -134.79 126.6 47.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.486 HD21 HD11 ' A' ' 245' ' ' LEU . 20.7 mt -93.58 129.33 39.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.936 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.574 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 17.8 mmm -89.85 128.49 36.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.85 165.42 18.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -85.57 170.21 12.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 27.4 p -106.54 -42.63 4.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.872 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.9 -46.62 71.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 36.3 p -93.95 -41.73 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.164 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 74.58 24.83 71.61 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.513 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 61.0 mtp180 -119.95 114.23 21.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.787 0.327 . . . . 0.0 110.927 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 24.9 m -38.94 112.06 0.22 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.86 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -58.91 -50.3 74.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 145.72 40.32 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.506 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.574 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.3 p90 -150.36 162.21 40.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.951 0.405 . . . . 0.0 110.944 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.59 177.32 37.92 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.5 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.771 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.1 m-85 -120.1 133.99 55.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.774 0.321 . . . . 0.0 110.925 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.529 HD11 ' HB3' ' A' ' 245' ' ' LEU . 67.9 mt -133.08 135.93 56.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 64.5 m -117.51 129.3 55.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.539 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.6 m-85 -100.68 178.74 4.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.6 t -114.98 12.84 16.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.858 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -155.66 128.5 8.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.4 t -64.0 -40.98 97.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 35.6 mm-40 -62.26 -43.93 97.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.897 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 98.7 m -64.51 -36.19 83.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.832 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.53 -43.7 89.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.087 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -61.11 -49.09 78.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 71.5 mtt180 -59.49 -44.32 93.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.407 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -62.61 -35.06 78.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.126 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.607 HD12 HG12 ' A' ' 302' ' ' VAL . 17.6 tp -64.74 -44.66 89.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -69.18 -35.02 75.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -73.59 -42.0 62.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.926 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.823 ' HB3' HG21 ' A' ' 302' ' ' VAL . 42.0 mt -75.25 -47.04 29.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.876 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -42.14 106.25 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.65 34.59 31.05 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -96.07 102.02 13.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.344 . . . . 0.0 110.891 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -56.22 90.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.909 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 25.6 tp -80.18 -58.53 3.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.76 40.34 2.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.53 -26.98 21.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 3.5 ptp85 -120.08 147.34 44.4 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 122.33 9.01 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.328 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -75.36 177.31 6.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 11.5 mmm-85 -110.85 122.68 48.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.823 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.0 t -128.99 123.51 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.113 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -156.47 161.25 30.78 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.444 ' CD2' HD22 ' A' ' 287' ' ' LEU . 90.4 m-70 -72.68 128.27 35.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.855 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 232' ' ' TYR . 21.5 m -59.5 -43.33 90.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 306' ' ' THR . . . . . 0.436 ' N ' HG23 ' A' ' 305' ' ' VAL . 10.5 t -78.52 131.18 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -52.29 125.66 16.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.405 ' HD2' ' C ' ' A' ' 308' ' ' ARG . 3.4 ppt_? -91.33 1.07 57.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 29.7 tp -57.76 -58.81 6.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -94.11 137.73 32.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.892 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 115.93 88.87 1.5 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 116.66 163.28 13.2 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 88.7 p -147.5 157.21 43.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.93 0.395 . . . . 0.0 110.864 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -116.45 179.53 17.73 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.468 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 172.94 11.68 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.652 2.235 . . . . 0.0 112.38 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 6.6 t -119.23 135.79 54.52 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.837 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 87.9 p -131.23 152.74 50.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.986 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 49.3 m -116.88 102.88 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 110.851 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 32.2 m -127.51 163.65 23.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.868 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -47.58 114.32 1.68 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.501 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 21.3 t -86.09 60.62 6.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 110.889 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 4.8 t -72.41 121.48 19.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -168.41 131.19 2.25 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.456 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.97 HD12 ' CE1' ' A' ' 277' ' ' PHE . 34.3 mt -118.6 146.83 44.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.806 0.336 . . . . 0.0 110.929 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.581 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.4 OUTLIER -118.6 141.3 48.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.915 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.64 ' CG2' HD11 ' A' ' 236' ' ' LEU . 12.0 p -123.08 131.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.14 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -136.91 165.9 25.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 58.5 m 62.54 49.87 3.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.884 0.373 . . . . 0.0 110.822 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.64 HD11 ' CG2' ' A' ' 233' ' ' VAL . 61.8 mt -103.67 -175.13 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 16.8 t-80 -110.39 142.31 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.474 ' CD1' ' HD2' ' A' ' 268' ' ' ARG . 3.2 t80 -49.47 -44.31 45.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -52.44 -33.74 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 10.5 mm -57.21 125.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.144 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.1 p -117.28 178.64 4.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.162 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -60.83 -36.67 79.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 243' ' ' ASP . . . . . 0.443 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 6.9 t0 -60.88 -34.37 74.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.807 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 21.6 mtt -72.05 -42.71 65.97 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 63.1 mt -66.8 -42.97 85.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.939 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.448 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 4.0 ptm180 -66.38 -38.74 88.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.866 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.448 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.45 -36.82 92.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 86.8 mt -78.56 -43.91 26.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.912 0.387 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.4 m-85 -81.75 -4.72 57.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.924 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.501 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.5 OUTLIER -66.55 -60.13 7.06 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.677 0.751 . . . . 0.0 110.897 -179.908 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.34 3.61 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.706 2.271 . . . . 0.0 112.321 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.824 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.3 m-85 -103.39 -23.33 13.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.881 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 168.35 158.98 13.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.466 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.47 117.58 7.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.768 0.318 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.68 HD13 HD11 ' A' ' 258' ' ' ILE . 45.4 mt -86.33 120.89 36.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.103 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -79.51 -41.23 27.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.851 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 38.4 t30 -167.7 145.78 4.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.68 HD11 HD13 ' A' ' 255' ' ' ILE . 93.9 mt -128.44 127.88 67.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.105 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.635 HG23 ' HB2' ' A' ' 274' ' ' PHE . 18.3 m -129.51 139.15 52.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.096 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 28.9 mt -111.41 139.49 46.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.572 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 29.8 mmt -97.78 120.34 37.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.53 131.06 39.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -51.5 -175.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.881 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 31.0 t -114.81 -66.12 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 -179.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -49.55 -40.84 39.63 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 18.1 p -91.62 -44.81 8.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 77.47 8.44 87.1 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.474 ' HD2' ' CD1' ' A' ' 238' ' ' PHE . 3.0 tpt180 -103.61 112.75 25.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.344 . . . . 0.0 110.877 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.403 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.7 OUTLIER -37.37 132.31 0.8 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 -179.856 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.09 -36.07 82.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.858 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.92 29.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.506 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.572 ' CE1' ' HB2' ' A' ' 261' ' ' MET . 2.1 p90 -151.01 165.18 34.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.926 0.393 . . . . 0.0 110.94 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -157.89 168.01 34.37 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.492 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.635 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.0 m-85 -114.44 137.79 51.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.864 0.364 . . . . 0.0 110.872 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 85.1 mt -137.24 134.45 47.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.6 m -117.76 129.18 55.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.191 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.97 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.4 m-85 -99.28 177.97 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 62.6 p -98.8 -36.28 9.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.819 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -115.97 129.19 56.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 32.8 p -57.48 -37.98 73.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.419 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 11.1 pt-20 -62.32 -43.35 99.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 282' ' ' CYS . . . . . 0.419 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 68.1 m -62.25 -37.49 85.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -40.17 90.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 47.6 ttt85 -62.08 -48.94 77.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.862 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.8 mmt180 -58.66 -51.02 71.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.57 -35.07 69.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.7 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -65.06 -41.96 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -68.99 -42.91 75.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.943 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.0 mm100 -71.98 -36.03 69.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.664 ' HB3' HG21 ' A' ' 302' ' ' VAL . 54.9 mt -75.3 -46.95 30.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -42.0 112.41 0.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.905 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 73.96 40.16 44.45 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 23.9 t80 -100.93 98.05 8.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.824 0.345 . . . . 0.0 110.861 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.19 105.83 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 5.7 tt -94.82 -53.68 3.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.926 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.14 40.64 2.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.2 -35.21 4.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.491 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 -110.23 149.1 39.66 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.576 0.703 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 119.16 6.15 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.724 2.283 . . . . 0.0 112.325 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptm -71.07 171.55 10.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -106.92 125.17 50.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.913 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.7 HG12 HD12 ' A' ' 287' ' ' LEU . 7.0 t -128.5 121.5 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.097 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.69 163.49 28.54 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.503 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.478 ' CE1' HD22 ' A' ' 287' ' ' LEU . 18.5 m170 -79.24 130.37 35.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.885 0.374 . . . . 0.0 110.82 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 83.9 t -53.4 -63.4 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.134 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 12.4 t -46.0 151.68 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -122.71 112.93 18.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.858 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.417 ' C ' ' HD3' ' A' ' 308' ' ' ARG . 0.4 OUTLIER -95.23 173.07 7.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.893 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 1.7 tt -128.43 121.67 29.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.889 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -54.22 179.78 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 148.0 150.56 5.23 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -162.13 41.96 0.37 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.504 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 14.7 m -79.76 158.34 26.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.957 0.408 . . . . 0.0 110.819 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -147.27 -100.88 0.26 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 108.56 2.1 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.697 2.265 . . . . 0.0 112.313 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 5.2 m -73.2 -50.56 21.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 2.1 m -75.63 91.59 2.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.812 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.488 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 51.8 p -103.12 155.83 18.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.872 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 59.7 p -90.52 -45.89 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.853 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -66.96 133.41 31.55 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.471 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 19.8 m -126.34 120.57 30.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.932 0.396 . . . . 0.0 110.795 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 23.1 t -132.1 -178.77 5.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 140.08 131.25 2.75 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.514 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.465 HD11 ' O ' ' A' ' 283' ' ' ALA . 37.0 mt -129.96 147.04 51.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.349 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.492 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.4 t80 -110.13 131.81 54.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.74 136.46 55.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.18 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.56 165.47 27.53 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.448 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.5 t 74.28 46.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.9 0.381 . . . . 0.0 110.85 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.37 170.7 7.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 238' ' ' PHE . 31.4 t-80 -98.65 132.16 44.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.437 ' C ' ' O ' ' A' ' 237' ' ' HIS . 0.9 OUTLIER -34.46 -61.07 0.4 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.878 -179.91 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 238' ' ' PHE . 4.5 p30 -36.95 -47.27 0.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.411 ' C ' ' O ' ' A' ' 239' ' ' ASN . 40.3 mm -36.74 128.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.181 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.0 p -118.44 175.57 5.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -60.61 -31.07 70.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.844 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -64.89 -32.45 74.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 13.5 mmt -71.74 -40.88 69.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.476 ' CD1' HD21 ' A' ' 260' ' ' LEU . 45.1 mt -69.35 -43.0 74.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.436 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 6.2 ptm180 -66.02 -40.11 90.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -66.48 -38.25 93.32 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.507 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.0 mt -77.27 -41.84 30.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.902 0.382 . . . . 0.0 111.131 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.591 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -83.74 -3.88 58.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.847 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.535 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.94 -58.34 5.42 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.654 0.74 . . . . 0.0 110.853 -179.932 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.74 2.74 3.25 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.734 2.289 . . . . 0.0 112.347 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.816 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.62 -33.11 9.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 175.67 138.66 2.88 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.449 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -45.64 116.64 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.769 0.319 . . . . 0.0 110.924 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 55.5 mt -85.3 134.7 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.12 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -91.38 -46.47 8.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.874 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 33.8 t30 -160.92 145.82 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.1 mt -124.14 133.1 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.151 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 89.4 t -131.86 125.78 55.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.13 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.476 HD21 ' CD1' ' A' ' 245' ' ' LEU . 26.2 mt -96.93 131.32 43.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.53 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.7 mmt -90.54 140.92 29.28 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.894 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 262' ' ' LYS . . . . . 0.432 ' HD2' ' C ' ' A' ' 261' ' ' MET . 0.0 OUTLIER -140.44 135.13 31.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.946 179.939 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -51.6 176.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 37.5 p -106.42 -58.8 1.88 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.899 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -55.79 -58.81 6.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.865 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 63.1 p -78.78 -39.69 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.131 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 71.77 14.7 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -100.95 134.56 43.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.859 0.361 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 1.5 p -50.18 111.59 0.55 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.49 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 1.1 mmmp? -69.34 -28.54 66.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.905 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 114.4 40.5 0.94 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.497 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.53 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 1.1 p90 -151.0 153.72 35.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 0.0 110.934 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.01 175.36 40.15 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -117.79 140.29 49.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.939 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.437 HD11 ' HB3' ' A' ' 245' ' ' LEU . 90.6 mt -138.25 128.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 83.5 m -110.02 130.0 55.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.444 ' CE1' HD12 ' A' ' 231' ' ' LEU . 32.7 m-85 -96.37 179.51 5.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 27.8 t -92.03 -42.73 9.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.83 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.41 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 10.9 t0 -114.1 139.35 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.7 m -60.75 -39.74 89.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.41 ' HG2' ' CG ' ' A' ' 279' ' ' ASP . 11.6 pt-20 -61.62 -43.73 98.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 87.9 m -60.13 -38.93 84.55 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.465 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -65.37 -40.93 94.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -60.1 -48.31 82.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 47.7 mmt-85 -58.25 -51.01 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.816 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.24 -35.54 69.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.593 HD12 HG12 ' A' ' 302' ' ' VAL . 12.4 tp -65.01 -40.55 95.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.902 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -68.41 -42.63 78.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.855 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 24.7 mm-40 -71.88 -38.99 69.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.997 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.8 mt -72.62 -45.87 56.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.924 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -47.81 108.07 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.833 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.46 36.11 27.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.474 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -100.45 121.64 41.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.832 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -73.68 96.64 2.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 42.5 tp -88.52 -47.83 8.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.927 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -121.9 43.57 2.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.133 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 93.78 -25.17 22.73 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.507 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 55.2 mtp180 -122.94 148.69 54.75 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.605 0.717 . . . . 0.0 110.844 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 121.17 7.85 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.635 2.223 . . . . 0.0 112.357 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -74.46 171.8 13.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.2 mmm180 -108.8 123.51 49.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.997 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.4 t -129.46 126.6 63.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.126 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -147.78 158.97 27.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -71.65 120.58 17.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.812 0.339 . . . . 0.0 110.873 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 96.4 t -42.87 -55.59 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 90.3 m -140.77 115.7 9.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 307' ' ' GLU . . . . . 0.608 ' OE2' HD23 ' A' ' 309' ' ' LEU . 0.0 OUTLIER -101.17 79.62 2.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.835 -179.95 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.428 ' HB2' ' NH1' ' A' ' 308' ' ' ARG . 0.5 OUTLIER -100.13 100.88 11.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.944 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.615 ' C ' HD12 ' A' ' 309' ' ' LEU . 1.4 pp -119.93 140.3 51.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -128.97 98.39 4.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 58.73 -113.07 4.6 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.516 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -84.91 113.02 3.72 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 313' ' ' SER . . . . . 0.414 ' HB2' ' CB ' ' A' ' 317' ' ' SER . 3.9 m -47.37 -64.75 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.889 0.376 . . . . 0.0 110.877 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -164.24 -162.89 16.04 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.488 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -0.02 6.27 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.736 2.291 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 4.0 t -118.37 -43.93 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 -179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 317' ' ' SER . . . . . 0.414 ' CB ' ' HB2' ' A' ' 313' ' ' SER . 2.6 m -102.57 108.37 19.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.898 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.999 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 83.7 p -162.28 153.81 18.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.86 0.362 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.5 p -66.11 95.48 0.28 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.889 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -74.84 -98.31 0.11 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 10.3 t -130.44 161.41 31.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 110.864 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 76.7 p -96.64 79.6 3.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -126.21 144.59 15.2 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.694 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.2 mt -122.18 144.82 48.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.358 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -109.52 141.97 41.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.948 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.92 135.75 63.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -142.59 166.06 26.61 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.8 m 64.03 49.82 2.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.892 0.377 . . . . 0.0 110.878 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 96.4 mt -103.06 -179.02 3.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.417 ' O ' ' C ' ' A' ' 238' ' ' PHE . 11.2 t-80 -109.85 133.11 53.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.528 ' CD1' ' O ' ' A' ' 269' ' ' SER . 71.7 m-85 -37.38 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.86 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.434 ' C ' ' O ' ' A' ' 238' ' ' PHE . 2.3 p30 -35.8 -40.86 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.908 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 37.4 mm -49.07 146.11 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 239' ' ' ASN . 12.6 p -143.2 -179.86 6.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.171 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -60.52 -35.82 76.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.882 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.23 -41.23 88.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 19.3 mtt -69.28 -44.92 70.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.464 HD22 HD11 ' A' ' 275' ' ' ILE . 47.4 mt -60.25 -36.38 77.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.486 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -39.73 68.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.953 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.482 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.65 -36.34 93.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.438 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.612 ' CG2' HD21 ' A' ' 290' ' ' LEU . 95.4 mt -81.78 -44.1 20.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.871 0.367 . . . . 0.0 111.103 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.628 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.3 m-85 -79.07 -8.08 58.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.525 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.1 tp10 -67.96 -58.78 7.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.525 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.78 1.88 4.05 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.779 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.0 -34.45 8.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -179.41 158.03 21.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 2.4 ttmp? -64.73 101.53 0.48 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.745 0.307 . . . . 0.0 110.932 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 38.4 mt -69.36 125.65 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.162 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -83.03 -42.53 17.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.823 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -168.82 146.77 3.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 95.9 mt -123.08 133.79 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.144 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.517 HG23 ' HB2' ' A' ' 274' ' ' PHE . 7.1 m -133.92 124.59 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 29.5 mt -92.04 138.05 31.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.562 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 10.5 mmm -102.63 122.36 44.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 262' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 262' ' ' LYS . 1.0 OUTLIER -131.88 150.9 52.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.886 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 13.1 t0 -69.54 169.31 12.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.846 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 31.0 t -105.2 -31.76 8.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -65.94 -63.13 1.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.825 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 15.4 p -86.42 -39.6 16.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.098 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 76.89 28.15 59.34 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 31.8 mmt180 -110.26 132.27 54.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 0.0 110.897 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.528 ' O ' ' CD1' ' A' ' 238' ' ' PHE . 1.6 m -61.26 92.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.885 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 24.0 mttm -46.14 -42.17 13.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 131.81 39.34 0.24 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.526 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.562 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -146.89 153.29 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.926 0.393 . . . . 0.0 110.927 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -159.66 -178.15 33.4 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.517 ' HB2' HG23 ' A' ' 259' ' ' VAL . 32.7 m-85 -129.71 140.11 51.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.5 mt -136.64 137.27 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.137 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.5 m -116.13 127.25 54.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.125 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.694 ' CE1' HD12 ' A' ' 231' ' ' LEU . 48.9 m-85 -96.92 -179.27 4.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.2 t -96.93 -41.85 8.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.863 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -112.52 138.12 49.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.1 p -61.51 -39.74 92.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.847 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -61.91 -44.04 97.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 72.2 m -60.4 -37.31 80.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.904 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.05 -41.44 86.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.4 ttt180 -59.96 -48.78 80.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.86 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -58.41 -51.02 71.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.779 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.15 -35.02 69.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.664 HD12 HG12 ' A' ' 302' ' ' VAL . 10.8 tp -63.88 -45.3 90.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -69.08 -39.01 79.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -69.46 -42.11 75.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.91 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 56.7 mt -74.45 -47.03 35.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -43.59 114.53 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 71.22 38.2 63.17 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -104.57 109.57 21.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.923 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -55.29 95.05 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.913 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.454 HD13 ' C ' ' A' ' 295' ' ' LEU . 0.5 OUTLIER -76.25 -64.78 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.6 37.41 3.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.62 -40.2 2.46 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 62.1 mtp180 -115.95 157.58 44.5 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 127.82 15.16 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.716 2.277 . . . . 0.0 112.356 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 300' ' ' MET . . . . . 0.41 ' HE2' HD23 ' A' ' 295' ' ' LEU . 2.1 ptp -79.51 179.53 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.875 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -110.73 123.36 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.89 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 14.8 t -132.75 125.35 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.56 160.83 28.3 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.436 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.534 ' CE1' HD22 ' A' ' 287' ' ' LEU . 9.6 m170 -75.55 111.6 11.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.834 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 304' ' ' HIS . 98.5 t -35.59 133.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 10.2 t -59.22 137.73 57.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.178 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -116.66 99.81 7.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 26.9 ttt85 -89.96 91.59 8.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.859 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 5.8 tp -148.76 125.5 11.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -94.27 157.31 16.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.873 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -156.72 129.45 2.42 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.454 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -116.5 173.43 14.71 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.2 t -127.73 -59.72 1.19 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.894 0.378 . . . . 0.0 110.827 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 148.81 -159.1 27.91 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.501 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 173.34 11.13 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.631 2.221 . . . . 0.0 112.332 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 7.4 t -97.63 138.61 34.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 8.0 t -45.32 -47.18 13.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.46 -179.951 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 16.5 t -163.39 157.19 19.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.873 0.368 . . . . 0.0 110.817 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 2.3 t -89.94 168.01 12.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.879 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 157.64 -112.25 0.52 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.478 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 5.2 t 41.69 40.21 1.38 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.91 0.385 . . . . 0.0 110.851 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 14.8 m -93.8 -41.14 9.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.888 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -51.17 138.52 26.97 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.611 HD11 ' O ' ' A' ' 283' ' ' ALA . 44.6 mt -116.85 144.66 44.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.847 0.356 . . . . 0.0 110.935 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.475 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 1.7 t80 -106.73 129.53 54.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.7 p -114.81 132.54 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.179 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.12 163.85 28.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.479 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 74.64 43.01 0.27 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.928 0.394 . . . . 0.0 110.881 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.428 HD11 ' CG2' ' A' ' 233' ' ' VAL . 23.1 mt -101.88 -177.41 3.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 240' ' ' ILE . 6.6 t-80 -103.75 126.77 51.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.865 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.49 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 4.2 p90 -35.89 -44.69 0.37 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.49 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 39.5 t30 -51.7 -46.15 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.44 ' N ' ' O ' ' A' ' 237' ' ' HIS . 40.3 mm -40.19 147.87 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.127 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.0 t -136.98 174.51 10.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.099 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 38.0 mp0 -56.89 -34.96 68.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -58.33 -44.18 88.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.4 mmt -65.08 -42.23 94.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.694 HD11 HD21 ' A' ' 260' ' ' LEU . 41.7 mt -61.19 -39.62 90.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.894 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.01 -37.97 69.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.454 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -63.37 -34.61 90.42 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 248' ' ' ILE . . . . . 0.437 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 68.1 mt -83.55 -44.81 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.618 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.7 m-85 -78.94 -5.97 55.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.58 -58.28 5.9 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 0.0 110.909 -179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.78 -0.95 7.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.63 2.22 . . . . 0.0 112.388 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.793 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 11.7 m-85 -100.05 -23.87 14.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 167.57 167.33 28.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm -68.43 115.09 7.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.71 0.29 . . . . 0.0 110.872 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.441 HG21 HD11 ' A' ' 258' ' ' ILE . 27.3 mt -83.41 120.65 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.126 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -77.63 -49.37 14.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -163.25 145.64 10.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.441 HD11 HG21 ' A' ' 255' ' ' ILE . 84.8 mt -124.42 129.6 73.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 51.8 t -131.03 131.94 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.165 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.694 HD21 HD11 ' A' ' 245' ' ' LEU . 30.0 mt -101.08 133.7 45.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.473 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 57.6 mmm -94.62 125.97 39.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.888 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.67 157.91 40.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.868 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -65.53 172.67 3.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 19.1 t -106.85 -41.8 5.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.844 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -75.5 -54.42 7.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.895 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 72.2 p -78.04 -41.2 36.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.177 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 72.53 21.05 79.72 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.458 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 23.2 mmm-85 -109.89 131.2 55.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.813 0.339 . . . . 0.0 110.874 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 14.9 m -61.18 125.97 25.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.846 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 52.4 mmtt -77.32 -39.5 47.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 131.25 37.92 0.29 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.481 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.473 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -148.19 159.09 44.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.904 0.383 . . . . 0.0 110.962 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -166.1 176.3 41.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -119.74 135.9 54.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.339 . . . . 0.0 110.886 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.428 HD12 ' CE2' ' A' ' 249' ' ' PHE . 75.8 mt -131.89 140.11 48.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 69.5 m -120.97 128.23 52.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.181 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -96.8 -175.34 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.841 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.4 t -105.23 -28.79 10.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.893 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.66 135.56 55.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.3 p -63.54 -40.52 97.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -61.68 -43.63 98.49 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.861 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.9 m -62.5 -38.81 91.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.905 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.611 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.92 -43.17 96.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.128 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -61.65 -47.58 84.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -57.98 -49.8 75.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.793 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.25 -39.47 75.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.683 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -61.68 -40.71 95.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -68.24 -35.04 77.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -82.58 -26.5 32.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.952 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.3 mt -81.71 -47.06 13.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 291' ' ' ASN . . . . . 0.444 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -51.36 117.17 2.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.25 32.45 55.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.446 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -97.49 106.89 19.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -59.73 102.53 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 39.7 tp -92.79 -63.36 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -107.88 39.79 1.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.109 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.88 -25.81 26.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -120.68 154.53 57.22 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.601 0.715 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.85 128.93 16.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.683 2.255 . . . . 0.0 112.333 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 300' ' ' MET . . . . . 0.605 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.9 ptt? -82.43 164.35 21.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 66.6 mmt-85 -102.28 121.19 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.952 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.9 t -130.28 121.32 51.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.15 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -140.78 163.98 26.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.514 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 305' ' ' VAL . 7.0 m170 -73.02 112.49 9.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 110.833 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' A' ' 304' ' ' HIS . 74.4 t -34.27 136.1 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.134 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 9.8 t -102.41 142.44 33.61 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.15 -175.49 2.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.29 153.55 46.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.894 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.47 99.23 5.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.944 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -108.61 108.66 19.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -159.82 130.09 2.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -161.31 111.86 0.5 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 6.9 t -70.83 -41.01 72.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.918 0.39 . . . . 0.0 110.891 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 113.19 145.55 9.38 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 126.2 13.07 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.719 2.279 . . . . 0.0 112.373 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.1 t -172.46 159.33 4.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 26.4 t -110.75 -54.76 2.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.824 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.493 -179.986 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 24.6 m -139.06 166.49 24.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 96.4 p -57.29 -46.92 82.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 103.98 164.55 24.93 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.48 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 47.7 t -68.06 139.72 56.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.882 0.373 . . . . 0.0 110.874 -179.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 36.9 p -69.05 101.54 1.43 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -128.34 149.97 18.39 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.444 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 63.5 mt -129.03 145.7 51.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.942 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.498 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 2.0 t80 -105.54 135.0 47.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.597 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.6 p -121.73 129.39 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -138.65 162.55 25.84 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 73.47 46.73 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.891 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.597 HD11 ' CG2' ' A' ' 233' ' ' VAL . 64.2 mt -106.73 -176.14 2.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.959 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -113.6 130.26 56.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.418 ' O ' ' C ' ' A' ' 239' ' ' ASN . 1.2 m-85 -38.12 -58.29 0.98 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 238' ' ' PHE . 18.3 m-20 -36.19 -46.1 0.49 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.0 mm -47.43 128.92 3.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.7 p -113.1 174.88 5.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -58.53 -33.86 70.35 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.876 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -61.58 -46.02 91.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 30.6 mtt -60.23 -42.49 95.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.735 HD11 HD21 ' A' ' 260' ' ' LEU . 42.4 mt -60.42 -40.5 91.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.498 ' O ' ' N ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -63.51 -43.98 95.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.467 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -64.87 -32.01 82.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.485 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 87.0 mt -78.4 -40.99 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.881 0.372 . . . . 0.0 111.175 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.701 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.2 m-85 -90.91 -8.65 48.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.886 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.515 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.6 tp10 -59.0 -59.28 14.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.636 0.731 . . . . 0.0 110.88 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.515 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 2.75 3.28 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.268 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.725 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.6 m-85 -106.41 -9.67 16.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 152.7 168.25 16.5 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.45 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 31.6 tttp -72.46 122.03 20.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.75 0.309 . . . . 0.0 110.932 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.468 HG21 HD11 ' A' ' 258' ' ' ILE . 33.4 mt -93.8 111.65 25.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -70.14 -39.34 75.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.883 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -167.66 155.05 8.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 255' ' ' ILE . 49.0 mt -131.57 131.99 62.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 8.1 t -128.4 137.8 56.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.161 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.735 HD21 HD11 ' A' ' 245' ' ' LEU . 48.3 mt -110.07 132.81 53.83 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.525 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.3 mmt -84.34 141.82 30.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 262' ' ' LYS . . . . . 0.416 ' HD2' ' C ' ' A' ' 261' ' ' MET . 0.0 OUTLIER -140.85 151.79 44.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -61.92 -176.97 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.903 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 3.2 m -124.83 -11.25 7.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.834 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 265' ' ' ASP . . . . . 0.482 ' CG ' HG23 ' A' ' 266' ' ' THR . 32.8 p-10 -87.4 -41.3 13.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.88 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 266' ' ' THR . . . . . 0.482 HG23 ' CG ' ' A' ' 265' ' ' ASP . 1.3 p -119.67 -53.6 2.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 116.74 14.07 7.58 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -89.93 123.04 33.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.76 143.89 1.29 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.831 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.461 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 6.5 mmmm -91.02 -8.2 49.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.897 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 96.98 27.81 9.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.496 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.525 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 0.5 OUTLIER -150.42 161.95 41.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.931 0.396 . . . . 0.0 110.879 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.9 -173.17 35.69 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.62 148.5 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.701 HD12 ' CE2' ' A' ' 249' ' ' PHE . 82.1 mt -138.58 139.66 40.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.4 m -118.21 129.98 55.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.16 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -103.48 -175.11 2.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 22.8 t -100.15 -41.76 6.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -113.93 139.94 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.852 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 60.9 p -63.14 -40.16 96.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.847 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.15 -42.77 99.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.904 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.2 m -60.7 -35.98 77.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -68.07 -41.98 81.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.081 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 19.6 ttm180 -59.23 -49.11 79.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 28.4 mmt180 -58.91 -50.93 72.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.885 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.725 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.41 -34.9 69.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.09 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.759 HD12 HG12 ' A' ' 302' ' ' VAL . 15.0 tp -64.09 -45.29 89.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -69.01 -42.03 76.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -67.81 -42.02 82.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.916 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.675 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 65.2 mt -73.72 -46.82 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 291' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 290' ' ' LEU . 0.7 OUTLIER -37.19 103.6 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 179.909 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.58 33.86 33.39 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 293' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 290' ' ' LEU . 22.6 t80 -87.42 105.48 17.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -57.67 96.75 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.404 HD23 ' C ' ' A' ' 295' ' ' LEU . 8.5 tt -89.72 -69.54 0.71 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.946 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -99.3 32.05 2.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 107.68 -36.86 4.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.512 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -108.94 148.01 37.03 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.58 0.705 . . . . 0.0 110.885 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.03 7.73 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.716 2.277 . . . . 0.0 112.325 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptm -74.02 171.96 12.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.0 mmt85 -111.73 122.95 49.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.759 HG12 HD12 ' A' ' 287' ' ' LEU . 4.2 t -124.17 122.32 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.49 162.54 26.92 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.449 ' O ' ' C ' ' A' ' 305' ' ' VAL . 5.0 m170 -71.4 127.27 32.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.812 0.339 . . . . 0.0 110.826 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 304' ' ' HIS . 54.0 t -34.17 123.35 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 38.7 p -79.2 -51.96 8.79 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.146 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -41.69 133.45 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -53.91 133.84 42.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.884 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 32.5 mt -115.09 44.96 1.71 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.927 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -165.32 166.73 18.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.905 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -164.82 -100.34 0.15 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.47 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 44.93 66.38 1.48 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.507 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 69.2 m -41.55 123.91 2.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 0.0 110.877 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -160.65 82.9 0.13 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 128.42 16.0 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.64 2.227 . . . . 0.0 112.334 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.3 t -135.57 145.6 47.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 60.8 p -93.62 142.82 26.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.89 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.496 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 1.8 m -169.19 134.77 1.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 110.88 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 34.3 p -108.06 176.05 5.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 134.29 -167.01 23.97 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.523 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 10.6 t -72.79 127.99 34.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 0.0 110.853 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 229' ' ' SER . . . . . 0.496 ' O ' HG23 ' A' ' 276' ' ' THR . 20.7 m -52.73 109.03 0.36 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.851 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -138.87 134.37 6.74 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.482 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.752 HD12 ' CE2' ' A' ' 277' ' ' PHE . 51.8 mt -123.94 145.22 49.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -112.51 133.79 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.946 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.415 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.7 p -122.07 132.85 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.113 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.76 165.78 27.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.474 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.3 m 74.03 47.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.415 HD11 ' CG2' ' A' ' 233' ' ' VAL . 74.7 mt -110.03 178.78 4.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.919 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -97.53 132.08 43.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.468 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.1 t80 -42.62 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.85 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 238' ' ' PHE . 59.4 t-20 -34.62 -33.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.468 ' N ' ' O ' ' A' ' 238' ' ' PHE . 21.8 mm -54.85 147.98 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.109 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.407 HG23 ' HB3' ' A' ' 243' ' ' ASP . 8.9 t -134.98 175.8 9.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.137 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 242' ' ' GLU . . . . . 0.431 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 11.8 mt-10 -57.82 -32.65 67.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 243' ' ' ASP . . . . . 0.407 ' HB3' HG23 ' A' ' 241' ' ' THR . 4.1 t70 -60.26 -33.83 72.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.89 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.4 mmt -71.98 -37.87 69.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 245' ' ' LEU . . . . . 0.666 ' HB3' HD11 ' A' ' 275' ' ' ILE . 39.1 mt -69.54 -42.89 74.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.959 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.489 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 14.9 ptt85 -67.53 -39.46 85.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.462 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.6 -35.63 86.58 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.492 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 73.3 mt -79.1 -45.19 24.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.815 0.341 . . . . 0.0 111.101 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 255' ' ' ILE . 3.1 m-85 -80.6 -4.9 55.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.537 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.89 -58.19 5.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.69 0.757 . . . . 0.0 110.875 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.537 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.81 3.2 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.479 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.6 m-85 -103.91 -25.84 12.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.93 166.14 29.33 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.464 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.2 ttmt -67.4 109.54 3.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 249' ' ' PHE . 33.6 mt -81.06 123.68 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.141 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -79.31 -44.53 21.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -168.33 151.16 5.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.865 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.513 HG23 HG12 ' A' ' 275' ' ' ILE . 36.7 mt -128.19 134.02 65.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.16 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.7 m -134.51 134.76 54.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 260' ' ' LEU . . . . . 0.431 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 32.3 mt -97.48 134.62 40.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.934 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.571 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 26.9 mmm -98.16 129.31 44.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.33 146.34 51.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.883 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.4 t0 -61.4 -176.69 0.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.868 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 72.6 m -118.35 -47.81 2.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -57.93 -38.33 75.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.825 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 5.4 p -107.31 -54.5 2.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.106 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 93.13 15.84 49.91 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.474 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 84.8 mtt-85 -105.88 117.55 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.854 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 6.5 t -43.81 128.83 5.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.569 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 32.5 mttm -86.89 8.87 21.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 83.12 40.28 9.38 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.477 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.571 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 3.7 p90 -148.69 155.92 41.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.931 0.396 . . . . 0.0 110.861 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.5 177.89 39.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.553 ' HE1' HG22 ' A' ' 305' ' ' VAL . 18.1 m-85 -117.56 139.43 50.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.866 0.365 . . . . 0.0 110.92 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 275' ' ' ILE . . . . . 0.666 HD11 ' HB3' ' A' ' 245' ' ' LEU . 71.0 mt -136.02 138.55 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.132 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 276' ' ' THR . . . . . 0.496 HG23 ' O ' ' A' ' 229' ' ' SER . 92.9 m -117.47 123.94 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.752 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.4 m-85 -91.24 -175.69 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 38.9 t -100.02 -34.3 10.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.867 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -122.94 138.27 54.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.903 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.8 p -61.72 -35.88 79.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -63.66 -44.11 94.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.879 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 74.0 m -62.42 -37.8 87.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.588 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.22 -36.94 82.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.073 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 284' ' ' ARG . . . . . 0.42 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 0.1 OUTLIER -64.13 -48.98 73.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.864 -179.891 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -59.83 -43.22 94.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.83 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.479 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -63.15 -35.23 79.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.138 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.816 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -65.07 -44.65 88.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.923 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -69.39 -38.98 78.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -71.5 -41.12 69.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.565 ' HB3' HG21 ' A' ' 302' ' ' VAL . 74.8 mt -74.29 -46.93 37.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -45.22 107.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.5 38.66 13.89 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.449 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -105.54 100.27 9.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.874 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -50.82 103.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 15.9 tp -94.67 -55.82 3.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.42 45.55 2.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.145 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.82 -37.19 3.65 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -117.03 150.45 46.01 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 123.36 10.01 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.64 2.226 . . . . 0.0 112.381 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -69.45 170.68 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 6.1 mmm180 -108.76 124.21 50.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.816 HG12 HD12 ' A' ' 287' ' ' LEU . 17.3 t -129.38 125.41 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.126 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -145.74 162.63 28.29 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.442 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.483 ' NE2' HD22 ' A' ' 287' ' ' LEU . 39.9 m-70 -76.92 126.88 31.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.861 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.553 HG22 ' HE1' ' A' ' 274' ' ' PHE . 82.5 t -45.1 94.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 306' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 304' ' ' HIS . 15.2 t -116.7 134.8 54.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -92.65 147.82 22.56 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.93 -2.08 53.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 309' ' ' LEU . . . . . 0.46 ' HA ' HD22 ' A' ' 309' ' ' LEU . 0.7 OUTLIER -74.67 -67.03 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.974 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.13 93.02 6.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.848 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -102.28 -78.81 1.34 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.431 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 142.64 179.35 19.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.531 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 91.9 p -170.6 121.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.901 0.382 . . . . 0.0 110.939 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -135.38 92.63 0.23 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 153.6 68.92 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.708 2.272 . . . . 0.0 112.345 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 26.3 m -121.92 179.1 4.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 35.5 t -88.11 135.09 33.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.519 179.987 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 68.9 m -101.58 43.58 1.06 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.861 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 3.1 m -71.68 90.14 1.04 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.856 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -168.57 158.24 30.81 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 15.9 t -157.85 162.26 38.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 13.3 p -89.26 90.57 8.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.413 ' O ' HG22 ' A' ' 305' ' ' VAL . . . -150.86 147.34 17.25 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.493 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 231' ' ' LEU . . . . . 0.639 HD11 ' O ' ' A' ' 283' ' ' ALA . 30.0 mt -121.78 139.12 53.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.948 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 232' ' ' TYR . . . . . 0.948 ' HB2' HG12 ' A' ' 305' ' ' VAL . 0.9 OUTLIER -106.47 137.79 43.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 233' ' ' VAL . . . . . 0.4 HG21 HD11 ' A' ' 236' ' ' LEU . 7.4 p -122.56 136.91 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.95 163.95 28.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.468 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 74.16 45.25 0.21 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.891 0.377 . . . . 0.0 110.902 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 236' ' ' LEU . . . . . 0.4 HD11 HG21 ' A' ' 233' ' ' VAL . 96.7 mt -104.9 -176.29 3.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 237' ' ' HIS . . . . . 0.438 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.2 t-80 -109.29 135.06 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.84 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 238' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 1.9 p90 -38.7 -44.14 0.97 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 239' ' ' ASN . . . . . 0.479 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 36.4 t30 -54.02 -42.18 68.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 240' ' ' ILE . . . . . 0.503 ' CD1' HD21 ' A' ' 295' ' ' LEU . 15.5 mm -50.63 106.25 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.152 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 241' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 243' ' ' ASP . 10.9 t -95.25 179.49 5.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.096 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -61.16 -30.83 70.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 243' ' ' ASP . . . . . 0.447 ' H ' HG23 ' A' ' 241' ' ' THR . 5.1 m-20 -61.11 -43.55 98.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.8 mtt -62.68 -46.03 90.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 31.9 mt -60.07 -38.75 83.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.02 -42.4 66.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 247' ' ' GLY . . . . . 0.435 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -61.48 -30.61 74.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.468 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 88.4 mt -88.33 -43.59 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 111.171 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 249' ' ' PHE . . . . . 0.534 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -82.23 -2.64 53.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.886 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 250' ' ' GLU . . . . . 0.528 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -70.34 -58.56 4.77 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.594 0.711 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 251' ' ' PRO . . . . . 0.528 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.1 Cg_endo -69.72 2.03 3.88 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 252' ' ' PHE . . . . . 0.496 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.5 m-85 -103.27 -11.12 18.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 154.23 177.34 27.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.51 131.13 41.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.762 0.315 . . . . 0.0 110.921 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.641 HG21 HD11 ' A' ' 258' ' ' ILE . 94.6 mt -98.76 98.7 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -59.43 -44.72 92.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.825 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -167.2 153.55 8.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.938 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 258' ' ' ILE . . . . . 0.641 HD11 HG21 ' A' ' 255' ' ' ILE . 78.3 mt -130.27 133.01 64.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 259' ' ' VAL . . . . . 0.476 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.6 m -134.41 134.28 54.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.6 mt -103.35 128.81 50.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 261' ' ' MET . . . . . 0.563 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 12.1 mmt -86.04 135.59 33.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.831 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.52 154.64 51.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.931 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -67.13 177.58 1.73 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.0 m -110.93 -35.15 6.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.845 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -67.62 -45.71 74.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.866 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 1.3 p -105.51 -54.63 2.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.094 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 96.18 26.67 10.93 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.531 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 268' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 269' ' ' SER . 6.5 ttm105 -110.2 124.17 51.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 0.0 110.846 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 269' ' ' SER . . . . . 0.402 ' C ' ' O ' ' A' ' 268' ' ' ARG . 6.4 m -38.06 124.79 1.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.888 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.34 -29.3 31.09 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 124.87 31.43 0.87 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.501 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 272' ' ' TYR . . . . . 0.563 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -146.96 154.86 41.76 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.934 0.397 . . . . 0.0 110.929 -179.827 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -162.21 172.89 38.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 274' ' ' PHE . . . . . 0.476 ' HB2' HG23 ' A' ' 259' ' ' VAL . 33.1 m-85 -119.8 134.39 55.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 110.848 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.74 137.4 56.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 90.9 m -110.42 129.77 55.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 277' ' ' PHE . . . . . 0.499 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.3 m-85 -103.68 170.83 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.845 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 1.1 t -115.38 24.79 11.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.843 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -162.59 113.09 1.49 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 95.2 p -53.12 -40.47 64.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 -179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -62.02 -43.99 97.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 85.6 m -64.56 -40.91 96.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 283' ' ' ALA . . . . . 0.639 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -58.08 -46.35 85.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -61.91 -47.4 85.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -59.15 -50.93 72.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.87 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 286' ' ' ALA . . . . . 0.496 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.71 -35.2 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.076 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.437 HD22 ' CD2' ' A' ' 304' ' ' HIS . 7.6 tp -64.59 -44.66 89.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.14 -42.5 75.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.895 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 68.2 mm-40 -67.44 -41.95 83.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 73.9 mt -73.73 -46.95 42.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -41.5 104.93 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.43 34.8 15.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.522 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -100.84 99.76 10.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -61.08 118.22 6.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.893 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 295' ' ' LEU . . . . . 0.503 HD21 ' CD1' ' A' ' 240' ' ' ILE . 10.0 tp -108.1 -50.26 3.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.883 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -113.11 42.81 1.83 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.082 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.33 -35.53 4.54 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.479 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -115.92 152.51 47.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 130.47 19.36 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.357 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -78.24 174.78 10.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 16.6 mmt180 -111.38 120.6 42.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 13.0 t -123.43 131.44 73.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.123 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.2 161.8 30.62 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.546 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 304' ' ' HIS . . . . . 0.442 ' HB3' HG22 ' A' ' 306' ' ' THR . 34.2 m-70 -70.12 121.94 18.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.865 0.364 . . . . 0.0 110.864 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 305' ' ' VAL . . . . . 0.948 HG12 ' HB2' ' A' ' 232' ' ' TYR . 17.2 m -63.11 -32.17 55.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 306' ' ' THR . . . . . 0.442 HG22 ' HB3' ' A' ' 304' ' ' HIS . 7.0 t -60.0 147.65 38.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.154 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 307' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 308' ' ' ARG . 6.7 tt0 67.48 40.24 2.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.87 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 308' ' ' ARG . . . . . 0.422 ' C ' ' O ' ' A' ' 307' ' ' GLU . 22.8 mtp180 -35.81 -62.38 0.42 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 7.6 mp -85.99 103.87 15.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -123.12 127.88 49.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -74.91 -66.81 1.85 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.503 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 124.52 78.94 0.37 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.48 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 34.2 p -104.49 86.24 2.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.89 0.376 . . . . 0.0 110.844 -179.76 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 60.03 68.56 1.62 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 123.36 10.02 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.363 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.7 p -57.75 169.96 0.65 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 7.3 t -113.32 167.05 10.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.848 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.53 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 N-CA-C 112.446 -0.262 . . . . 0.0 112.446 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.452 HD12 ' CE1' ' A' ' 277' ' ' PHE . 25.0 mt -121.09 146.99 46.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 110.922 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.558 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -111.9 139.65 47.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.676 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.2 p -124.44 131.29 72.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.114 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.23 165.38 27.43 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.498 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.2 m 72.82 44.67 0.35 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 0.0 110.883 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.676 HD11 ' CG2' ' A' ' 233' ' ' VAL . 79.5 mt -109.24 172.09 7.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.914 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -90.32 126.99 36.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -41.48 -42.46 2.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -51.09 -42.1 60.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.545 ' CD1' HD21 ' A' ' 295' ' ' LEU . 47.8 mm -44.66 152.2 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.161 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 240' ' ' ILE . 76.1 p -137.02 178.58 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.152 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . 0.437 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 12.1 mt-10 -61.67 -35.83 79.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -60.16 -34.87 74.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 240' ' ' ILE . 27.7 mtt -72.04 -41.17 67.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 59.8 mt -68.67 -42.24 78.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.919 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.428 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 6.1 ptm180 -67.3 -39.87 86.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.428 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.27 -34.75 86.51 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.464 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 92.2 mt -80.98 -42.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.854 0.359 . . . . 0.0 111.103 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.788 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.48 -1.65 54.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.863 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.7 OUTLIER -70.29 -59.79 3.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.654 0.74 . . . . 0.0 110.883 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.81 2.88 3.16 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -102.97 -30.41 10.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 176.62 149.01 7.38 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.453 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 7.4 ttpp -56.29 111.42 0.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 110.854 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.495 HG21 HD11 ' A' ' 258' ' ' ILE . 57.0 mt -80.62 124.97 39.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.161 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -82.28 -43.14 17.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -168.25 149.3 4.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.495 HD11 HG21 ' A' ' 255' ' ' ILE . 41.9 mt -128.25 132.72 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.158 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.552 HG23 ' HB2' ' A' ' 274' ' ' PHE . 4.9 m -134.99 127.02 47.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.437 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 31.6 mt -92.11 136.29 33.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 29.9 mmm . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.87 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -148.63 163.32 37.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.868 0.366 . . . . 0.0 110.947 -179.814 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.32 175.56 39.58 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.552 ' HB2' HG23 ' A' ' 259' ' ' VAL . 31.4 m-85 -120.37 137.74 54.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.859 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 30.1 mt -138.48 137.35 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.16 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.7 m -118.53 129.46 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.452 ' CE1' HD12 ' A' ' 231' ' ' LEU . 39.2 m-85 -97.76 -177.9 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.873 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.9 t -95.51 -41.55 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -116.59 141.23 48.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.1 m -63.87 -36.23 83.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -61.72 -43.65 98.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.94 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 99.2 m -62.06 -40.5 96.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.8 -42.84 99.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . 0.427 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 13.0 ttm105 -60.73 -48.05 83.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 23.2 mtp180 -58.31 -50.88 72.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.49 -34.93 71.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.123 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.454 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -64.72 -40.81 95.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -68.96 -42.16 77.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.891 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -71.72 -38.43 70.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.924 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.788 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 56.7 mt -74.08 -47.04 39.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.931 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -44.51 110.16 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.71 37.19 40.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 28.1 t80 -104.83 91.79 3.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.849 0.357 . . . . 0.0 110.825 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -48.91 118.4 2.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.545 HD21 ' CD1' ' A' ' 240' ' ' ILE . 45.6 tp -103.85 -44.73 4.97 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -122.95 40.15 3.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.06 -27.75 18.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 29.6 mtp85 -118.32 148.46 43.9 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.558 0.694 . . . . 0.0 110.891 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 132.62 23.79 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.696 2.264 . . . . 0.0 112.336 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . 0.431 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -86.88 170.93 11.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.898 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -108.64 127.82 54.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.897 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.784 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.4 t -132.47 127.6 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -152.47 163.87 30.44 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -71.13 146.41 49.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 0.0 110.863 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 95.3 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.133 179.977 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.375 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.495 ' CA ' HG23 ' A' ' 305' ' ' VAL . 53.7 mt -127.24 144.77 50.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.81 0.338 . . . . 0.0 110.93 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.482 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.5 t80 -109.69 136.29 49.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.8 p -122.87 137.77 55.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.089 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.65 164.32 28.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.466 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.3 t 74.12 47.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.891 0.376 . . . . 0.0 110.807 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 91.3 mt -109.28 170.29 8.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.586 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 8.0 t-80 -92.93 126.08 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.876 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.586 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 4.8 p90 -38.83 -48.36 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -46.31 -44.54 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.871 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.44 HG22 ' N ' ' A' ' 241' ' ' THR . 47.9 mm -40.07 154.47 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 240' ' ' ILE . 14.4 t -137.42 173.72 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -60.69 -35.02 75.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.887 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -59.49 -34.53 72.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.7 mmt -71.77 -39.51 69.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.869 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.453 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.6 mt -68.89 -41.85 77.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.554 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.7 ptm180 -68.55 -36.15 78.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.42 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.06 -41.82 92.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.471 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.433 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 76.5 mt -75.18 -41.32 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.841 0.353 . . . . 0.0 111.097 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.676 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -81.56 -4.03 54.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.51 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.0 tp10 -69.48 -59.7 4.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.643 0.735 . . . . 0.0 110.871 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.5 Cg_endo -69.79 3.02 3.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.665 2.243 . . . . 0.0 112.285 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.823 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -103.16 -39.33 6.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.92 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -176.01 148.06 9.04 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -51.75 117.24 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 246' ' ' ARG . 31.2 mt -87.07 124.56 40.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -83.61 -44.7 14.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 11.7 t30 -167.51 150.01 5.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.412 HD11 HG21 ' A' ' 255' ' ' ILE . 34.6 mt -126.6 136.13 61.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 84.8 t -134.97 130.86 52.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.13 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.51 131.66 47.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.455 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 68.4 mmm . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.528 -0.229 . . . . 0.0 112.528 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.8 p90 -149.2 161.78 41.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 110.903 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -165.66 171.15 40.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.485 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -117.13 134.82 54.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.842 0.354 . . . . 0.0 110.856 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.453 HD11 ' HB3' ' A' ' 245' ' ' LEU . 97.2 mt -132.28 137.69 53.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.159 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 96.4 m -117.22 129.51 55.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.209 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.485 ' CE1' HD12 ' A' ' 231' ' ' LEU . 43.6 m-85 -97.99 -177.27 3.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.9 t -101.48 -41.37 6.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -112.02 138.81 48.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.7 p -63.52 -40.93 98.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -61.3 -43.62 98.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 95.2 m -60.56 -42.96 97.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.67 -40.07 95.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -60.07 -48.91 79.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -58.96 -49.79 76.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.917 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.823 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.54 -35.79 70.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.404 HD22 ' CD2' ' A' ' 304' ' ' HIS . 12.9 tp -64.54 -43.36 94.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.891 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -68.8 -42.43 77.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 22.2 mm100 -69.1 -41.1 77.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 58.6 mt -73.12 -46.31 51.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.884 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -45.91 112.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.905 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.73 38.73 36.13 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 73.4 t80 -106.51 120.86 43.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.818 0.342 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -67.11 114.56 5.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.5 tp -98.17 -62.12 1.29 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.17 34.76 4.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.064 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 117.0 -35.42 4.17 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.502 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -120.42 156.51 55.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.627 0.727 . . . . 0.0 110.852 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 130.84 20.07 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.65 2.234 . . . . 0.0 112.334 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -79.54 170.92 15.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -105.99 119.08 38.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -124.11 132.38 71.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -154.65 163.9 31.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.404 ' CD2' HD22 ' A' ' 287' ' ' LEU . 16.5 m-70 -70.13 135.99 49.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.809 0.337 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.495 HG23 ' CA ' ' A' ' 231' ' ' LEU . 94.9 t . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.499 -0.24 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.502 HD23 ' HD2' ' A' ' 304' ' ' HIS . 31.1 mt -111.8 147.03 36.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 110.881 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.514 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -107.23 137.11 45.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.506 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.4 p -123.76 131.86 72.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.077 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.0 165.66 27.27 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 72.71 43.67 0.43 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.853 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.506 HD11 ' CG2' ' A' ' 233' ' ' VAL . 30.3 mt -103.75 166.2 10.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.628 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 5.4 t-80 -86.42 128.47 34.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.628 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 36.9 p90 -37.88 -50.22 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.851 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.433 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 10.1 t-20 -47.53 -43.4 24.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' A' ' 237' ' ' HIS . 43.6 mm -38.64 147.9 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -138.88 178.42 7.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -60.65 -35.76 77.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . 0.464 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 1.3 m-20 -61.89 -32.86 73.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.9 mmt -71.98 -41.47 67.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.454 ' HB3' HD11 ' A' ' 275' ' ' ILE . 86.9 mt -69.88 -42.94 72.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.464 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 5.2 ptm180 -64.38 -37.74 88.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.445 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.56 -39.12 79.2 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.468 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.8 mt -75.86 -44.3 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.367 . . . . 0.0 111.11 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.61 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.86 -2.77 48.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.5 tp10 -70.61 -59.86 3.52 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.595 0.712 . . . . 0.0 110.871 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.7 2.42 3.52 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.728 2.286 . . . . 0.0 112.339 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.687 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.47 -31.42 10.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.76 149.86 7.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -54.77 113.32 1.28 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.759 0.314 . . . . 0.0 110.875 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.45 HD13 HD11 ' A' ' 258' ' ' ILE . 64.2 mt -83.35 122.65 37.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -78.83 -43.4 25.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -167.74 145.13 4.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.863 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.45 HD11 HD13 ' A' ' 255' ' ' ILE . 81.1 mt -120.24 135.29 61.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.74 128.87 51.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.0 mt -97.99 139.84 33.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.533 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 28.7 mmt . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.533 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.7 p90 -147.48 155.91 42.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.908 0.385 . . . . 0.0 110.93 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.54 -178.55 39.76 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.488 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.29 137.98 54.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.899 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.454 HD11 ' HB3' ' A' ' 245' ' ' LEU . 92.6 mt -132.03 140.87 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.077 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.3 m -118.83 129.94 55.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.147 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -98.63 -178.05 3.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.1 t -100.98 -39.47 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.812 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -112.84 135.62 53.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 4.5 m -60.54 -39.38 87.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -62.68 -42.74 99.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 75.4 m -61.96 -36.76 82.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.82 -41.8 86.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -61.84 -48.72 79.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -58.3 -50.91 71.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.687 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.89 -35.05 68.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.107 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.703 HD12 HG12 ' A' ' 302' ' ' VAL . 12.9 tp -64.65 -43.7 92.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.947 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -68.93 -42.77 76.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 25.7 mm100 -68.4 -41.85 79.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.704 ' HB3' HG21 ' A' ' 302' ' ' VAL . 67.0 mt -72.93 -46.14 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -46.03 108.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.82 31.57 39.49 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.486 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -94.32 123.01 37.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.842 0.354 . . . . 0.0 110.881 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 71.2 mt-10 -70.83 96.1 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.402 HD21 ' CD1' ' A' ' 240' ' ' ILE . 9.5 tp -78.87 -62.03 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -115.9 41.57 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.056 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.69 -21.44 43.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -124.31 149.58 61.47 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.581 0.705 . . . . 0.0 110.865 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.84 11.49 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -77.52 173.47 11.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.893 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -108.08 119.01 38.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.879 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' A' ' 290' ' ' LEU . 18.2 t -124.88 129.37 73.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.85 161.17 30.51 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.502 ' HD2' HD23 ' A' ' 231' ' ' LEU . 10.6 m170 -73.04 134.4 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.87 0.367 . . . . 0.0 110.838 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.7 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.168 179.957 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.463 HD11 ' O ' ' A' ' 283' ' ' ALA . 31.4 mt -124.65 144.8 49.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.857 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.905 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.6 t80 -109.19 128.76 55.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.616 ' CG2' HD11 ' A' ' 236' ' ' LEU . 10.4 p -113.92 133.5 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.42 166.02 26.94 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 7.7 t 71.98 44.2 0.48 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.876 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.616 HD11 ' CG2' ' A' ' 233' ' ' VAL . 81.6 mt -106.76 167.39 9.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.909 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.409 ' O ' ' C ' ' A' ' 238' ' ' PHE . 5.7 t-80 -93.15 130.96 38.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.409 ' C ' ' O ' ' A' ' 237' ' ' HIS . 4.2 m-85 -36.79 -54.21 0.91 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -41.76 -43.48 2.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.415 HD13 ' SD ' ' A' ' 244' ' ' MET . 31.1 mm -41.05 127.73 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 47.8 p -114.71 172.2 7.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 39.3 mp0 -60.27 -33.94 73.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -62.51 -32.46 73.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.848 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . 0.415 ' SD ' HD13 ' A' ' 240' ' ' ILE . 52.0 mtt -72.01 -41.33 67.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 29.9 mt -66.91 -42.95 84.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.454 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.8 ptm180 -67.18 -39.69 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.44 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.12 -34.82 89.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.486 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.409 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 81.7 mt -81.56 -40.48 17.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.883 0.373 . . . . 0.0 111.141 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.703 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -84.72 -0.97 55.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.514 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.6 tp10 -70.77 -59.42 3.68 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.79 2.92 3.11 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.259 . . . . 0.0 112.36 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.647 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.2 -31.08 10.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 178.28 157.31 18.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -63.2 108.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.707 0.289 . . . . 0.0 110.909 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.454 HD13 ' HA ' ' A' ' 246' ' ' ARG . 37.3 mt -77.15 125.01 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.125 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -86.39 -43.69 12.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.877 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -163.56 143.65 8.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.449 HD11 HD13 ' A' ' 255' ' ' ILE . 71.0 mt -123.13 127.53 74.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.7 m -134.04 129.35 54.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.12 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 33.3 mt -92.38 139.07 30.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.652 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 15.7 mmt . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.652 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.9 p90 -150.14 164.04 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.922 0.392 . . . . 0.0 110.922 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -172.57 176.38 45.49 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.407 ' HB2' HG23 ' A' ' 259' ' ' VAL . 42.6 m-85 -117.11 136.1 53.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.886 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -132.26 140.59 47.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.1 m -120.98 127.7 52.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -97.43 -175.14 3.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.3 t -100.28 -40.5 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -115.22 140.05 49.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 13.0 p -62.51 -39.19 92.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -62.05 -42.93 99.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.3 m -60.38 -39.22 86.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.463 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.67 -40.69 88.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 32.6 ttp85 -59.07 -49.02 79.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -59.38 -48.94 79.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.647 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.04 -35.6 71.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.444 HD12 HG12 ' A' ' 302' ' ' VAL . 12.0 tp -65.06 -43.58 91.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -68.96 -43.03 75.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 67.6 mm-40 -68.85 -41.21 78.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.818 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.2 mt -73.27 -45.02 58.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.901 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -45.15 98.16 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 96.01 24.46 14.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . 0.416 ' N ' ' O ' ' A' ' 290' ' ' LEU . 10.5 t80 -79.58 116.36 19.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.81 0.338 . . . . 0.0 110.901 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -80.25 89.06 5.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 12.1 tp -86.66 -59.75 2.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.02 45.09 0.98 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.112 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 84.42 -27.75 4.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -113.23 143.93 30.21 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.573 0.702 . . . . 0.0 110.837 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 123.14 9.8 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.644 2.229 . . . . 0.0 112.367 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -73.96 169.71 16.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.852 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 40.3 mmt-85 -109.12 122.19 46.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -126.22 120.63 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -144.71 160.14 27.91 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 8.9 m170 -70.69 121.72 18.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.847 0.356 . . . . 0.0 110.832 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.905 HG12 ' HB2' ' A' ' 232' ' ' TYR . 15.6 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 68.3 mt -124.41 145.69 49.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.773 0.32 . . . . 0.0 110.923 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.507 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.2 t80 -110.78 131.1 55.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.662 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.9 p -113.62 134.94 54.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.13 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.81 165.73 27.57 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.5 t 71.32 45.71 0.47 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.925 0.393 . . . . 0.0 110.823 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.662 HD11 ' CG2' ' A' ' 233' ' ' VAL . 86.8 mt -109.76 176.35 5.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -102.89 135.33 44.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 239' ' ' ASN . 0.6 OUTLIER -46.47 -51.37 15.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.902 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.407 ' N ' ' CD1' ' A' ' 238' ' ' PHE . 6.7 t-20 -42.15 -41.25 2.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.834 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 16.0 mm -47.94 139.91 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -121.61 167.65 12.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.156 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -55.06 -33.71 62.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . 0.467 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 35.5 t0 -59.97 -36.9 78.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 4.8 mmt -71.38 -37.72 71.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.664 ' CD1' HD21 ' A' ' 260' ' ' LEU . 73.2 mt -69.98 -39.97 75.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.511 ' HA ' HD13 ' A' ' 255' ' ' ILE . 2.9 ptm180 -70.53 -35.3 73.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.456 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -69.79 -38.83 76.69 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.414 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 80.2 mt -75.72 -41.12 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.853 0.359 . . . . 0.0 111.113 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.622 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 4.5 m-85 -83.43 -4.19 58.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -69.47 -58.33 5.97 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.598 0.713 . . . . 0.0 110.901 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.76 2.52 3.46 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.736 2.291 . . . . 0.0 112.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.783 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.6 -26.93 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 172.87 162.05 24.32 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.504 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 20.4 ttpt -63.61 110.72 2.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.781 0.324 . . . . 0.0 110.936 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.622 HG21 HD11 ' A' ' 258' ' ' ILE . 25.2 mt -80.58 117.18 26.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -77.0 -46.4 23.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.828 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -168.89 142.46 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.903 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.622 HD11 HG21 ' A' ' 255' ' ' ILE . 46.0 mt -121.09 135.4 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.124 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.37 127.81 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.143 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.664 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.6 mt -98.15 136.54 38.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.523 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 20.2 mmt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.523 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 2.4 p90 -146.92 155.5 42.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.933 0.397 . . . . 0.0 110.962 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -160.39 170.17 36.34 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.51 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -113.52 138.74 49.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.855 0.359 . . . . 0.0 110.857 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 68.0 mt -136.01 134.16 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.0 m -118.19 129.01 55.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.166 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -99.15 -176.19 3.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.915 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 17.7 t -97.49 -41.85 7.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.426 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 26.1 t0 -115.42 142.59 46.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.858 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 29.2 t -63.99 -38.77 92.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . 0.478 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 10.7 pt-20 -61.52 -41.66 97.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . 0.478 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 84.0 m -61.35 -38.94 88.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.74 90.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 40.0 mtp180 -59.1 -48.89 79.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -58.78 -50.4 74.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.783 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -59.52 -34.99 73.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.083 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.531 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.3 tp -62.43 -45.26 93.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -68.83 -38.23 79.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -71.77 -36.62 70.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.6 mt -78.8 -39.97 34.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.917 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -55.09 103.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 87.91 30.89 16.35 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -98.49 109.79 22.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 110.842 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -56.7 99.31 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.431 ' C ' HD13 ' A' ' 295' ' ' LEU . 0.9 OUTLIER -78.77 -65.52 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -119.5 39.62 3.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.08 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 112.44 -34.61 5.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.95 151.35 46.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.865 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 120.94 7.66 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.304 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -71.12 171.89 10.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -110.26 122.51 47.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.2 t -128.88 126.12 64.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.26 160.99 28.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.492 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.531 ' CD2' HD22 ' A' ' 287' ' ' LEU . 26.0 m-70 -70.46 128.04 34.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.766 0.317 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 59.5 t . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.143 179.949 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.432 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.5 mt -131.56 144.78 51.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.806 0.336 . . . . 0.0 110.874 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.58 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.5 OUTLIER -110.3 137.17 48.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.956 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.42 133.12 70.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.79 165.65 27.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 m 72.29 45.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.86 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 37.3 mt -104.78 173.45 6.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -96.89 137.92 35.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.835 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -43.23 -49.41 6.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.516 ' O ' HG23 ' A' ' 241' ' ' THR . 16.0 t-20 -47.78 -40.2 20.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 43.0 mm -43.71 145.73 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.516 HG23 ' O ' ' A' ' 239' ' ' ASN . 33.5 p -143.07 173.65 11.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . 0.413 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 28.5 mp0 -54.97 -36.2 65.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -62.29 -35.5 79.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.847 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -72.01 -40.98 68.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 40.5 mt -68.17 -43.04 79.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.403 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.1 ptm180 -66.12 -37.62 86.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.403 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.85 -36.0 80.94 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.428 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.2 mt -80.36 -42.76 21.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.81 0.338 . . . . 0.0 111.117 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.516 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -81.45 -4.13 54.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.956 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tp10 -68.52 -59.93 5.31 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.646 0.736 . . . . 0.0 110.879 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.82 2.93 3.12 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.347 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.748 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -103.31 -22.03 13.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 163.72 158.54 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -61.32 117.09 5.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.766 0.317 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.66 HG21 HD11 ' A' ' 258' ' ' ILE . 57.2 mt -88.19 120.63 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -76.55 -49.03 17.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -158.17 155.45 29.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.66 HD11 HG21 ' A' ' 255' ' ' ILE . 44.6 mt -136.63 129.91 45.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.3 t -133.84 135.81 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.113 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.413 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 27.8 mt -102.62 139.63 37.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.594 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 24.7 mmt . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.869 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.594 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 2.2 p90 -147.79 158.53 44.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.924 0.392 . . . . 0.0 110.905 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.6 172.28 39.48 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.494 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -118.35 136.28 53.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.884 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.567 HG12 HG23 ' A' ' 258' ' ' ILE . 78.1 mt -136.46 140.44 43.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 99.4 m -120.67 129.36 53.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.13 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.432 ' CE1' HD12 ' A' ' 231' ' ' LEU . 41.8 m-85 -98.46 -178.82 4.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 24.6 t -101.18 -33.97 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -117.6 136.28 53.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.7 p -64.04 -39.83 94.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.863 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -62.65 -43.83 97.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.889 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 32.7 m -62.89 -41.58 99.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.909 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.424 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.14 -41.46 97.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.036 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -59.78 -49.07 79.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -57.57 -48.99 77.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.748 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.8 -38.57 67.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.437 HD22 ' CD2' ' A' ' 304' ' ' HIS . 9.0 tp -65.18 -39.84 93.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.908 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -64.46 -34.94 79.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -83.91 -34.75 24.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.943 ' HB3' HG21 ' A' ' 302' ' ' VAL . 76.3 mt -71.77 -47.07 56.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -55.02 118.31 4.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.24 23.2 63.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.456 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -93.87 111.63 23.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . 0.46 ' HG3' ' N ' ' A' ' 299' ' ' PRO . 2.4 mp0 -76.27 104.45 6.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -94.42 -57.44 2.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.7 41.02 1.45 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 102.66 -42.94 1.78 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 2.8 ptp180 -111.02 153.26 43.93 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.65 0.738 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . 0.46 ' N ' ' HG3' ' A' ' 294' ' ' GLU . 54.0 Cg_endo -69.76 135.42 30.43 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 3.4 ptp -82.85 162.91 21.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -106.28 121.28 43.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.943 HG21 ' HB3' ' A' ' 290' ' ' LEU . 22.1 t -130.81 125.47 58.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.14 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.26 161.36 26.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.437 ' CD2' HD22 ' A' ' 287' ' ' LEU . 22.1 m-70 -72.47 109.31 6.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.836 0.35 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.6 p . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.095 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.509 ' O ' HG12 ' A' ' 305' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.853 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.1 mt -125.77 143.62 50.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 110.93 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.17 130.58 56.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.903 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.493 HG21 HD11 ' A' ' 236' ' ' LEU . 10.8 p -110.39 135.2 50.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -140.24 166.04 25.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.469 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.9 m 63.96 47.81 3.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.86 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 233' ' ' VAL . 72.5 mt -100.11 -175.94 3.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.484 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 4.0 t-80 -115.26 124.5 51.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.89 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.484 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 23.2 p90 -34.48 -54.13 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.414 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 2.1 t-20 -41.52 -46.76 3.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 51.7 mm -41.29 139.07 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.114 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 11.5 t -122.91 170.88 9.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.148 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 43.5 mp0 -57.69 -32.78 67.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -64.95 -32.51 74.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.86 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 17.5 mtt -71.98 -43.84 64.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.939 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.446 HD22 HD11 ' A' ' 275' ' ' ILE . 36.1 mt -65.51 -43.0 91.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.422 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.3 ptm180 -67.14 -38.36 85.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.34 -33.22 81.62 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.67 -45.48 23.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.87 0.367 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.47 -2.01 44.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.936 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.504 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.9 OUTLIER -69.8 -59.95 4.14 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.719 . . . . 0.0 110.891 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.27 3.69 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.69 2.26 . . . . 0.0 112.342 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.802 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.9 m-85 -102.47 -34.1 9.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 179.21 157.59 19.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.479 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -60.7 115.33 3.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.677 HD13 HD11 ' A' ' 258' ' ' ILE . 66.0 mt -85.85 121.47 37.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -80.61 -40.55 25.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 16.5 t30 -168.61 148.03 4.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.677 HD11 HD13 ' A' ' 255' ' ' ILE . 52.5 mt -129.78 128.35 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.585 HG23 ' HB2' ' A' ' 274' ' ' PHE . 16.1 m -130.03 136.97 57.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.88 130.95 48.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.534 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 21.6 mmt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.866 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.534 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -147.16 162.93 37.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.911 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.23 173.71 39.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.585 ' HB2' HG23 ' A' ' 259' ' ' VAL . 18.7 m-85 -119.91 134.09 55.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.446 HD11 HD22 ' A' ' 245' ' ' LEU . 88.1 mt -135.28 127.91 47.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.5 m -113.27 128.72 56.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.853 ' CE1' HD12 ' A' ' 231' ' ' LEU . 51.3 m-85 -95.65 -175.07 3.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.922 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 7.3 t -102.03 -39.37 7.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -112.61 139.15 48.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.88 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 76.9 p -63.27 -40.22 96.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -63.97 -42.58 97.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 93.3 m -62.04 -42.08 98.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.555 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -62.93 -40.28 97.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.07 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 12.2 ttt85 -61.77 -46.64 88.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.825 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 49.6 mtt180 -58.42 -51.01 71.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.802 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.14 -35.78 69.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.64 HD12 HG12 ' A' ' 302' ' ' VAL . 12.6 tp -63.85 -43.87 94.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.921 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -69.02 -35.01 76.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -73.55 -41.99 62.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.775 ' HB3' HG21 ' A' ' 302' ' ' VAL . 38.2 mt -74.88 -46.97 32.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -43.52 105.76 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.32 33.88 27.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.51 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -102.68 116.29 32.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.336 . . . . 0.0 110.882 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -61.59 114.22 3.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.886 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 13.4 tp -101.13 -55.92 2.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -123.04 42.23 3.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.115 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.79 -21.24 44.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -128.5 149.29 71.3 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.629 0.728 . . . . 0.0 110.837 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 125.5 12.25 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.622 2.214 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.5 ptp -76.09 172.99 11.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -110.58 122.21 47.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.775 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.2 t -129.27 123.58 58.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.24 26.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.487 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.479 ' CE1' HD22 ' A' ' 287' ' ' LEU . 10.2 m170 -74.12 100.94 3.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 230' ' ' GLY . 4.8 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.421 -0.271 . . . . 0.0 112.421 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 277' ' ' PHE . 29.7 mt -124.49 145.34 49.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.823 0.344 . . . . 0.0 110.886 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.529 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.8 OUTLIER -111.65 136.83 50.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.956 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.456 ' CG2' HD21 ' A' ' 236' ' ' LEU . 7.3 p -121.96 133.63 67.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.106 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.15 166.03 26.83 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 4.7 t 73.05 43.2 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.903 0.382 . . . . 0.0 110.827 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.456 HD21 ' CG2' ' A' ' 233' ' ' VAL . 49.4 mt -100.03 177.17 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.425 ' O ' ' C ' ' A' ' 238' ' ' PHE . 2.3 t-80 -102.09 133.04 47.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.844 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.425 ' C ' ' O ' ' A' ' 237' ' ' HIS . 59.3 m-85 -35.78 -52.51 0.71 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.43 ' O ' ' C ' ' A' ' 240' ' ' ILE . 16.5 m120 -45.14 -47.38 12.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.613 HD11 HD21 ' A' ' 295' ' ' LEU . 48.8 mm -35.38 150.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.179 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -147.13 179.96 7.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.181 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -60.19 -39.94 88.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -58.44 -36.88 74.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.845 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . 0.477 ' SD ' HD13 ' A' ' 240' ' ' ILE . 18.9 mtt -72.09 -41.54 67.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.521 ' CD1' HD21 ' A' ' 260' ' ' LEU . 75.0 mt -68.21 -41.72 80.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.479 ' HA ' HD13 ' A' ' 255' ' ' ILE . 13.4 ptt180 -67.92 -42.95 80.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' CG ' ' A' ' 246' ' ' ARG . . . -63.3 -36.72 93.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.505 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.402 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.2 mt -76.23 -39.85 35.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.88 0.371 . . . . 0.0 111.13 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.755 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -88.42 -1.15 57.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.2 tp10 -70.34 -58.75 4.59 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 0.0 110.831 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.7 3.46 2.73 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.698 2.265 . . . . 0.0 112.332 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.2 m-85 -104.14 -37.99 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.883 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -174.77 160.14 29.14 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.476 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -65.48 109.08 2.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.735 0.302 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.708 HG21 HD11 ' A' ' 258' ' ' ILE . 36.7 mt -77.23 114.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.171 179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -73.83 -43.99 57.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -162.54 152.09 15.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 255' ' ' ILE . 63.2 mt -133.29 129.64 56.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.073 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 52.8 t -129.37 128.05 65.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.154 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.521 HD21 ' CD1' ' A' ' 245' ' ' LEU . 19.0 mt -97.13 127.72 43.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.573 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 40.6 mmm . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.573 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -149.39 154.39 38.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.885 0.374 . . . . 0.0 110.95 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.14 168.24 36.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -115.29 138.66 50.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.854 0.359 . . . . 0.0 110.865 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 70.2 mt -136.46 138.42 46.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.113 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 89.2 m -117.77 122.97 44.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.154 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 231' ' ' LEU . 44.1 m-85 -91.62 -178.04 4.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.915 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 4.3 t -122.41 24.95 9.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.453 ' OD2' ' CG ' ' A' ' 281' ' ' GLU . 26.4 t0 -165.14 126.45 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.884 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 92.8 p -58.24 -40.98 83.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.891 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . 0.453 ' CG ' ' OD2' ' A' ' 279' ' ' ASP . 6.2 pt-20 -63.37 -40.96 98.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.868 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 36.1 m -64.14 -41.56 97.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.486 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.17 -44.05 97.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.125 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 48.9 mtm180 -63.09 -49.02 76.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 19.5 mmt-85 -59.67 -51.04 71.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -54.96 -36.36 65.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.061 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.421 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.0 tp -65.33 -43.59 90.45 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.923 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.57 -43.1 73.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.908 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 65.1 mm-40 -68.87 -42.14 77.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.755 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 84.1 mt -73.76 -47.02 42.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -46.2 103.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.02 36.47 13.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . 0.424 ' O ' ' N ' ' A' ' 295' ' ' LEU . 37.3 t80 -98.22 93.22 6.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -43.35 95.07 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.613 HD21 HD11 ' A' ' 240' ' ' ILE . 9.3 tt -82.39 -67.38 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -109.0 39.11 2.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 108.91 -41.42 2.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 22.6 ptt-85 -109.9 152.39 42.96 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.634 0.73 . . . . 0.0 110.834 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 118.38 5.64 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.5 ptt? -68.67 169.76 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.6 mmt180 -104.98 121.43 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.9 t -126.95 127.77 70.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.09 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.78 160.34 28.35 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.421 ' CD2' HD22 ' A' ' 287' ' ' LEU . 18.9 m-70 -71.66 125.03 26.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.343 . . . . 0.0 110.889 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.4 t . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.098 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.691 HD12 ' CE2' ' A' ' 277' ' ' PHE . 24.2 mt -126.22 146.63 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.551 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -109.92 136.74 48.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.648 HG21 HD11 ' A' ' 236' ' ' LEU . 7.1 p -120.37 138.13 51.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.96 165.25 28.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 t 71.27 46.59 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.945 0.402 . . . . 0.0 110.85 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.648 HD11 HG21 ' A' ' 233' ' ' VAL . 95.7 mt -109.7 154.02 23.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.956 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 31.9 t-80 -74.45 139.44 43.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -46.58 -45.22 18.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 240' ' ' ILE . 34.1 t-20 -49.88 -46.53 51.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.428 ' C ' ' O ' ' A' ' 239' ' ' ASN . 47.3 mm -35.55 131.67 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.9 p -120.2 177.23 5.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -62.42 -34.65 77.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.898 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -63.16 -33.86 76.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.873 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . 0.401 ' SD ' HD13 ' A' ' 240' ' ' ILE . 38.1 mtt -71.9 -39.28 69.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.0 -42.91 72.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.624 ' HA ' HD13 ' A' ' 255' ' ' ILE . 17.8 ptt180 -66.77 -40.46 88.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.468 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.75 -36.39 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 90.4 mt -76.38 -42.6 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.832 0.349 . . . . 0.0 111.15 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.583 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -85.47 -2.83 58.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.534 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -69.79 -58.35 5.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.855 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.534 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 0.84 5.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.659 2.24 . . . . 0.0 112.347 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.831 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -101.55 -37.05 8.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -173.56 155.66 22.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -57.89 108.11 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.759 0.314 . . . . 0.0 110.891 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 258' ' ' ILE . 43.4 mt -78.11 112.49 16.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -76.76 -41.71 43.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -165.23 149.99 9.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.891 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 255' ' ' ILE . 48.8 mt -132.41 126.19 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.426 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.5 m -133.12 129.93 57.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.138 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 36.4 mt -91.2 137.7 32.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.496 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.2 mmt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.847 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.479 -0.249 . . . . 0.0 112.479 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.496 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.8 p90 -145.75 156.09 43.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.93 0.395 . . . . 0.0 110.944 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -158.06 176.17 35.13 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.426 ' HB2' HG23 ' A' ' 259' ' ' VAL . 22.3 m-85 -121.29 134.02 55.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 0.0 110.836 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.421 HD12 ' CE2' ' A' ' 249' ' ' PHE . 97.3 mt -131.23 145.52 35.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.2 m -120.98 129.66 53.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.691 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.7 m-85 -104.24 175.9 5.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.899 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 3.1 t -120.19 24.87 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.898 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -165.13 127.61 2.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.862 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.5 p -64.05 -40.96 97.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.811 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.47 -43.02 82.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 43.6 m -63.22 -42.73 99.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.438 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.97 -42.44 97.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.049 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 21.4 mtm180 -60.14 -48.98 79.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.879 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.8 mmt85 -58.06 -47.73 82.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.841 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.831 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.03 -40.41 80.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.083 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.496 ' CD1' HG12 ' A' ' 302' ' ' VAL . 9.3 tp -61.66 -40.7 95.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -67.71 -35.0 77.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.938 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -84.11 -22.22 31.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.922 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.9 mt -86.54 -38.51 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . 0.409 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -60.02 119.98 8.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.891 179.893 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.53 20.82 78.2 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.507 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -84.78 105.13 15.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.807 0.337 . . . . 0.0 110.882 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -67.2 96.29 0.46 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.4 tt -91.12 -64.2 1.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.928 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -98.71 36.59 1.63 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.13 -35.22 4.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 40.6 mtp180 -113.68 154.11 45.77 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.626 0.727 . . . . 0.0 110.891 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 132.26 22.98 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.656 2.237 . . . . 0.0 112.345 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.9 ptp -83.44 165.89 18.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.875 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.8 122.74 47.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' A' ' 290' ' ' LEU . 47.7 t -131.41 135.44 59.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -153.06 163.58 30.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.534 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -71.97 112.34 7.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.482 HG23 ' CA ' ' A' ' 231' ' ' LEU . 64.5 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.365 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.842 HD12 ' CE1' ' A' ' 277' ' ' PHE . 38.3 mt -104.06 144.75 31.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 2.3 t80 -111.21 131.46 55.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.507 HG22 HD11 ' A' ' 236' ' ' LEU . 7.7 p -116.0 134.23 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.125 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.42 165.85 27.8 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 6.2 t 73.85 47.09 0.17 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.507 HD11 HG22 ' A' ' 233' ' ' VAL . 15.0 mt -109.53 166.08 11.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.907 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -94.31 140.59 29.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -45.44 -37.07 4.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -57.88 -37.86 74.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.935 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 36.7 mm -47.59 139.04 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.159 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.4 t -125.29 174.34 8.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.099 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -62.3 -36.55 82.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -58.37 -34.64 70.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.902 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 63.3 mtt -70.49 -37.07 74.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 81.9 mt -69.82 -42.34 73.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.505 ' HA ' HD13 ' A' ' 255' ' ' ILE . 20.5 ptt85 -69.65 -40.21 76.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -66.41 -35.16 89.75 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.5 mt -81.04 -44.22 20.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.844 0.354 . . . . 0.0 111.148 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.69 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -81.83 -2.43 50.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.508 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.0 tp10 -70.65 -59.66 3.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.677 0.751 . . . . 0.0 110.931 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.6 3.37 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.333 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.834 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.46 -44.17 5.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.903 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -171.21 139.03 5.22 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -44.61 119.0 1.74 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.744 0.307 . . . . 0.0 110.919 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.505 HD13 ' HA ' ' A' ' 246' ' ' ARG . 28.3 mt -88.85 133.31 31.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.149 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.27 -43.43 8.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -163.47 147.02 10.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 255' ' ' ILE . 61.1 mt -128.91 132.37 67.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 74.4 t -134.93 129.24 50.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.137 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 23.5 mt -94.01 129.55 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.616 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.3 mmt . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.861 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.491 -0.243 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.616 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 0.9 OUTLIER -150.5 157.42 43.0 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.919 0.39 . . . . 0.0 110.935 -179.832 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.56 169.37 38.56 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -113.58 137.97 50.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.363 . . . . 0.0 110.874 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 77.3 mt -136.43 132.61 49.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.9 m -113.51 129.23 56.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.842 ' CE1' HD12 ' A' ' 231' ' ' LEU . 42.6 m-85 -98.96 171.27 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 48.1 t -86.88 -40.08 15.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -116.2 141.13 48.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 40.6 p -63.99 -41.01 97.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . 0.423 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 13.3 pt-20 -60.97 -43.97 98.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . 0.423 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 73.9 m -60.01 -40.96 91.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.585 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.55 -37.84 88.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . 0.418 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 12.4 ttm105 -62.01 -48.73 79.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.6 mmt180 -58.02 -49.8 75.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.834 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.99 -35.54 71.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.091 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.431 HD22 ' CD2' ' A' ' 304' ' ' HIS . 8.4 tp -65.09 -40.83 95.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -68.34 -42.96 78.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -71.91 -38.2 69.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.854 ' HB3' HG21 ' A' ' 302' ' ' VAL . 82.4 mt -73.15 -47.03 47.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -44.47 107.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 77.82 39.3 24.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.462 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' LEU . 14.7 t80 -101.32 97.78 8.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.816 0.341 . . . . 0.0 110.871 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -43.96 93.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 293' ' ' PHE . 61.8 tp -81.03 -56.95 3.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -129.12 73.13 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.07 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 82.45 -35.53 2.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -125.77 154.85 73.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.579 0.705 . . . . 0.0 110.898 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 136.67 33.68 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.719 2.28 . . . . 0.0 112.336 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . 0.596 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.3 ptt? -86.68 166.66 15.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 4.2 mmm180 -101.75 128.59 48.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' A' ' 290' ' ' LEU . 9.8 t -131.88 128.92 60.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -157.7 158.8 29.36 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.431 ' CD2' HD22 ' A' ' 287' ' ' LEU . 4.5 m170 -77.73 124.51 28.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 15.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.141 179.967 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.434 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.0 mt -115.1 145.62 42.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.848 0.356 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.573 ' HB2' HG22 ' A' ' 305' ' ' VAL . 1.5 t80 -111.53 133.69 53.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.921 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 13.1 p -118.64 135.35 59.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.141 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.61 163.56 27.89 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 m 74.39 46.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.905 0.384 . . . . 0.0 110.81 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 14.4 mt -108.98 170.19 8.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.408 ' O ' ' C ' ' A' ' 238' ' ' PHE . 13.7 t-80 -98.89 137.95 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.41 ' O ' ' C ' ' A' ' 239' ' ' ASN . 5.2 m-85 -37.82 -57.02 1.04 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 241' ' ' THR . 45.9 t30 -37.58 -42.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.901 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.7 mm -47.21 130.1 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.463 HG23 ' O ' ' A' ' 239' ' ' ASN . 79.4 p -123.04 -175.63 3.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.145 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -62.38 -41.77 98.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -59.45 -29.75 68.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 20.0 mmt -71.87 -44.52 63.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.465 HD22 HD11 ' A' ' 275' ' ' ILE . 34.7 mt -68.25 -43.04 78.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.503 ' O ' ' N ' ' A' ' 250' ' ' GLU . 5.6 ptp180 -66.35 -44.55 82.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.499 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -61.08 -39.49 97.18 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.9 mt -76.17 -41.37 37.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.868 0.366 . . . . 0.0 111.147 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.762 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -86.42 -5.55 59.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.541 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -67.36 -58.05 9.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.683 0.754 . . . . 0.0 110.894 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.541 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.72 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.856 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -104.77 -25.32 12.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.88 159.04 15.91 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.53 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -62.22 117.82 6.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.724 0.297 . . . . 0.0 110.91 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.645 HD13 HD11 ' A' ' 258' ' ' ILE . 70.3 mt -90.99 114.06 27.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -69.77 -42.99 73.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -167.96 153.55 7.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.645 HD11 HD13 ' A' ' 255' ' ' ILE . 87.6 mt -132.94 128.43 56.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 75.8 t -127.42 129.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.093 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 35.9 mt -96.6 135.82 37.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.549 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 35.2 mmm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.893 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.549 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.4 p90 -149.38 160.32 43.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.914 -179.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.52 171.65 42.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.508 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -113.31 139.28 48.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.802 0.334 . . . . 0.0 110.887 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.465 HD11 HD22 ' A' ' 245' ' ' LEU . 54.1 mt -135.95 139.38 46.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.167 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 85.8 m -119.09 122.26 41.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.434 ' CE1' HD12 ' A' ' 231' ' ' LEU . 36.3 m-85 -91.08 -177.14 4.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.5 t -104.56 -22.14 13.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -133.62 134.94 43.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.8 p -61.7 -36.99 82.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -63.57 -44.0 95.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.875 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.4 m -61.94 -40.04 94.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.16 -41.7 97.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.079 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 11.8 mmt85 -60.0 -49.06 79.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -58.31 -50.6 73.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.885 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.856 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.55 -39.45 73.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.063 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.517 HD22 ' CD2' ' A' ' 304' ' ' HIS . 13.2 tp -62.08 -40.09 94.65 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -67.32 -34.96 78.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -84.6 -25.86 28.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.92 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.763 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.9 mt -81.87 -41.48 20.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . 0.435 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.6 OUTLIER -59.55 117.62 5.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.03 27.32 58.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -95.61 103.35 15.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.854 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -56.97 97.92 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.925 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -87.57 -54.31 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.04 55.01 1.01 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.85 -37.23 3.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -117.03 156.46 48.29 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.622 0.725 . . . . 0.0 110.864 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.56 40.44 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . 0.549 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.0 ptt? -91.25 162.8 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -99.71 122.06 42.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.763 HG21 ' HB3' ' A' ' 290' ' ' LEU . 5.1 t -129.26 128.77 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -151.19 162.09 29.35 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.484 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.517 ' CD2' HD22 ' A' ' 287' ' ' LEU . 7.0 m170 -75.51 123.32 25.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.826 0.346 . . . . 0.0 110.887 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.573 HG22 ' HB2' ' A' ' 232' ' ' TYR . 87.1 t . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.843 HD12 ' CE1' ' A' ' 277' ' ' PHE . 33.4 mt -133.83 144.07 48.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.508 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -113.08 139.1 48.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 -179.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.449 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.9 p -127.42 134.69 65.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.106 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.39 166.02 27.33 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.501 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 73.71 46.15 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.896 0.379 . . . . 0.0 110.842 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 233' ' ' VAL . 65.2 mt -108.5 174.55 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.426 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 4.5 t-80 -94.66 126.42 39.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.825 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.426 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 5.8 p90 -39.35 -50.28 2.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.864 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -43.53 -49.42 7.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 45.1 mm -38.73 139.59 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.119 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 30.8 p -120.09 175.15 6.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.156 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.12 -31.01 70.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . 0.454 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 2.2 m-20 -63.37 -35.84 81.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 8.2 mmt -72.08 -39.28 69.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.59 ' CD1' HD21 ' A' ' 260' ' ' LEU . 54.6 mt -68.23 -39.87 82.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.92 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.487 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 3.8 ptm180 -70.48 -37.31 74.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.45 -35.35 81.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.492 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.428 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 93.7 mt -77.5 -42.41 29.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.899 0.381 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.602 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.86 -4.12 58.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.8 OUTLIER -69.7 -58.29 5.76 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.637 0.732 . . . . 0.0 110.897 -179.901 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.3 Cg_endo -69.8 2.78 3.24 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.671 2.247 . . . . 0.0 112.34 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.96 -35.55 8.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -177.57 159.84 26.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 16.6 ttmt -60.24 120.15 9.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.732 HG21 HD11 ' A' ' 258' ' ' ILE . 64.5 mt -90.74 113.78 27.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.117 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' A' ' 256' ' ' ASP . 31.1 t0 -77.2 -40.61 44.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.826 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -168.33 147.76 4.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.89 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 255' ' ' ILE . 53.3 mt -129.36 132.83 66.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.485 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.5 m -134.07 138.43 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.164 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.59 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.2 mt -104.16 132.6 50.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 26.3 mmt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 2.6 p90 -145.06 161.8 38.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.936 0.398 . . . . 0.0 110.907 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.72 171.55 37.7 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.477 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.485 ' HB2' HG23 ' A' ' 259' ' ' VAL . 16.2 m-85 -118.86 136.76 53.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.859 0.362 . . . . 0.0 110.873 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.421 HG12 HG23 ' A' ' 258' ' ' ILE . 89.3 mt -135.73 138.7 47.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.134 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 61.0 m -113.03 128.77 56.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.843 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.1 m-85 -101.98 170.45 8.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 14.6 t -115.79 33.15 5.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -172.58 124.97 0.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 23.0 t -62.74 -40.52 97.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -66.8 -43.71 83.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.86 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 51.9 m -64.36 -42.58 96.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.913 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.74 -44.03 97.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -59.31 -48.56 81.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.87 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -57.96 -51.17 70.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.96 -39.62 69.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.098 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.645 HD22 ' CE1' ' A' ' 304' ' ' HIS . 11.7 tp -63.33 -39.99 96.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -68.49 -34.95 76.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 49.4 mm-40 -83.97 -26.77 28.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.771 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.2 mt -81.4 -47.02 13.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . 0.456 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.7 OUTLIER -53.07 114.71 1.54 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.18 34.99 35.39 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.488 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -105.04 122.53 46.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -77.17 112.02 13.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 40.7 tp -93.99 -60.47 1.74 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.964 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -102.93 -21.81 13.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.088 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 169.95 -33.94 0.17 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.79 152.5 45.63 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.67 0.747 . . . . 0.0 110.859 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 120.43 7.21 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.668 2.246 . . . . 0.0 112.344 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . 0.643 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -72.41 168.54 18.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 41.7 mmt-85 -111.91 125.0 53.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 290' ' ' LEU . 57.8 t -131.37 129.62 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.63 163.01 26.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.645 ' CE1' HD22 ' A' ' 287' ' ' LEU . 20.3 m170 -75.21 98.38 3.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 0.0 110.857 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.147 179.984 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.539 HD12 ' CE2' ' A' ' 277' ' ' PHE . 20.6 mt -128.29 146.97 50.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.92 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.683 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.7 t80 -114.39 136.53 52.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.604 ' CG2' HD11 ' A' ' 236' ' ' LEU . 7.4 p -121.12 134.53 64.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.099 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.47 165.05 27.97 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 3.8 t 74.58 46.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.933 0.397 . . . . 0.0 110.875 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.604 HD11 ' CG2' ' A' ' 233' ' ' VAL . 85.8 mt -111.49 170.69 7.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.934 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 18.4 t-80 -88.82 147.28 24.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.412 ' O ' ' C ' ' A' ' 239' ' ' ASN . 2.9 m-85 -52.91 -59.76 4.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.412 ' C ' ' O ' ' A' ' 238' ' ' PHE . 1.0 OUTLIER -36.17 -47.32 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 23.5 mm -38.42 136.7 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 7.8 t -123.03 179.55 4.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.158 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 45.7 mp0 -63.05 -35.23 79.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -58.78 -38.51 78.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -64.68 -45.98 84.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.529 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.0 mt -59.98 -39.24 85.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.536 ' HA ' HD13 ' A' ' 255' ' ' ILE . 0.0 OUTLIER -72.05 -40.8 68.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.46 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.91 -29.6 74.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.0 mt -87.51 -43.53 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 111.096 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.557 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 2.7 m-85 -85.17 -0.11 53.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.502 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 4.0 tt0 -68.99 -59.88 4.87 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.652 0.739 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.4 Cg_endo -69.7 -9.45 26.15 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.256 . . . . 0.0 112.388 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.7 m-85 -88.78 -24.8 22.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.01 164.43 25.72 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.514 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -68.3 108.84 3.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.857 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.74 HG21 HD11 ' A' ' 258' ' ' ILE . 19.4 mt -77.23 113.63 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.094 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -72.19 -45.2 61.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.921 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -163.32 157.68 20.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.74 HD11 HG21 ' A' ' 255' ' ' ILE . 71.6 mt -138.6 131.85 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 274' ' ' PHE . 3.8 m -134.79 126.6 47.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.486 HD21 HD11 ' A' ' 245' ' ' LEU . 20.7 mt -93.58 129.33 39.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.936 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.574 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 17.8 mmm . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.574 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.3 p90 -150.36 162.21 40.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.951 0.405 . . . . 0.0 110.944 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.59 177.32 37.92 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.5 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.771 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.1 m-85 -120.1 133.99 55.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.774 0.321 . . . . 0.0 110.925 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.529 HD11 ' HB3' ' A' ' 245' ' ' LEU . 67.9 mt -133.08 135.93 56.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 64.5 m -117.51 129.3 55.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.539 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.6 m-85 -100.68 178.74 4.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.6 t -114.98 12.84 16.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.858 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -155.66 128.5 8.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.4 t -64.0 -40.98 97.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 35.6 mm-40 -62.26 -43.93 97.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.897 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 98.7 m -64.51 -36.19 83.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.832 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.53 -43.7 89.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.087 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -61.11 -49.09 78.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 71.5 mtt180 -59.49 -44.32 93.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.407 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -62.61 -35.06 78.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.126 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.607 HD12 HG12 ' A' ' 302' ' ' VAL . 17.6 tp -64.74 -44.66 89.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -69.18 -35.02 75.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -73.59 -42.0 62.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.926 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.823 ' HB3' HG21 ' A' ' 302' ' ' VAL . 42.0 mt -75.25 -47.04 29.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.876 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -42.14 106.25 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.65 34.59 31.05 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -96.07 102.02 13.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.344 . . . . 0.0 110.891 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -56.22 90.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.909 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 25.6 tp -80.18 -58.53 3.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.76 40.34 2.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.53 -26.98 21.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 3.5 ptp85 -120.08 147.34 44.4 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 122.33 9.01 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.328 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -75.36 177.31 6.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 11.5 mmm-85 -110.85 122.68 48.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.823 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.0 t -128.99 123.51 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.113 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -156.47 161.25 30.78 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.444 ' CD2' HD22 ' A' ' 287' ' ' LEU . 90.4 m-70 -72.68 128.27 35.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.855 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 232' ' ' TYR . 21.5 m . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.115 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.456 -0.257 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.97 HD12 ' CE1' ' A' ' 277' ' ' PHE . 34.3 mt -118.6 146.83 44.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.806 0.336 . . . . 0.0 110.929 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.4 OUTLIER -118.6 141.3 48.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.915 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.64 ' CG2' HD11 ' A' ' 236' ' ' LEU . 12.0 p -123.08 131.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.14 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -136.91 165.9 25.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 58.5 m 62.54 49.87 3.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.884 0.373 . . . . 0.0 110.822 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.64 HD11 ' CG2' ' A' ' 233' ' ' VAL . 61.8 mt -103.67 -175.13 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 16.8 t-80 -110.39 142.31 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -49.47 -44.31 45.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -52.44 -33.74 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 10.5 mm -57.21 125.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.144 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.1 p -117.28 178.64 4.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.162 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -60.83 -36.67 79.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . 0.443 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 6.9 t0 -60.88 -34.37 74.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.807 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 21.6 mtt -72.05 -42.71 65.97 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 63.1 mt -66.8 -42.97 85.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.939 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.448 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 4.0 ptm180 -66.38 -38.74 88.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.866 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.448 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.45 -36.82 92.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 86.8 mt -78.56 -43.91 26.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.912 0.387 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.4 m-85 -81.75 -4.72 57.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.924 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.501 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.5 OUTLIER -66.55 -60.13 7.06 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.677 0.751 . . . . 0.0 110.897 -179.908 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.34 3.61 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.706 2.271 . . . . 0.0 112.321 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.824 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.3 m-85 -103.39 -23.33 13.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.881 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 168.35 158.98 13.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.466 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.47 117.58 7.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.768 0.318 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.68 HD13 HD11 ' A' ' 258' ' ' ILE . 45.4 mt -86.33 120.89 36.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.103 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -79.51 -41.23 27.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.851 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 38.4 t30 -167.7 145.78 4.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.68 HD11 HD13 ' A' ' 255' ' ' ILE . 93.9 mt -128.44 127.88 67.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.105 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.635 HG23 ' HB2' ' A' ' 274' ' ' PHE . 18.3 m -129.51 139.15 52.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.096 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 28.9 mt -111.41 139.49 46.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.572 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 29.8 mmt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.572 ' CE1' ' HB2' ' A' ' 261' ' ' MET . 2.1 p90 -151.01 165.18 34.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.926 0.393 . . . . 0.0 110.94 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -157.89 168.01 34.37 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.492 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.635 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.0 m-85 -114.44 137.79 51.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.864 0.364 . . . . 0.0 110.872 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 85.1 mt -137.24 134.45 47.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.6 m -117.76 129.18 55.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.191 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.97 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.4 m-85 -99.28 177.97 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 62.6 p -98.8 -36.28 9.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.819 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -115.97 129.19 56.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 32.8 p -57.48 -37.98 73.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . 0.419 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 11.1 pt-20 -62.32 -43.35 99.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . 0.419 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 68.1 m -62.25 -37.49 85.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -40.17 90.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 47.6 ttt85 -62.08 -48.94 77.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.862 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.8 mmt180 -58.66 -51.02 71.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.57 -35.07 69.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.7 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -65.06 -41.96 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -68.99 -42.91 75.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.943 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.0 mm100 -71.98 -36.03 69.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.664 ' HB3' HG21 ' A' ' 302' ' ' VAL . 54.9 mt -75.3 -46.95 30.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -42.0 112.41 0.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.905 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 73.96 40.16 44.45 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 23.9 t80 -100.93 98.05 8.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.824 0.345 . . . . 0.0 110.861 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.19 105.83 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 5.7 tt -94.82 -53.68 3.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.926 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.14 40.64 2.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.2 -35.21 4.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.491 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 -110.23 149.1 39.66 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.576 0.703 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 119.16 6.15 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.724 2.283 . . . . 0.0 112.325 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptm -71.07 171.55 10.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -106.92 125.17 50.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.913 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.7 HG12 HD12 ' A' ' 287' ' ' LEU . 7.0 t -128.5 121.5 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.097 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.69 163.49 28.54 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.503 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.478 ' CE1' HD22 ' A' ' 287' ' ' LEU . 18.5 m170 -79.24 130.37 35.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.885 0.374 . . . . 0.0 110.82 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 83.9 t . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.134 179.959 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.465 HD11 ' O ' ' A' ' 283' ' ' ALA . 37.0 mt -129.96 147.04 51.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.349 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.492 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.4 t80 -110.13 131.81 54.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.74 136.46 55.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.18 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.56 165.47 27.53 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.448 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.5 t 74.28 46.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.9 0.381 . . . . 0.0 110.85 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.37 170.7 7.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 238' ' ' PHE . 31.4 t-80 -98.65 132.16 44.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.437 ' C ' ' O ' ' A' ' 237' ' ' HIS . 0.9 OUTLIER -34.46 -61.07 0.4 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.878 -179.91 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.533 ' ND2' ' N ' ' A' ' 240' ' ' ILE . 0.3 OUTLIER -36.95 -47.27 0.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.941 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.533 ' N ' ' ND2' ' A' ' 239' ' ' ASN . 40.3 mm -36.74 128.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.181 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.0 p -118.44 175.57 5.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -60.61 -31.07 70.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.844 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -64.89 -32.45 74.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 13.5 mmt -71.74 -40.88 69.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.476 ' CD1' HD21 ' A' ' 260' ' ' LEU . 45.1 mt -69.35 -43.0 74.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.436 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 6.2 ptm180 -66.02 -40.11 90.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -66.48 -38.25 93.32 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.507 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.0 mt -77.27 -41.84 30.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.902 0.382 . . . . 0.0 111.131 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.591 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -83.74 -3.88 58.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.847 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.535 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.94 -58.34 5.42 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.654 0.74 . . . . 0.0 110.853 -179.932 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.74 2.74 3.25 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.734 2.289 . . . . 0.0 112.347 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.816 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.62 -33.11 9.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 175.67 138.66 2.88 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.449 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -45.64 116.64 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.769 0.319 . . . . 0.0 110.924 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 55.5 mt -85.3 134.7 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.12 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -91.38 -46.47 8.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.874 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 33.8 t30 -160.92 145.82 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.1 mt -124.14 133.1 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.151 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 89.4 t -131.86 125.78 55.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.13 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.476 HD21 ' CD1' ' A' ' 245' ' ' LEU . 26.2 mt -96.93 131.32 43.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.53 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.7 mmt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.894 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.53 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 1.1 p90 -151.0 153.72 35.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 0.0 110.934 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.01 175.36 40.15 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -117.79 140.29 49.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.939 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.437 HD11 ' HB3' ' A' ' 245' ' ' LEU . 90.6 mt -138.25 128.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 83.5 m -110.02 130.0 55.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.444 ' CE1' HD12 ' A' ' 231' ' ' LEU . 32.7 m-85 -96.37 179.51 5.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 27.8 t -92.03 -42.73 9.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.83 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.41 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 10.9 t0 -114.1 139.35 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.7 m -60.75 -39.74 89.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . 0.41 ' HG2' ' CG ' ' A' ' 279' ' ' ASP . 11.6 pt-20 -61.62 -43.73 98.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 87.9 m -60.13 -38.93 84.55 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.465 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -65.37 -40.93 94.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -60.1 -48.31 82.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 47.7 mmt-85 -58.25 -51.01 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.816 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.24 -35.54 69.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.593 HD12 HG12 ' A' ' 302' ' ' VAL . 12.4 tp -65.01 -40.55 95.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.902 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -68.41 -42.63 78.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.855 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 24.7 mm-40 -71.88 -38.99 69.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.997 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.8 mt -72.62 -45.87 56.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.924 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -47.81 108.07 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.833 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.46 36.11 27.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.474 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -100.45 121.64 41.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.832 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -73.68 96.64 2.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 42.5 tp -88.52 -47.83 8.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.927 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -121.9 43.57 2.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.133 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 93.78 -25.17 22.73 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.507 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 55.2 mtp180 -122.94 148.69 54.75 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.605 0.717 . . . . 0.0 110.844 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 121.17 7.85 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.635 2.223 . . . . 0.0 112.357 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -74.46 171.8 13.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.2 mmm180 -108.8 123.51 49.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.997 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.4 t -129.46 126.6 63.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.126 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -147.78 158.97 27.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 6.3 m170 -71.65 120.58 17.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.812 0.339 . . . . 0.0 110.873 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.987 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.694 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.2 mt -122.18 144.82 48.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.358 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -109.52 141.97 41.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.948 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.92 135.75 63.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -142.59 166.06 26.61 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.8 m 64.03 49.82 2.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.892 0.377 . . . . 0.0 110.878 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 96.4 mt -103.06 -179.02 3.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.417 ' O ' ' C ' ' A' ' 238' ' ' PHE . 11.2 t-80 -109.85 133.11 53.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.434 ' O ' ' C ' ' A' ' 239' ' ' ASN . 71.7 m-85 -37.38 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.86 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.448 ' ND2' ' C ' ' A' ' 239' ' ' ASN . 0.2 OUTLIER -35.8 -40.86 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.908 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 37.4 mm -49.07 146.11 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 239' ' ' ASN . 12.6 p -143.2 -179.86 6.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.171 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -60.52 -35.82 76.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.882 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.23 -41.23 88.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 19.3 mtt -69.28 -44.92 70.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.464 HD22 HD11 ' A' ' 275' ' ' ILE . 47.4 mt -60.25 -36.38 77.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.486 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -39.73 68.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.953 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.482 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.65 -36.34 93.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.438 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.612 ' CG2' HD21 ' A' ' 290' ' ' LEU . 95.4 mt -81.78 -44.1 20.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.871 0.367 . . . . 0.0 111.103 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.628 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.3 m-85 -79.07 -8.08 58.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.525 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.1 tp10 -67.96 -58.78 7.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.525 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.78 1.88 4.05 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.779 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.0 -34.45 8.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -179.41 158.03 21.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 2.4 ttmp? -64.73 101.53 0.48 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.745 0.307 . . . . 0.0 110.932 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 38.4 mt -69.36 125.65 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.162 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -83.03 -42.53 17.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.823 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -168.82 146.77 3.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 95.9 mt -123.08 133.79 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.144 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.517 HG23 ' HB2' ' A' ' 274' ' ' PHE . 7.1 m -133.92 124.59 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 29.5 mt -92.04 138.05 31.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.562 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 10.5 mmm . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.562 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -146.89 153.29 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.926 0.393 . . . . 0.0 110.927 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -159.66 -178.15 33.4 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.517 ' HB2' HG23 ' A' ' 259' ' ' VAL . 32.7 m-85 -129.71 140.11 51.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.5 mt -136.64 137.27 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.137 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.5 m -116.13 127.25 54.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.125 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.694 ' CE1' HD12 ' A' ' 231' ' ' LEU . 48.9 m-85 -96.92 -179.27 4.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.2 t -96.93 -41.85 8.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.863 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -112.52 138.12 49.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.1 p -61.51 -39.74 92.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.847 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -61.91 -44.04 97.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 72.2 m -60.4 -37.31 80.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.904 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.05 -41.44 86.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.4 ttt180 -59.96 -48.78 80.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.86 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -58.41 -51.02 71.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.779 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.15 -35.02 69.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.664 HD12 HG12 ' A' ' 302' ' ' VAL . 10.8 tp -63.88 -45.3 90.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -69.08 -39.01 79.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -69.46 -42.11 75.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.91 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 56.7 mt -74.45 -47.03 35.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -43.59 114.53 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 71.22 38.2 63.17 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -104.57 109.57 21.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.923 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -55.29 95.05 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.913 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.454 ' C ' HD13 ' A' ' 295' ' ' LEU . 0.5 OUTLIER -76.25 -64.78 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.6 37.41 3.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.62 -40.2 2.46 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 62.1 mtp180 -115.95 157.58 44.5 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 127.82 15.16 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.716 2.277 . . . . 0.0 112.356 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . 0.41 ' HE2' HD23 ' A' ' 295' ' ' LEU . 2.1 ptp -79.51 179.53 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.875 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -110.73 123.36 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.89 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 14.8 t -132.75 125.35 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.56 160.83 28.3 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.436 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.534 ' CE1' HD22 ' A' ' 287' ' ' LEU . 9.6 m170 -75.55 111.6 11.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.834 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 304' ' ' HIS . 98.5 t . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.611 HD11 ' O ' ' A' ' 283' ' ' ALA . 44.6 mt -116.85 144.66 44.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.847 0.356 . . . . 0.0 110.935 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.475 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.7 t80 -106.73 129.53 54.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.7 p -114.81 132.54 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.179 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.12 163.85 28.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.479 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 74.64 43.01 0.27 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.928 0.394 . . . . 0.0 110.881 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.428 HD11 ' CG2' ' A' ' 233' ' ' VAL . 23.1 mt -101.88 -177.41 3.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 240' ' ' ILE . 6.6 t-80 -103.75 126.77 51.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.865 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.49 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 4.2 p90 -35.89 -44.69 0.37 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.49 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 39.5 t30 -51.7 -46.15 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.44 ' N ' ' O ' ' A' ' 237' ' ' HIS . 40.3 mm -40.19 147.87 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.127 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.0 t -136.98 174.51 10.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.099 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 38.0 mp0 -56.89 -34.96 68.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -58.33 -44.18 88.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.4 mmt -65.08 -42.23 94.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.694 HD11 HD21 ' A' ' 260' ' ' LEU . 41.7 mt -61.19 -39.62 90.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.894 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.01 -37.97 69.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.454 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -63.37 -34.61 90.42 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . 0.437 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 68.1 mt -83.55 -44.81 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.618 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.7 m-85 -78.94 -5.97 55.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.58 -58.28 5.9 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 0.0 110.909 -179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.78 -0.95 7.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.63 2.22 . . . . 0.0 112.388 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.793 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 11.7 m-85 -100.05 -23.87 14.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 167.57 167.33 28.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm -68.43 115.09 7.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.71 0.29 . . . . 0.0 110.872 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.441 HG21 HD11 ' A' ' 258' ' ' ILE . 27.3 mt -83.41 120.65 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.126 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -77.63 -49.37 14.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -163.25 145.64 10.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.441 HD11 HG21 ' A' ' 255' ' ' ILE . 84.8 mt -124.42 129.6 73.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 51.8 t -131.03 131.94 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.165 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.694 HD21 HD11 ' A' ' 245' ' ' LEU . 30.0 mt -101.08 133.7 45.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.473 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 57.6 mmm . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.888 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.473 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -148.19 159.09 44.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.904 0.383 . . . . 0.0 110.962 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -166.1 176.3 41.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -119.74 135.9 54.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.339 . . . . 0.0 110.886 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.428 HD12 ' CE2' ' A' ' 249' ' ' PHE . 75.8 mt -131.89 140.11 48.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 69.5 m -120.97 128.23 52.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.181 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -96.8 -175.34 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.841 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.4 t -105.23 -28.79 10.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.893 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.66 135.56 55.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.3 p -63.54 -40.52 97.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -61.68 -43.63 98.49 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.861 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.9 m -62.5 -38.81 91.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.905 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.611 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.92 -43.17 96.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.128 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -61.65 -47.58 84.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -57.98 -49.8 75.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.793 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.25 -39.47 75.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.683 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -61.68 -40.71 95.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -68.24 -35.04 77.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -82.58 -26.5 32.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.952 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.3 mt -81.71 -47.06 13.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . 0.444 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -51.36 117.17 2.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.25 32.45 55.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.446 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -97.49 106.89 19.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -59.73 102.53 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 39.7 tp -92.79 -63.36 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -107.88 39.79 1.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.109 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.88 -25.81 26.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -120.68 154.53 57.22 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.601 0.715 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.85 128.93 16.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.683 2.255 . . . . 0.0 112.333 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . 0.605 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.9 ptt? -82.43 164.35 21.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 66.6 mmt-85 -102.28 121.19 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.952 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.9 t -130.28 121.32 51.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.15 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -140.78 163.98 26.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.514 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 305' ' ' VAL . 7.0 m170 -73.02 112.49 9.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 110.833 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' A' ' 304' ' ' HIS . 74.4 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.134 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 63.5 mt -129.03 145.7 51.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.942 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.498 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 2.0 t80 -105.54 135.0 47.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.597 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.6 p -121.73 129.39 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -138.65 162.55 25.84 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 73.47 46.73 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.891 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.597 HD11 ' CG2' ' A' ' 233' ' ' VAL . 64.2 mt -106.73 -176.14 2.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.959 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -113.6 130.26 56.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.418 ' O ' ' C ' ' A' ' 239' ' ' ASN . 1.2 m-85 -38.12 -58.29 0.98 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 238' ' ' PHE . 18.3 m-20 -36.19 -46.1 0.49 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.0 mm -47.43 128.92 3.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.7 p -113.1 174.88 5.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -58.53 -33.86 70.35 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.876 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -61.58 -46.02 91.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 30.6 mtt -60.23 -42.49 95.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.735 HD11 HD21 ' A' ' 260' ' ' LEU . 42.4 mt -60.42 -40.5 91.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.498 ' O ' ' N ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -63.51 -43.98 95.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.467 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -64.87 -32.01 82.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.485 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 87.0 mt -78.4 -40.99 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.881 0.372 . . . . 0.0 111.175 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.701 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.2 m-85 -90.91 -8.65 48.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.886 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.515 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.6 tp10 -59.0 -59.28 14.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.636 0.731 . . . . 0.0 110.88 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.515 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 2.75 3.28 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.268 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.725 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.6 m-85 -106.41 -9.67 16.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 152.7 168.25 16.5 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.45 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 31.6 tttp -72.46 122.03 20.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.75 0.309 . . . . 0.0 110.932 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.468 HG21 HD11 ' A' ' 258' ' ' ILE . 33.4 mt -93.8 111.65 25.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -70.14 -39.34 75.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.883 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -167.66 155.05 8.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 255' ' ' ILE . 49.0 mt -131.57 131.99 62.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 8.1 t -128.4 137.8 56.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.161 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.735 HD21 HD11 ' A' ' 245' ' ' LEU . 48.3 mt -110.07 132.81 53.83 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.525 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.3 mmt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.525 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 0.5 OUTLIER -150.42 161.95 41.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.931 0.396 . . . . 0.0 110.879 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.9 -173.17 35.69 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.62 148.5 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.701 HD12 ' CE2' ' A' ' 249' ' ' PHE . 82.1 mt -138.58 139.66 40.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.4 m -118.21 129.98 55.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.16 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -103.48 -175.11 2.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 22.8 t -100.15 -41.76 6.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -113.93 139.94 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.852 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 60.9 p -63.14 -40.16 96.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.847 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.15 -42.77 99.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.904 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.2 m -60.7 -35.98 77.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -68.07 -41.98 81.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.081 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 19.6 ttm180 -59.23 -49.11 79.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 28.4 mmt180 -58.91 -50.93 72.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.885 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.725 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.41 -34.9 69.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.09 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.759 HD12 HG12 ' A' ' 302' ' ' VAL . 15.0 tp -64.09 -45.29 89.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -69.01 -42.03 76.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -67.81 -42.02 82.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.916 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.675 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 65.2 mt -73.72 -46.82 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 290' ' ' LEU . 0.7 OUTLIER -37.19 103.6 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 179.909 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.58 33.86 33.39 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 290' ' ' LEU . 22.6 t80 -87.42 105.48 17.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -57.67 96.75 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.404 HD23 ' C ' ' A' ' 295' ' ' LEU . 8.5 tt -89.72 -69.54 0.71 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.946 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -99.3 32.05 2.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 107.68 -36.86 4.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.512 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -108.94 148.01 37.03 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.58 0.705 . . . . 0.0 110.885 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.03 7.73 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.716 2.277 . . . . 0.0 112.325 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptm -74.02 171.96 12.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.0 mmt85 -111.73 122.95 49.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.759 HG12 HD12 ' A' ' 287' ' ' LEU . 4.2 t -124.17 122.32 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.49 162.54 26.92 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.449 ' O ' ' C ' ' A' ' 305' ' ' VAL . 5.0 m170 -71.4 127.27 32.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.812 0.339 . . . . 0.0 110.826 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 304' ' ' HIS . 54.0 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.11 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.752 HD12 ' CE2' ' A' ' 277' ' ' PHE . 51.8 mt -123.94 145.22 49.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.545 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -112.51 133.79 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.946 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.415 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.7 p -122.07 132.85 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.113 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.76 165.78 27.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.474 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.3 m 74.03 47.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.415 HD11 ' CG2' ' A' ' 233' ' ' VAL . 74.7 mt -110.03 178.78 4.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.919 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -97.53 132.08 43.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.468 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.1 t80 -42.62 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.85 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 238' ' ' PHE . 59.4 t-20 -34.62 -33.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.468 ' N ' ' O ' ' A' ' 238' ' ' PHE . 21.8 mm -54.85 147.98 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.109 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.407 HG23 ' HB3' ' A' ' 243' ' ' ASP . 8.9 t -134.98 175.8 9.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.137 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . 0.431 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 11.8 mt-10 -57.82 -32.65 67.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . 0.407 ' HB3' HG23 ' A' ' 241' ' ' THR . 4.1 t70 -60.26 -33.83 72.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.89 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.4 mmt -71.98 -37.87 69.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . 0.666 ' HB3' HD11 ' A' ' 275' ' ' ILE . 39.1 mt -69.54 -42.89 74.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.959 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.489 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 14.9 ptt85 -67.53 -39.46 85.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.462 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.6 -35.63 86.58 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.492 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 73.3 mt -79.1 -45.19 24.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.815 0.341 . . . . 0.0 111.101 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 255' ' ' ILE . 3.1 m-85 -80.6 -4.9 55.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.537 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.89 -58.19 5.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.69 0.757 . . . . 0.0 110.875 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.537 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.81 3.2 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.479 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.6 m-85 -103.91 -25.84 12.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.93 166.14 29.33 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.464 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.2 ttmt -67.4 109.54 3.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 249' ' ' PHE . 33.6 mt -81.06 123.68 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.141 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -79.31 -44.53 21.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -168.33 151.16 5.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.865 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.513 HG23 HG12 ' A' ' 275' ' ' ILE . 36.7 mt -128.19 134.02 65.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.16 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.7 m -134.51 134.76 54.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . 0.431 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 32.3 mt -97.48 134.62 40.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.934 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.571 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 26.9 mmm . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.571 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 3.7 p90 -148.69 155.92 41.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.931 0.396 . . . . 0.0 110.861 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.5 177.89 39.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.553 ' HE1' HG22 ' A' ' 305' ' ' VAL . 18.1 m-85 -117.56 139.43 50.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.866 0.365 . . . . 0.0 110.92 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . 0.666 HD11 ' HB3' ' A' ' 245' ' ' LEU . 71.0 mt -136.02 138.55 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.132 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.9 m -117.47 123.94 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.752 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.4 m-85 -91.24 -175.69 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 38.9 t -100.02 -34.3 10.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.867 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -122.94 138.27 54.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.903 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.8 p -61.72 -35.88 79.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -63.66 -44.11 94.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.879 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 74.0 m -62.42 -37.8 87.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.588 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.22 -36.94 82.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.073 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . 0.42 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 0.1 OUTLIER -64.13 -48.98 73.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.864 -179.891 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -59.83 -43.22 94.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.83 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.479 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -63.15 -35.23 79.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.138 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.816 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -65.07 -44.65 88.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.923 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -69.39 -38.98 78.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -71.5 -41.12 69.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.565 ' HB3' HG21 ' A' ' 302' ' ' VAL . 74.8 mt -74.29 -46.93 37.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -45.22 107.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.5 38.66 13.89 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.449 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -105.54 100.27 9.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.874 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -50.82 103.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 15.9 tp -94.67 -55.82 3.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.42 45.55 2.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.145 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.82 -37.19 3.65 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -117.03 150.45 46.01 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 123.36 10.01 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.64 2.226 . . . . 0.0 112.381 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -69.45 170.68 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 6.1 mmm180 -108.76 124.21 50.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.816 HG12 HD12 ' A' ' 287' ' ' LEU . 17.3 t -129.38 125.41 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.126 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -145.74 162.63 28.29 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.442 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.483 ' NE2' HD22 ' A' ' 287' ' ' LEU . 39.9 m-70 -76.92 126.88 31.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.861 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.553 HG22 ' HE1' ' A' ' 274' ' ' PHE . 82.5 t . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.413 ' O ' HG22 ' A' ' 305' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.347 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 231' ' ' LEU . . . . . 0.639 HD11 ' O ' ' A' ' 283' ' ' ALA . 30.0 mt -121.78 139.12 53.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.948 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 232' ' ' TYR . . . . . 0.948 ' HB2' HG12 ' A' ' 305' ' ' VAL . 0.9 OUTLIER -106.47 137.79 43.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 233' ' ' VAL . . . . . 0.4 HG21 HD11 ' A' ' 236' ' ' LEU . 7.4 p -122.56 136.91 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.95 163.95 28.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.468 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 74.16 45.25 0.21 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.891 0.377 . . . . 0.0 110.902 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 236' ' ' LEU . . . . . 0.4 HD11 HG21 ' A' ' 233' ' ' VAL . 96.7 mt -104.9 -176.29 3.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 237' ' ' HIS . . . . . 0.438 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.2 t-80 -109.29 135.06 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.84 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 238' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 1.9 p90 -38.7 -44.14 0.97 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 239' ' ' ASN . . . . . 0.479 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 36.4 t30 -54.02 -42.18 68.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 240' ' ' ILE . . . . . 0.503 ' CD1' HD21 ' A' ' 295' ' ' LEU . 15.5 mm -50.63 106.25 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.152 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 241' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 243' ' ' ASP . 10.9 t -95.25 179.49 5.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.096 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -61.16 -30.83 70.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 243' ' ' ASP . . . . . 0.447 ' H ' HG23 ' A' ' 241' ' ' THR . 5.1 m-20 -61.11 -43.55 98.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.8 mtt -62.68 -46.03 90.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 31.9 mt -60.07 -38.75 83.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.02 -42.4 66.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . 0.435 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -61.48 -30.61 74.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.468 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 88.4 mt -88.33 -43.59 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 111.171 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 249' ' ' PHE . . . . . 0.534 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -82.23 -2.64 53.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.886 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 250' ' ' GLU . . . . . 0.528 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -70.34 -58.56 4.77 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.594 0.711 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 251' ' ' PRO . . . . . 0.528 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.1 Cg_endo -69.72 2.03 3.88 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' PHE . . . . . 0.496 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.5 m-85 -103.27 -11.12 18.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 154.23 177.34 27.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.51 131.13 41.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.762 0.315 . . . . 0.0 110.921 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.641 HG21 HD11 ' A' ' 258' ' ' ILE . 94.6 mt -98.76 98.7 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -59.43 -44.72 92.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.825 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -167.2 153.55 8.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.938 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 258' ' ' ILE . . . . . 0.641 HD11 HG21 ' A' ' 255' ' ' ILE . 78.3 mt -130.27 133.01 64.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 259' ' ' VAL . . . . . 0.476 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.6 m -134.41 134.28 54.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.6 mt -103.35 128.81 50.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 261' ' ' MET . . . . . 0.563 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 12.1 mmt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.831 179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' TYR . . . . . 0.563 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -146.96 154.86 41.76 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.934 0.397 . . . . 0.0 110.929 -179.827 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -162.21 172.89 38.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' PHE . . . . . 0.476 ' HB2' HG23 ' A' ' 259' ' ' VAL . 33.1 m-85 -119.8 134.39 55.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 110.848 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.74 137.4 56.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 90.9 m -110.42 129.77 55.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' PHE . . . . . 0.499 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.3 m-85 -103.68 170.83 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.845 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 1.1 t -115.38 24.79 11.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.843 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -162.59 113.09 1.49 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 95.2 p -53.12 -40.47 64.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 -179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -62.02 -43.99 97.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 85.6 m -64.56 -40.91 96.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 283' ' ' ALA . . . . . 0.639 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -58.08 -46.35 85.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -61.91 -47.4 85.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -59.15 -50.93 72.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.87 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 286' ' ' ALA . . . . . 0.496 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.71 -35.2 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.076 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 287' ' ' LEU . . . . . 0.437 HD22 ' CD2' ' A' ' 304' ' ' HIS . 7.6 tp -64.59 -44.66 89.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.14 -42.5 75.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.895 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 68.2 mm-40 -67.44 -41.95 83.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 73.9 mt -73.73 -46.95 42.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -41.5 104.93 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.43 34.8 15.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.522 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -100.84 99.76 10.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -61.08 118.22 6.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.893 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 295' ' ' LEU . . . . . 0.503 HD21 ' CD1' ' A' ' 240' ' ' ILE . 10.0 tp -108.1 -50.26 3.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.883 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -113.11 42.81 1.83 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.082 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.33 -35.53 4.54 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.479 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -115.92 152.51 47.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 130.47 19.36 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.357 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -78.24 174.78 10.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 16.6 mmt180 -111.38 120.6 42.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 13.0 t -123.43 131.44 73.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.123 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.2 161.8 30.62 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.546 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 304' ' ' HIS . . . . . 0.437 ' CD2' HD22 ' A' ' 287' ' ' LEU . 34.2 m-70 -70.12 121.94 18.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.865 0.364 . . . . 0.0 110.864 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 305' ' ' VAL . . . . . 0.948 HG12 ' HB2' ' A' ' 232' ' ' TYR . 17.2 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.099 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 80.7 p -96.17 -49.42 5.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.902 0.382 . . . . 0.0 110.919 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 56.5 p -99.09 88.19 3.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.89 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' A' ' 228' ' ' SER . . . 179.51 -42.34 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 227' ' ' GLY . 18.1 m -37.13 120.3 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 0.0 110.865 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 77.7 p -85.39 87.36 7.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.849 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -127.96 140.67 11.97 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.452 HD12 ' CE1' ' A' ' 277' ' ' PHE . 25.0 mt -121.09 146.99 46.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 110.922 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.558 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -111.9 139.65 47.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.676 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.2 p -124.44 131.29 72.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.114 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.23 165.38 27.43 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.498 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.2 m 72.82 44.67 0.35 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 0.0 110.883 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.676 HD11 ' CG2' ' A' ' 233' ' ' VAL . 79.5 mt -109.24 172.09 7.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.914 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -90.32 126.99 36.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -41.48 -42.46 2.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -51.09 -42.1 60.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.545 ' CD1' HD21 ' A' ' 295' ' ' LEU . 47.8 mm -44.66 152.2 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.161 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.401 ' N ' HG22 ' A' ' 240' ' ' ILE . 76.1 p -137.02 178.58 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.152 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . 0.437 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 12.1 mt-10 -61.67 -35.83 79.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -60.16 -34.87 74.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 240' ' ' ILE . 27.7 mtt -72.04 -41.17 67.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.844 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 59.8 mt -68.67 -42.24 78.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.919 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.428 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 6.1 ptm180 -67.3 -39.87 86.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.428 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.27 -34.75 86.51 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.464 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 92.2 mt -80.98 -42.35 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.854 0.359 . . . . 0.0 111.103 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.788 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.48 -1.65 54.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.863 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.7 OUTLIER -70.29 -59.79 3.84 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.654 0.74 . . . . 0.0 110.883 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.81 2.88 3.16 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -102.97 -30.41 10.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.876 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 176.62 149.01 7.38 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.453 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 7.4 ttpp -56.29 111.42 0.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 110.854 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.495 HG21 HD11 ' A' ' 258' ' ' ILE . 57.0 mt -80.62 124.97 39.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.161 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -82.28 -43.14 17.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -168.25 149.3 4.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.854 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.495 HD11 HG21 ' A' ' 255' ' ' ILE . 41.9 mt -128.25 132.72 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.158 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.552 HG23 ' HB2' ' A' ' 274' ' ' PHE . 4.9 m -134.99 127.02 47.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.437 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 31.6 mt -92.11 136.29 33.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.935 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 29.9 mmm -103.91 134.32 47.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.87 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.29 -175.85 4.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.9 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -102.79 -175.99 2.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 11.3 p -118.42 -47.42 2.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.876 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -68.45 -24.11 64.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 43.0 p -114.81 -38.1 4.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.142 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 62.3 24.86 65.99 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.468 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.404 ' O ' ' C ' ' A' ' 269' ' ' SER . 47.5 mmt-85 -113.95 110.69 20.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 110.847 -179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.404 ' C ' ' O ' ' A' ' 268' ' ' ARG . 5.3 p -38.18 103.78 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.841 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 20.5 mttm -52.2 -29.58 23.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 117.01 37.37 0.96 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.518 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -148.63 163.32 37.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.868 0.366 . . . . 0.0 110.947 -179.814 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.32 175.56 39.58 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.552 ' HB2' HG23 ' A' ' 259' ' ' VAL . 31.4 m-85 -120.37 137.74 54.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.859 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 30.1 mt -138.48 137.35 43.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.16 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.7 m -118.53 129.46 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.452 ' CE1' HD12 ' A' ' 231' ' ' LEU . 39.2 m-85 -97.76 -177.9 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.873 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.9 t -95.51 -41.55 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -116.59 141.23 48.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.1 m -63.87 -36.23 83.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -61.72 -43.65 98.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.94 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 99.2 m -62.06 -40.5 96.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.8 -42.84 99.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . 0.427 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 13.0 ttm105 -60.73 -48.05 83.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 23.2 mtp180 -58.31 -50.88 72.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.89 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.49 -34.93 71.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.123 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.454 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -64.72 -40.81 95.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -68.96 -42.16 77.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.891 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -71.72 -38.43 70.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.924 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.788 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 56.7 mt -74.08 -47.04 39.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.931 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -44.51 110.16 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.71 37.19 40.46 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 28.1 t80 -104.83 91.79 3.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.849 0.357 . . . . 0.0 110.825 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -48.91 118.4 2.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.545 HD21 ' CD1' ' A' ' 240' ' ' ILE . 45.6 tp -103.85 -44.73 4.97 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -122.95 40.15 3.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.06 -27.75 18.53 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 29.6 mtp85 -118.32 148.46 43.9 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.558 0.694 . . . . 0.0 110.891 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 132.62 23.79 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.696 2.264 . . . . 0.0 112.336 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . 0.431 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -86.88 170.93 11.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.898 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -108.64 127.82 54.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.897 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.784 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.4 t -132.47 127.6 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -152.47 163.87 30.44 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.505 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -71.13 146.41 49.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 0.0 110.863 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 95.3 t -73.93 -41.04 53.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . 0.456 HG23 ' H ' ' A' ' 308' ' ' ARG . 10.8 t -79.55 -12.64 59.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.138 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 44.73 41.96 5.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.456 ' H ' HG23 ' A' ' 306' ' ' THR . 33.9 tpt85 -129.67 134.99 47.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.33 166.14 23.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.863 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.32 162.87 5.6 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 157.26 172.92 25.02 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.481 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -100.05 111.47 4.19 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.473 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 2.9 t -70.63 158.31 36.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.929 0.395 . . . . 0.0 110.847 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 152.27 76.44 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.481 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.12 20.25 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.702 2.268 . . . . 0.0 112.341 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 2.4 t -41.84 146.68 0.25 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 48.9 m 53.02 42.53 32.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.468 -179.977 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.6 m -131.57 146.47 52.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.915 0.388 . . . . 0.0 110.811 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 94.4 p -101.38 130.24 47.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.859 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 76.27 88.01 0.3 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.512 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 41.0 t -85.39 101.71 12.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 0.0 110.881 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 23.4 t -92.2 33.48 1.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -92.19 150.05 19.98 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.495 ' CA ' HG23 ' A' ' 305' ' ' VAL . 53.7 mt -127.24 144.77 50.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.81 0.338 . . . . 0.0 110.93 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.482 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.5 t80 -109.69 136.29 49.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 10.8 p -122.87 137.77 55.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.089 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.65 164.32 28.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.466 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.3 t 74.12 47.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.891 0.376 . . . . 0.0 110.807 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 91.3 mt -109.28 170.29 8.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.586 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 8.0 t-80 -92.93 126.08 37.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.876 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.586 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 4.8 p90 -38.83 -48.36 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 12.4 t-20 -46.31 -44.54 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.871 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.44 HG22 ' N ' ' A' ' 241' ' ' THR . 47.9 mm -40.07 154.47 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.44 ' N ' HG22 ' A' ' 240' ' ' ILE . 14.4 t -137.42 173.72 11.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -60.69 -35.02 75.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.887 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -59.49 -34.53 72.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.7 mmt -71.77 -39.51 69.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.869 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.453 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.6 mt -68.89 -41.85 77.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.554 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.7 ptm180 -68.55 -36.15 78.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.42 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.06 -41.82 92.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.471 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.433 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 76.5 mt -75.18 -41.32 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.841 0.353 . . . . 0.0 111.097 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.676 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -81.56 -4.03 54.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.51 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.0 tp10 -69.48 -59.7 4.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.643 0.735 . . . . 0.0 110.871 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.5 Cg_endo -69.79 3.02 3.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.665 2.243 . . . . 0.0 112.285 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.823 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -103.16 -39.33 6.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.92 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -176.01 148.06 9.04 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -51.75 117.24 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 246' ' ' ARG . 31.2 mt -87.07 124.56 40.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.155 179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -83.61 -44.7 14.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 11.7 t30 -167.51 150.01 5.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.412 HD11 HG21 ' A' ' 255' ' ' ILE . 34.6 mt -126.6 136.13 61.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.142 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 84.8 t -134.97 130.86 52.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.13 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.51 131.66 47.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.455 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 68.4 mmm -98.04 126.25 43.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.46 167.11 18.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.929 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.38 -178.9 4.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 28.0 p -111.94 -52.64 2.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.897 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -59.5 -38.65 81.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 61.6 p -101.58 -32.51 10.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.109 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 55.19 28.9 51.09 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.463 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.431 ' O ' ' C ' ' A' ' 269' ' ' SER . 14.9 ttt180 -120.98 109.02 14.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.833 0.349 . . . . 0.0 110.868 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 268' ' ' ARG . 12.0 p -35.34 103.32 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.848 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 47.1 mttt -48.96 -35.32 14.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.891 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 124.14 38.23 0.54 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.528 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.455 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 1.8 p90 -149.2 161.78 41.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 110.903 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -165.66 171.15 40.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.485 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -117.13 134.82 54.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.842 0.354 . . . . 0.0 110.856 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.453 HD11 ' HB3' ' A' ' 245' ' ' LEU . 97.2 mt -132.28 137.69 53.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.159 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 96.4 m -117.22 129.51 55.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.209 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.485 ' CE1' HD12 ' A' ' 231' ' ' LEU . 43.6 m-85 -97.99 -177.27 3.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.9 t -101.48 -41.37 6.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -112.02 138.81 48.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.859 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.7 p -63.52 -40.93 98.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.829 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -61.3 -43.62 98.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 95.2 m -60.56 -42.96 97.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.843 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.67 -40.07 95.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -60.07 -48.91 79.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.0 mmt85 -58.96 -49.79 76.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.917 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.823 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.54 -35.79 70.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.404 HD22 ' CD2' ' A' ' 304' ' ' HIS . 12.9 tp -64.54 -43.36 94.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.891 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -68.8 -42.43 77.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 22.2 mm100 -69.1 -41.1 77.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 58.6 mt -73.12 -46.31 51.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.884 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -45.91 112.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.905 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.73 38.73 36.13 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.476 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 73.4 t80 -106.51 120.86 43.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.818 0.342 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -67.11 114.56 5.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.5 tp -98.17 -62.12 1.29 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.17 34.76 4.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.064 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 117.0 -35.42 4.17 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.502 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -120.42 156.51 55.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.627 0.727 . . . . 0.0 110.852 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 130.84 20.07 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.65 2.234 . . . . 0.0 112.334 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -79.54 170.92 15.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -105.99 119.08 38.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -124.11 132.38 71.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.161 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -154.65 163.9 31.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.404 ' CD2' HD22 ' A' ' 287' ' ' LEU . 16.5 m-70 -70.13 135.99 49.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.809 0.337 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.495 HG23 ' CA ' ' A' ' 231' ' ' LEU . 94.9 t -73.92 107.74 4.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.167 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 15.2 t -158.17 142.92 16.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.106 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . 0.408 ' O ' ' CG ' ' A' ' 307' ' ' GLU . 6.5 pt-20 -104.05 94.32 5.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 8.4 ttt85 -165.66 145.14 6.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 79.9 mt -96.27 168.56 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.891 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -115.52 154.47 29.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.887 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 167.84 114.65 0.3 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.479 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 158.96 105.43 0.21 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.455 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 48.8 m -144.2 149.25 36.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.946 0.403 . . . . 0.0 110.864 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 114.44 77.32 0.74 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -9.68 26.71 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.699 2.266 . . . . 0.0 112.376 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 51.7 p -129.44 166.9 18.67 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 78.3 p -69.15 99.93 1.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.89 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.446 -179.949 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.5 m -81.09 167.12 20.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 72.7 m -87.43 151.24 23.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.844 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -102.87 -82.44 1.64 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 83.8 p 44.0 39.09 2.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 0.0 110.886 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 97.0 p -123.41 -45.29 2.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.852 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -54.22 121.03 17.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.499 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.502 HD23 ' HD2' ' A' ' 304' ' ' HIS . 31.1 mt -111.8 147.03 36.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.846 0.355 . . . . 0.0 110.881 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.514 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -107.23 137.11 45.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.506 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.4 p -123.76 131.86 72.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.077 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.0 165.66 27.27 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.52 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 72.71 43.67 0.43 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.938 0.399 . . . . 0.0 110.853 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.506 HD11 ' CG2' ' A' ' 233' ' ' VAL . 30.3 mt -103.75 166.2 10.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.628 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 5.4 t-80 -86.42 128.47 34.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.872 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.628 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 36.9 p90 -37.88 -50.22 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.851 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.433 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 10.1 t-20 -47.53 -43.4 24.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.873 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' A' ' 237' ' ' HIS . 43.6 mm -38.64 147.9 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -138.88 178.42 7.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.103 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -60.65 -35.76 77.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . 0.464 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 1.3 m-20 -61.89 -32.86 73.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.9 mmt -71.98 -41.47 67.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.454 ' HB3' HD11 ' A' ' 275' ' ' ILE . 86.9 mt -69.88 -42.94 72.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.464 ' CD ' ' HA ' ' A' ' 243' ' ' ASP . 5.2 ptm180 -64.38 -37.74 88.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.445 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -69.56 -39.12 79.2 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.468 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.8 mt -75.86 -44.3 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.367 . . . . 0.0 111.11 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.61 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.86 -2.77 48.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.506 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.5 tp10 -70.61 -59.86 3.52 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.595 0.712 . . . . 0.0 110.871 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.7 2.42 3.52 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.728 2.286 . . . . 0.0 112.339 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.687 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.47 -31.42 10.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.76 149.86 7.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -54.77 113.32 1.28 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.759 0.314 . . . . 0.0 110.875 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.45 HD13 HD11 ' A' ' 258' ' ' ILE . 64.2 mt -83.35 122.65 37.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.166 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -78.83 -43.4 25.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -167.74 145.13 4.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.863 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.45 HD11 HD13 ' A' ' 255' ' ' ILE . 81.1 mt -120.24 135.29 61.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.137 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.74 128.87 51.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.0 mt -97.99 139.84 33.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.533 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 28.7 mmt -92.77 133.85 35.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -139.62 140.84 37.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -58.04 -179.4 0.05 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.848 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 20.2 m -111.48 -28.43 8.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.851 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -87.13 -51.12 6.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 82.4 p -90.69 -26.22 19.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.166 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 52.69 26.35 24.51 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.438 ' O ' ' C ' ' A' ' 269' ' ' SER . 3.6 ttp85 -109.82 107.34 17.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.815 0.34 . . . . 0.0 110.898 -179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.438 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.8 OUTLIER -34.94 118.63 0.44 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 -179.774 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -75.82 -25.61 56.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.897 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 120.34 35.69 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.441 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.533 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.7 p90 -147.48 155.91 42.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.908 0.385 . . . . 0.0 110.93 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.54 -178.55 39.76 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.488 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.29 137.98 54.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.899 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.454 HD11 ' HB3' ' A' ' 245' ' ' LEU . 92.6 mt -132.03 140.87 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.077 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 92.3 m -118.83 129.94 55.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.147 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -98.63 -178.05 3.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 2.1 t -100.98 -39.47 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.812 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -112.84 135.62 53.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.854 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 4.5 m -60.54 -39.38 87.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.839 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -62.68 -42.74 99.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.891 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 75.4 m -61.96 -36.76 82.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.441 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.82 -41.8 86.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 4.9 tpp85 -61.84 -48.72 79.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -58.3 -50.91 71.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.687 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.89 -35.05 68.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.107 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.703 HD12 HG12 ' A' ' 302' ' ' VAL . 12.9 tp -64.65 -43.7 92.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.947 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -68.93 -42.77 76.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.863 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 25.7 mm100 -68.4 -41.85 79.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.704 ' HB3' HG21 ' A' ' 302' ' ' VAL . 67.0 mt -72.93 -46.14 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -46.03 108.78 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.82 31.57 39.49 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.486 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -94.32 123.01 37.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.842 0.354 . . . . 0.0 110.881 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 71.2 mt-10 -70.83 96.1 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.402 HD21 ' CD1' ' A' ' 240' ' ' ILE . 9.5 tp -78.87 -62.03 1.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -115.9 41.57 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.056 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.69 -21.44 43.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -124.31 149.58 61.47 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.581 0.705 . . . . 0.0 110.865 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.84 11.49 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -77.52 173.47 11.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.893 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -108.08 119.01 38.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.879 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.704 HG21 ' HB3' ' A' ' 290' ' ' LEU . 18.2 t -124.88 129.37 73.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.85 161.17 30.51 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.502 ' HD2' HD23 ' A' ' 231' ' ' LEU . 10.6 m170 -73.04 134.4 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.87 0.367 . . . . 0.0 110.838 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.85 -66.62 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.168 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 40.2 p -56.35 132.57 51.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.15 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -105.82 78.5 1.34 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 16.5 ttt85 -105.08 147.74 27.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.09 41.33 3.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.891 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.1 154.61 20.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 121.18 160.47 11.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 160.63 -55.77 0.32 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.494 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 42.5 m -68.15 -42.83 79.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.888 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 83.02 -158.18 36.2 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 130.03 18.64 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.698 2.265 . . . . 0.0 112.323 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 p -72.58 176.09 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.825 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 67.5 m -118.51 132.11 56.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.464 -179.98 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.468 -0.253 . . . . 0.0 112.468 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 37.5 m -123.14 154.86 38.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.877 0.37 . . . . 0.0 110.817 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 6.1 t -55.72 -52.23 64.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.828 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 142.42 -131.83 4.86 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.499 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 43.9 m -113.83 100.27 8.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.873 0.368 . . . . 0.0 110.849 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 3.3 t -65.43 91.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -131.83 140.42 11.78 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.474 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.463 HD11 ' O ' ' A' ' 283' ' ' ALA . 31.4 mt -124.65 144.8 49.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.857 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.905 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.6 t80 -109.19 128.76 55.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.616 ' CG2' HD11 ' A' ' 236' ' ' LEU . 10.4 p -113.92 133.5 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.42 166.02 26.94 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 7.7 t 71.98 44.2 0.48 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.876 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.616 HD11 ' CG2' ' A' ' 233' ' ' VAL . 81.6 mt -106.76 167.39 9.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.909 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.409 ' O ' ' C ' ' A' ' 238' ' ' PHE . 5.7 t-80 -93.15 130.96 38.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.874 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.409 ' C ' ' O ' ' A' ' 237' ' ' HIS . 4.2 m-85 -36.79 -54.21 0.91 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -41.76 -43.48 2.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.415 HD13 ' SD ' ' A' ' 244' ' ' MET . 31.1 mm -41.05 127.73 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 47.8 p -114.71 172.2 7.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.159 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 39.3 mp0 -60.27 -33.94 73.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -62.51 -32.46 73.38 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.848 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . 0.415 ' SD ' HD13 ' A' ' 240' ' ' ILE . 52.0 mtt -72.01 -41.33 67.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.875 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 29.9 mt -66.91 -42.95 84.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.454 ' HA ' HD13 ' A' ' 255' ' ' ILE . 4.8 ptm180 -67.18 -39.69 86.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.44 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.12 -34.82 89.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.486 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.409 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 81.7 mt -81.56 -40.48 17.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.883 0.373 . . . . 0.0 111.141 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.703 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -84.72 -0.97 55.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.514 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.6 tp10 -70.77 -59.42 3.68 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.79 2.92 3.11 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.259 . . . . 0.0 112.36 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.647 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.2 -31.08 10.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 178.28 157.31 18.73 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -63.2 108.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.707 0.289 . . . . 0.0 110.909 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.454 HD13 ' HA ' ' A' ' 246' ' ' ARG . 37.3 mt -77.15 125.01 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.125 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -86.39 -43.69 12.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.877 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 9.2 t-20 -163.56 143.65 8.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.449 HD11 HD13 ' A' ' 255' ' ' ILE . 71.0 mt -123.13 127.53 74.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.407 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.7 m -134.04 129.35 54.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.12 179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 33.3 mt -92.38 139.07 30.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.652 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 15.7 mmt -95.94 125.77 40.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.846 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.75 158.37 39.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.889 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -68.36 -179.26 1.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.857 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.3 m -111.27 -34.23 6.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.854 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -90.97 -55.34 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.882 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 72.5 p -74.19 -18.15 60.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 48.54 26.98 5.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.467 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 90.6 mtt180 -121.04 126.26 49.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.867 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 30.9 t -52.89 147.22 9.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.856 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.561 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 14.4 mmtp -104.34 16.41 26.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.889 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 76.86 40.01 26.99 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.514 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.652 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.9 p90 -150.14 164.04 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.922 0.392 . . . . 0.0 110.922 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -172.57 176.38 45.49 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.407 ' HB2' HG23 ' A' ' 259' ' ' VAL . 42.6 m-85 -117.11 136.1 53.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.886 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -132.26 140.59 47.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.1 m -120.98 127.7 52.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -97.43 -175.14 3.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 42.3 t -100.28 -40.5 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -115.22 140.05 49.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.87 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 13.0 p -62.51 -39.19 92.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.851 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -62.05 -42.93 99.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.3 m -60.38 -39.22 86.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.463 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -66.67 -40.69 88.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.109 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 32.6 ttp85 -59.07 -49.02 79.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 5.2 mpt_? -59.38 -48.94 79.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.837 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.647 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.04 -35.6 71.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.444 HD12 HG12 ' A' ' 302' ' ' VAL . 12.0 tp -65.06 -43.58 91.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -68.96 -43.03 75.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 67.6 mm-40 -68.85 -41.21 78.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.943 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.818 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.2 mt -73.27 -45.02 58.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.901 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -45.15 98.16 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 96.01 24.46 14.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.511 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . 0.416 ' N ' ' O ' ' A' ' 290' ' ' LEU . 10.5 t80 -79.58 116.36 19.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.81 0.338 . . . . 0.0 110.901 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -80.25 89.06 5.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 12.1 tp -86.66 -59.75 2.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.02 45.09 0.98 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.112 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 84.42 -27.75 4.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -113.23 143.93 30.21 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.573 0.702 . . . . 0.0 110.837 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 123.14 9.8 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.644 2.229 . . . . 0.0 112.367 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.9 ptp -73.96 169.71 16.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.852 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 40.3 mmt-85 -109.12 122.19 46.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.2 t -126.22 120.63 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -144.71 160.14 27.91 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 8.9 m170 -70.69 121.72 18.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.847 0.356 . . . . 0.0 110.832 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.905 HG12 ' HB2' ' A' ' 232' ' ' TYR . 15.6 m -60.99 -44.37 98.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . 0.512 ' N ' HG23 ' A' ' 305' ' ' VAL . 96.3 m -152.81 113.54 4.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -129.49 153.19 48.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 20.2 ttp180 -156.55 133.42 10.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.843 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.503 HD23 ' N ' ' A' ' 309' ' ' LEU . 0.7 OUTLIER -125.47 131.13 52.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.925 -179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -124.52 138.89 54.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -134.65 -129.89 2.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.446 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 170.1 -118.05 0.74 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 46.8 t -79.59 135.87 36.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 110.846 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -174.46 85.29 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.486 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -1.42 8.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.704 2.269 . . . . 0.0 112.328 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.4 m 72.33 52.34 0.18 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.83 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 3.2 m -104.3 160.8 14.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.883 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.485 -179.985 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 34.8 t -40.91 144.57 0.26 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.893 0.378 . . . . 0.0 110.883 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 29.1 t -117.78 88.78 2.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -63.32 128.95 39.79 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.523 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 25.4 m -107.7 98.46 8.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.876 0.37 . . . . 0.0 110.916 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 59.4 p -104.25 83.1 2.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.889 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -128.56 141.58 12.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 68.3 mt -124.41 145.69 49.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.773 0.32 . . . . 0.0 110.923 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.507 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.2 t80 -110.78 131.1 55.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.662 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.9 p -113.62 134.94 54.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.13 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.81 165.73 27.57 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 2.5 t 71.32 45.71 0.47 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.925 0.393 . . . . 0.0 110.823 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.662 HD11 ' CG2' ' A' ' 233' ' ' VAL . 86.8 mt -109.76 176.35 5.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -102.89 135.33 44.76 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 239' ' ' ASN . 0.6 OUTLIER -46.47 -51.37 15.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.852 -179.902 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.407 ' N ' ' CD1' ' A' ' 238' ' ' PHE . 6.7 t-20 -42.15 -41.25 2.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.834 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 16.0 mm -47.94 139.91 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 8.9 t -121.61 167.65 12.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.156 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -55.06 -33.71 62.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . 0.467 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 35.5 t0 -59.97 -36.9 78.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 4.8 mmt -71.38 -37.72 71.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.664 ' CD1' HD21 ' A' ' 260' ' ' LEU . 73.2 mt -69.98 -39.97 75.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.511 ' HA ' HD13 ' A' ' 255' ' ' ILE . 2.9 ptm180 -70.53 -35.3 73.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.456 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -69.79 -38.83 76.69 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.414 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 80.2 mt -75.72 -41.12 40.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.853 0.359 . . . . 0.0 111.113 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.622 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 4.5 m-85 -83.43 -4.19 58.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.892 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -69.47 -58.33 5.97 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.598 0.713 . . . . 0.0 110.901 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.76 2.52 3.46 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.736 2.291 . . . . 0.0 112.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.783 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.6 -26.93 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.903 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 172.87 162.05 24.32 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.504 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 20.4 ttpt -63.61 110.72 2.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.781 0.324 . . . . 0.0 110.936 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.622 HG21 HD11 ' A' ' 258' ' ' ILE . 25.2 mt -80.58 117.18 26.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -77.0 -46.4 23.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.828 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -168.89 142.46 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.903 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.622 HD11 HG21 ' A' ' 255' ' ' ILE . 46.0 mt -121.09 135.4 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.124 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.37 127.81 57.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.143 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.664 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.6 mt -98.15 136.54 38.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.523 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 20.2 mmt -96.29 134.06 39.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.91 136.04 30.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.43 177.31 0.39 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.899 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.1 t -110.35 -61.94 1.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -49.25 -47.22 46.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 30.3 p -94.07 -42.01 9.24 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.142 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 74.46 15.1 80.51 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 13.1 mtp85 -101.69 106.82 17.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.835 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 20.4 p -38.59 106.76 0.06 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.408 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 19.9 mmtm -50.21 -32.76 17.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 118.66 37.76 0.82 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.523 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 2.4 p90 -146.92 155.5 42.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.933 0.397 . . . . 0.0 110.962 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -160.39 170.17 36.34 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.51 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -113.52 138.74 49.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.855 0.359 . . . . 0.0 110.857 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 68.0 mt -136.01 134.16 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.0 m -118.19 129.01 55.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.166 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -99.15 -176.19 3.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.915 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 17.7 t -97.49 -41.85 7.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.426 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 26.1 t0 -115.42 142.59 46.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.858 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 29.2 t -63.99 -38.77 92.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.858 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.478 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 10.7 pt-20 -61.52 -41.66 97.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.867 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . 0.478 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 84.0 m -61.35 -38.94 88.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.74 90.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 40.0 mtp180 -59.1 -48.89 79.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -58.78 -50.4 74.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.783 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -59.52 -34.99 73.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.083 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.531 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.3 tp -62.43 -45.26 93.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.911 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -68.83 -38.23 79.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -71.77 -36.62 70.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.949 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.6 mt -78.8 -39.97 34.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.917 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -55.09 103.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.878 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 87.91 30.89 16.35 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -98.49 109.79 22.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 110.842 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -56.7 99.31 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.914 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.431 ' C ' HD13 ' A' ' 295' ' ' LEU . 0.9 OUTLIER -78.77 -65.52 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -119.5 39.62 3.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.08 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 112.44 -34.61 5.06 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.95 151.35 46.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.865 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 120.94 7.66 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.304 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -71.12 171.89 10.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.889 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -110.26 122.51 47.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.2 t -128.88 126.12 64.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.26 160.99 28.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.492 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.531 ' CD2' HD22 ' A' ' 287' ' ' LEU . 26.0 m-70 -70.46 128.04 34.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.766 0.317 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 59.5 t -56.18 -58.57 4.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.143 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 6.4 t -68.33 151.68 46.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.122 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 12.1 tt0 -99.67 85.14 3.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.884 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 16.3 mmm180 -96.13 152.35 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.828 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 5.2 mt -147.99 133.49 18.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -152.86 143.02 22.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.85 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 166.11 74.46 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 130.31 95.79 0.74 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.502 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 98.9 p -73.12 -43.13 62.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 0.0 110.86 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 157.3 -159.16 29.52 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.473 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 126.8 13.73 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.698 2.265 . . . . 0.0 112.346 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.449 ' O ' ' C ' ' A' ' 317' ' ' SER . 11.8 t -85.04 -54.4 4.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.844 -179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 316' ' ' SER . 37.4 p 34.55 42.53 0.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.445 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 27.9 t -139.1 135.71 34.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.885 0.374 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 22.0 p -109.38 144.53 37.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.874 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 154.72 -76.25 0.22 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 58.9 m -157.55 141.75 16.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.903 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 80.3 p -84.7 86.72 7.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -99.2 142.54 16.09 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.486 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.432 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.5 mt -131.56 144.78 51.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.806 0.336 . . . . 0.0 110.874 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.58 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.5 OUTLIER -110.3 137.17 48.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.956 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.42 133.12 70.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.79 165.65 27.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 m 72.29 45.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.86 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 37.3 mt -104.78 173.45 6.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -96.89 137.92 35.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.835 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -43.23 -49.41 6.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.516 ' O ' HG23 ' A' ' 241' ' ' THR . 16.0 t-20 -47.78 -40.2 20.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 43.0 mm -43.71 145.73 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.152 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.516 HG23 ' O ' ' A' ' 239' ' ' ASN . 33.5 p -143.07 173.65 11.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . 0.413 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 28.5 mp0 -54.97 -36.2 65.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -62.29 -35.5 79.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.847 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -72.01 -40.98 68.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 40.5 mt -68.17 -43.04 79.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.403 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.1 ptm180 -66.12 -37.62 86.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.403 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.85 -36.0 80.94 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.428 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.2 mt -80.36 -42.76 21.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.81 0.338 . . . . 0.0 111.117 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.516 ' CZ ' ' CD1' ' A' ' 290' ' ' LEU . 3.1 m-85 -81.45 -4.13 54.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.956 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.505 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tp10 -68.52 -59.93 5.31 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.646 0.736 . . . . 0.0 110.879 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.82 2.93 3.12 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.685 2.257 . . . . 0.0 112.347 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.748 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -103.31 -22.03 13.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 163.72 158.54 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.449 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -61.32 117.09 5.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.766 0.317 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.66 HG21 HD11 ' A' ' 258' ' ' ILE . 57.2 mt -88.19 120.63 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -76.55 -49.03 17.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -158.17 155.45 29.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.66 HD11 HG21 ' A' ' 255' ' ' ILE . 44.6 mt -136.63 129.91 45.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.114 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 85.3 t -133.84 135.81 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.113 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.413 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 27.8 mt -102.62 139.63 37.96 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.594 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 24.7 mmt -94.92 128.61 41.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.869 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.74 145.6 49.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -62.46 -178.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.88 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 17.6 t -112.59 -49.9 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.857 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -54.97 -40.31 69.87 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.845 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 267' ' ' GLY . 2.2 p -113.04 -57.95 2.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 266' ' ' THR . . . 94.22 26.87 13.03 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.452 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.436 ' O ' ' C ' ' A' ' 269' ' ' SER . 10.9 ttm180 -102.45 105.26 15.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 268' ' ' ARG . 19.9 m -34.98 110.15 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.4 mmtp -61.04 -44.58 97.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.903 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 141.12 37.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.594 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 2.2 p90 -147.79 158.53 44.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.924 0.392 . . . . 0.0 110.905 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.6 172.28 39.48 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.494 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -118.35 136.28 53.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.884 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.567 HG12 HG23 ' A' ' 258' ' ' ILE . 78.1 mt -136.46 140.44 43.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 99.4 m -120.67 129.36 53.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.13 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.432 ' CE1' HD12 ' A' ' 231' ' ' LEU . 41.8 m-85 -98.46 -178.82 4.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 24.6 t -101.18 -33.97 9.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.897 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -117.6 136.28 53.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.7 p -64.04 -39.83 94.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.863 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -62.65 -43.83 97.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.889 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 32.7 m -62.89 -41.58 99.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.909 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.424 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.14 -41.46 97.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.036 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -59.78 -49.07 79.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -57.57 -48.99 77.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.748 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.8 -38.57 67.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.437 HD22 ' CD2' ' A' ' 304' ' ' HIS . 9.0 tp -65.18 -39.84 93.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.908 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -64.46 -34.94 79.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -83.91 -34.75 24.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.943 ' HB3' HG21 ' A' ' 302' ' ' VAL . 76.3 mt -71.77 -47.07 56.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.888 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . 0.428 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -55.02 118.31 4.2 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.24 23.2 63.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.456 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -93.87 111.63 23.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . 0.46 ' HG3' ' N ' ' A' ' 299' ' ' PRO . 2.4 mp0 -76.27 104.45 6.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -94.42 -57.44 2.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -105.7 41.02 1.45 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.106 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 102.66 -42.94 1.78 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 2.8 ptp180 -111.02 153.26 43.93 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.65 0.738 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . 0.46 ' N ' ' HG3' ' A' ' 294' ' ' GLU . 54.0 Cg_endo -69.76 135.42 30.43 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.714 2.276 . . . . 0.0 112.339 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 3.4 ptp -82.85 162.91 21.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.887 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -106.28 121.28 43.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.943 HG21 ' HB3' ' A' ' 290' ' ' LEU . 22.1 t -130.81 125.47 58.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.14 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.26 161.36 26.88 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.437 ' CD2' HD22 ' A' ' 287' ' ' LEU . 22.1 m-70 -72.47 109.31 6.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.836 0.35 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.6 p -63.97 -41.04 91.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.095 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 28.4 m -66.91 97.16 0.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.143 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . 0.431 ' HG3' ' N ' ' A' ' 308' ' ' ARG . 13.3 tp10 -63.88 156.08 28.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.909 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.431 ' N ' ' HG3' ' A' ' 307' ' ' GLU . 3.0 ptt180 -131.03 156.38 45.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.882 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 63.2 mt -117.82 -44.37 2.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -94.95 136.12 35.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -158.47 76.01 0.2 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.452 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . 0.42 ' O ' ' C ' ' A' ' 313' ' ' SER . . . 88.81 68.09 1.27 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.494 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . 0.42 ' C ' ' O ' ' A' ' 312' ' ' GLY . 16.3 t -36.84 123.66 0.85 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.853 0.359 . . . . 0.0 110.886 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 82.39 177.61 51.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.504 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 316' ' ' SER . 54.0 Cg_endo -69.78 2.46 3.52 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.447 ' C ' ' O ' ' A' ' 315' ' ' PRO . 21.5 p -34.58 144.27 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 1.7 t -43.05 137.53 2.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.902 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.513 -179.949 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 2.5 t -121.48 162.17 20.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.919 0.39 . . . . 0.0 110.845 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 2.4 m -100.76 91.31 4.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.851 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -104.49 149.24 16.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.526 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 35.1 t -119.42 95.99 5.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.868 0.366 . . . . 0.0 110.809 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . 0.405 ' O ' ' HB1' ' A' ' 283' ' ' ALA . 32.1 t -67.59 -47.67 69.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.885 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.509 ' O ' HG12 ' A' ' 305' ' ' VAL . . . -38.68 137.85 0.89 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.472 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.853 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.1 mt -125.77 143.62 50.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 110.93 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.17 130.58 56.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.903 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.493 HG21 HD11 ' A' ' 236' ' ' LEU . 10.8 p -110.39 135.2 50.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.135 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -140.24 166.04 25.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.469 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.9 m 63.96 47.81 3.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.925 0.393 . . . . 0.0 110.86 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.493 HD11 HG21 ' A' ' 233' ' ' VAL . 72.5 mt -100.11 -175.94 3.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.484 ' CE1' ' CE1' ' A' ' 238' ' ' PHE . 4.0 t-80 -115.26 124.5 51.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.89 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.484 ' CE1' ' CE1' ' A' ' 237' ' ' HIS . 23.2 p90 -34.48 -54.13 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.866 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.414 ' N ' ' CD2' ' A' ' 238' ' ' PHE . 2.1 t-20 -41.52 -46.76 3.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 51.7 mm -41.29 139.07 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.114 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 11.5 t -122.91 170.88 9.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.148 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 43.5 mp0 -57.69 -32.78 67.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -64.95 -32.51 74.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.86 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 17.5 mtt -71.98 -43.84 64.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.939 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.446 HD22 HD11 ' A' ' 275' ' ' ILE . 36.1 mt -65.51 -43.0 91.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.422 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 5.3 ptm180 -67.14 -38.36 85.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -67.34 -33.22 81.62 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 96.8 mt -79.67 -45.48 23.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.87 0.367 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -80.47 -2.01 44.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.936 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.504 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.9 OUTLIER -69.8 -59.95 4.14 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.719 . . . . 0.0 110.891 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.27 3.69 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.69 2.26 . . . . 0.0 112.342 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.802 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.9 m-85 -102.47 -34.1 9.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 179.21 157.59 19.94 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.479 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 25.6 ttmt -60.7 115.33 3.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.677 HD13 HD11 ' A' ' 258' ' ' ILE . 66.0 mt -85.85 121.47 37.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -80.61 -40.55 25.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 16.5 t30 -168.61 148.03 4.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.677 HD11 HD13 ' A' ' 255' ' ' ILE . 52.5 mt -129.78 128.35 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.585 HG23 ' HB2' ' A' ' 274' ' ' PHE . 16.1 m -130.03 136.97 57.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 25.5 mt -101.88 130.95 48.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.534 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 21.6 mmt -88.62 131.36 35.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.866 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.03 158.51 42.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.882 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -88.37 179.19 6.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.8 t -107.82 -45.4 4.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.866 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.44 -45.37 80.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 78.1 p -91.61 -44.72 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.161 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 73.65 24.78 73.83 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.46 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.434 ' O ' ' C ' ' A' ' 269' ' ' SER . 47.7 mtp180 -128.12 114.1 16.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.823 0.344 . . . . 0.0 110.851 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 268' ' ' ARG . 29.7 t -34.94 106.67 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.85 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 33.7 mttt -51.3 -28.69 12.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.884 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.79 37.01 0.46 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.534 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -147.16 162.93 37.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.911 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.23 173.71 39.42 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.585 ' HB2' HG23 ' A' ' 259' ' ' VAL . 18.7 m-85 -119.91 134.09 55.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.874 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.446 HD11 HD22 ' A' ' 245' ' ' LEU . 88.1 mt -135.28 127.91 47.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 91.5 m -113.27 128.72 56.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.853 ' CE1' HD12 ' A' ' 231' ' ' LEU . 51.3 m-85 -95.65 -175.07 3.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.922 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 7.3 t -102.03 -39.37 7.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -112.61 139.15 48.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.88 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 76.9 p -63.27 -40.22 96.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -63.97 -42.58 97.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 93.3 m -62.04 -42.08 98.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.555 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -62.93 -40.28 97.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.07 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 12.2 ttt85 -61.77 -46.64 88.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.825 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 49.6 mtt180 -58.42 -51.01 71.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.802 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.14 -35.78 69.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.64 HD12 HG12 ' A' ' 302' ' ' VAL . 12.6 tp -63.85 -43.87 94.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.921 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -69.02 -35.01 76.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -73.55 -41.99 62.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.775 ' HB3' HG21 ' A' ' 302' ' ' VAL . 38.2 mt -74.88 -46.97 32.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -43.52 105.76 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.32 33.88 27.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.51 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -102.68 116.29 32.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.805 0.336 . . . . 0.0 110.882 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -61.59 114.22 3.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.886 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 13.4 tp -101.13 -55.92 2.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -123.04 42.23 3.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.115 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.79 -21.24 44.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -128.5 149.29 71.3 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.629 0.728 . . . . 0.0 110.837 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 125.5 12.25 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.622 2.214 . . . . 0.0 112.413 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.5 ptp -76.09 172.99 11.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -110.58 122.21 47.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.775 HG21 ' HB3' ' A' ' 290' ' ' LEU . 16.2 t -129.27 123.58 58.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.24 26.57 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.487 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.479 ' CE1' HD22 ' A' ' 287' ' ' LEU . 10.2 m170 -74.12 100.94 3.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 230' ' ' GLY . 4.8 p -39.3 125.06 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 3.1 t -80.06 141.02 36.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 10.1 tm-20 -173.87 156.87 2.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 11.9 tpt85 -156.51 159.41 38.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.508 ' C ' HD12 ' A' ' 309' ' ' LEU . 2.8 pp -90.98 -38.86 12.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.898 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . 0.458 ' N ' HD12 ' A' ' 309' ' ' LEU . 1.0 OUTLIER -117.53 -69.87 0.83 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.832 179.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 95.99 117.97 3.34 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.503 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 148.55 -171.05 28.99 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.4 t 53.68 36.24 23.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.937 0.399 . . . . 0.0 110.861 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -97.11 -95.07 1.88 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.495 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 176.09 7.28 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.711 2.274 . . . . 0.0 112.347 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 55.3 p -147.19 174.47 11.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.865 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 8.5 t -123.57 -49.24 1.9 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.496 -179.975 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 8.0 t -46.74 -48.49 20.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.844 0.354 . . . . 0.0 110.885 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 93.6 p -76.24 163.36 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 97.4 -142.97 16.45 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.499 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 5.7 m 56.41 43.1 26.68 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.857 0.361 . . . . 0.0 110.852 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 59.6 p -128.32 -49.92 1.3 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.872 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -66.21 141.36 41.06 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.421 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 277' ' ' PHE . 29.7 mt -124.49 145.34 49.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.823 0.344 . . . . 0.0 110.886 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.529 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.8 OUTLIER -111.65 136.83 50.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.956 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.456 ' CG2' HD21 ' A' ' 236' ' ' LEU . 7.3 p -121.96 133.63 67.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.106 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -143.15 166.03 26.83 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 4.7 t 73.05 43.2 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.903 0.382 . . . . 0.0 110.827 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.456 HD21 ' CG2' ' A' ' 233' ' ' VAL . 49.4 mt -100.03 177.17 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.425 ' O ' ' C ' ' A' ' 238' ' ' PHE . 2.3 t-80 -102.09 133.04 47.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.844 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 269' ' ' SER . 59.3 m-85 -35.78 -52.51 0.71 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.43 ' O ' ' C ' ' A' ' 240' ' ' ILE . 16.5 m120 -45.14 -47.38 12.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.613 HD11 HD21 ' A' ' 295' ' ' LEU . 48.8 mm -35.38 150.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.179 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.9 t -147.13 179.96 7.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.181 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -60.19 -39.94 88.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -58.44 -36.88 74.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.845 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . 0.477 ' SD ' HD13 ' A' ' 240' ' ' ILE . 18.9 mtt -72.09 -41.54 67.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.521 ' CD1' HD21 ' A' ' 260' ' ' LEU . 75.0 mt -68.21 -41.72 80.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.479 ' HA ' HD13 ' A' ' 255' ' ' ILE . 13.4 ptt180 -67.92 -42.95 80.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.422 ' N ' ' CG ' ' A' ' 246' ' ' ARG . . . -63.3 -36.72 93.79 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.505 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.402 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.2 mt -76.23 -39.85 35.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.88 0.371 . . . . 0.0 111.13 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.755 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -88.42 -1.15 57.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.2 tp10 -70.34 -58.75 4.59 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 0.0 110.831 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.0 Cg_endo -69.7 3.46 2.73 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.698 2.265 . . . . 0.0 112.332 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.2 m-85 -104.14 -37.99 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.883 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -174.77 160.14 29.14 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.476 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -65.48 109.08 2.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.735 0.302 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.708 HG21 HD11 ' A' ' 258' ' ' ILE . 36.7 mt -77.23 114.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.171 179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -73.83 -43.99 57.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.867 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -162.54 152.09 15.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 255' ' ' ILE . 63.2 mt -133.29 129.64 56.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.073 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 52.8 t -129.37 128.05 65.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.154 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.521 HD21 ' CD1' ' A' ' 245' ' ' LEU . 19.0 mt -97.13 127.72 43.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.573 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 40.6 mmm -89.71 118.38 29.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.93 143.67 51.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.903 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -66.11 173.26 3.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.897 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 5.7 t -107.17 -41.08 5.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -71.5 -44.76 64.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.907 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 33.2 p -96.65 -34.77 11.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.132 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 58.59 25.66 58.71 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.481 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.465 ' O ' ' N ' ' A' ' 270' ' ' LYS . 12.0 mmt180 -109.27 109.71 20.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.578 ' O ' ' CD1' ' A' ' 238' ' ' PHE . 19.4 m -39.21 94.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.465 ' N ' ' O ' ' A' ' 268' ' ' ARG . 18.2 mttp -47.12 -40.67 15.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.866 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 129.66 41.32 0.25 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.573 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.0 OUTLIER -149.39 154.39 38.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.885 0.374 . . . . 0.0 110.95 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.14 168.24 36.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -115.29 138.66 50.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.854 0.359 . . . . 0.0 110.865 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 70.2 mt -136.46 138.42 46.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.113 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 89.2 m -117.77 122.97 44.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.154 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 231' ' ' LEU . 44.1 m-85 -91.62 -178.04 4.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.915 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 4.3 t -122.41 24.95 9.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.453 ' OD2' ' CG ' ' A' ' 281' ' ' GLU . 26.4 t0 -165.14 126.45 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.884 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 92.8 p -58.24 -40.98 83.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.891 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.453 ' CG ' ' OD2' ' A' ' 279' ' ' ASP . 6.2 pt-20 -63.37 -40.96 98.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.868 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 36.1 m -64.14 -41.56 97.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.486 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -61.17 -44.05 97.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.125 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 48.9 mtm180 -63.09 -49.02 76.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 19.5 mmt-85 -59.67 -51.04 71.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.843 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . . . . . . . . . . . -54.96 -36.36 65.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.061 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.421 HD22 ' CD2' ' A' ' 304' ' ' HIS . 15.0 tp -65.33 -43.59 90.45 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.923 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.57 -43.1 73.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.908 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 65.1 mm-40 -68.87 -42.14 77.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.755 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 84.1 mt -73.76 -47.02 42.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.904 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -46.2 103.41 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.02 36.47 13.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . 0.424 ' O ' ' N ' ' A' ' 295' ' ' LEU . 37.3 t80 -98.22 93.22 6.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -43.35 95.07 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.613 HD21 HD11 ' A' ' 240' ' ' ILE . 9.3 tt -82.39 -67.38 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -109.0 39.11 2.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 108.91 -41.42 2.23 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.489 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 22.6 ptt-85 -109.9 152.39 42.96 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.634 0.73 . . . . 0.0 110.834 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 118.38 5.64 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.5 ptt? -68.67 169.76 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.6 mmt180 -104.98 121.43 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 290' ' ' LEU . 6.9 t -126.95 127.77 70.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.09 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -148.78 160.34 28.35 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.421 ' CD2' HD22 ' A' ' 287' ' ' LEU . 18.9 m-70 -71.66 125.03 26.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.343 . . . . 0.0 110.889 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 84.4 t -50.49 118.7 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 11.8 t -121.51 147.53 45.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.163 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -105.19 -43.57 4.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.865 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -151.16 139.04 19.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 6.1 mp -72.65 119.45 16.89 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.934 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.11 139.2 46.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.849 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -56.1 -168.71 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.479 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -150.95 158.04 27.48 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.531 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 65.0 p -43.91 141.41 1.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.959 0.409 . . . . 0.0 110.861 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -120.57 176.45 16.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.503 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -23.09 31.1 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.657 2.238 . . . . 0.0 112.353 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 8.3 t -118.06 142.23 47.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.822 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 4.8 m -67.11 -58.8 4.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.897 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.485 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 21.8 m 37.35 51.33 1.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 -179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 92.7 p -101.53 178.91 4.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.838 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -138.45 81.49 0.27 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.482 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 74.9 m -113.07 121.97 46.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.873 0.368 . . . . 0.0 110.909 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 87.4 p -76.59 -45.45 30.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -39.5 141.85 0.59 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.502 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.691 HD12 ' CE2' ' A' ' 277' ' ' PHE . 24.2 mt -126.22 146.63 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.766 0.317 . . . . 0.0 110.909 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.551 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -109.92 136.74 48.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.648 HG21 HD11 ' A' ' 236' ' ' LEU . 7.1 p -120.37 138.13 51.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.96 165.25 28.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.7 t 71.27 46.59 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.945 0.402 . . . . 0.0 110.85 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.648 HD11 HG21 ' A' ' 233' ' ' VAL . 95.7 mt -109.7 154.02 23.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.956 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 31.9 t-80 -74.45 139.44 43.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -46.58 -45.22 18.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 240' ' ' ILE . 34.1 t-20 -49.88 -46.53 51.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.428 ' C ' ' O ' ' A' ' 239' ' ' ASN . 47.3 mm -35.55 131.67 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.9 p -120.2 177.23 5.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -62.42 -34.65 77.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.898 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -63.16 -33.86 76.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.873 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . 0.401 ' SD ' HD13 ' A' ' 240' ' ' ILE . 38.1 mtt -71.9 -39.28 69.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.0 -42.91 72.4 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.624 ' HA ' HD13 ' A' ' 255' ' ' ILE . 17.8 ptt180 -66.77 -40.46 88.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.468 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.75 -36.39 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 90.4 mt -76.38 -42.6 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.832 0.349 . . . . 0.0 111.15 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.583 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -85.47 -2.83 58.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.534 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -69.79 -58.35 5.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.629 0.728 . . . . 0.0 110.855 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.534 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 0.84 5.1 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.659 2.24 . . . . 0.0 112.347 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.831 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -101.55 -37.05 8.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -173.56 155.66 22.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 41.9 tttp -57.89 108.11 0.54 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.759 0.314 . . . . 0.0 110.891 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 258' ' ' ILE . 43.4 mt -78.11 112.49 16.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.096 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -76.76 -41.71 43.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -165.23 149.99 9.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.891 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 255' ' ' ILE . 48.8 mt -132.41 126.19 54.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.426 HG23 ' HB2' ' A' ' 274' ' ' PHE . 2.5 m -133.12 129.93 57.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.138 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 36.4 mt -91.2 137.7 32.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.496 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.2 mmt -93.82 112.23 24.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.847 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . 0.463 ' HD3' ' N ' ' A' ' 262' ' ' LYS . 0.0 OUTLIER -125.18 146.75 49.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.877 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -67.83 178.61 1.68 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.856 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 t -106.04 -48.26 3.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.83 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -62.34 -61.23 2.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 11.7 p -82.77 -31.3 28.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.134 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 60.01 14.36 31.15 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.474 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 -97.56 119.3 35.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 0.0 110.875 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 16.1 m -49.21 123.09 6.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.831 -179.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -74.36 -31.63 62.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.905 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 125.63 33.75 0.69 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.496 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 4.8 p90 -145.75 156.09 43.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.93 0.395 . . . . 0.0 110.944 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -158.06 176.17 35.13 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.466 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.426 ' HB2' HG23 ' A' ' 259' ' ' VAL . 22.3 m-85 -121.29 134.02 55.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.853 0.359 . . . . 0.0 110.836 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.421 HD12 ' CE2' ' A' ' 249' ' ' PHE . 97.3 mt -131.23 145.52 35.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.132 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.2 m -120.98 129.66 53.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.691 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.7 m-85 -104.24 175.9 5.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.899 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 3.1 t -120.19 24.87 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.898 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -165.13 127.61 2.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.862 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 80.5 p -64.05 -40.96 97.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.811 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.47 -43.02 82.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 43.6 m -63.22 -42.73 99.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.438 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.97 -42.44 97.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.049 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 21.4 mtm180 -60.14 -48.98 79.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.879 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 14.8 mmt85 -58.06 -47.73 82.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.841 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.831 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -58.03 -40.41 80.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.083 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.496 ' CD1' HG12 ' A' ' 302' ' ' VAL . 9.3 tp -61.66 -40.7 95.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -67.71 -35.0 77.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.938 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -84.11 -22.22 31.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.914 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.922 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.9 mt -86.54 -38.51 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . 0.409 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -60.02 119.98 8.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.891 179.893 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.53 20.82 78.2 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.507 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -84.78 105.13 15.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.807 0.337 . . . . 0.0 110.882 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -67.2 96.29 0.46 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.892 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 7.4 tt -91.12 -64.2 1.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.928 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -98.71 36.59 1.63 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 100.13 -35.22 4.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 40.6 mtp180 -113.68 154.11 45.77 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.626 0.727 . . . . 0.0 110.891 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 132.26 22.98 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.656 2.237 . . . . 0.0 112.345 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.9 ptp -83.44 165.89 18.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.875 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.8 122.74 47.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.832 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' A' ' 290' ' ' LEU . 47.7 t -131.41 135.44 59.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -153.06 163.58 30.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.534 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -71.97 112.34 7.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.482 HG23 ' CA ' ' A' ' 231' ' ' LEU . 64.5 t -46.26 97.46 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.119 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 14.9 m -95.99 141.59 29.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.162 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -118.84 -48.5 2.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 76.9 mtt180 -150.09 138.51 20.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.523 ' N ' ' CD2' ' A' ' 309' ' ' LEU . 0.3 OUTLIER -82.0 155.34 25.23 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -119.76 91.61 3.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -45.91 97.66 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.472 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -89.8 81.91 1.42 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.474 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 8.5 t -141.52 108.82 5.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.88 0.371 . . . . 0.0 110.858 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -159.21 64.79 0.29 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.481 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -176.83 1.61 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.686 2.257 . . . . 0.0 112.362 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 54.2 p -155.26 158.6 39.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.86 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . 0.422 ' O ' ' C ' ' A' ' 318' ' ' GLY . 84.0 p -85.55 88.36 7.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.879 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 317' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.523 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 87.4 p -144.0 175.22 10.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.872 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 73.2 m -146.45 132.04 18.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -47.58 109.56 0.46 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.481 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 52.5 p -68.17 143.26 55.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.87 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 10.0 t -82.41 161.87 22.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.869 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 159.4 109.76 0.27 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.481 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.842 HD12 ' CE1' ' A' ' 277' ' ' PHE . 38.3 mt -104.06 144.75 31.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 2.3 t80 -111.21 131.46 55.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.507 HG22 HD11 ' A' ' 236' ' ' LEU . 7.7 p -116.0 134.23 59.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.125 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.42 165.85 27.8 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 6.2 t 73.85 47.09 0.17 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.931 0.396 . . . . 0.0 110.882 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.507 HD11 HG22 ' A' ' 233' ' ' VAL . 15.0 mt -109.53 166.08 11.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.907 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -94.31 140.59 29.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -45.44 -37.07 4.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -57.88 -37.86 74.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.935 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 36.7 mm -47.59 139.04 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.159 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.4 t -125.29 174.34 8.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.099 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -62.3 -36.55 82.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -58.37 -34.64 70.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.902 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 63.3 mtt -70.49 -37.07 74.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 81.9 mt -69.82 -42.34 73.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.505 ' HA ' HD13 ' A' ' 255' ' ' ILE . 20.5 ptt85 -69.65 -40.21 76.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -66.41 -35.16 89.75 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.421 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.5 mt -81.04 -44.22 20.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.844 0.354 . . . . 0.0 111.148 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.69 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -81.83 -2.43 50.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.508 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.0 tp10 -70.65 -59.66 3.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.677 0.751 . . . . 0.0 110.931 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.6 3.37 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.333 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.834 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.8 m-85 -102.46 -44.17 5.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.903 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -171.21 139.03 5.22 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -44.61 119.0 1.74 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.744 0.307 . . . . 0.0 110.919 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.505 HD13 ' HA ' ' A' ' 246' ' ' ARG . 28.3 mt -88.85 133.31 31.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.149 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.27 -43.43 8.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -163.47 147.02 10.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 255' ' ' ILE . 61.1 mt -128.91 132.37 67.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 74.4 t -134.93 129.24 50.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.137 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 23.5 mt -94.01 129.55 40.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.961 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.616 ' CB ' ' CE2' ' A' ' 272' ' ' TYR . 20.3 mmt -91.88 135.26 34.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.95 149.96 51.28 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.909 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -50.63 -177.43 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 34.6 p -105.32 -58.15 1.93 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.818 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -62.71 -58.59 6.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 25.4 p -72.57 -41.36 65.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 73.63 18.45 79.47 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.498 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 4.3 ptt180 -98.01 162.35 13.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.86 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 15.5 m -78.21 100.83 6.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.821 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -58.99 -35.43 73.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.917 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.93 40.1 0.33 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.491 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.616 ' CE2' ' CB ' ' A' ' 261' ' ' MET . 0.9 OUTLIER -150.5 157.42 43.0 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.919 0.39 . . . . 0.0 110.935 -179.832 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -163.56 169.37 38.56 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -113.58 137.97 50.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.363 . . . . 0.0 110.874 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 77.3 mt -136.43 132.61 49.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 97.9 m -113.51 129.23 56.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.842 ' CE1' HD12 ' A' ' 231' ' ' LEU . 42.6 m-85 -98.96 171.27 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.886 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 48.1 t -86.88 -40.08 15.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -116.2 141.13 48.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.833 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 40.6 p -63.99 -41.01 97.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.423 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 13.3 pt-20 -60.97 -43.97 98.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . 0.423 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 73.9 m -60.01 -40.96 91.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.585 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -64.55 -37.84 88.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . 0.418 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 12.4 ttm105 -62.01 -48.73 79.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.6 mmt180 -58.02 -49.8 75.6 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.834 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.99 -35.54 71.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.091 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.431 HD22 ' CD2' ' A' ' 304' ' ' HIS . 8.4 tp -65.09 -40.83 95.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -68.34 -42.96 78.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -71.91 -38.2 69.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.854 ' HB3' HG21 ' A' ' 302' ' ' VAL . 82.4 mt -73.15 -47.03 47.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -44.47 107.29 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 77.82 39.3 24.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.462 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' LEU . 14.7 t80 -101.32 97.78 8.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.816 0.341 . . . . 0.0 110.871 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -43.96 93.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 293' ' ' PHE . 61.8 tp -81.03 -56.95 3.76 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -129.12 73.13 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.07 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 82.45 -35.53 2.63 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -125.77 154.85 73.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.579 0.705 . . . . 0.0 110.898 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 136.67 33.68 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.719 2.28 . . . . 0.0 112.336 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . 0.596 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.3 ptt? -86.68 166.66 15.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 4.2 mmm180 -101.75 128.59 48.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' A' ' 290' ' ' LEU . 9.8 t -131.88 128.92 60.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -157.7 158.8 29.36 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.431 ' CD2' HD22 ' A' ' 287' ' ' LEU . 4.5 m170 -77.73 124.51 28.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 306' ' ' THR . 15.3 m -53.29 -47.76 56.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.141 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . 0.473 ' N ' HG23 ' A' ' 305' ' ' VAL . 23.8 m -113.72 141.12 47.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.106 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -159.45 149.23 18.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 13.5 mtp85 -91.42 -57.46 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.866 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.559 HD13 ' N ' ' A' ' 310' ' ' ASP . 0.4 OUTLIER -138.66 127.07 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.951 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . 0.559 ' N ' HD13 ' A' ' 309' ' ' LEU . 2.9 p30 -50.15 121.05 5.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.864 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 134.35 -77.47 0.37 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.485 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 68.47 143.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.484 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 80.8 p -123.85 169.64 11.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.946 0.403 . . . . 0.0 110.82 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -78.89 141.19 24.08 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 2.47 3.47 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.654 2.236 . . . . 0.0 112.39 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.8 m 63.89 34.76 11.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 3.0 t -53.97 -53.43 52.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.48 -179.986 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 8.5 t 49.6 42.95 23.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 0.0 110.86 -179.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 4.2 m -77.49 140.67 39.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -171.31 173.01 44.77 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.464 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 34.6 m -74.56 150.51 39.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 96.7 p -106.96 94.25 5.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.871 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -133.87 133.6 7.0 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.475 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.434 HD12 ' CE1' ' A' ' 277' ' ' PHE . 35.0 mt -115.1 145.62 42.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.848 0.356 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.573 ' HB2' HG22 ' A' ' 305' ' ' VAL . 1.5 t80 -111.53 133.69 53.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.921 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 13.1 p -118.64 135.35 59.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.141 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.61 163.56 27.89 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 m 74.39 46.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.905 0.384 . . . . 0.0 110.81 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 14.4 mt -108.98 170.19 8.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.408 ' O ' ' C ' ' A' ' 238' ' ' PHE . 13.7 t-80 -98.89 137.95 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.41 ' O ' ' C ' ' A' ' 239' ' ' ASN . 5.2 m-85 -37.82 -57.02 1.04 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 241' ' ' THR . 45.9 t30 -37.58 -42.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.901 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.7 mm -47.21 130.1 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.135 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.463 HG23 ' O ' ' A' ' 239' ' ' ASN . 79.4 p -123.04 -175.63 3.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.145 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -62.38 -41.77 98.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -59.45 -29.75 68.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 20.0 mmt -71.87 -44.52 63.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.465 HD22 HD11 ' A' ' 275' ' ' ILE . 34.7 mt -68.25 -43.04 78.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.503 ' O ' ' N ' ' A' ' 250' ' ' GLU . 5.6 ptp180 -66.35 -44.55 82.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.499 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -61.08 -39.49 97.18 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.475 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 96.9 mt -76.17 -41.37 37.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.868 0.366 . . . . 0.0 111.147 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.762 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.0 m-85 -86.42 -5.55 59.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.541 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 1.0 OUTLIER -67.36 -58.05 9.49 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.683 0.754 . . . . 0.0 110.894 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.541 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.6 Cg_endo -69.72 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.856 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.7 m-85 -104.77 -25.32 12.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.88 159.04 15.91 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.53 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 32.0 tttp -62.22 117.82 6.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.724 0.297 . . . . 0.0 110.91 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.645 HD13 HD11 ' A' ' 258' ' ' ILE . 70.3 mt -90.99 114.06 27.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -69.77 -42.99 73.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.854 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -167.96 153.55 7.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.922 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.645 HD11 HD13 ' A' ' 255' ' ' ILE . 87.6 mt -132.94 128.43 56.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 75.8 t -127.42 129.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.093 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 35.9 mt -96.6 135.82 37.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.549 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 35.2 mmm -96.09 133.0 40.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.893 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.83 152.21 51.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -66.35 170.49 5.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.857 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 60.7 p -103.78 -41.01 6.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.819 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -61.2 -41.97 97.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.909 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 267' ' ' GLY . 2.2 p -111.94 -58.61 2.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.143 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 266' ' ' THR . . . 99.03 18.46 24.57 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.547 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 89.2 mmt-85 -95.64 113.4 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.804 0.335 . . . . 0.0 110.83 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 1.8 m -41.34 107.87 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 33.4 mmtt -60.05 -39.31 85.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.943 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 133.12 38.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.482 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.549 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.4 p90 -149.38 160.32 43.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.914 -179.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.52 171.65 42.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.508 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -113.31 139.28 48.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.802 0.334 . . . . 0.0 110.887 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.465 HD11 HD22 ' A' ' 245' ' ' LEU . 54.1 mt -135.95 139.38 46.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.167 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 85.8 m -119.09 122.26 41.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.184 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.434 ' CE1' HD12 ' A' ' 231' ' ' LEU . 36.3 m-85 -91.08 -177.14 4.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.5 t -104.56 -22.14 13.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -133.62 134.94 43.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.8 p -61.7 -36.99 82.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -63.57 -44.0 95.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.875 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 89.4 m -61.94 -40.04 94.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -64.16 -41.7 97.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.079 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 11.8 mmt85 -60.0 -49.06 79.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.821 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 87.5 mtt-85 -58.31 -50.6 73.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.885 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.856 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.55 -39.45 73.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.063 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.517 HD22 ' CD2' ' A' ' 304' ' ' HIS . 13.2 tp -62.08 -40.09 94.65 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -67.32 -34.96 78.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.895 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -84.6 -25.86 28.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.92 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.763 ' HB3' HG21 ' A' ' 302' ' ' VAL . 66.9 mt -81.87 -41.48 20.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . 0.435 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.6 OUTLIER -59.55 117.62 5.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.03 27.32 58.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.472 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -95.61 103.35 15.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.854 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -56.97 97.92 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.925 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 6.6 tt -87.57 -54.31 4.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.04 55.01 1.01 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.85 -37.23 3.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -117.03 156.46 48.29 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.622 0.725 . . . . 0.0 110.864 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.56 40.44 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . 0.549 ' CE ' HD22 ' A' ' 290' ' ' LEU . 2.0 ptt? -91.25 162.8 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.874 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 26.7 mmt180 -99.71 122.06 42.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.763 HG21 ' HB3' ' A' ' 290' ' ' LEU . 5.1 t -129.26 128.77 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -151.19 162.09 29.35 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.484 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.517 ' CD2' HD22 ' A' ' 287' ' ' LEU . 7.0 m170 -75.51 123.32 25.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.826 0.346 . . . . 0.0 110.887 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.573 HG22 ' HB2' ' A' ' 232' ' ' TYR . 87.1 t -52.32 94.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 81.3 p -72.67 135.71 45.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.159 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -109.33 118.31 36.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 10.6 ttm-85 -110.61 110.29 20.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.849 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.515 HD23 ' N ' ' A' ' 309' ' ' LEU . 1.0 OUTLIER -157.97 173.47 16.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 -179.937 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.68 119.64 32.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 139.43 115.1 1.24 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.448 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -82.58 106.09 2.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.458 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 78.5 p -65.89 -48.78 70.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.851 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -79.95 146.32 28.03 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.516 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 94.45 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.7 2.267 . . . . 0.0 112.362 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 317' ' ' SER . 40.6 m -165.79 170.73 13.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.893 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 316' ' ' SER . 93.0 p -37.43 139.49 0.26 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.489 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.511 -0.235 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 48.9 m -119.27 124.43 46.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.879 0.371 . . . . 0.0 110.825 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 53.1 p -59.87 175.48 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.854 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 175.29 85.17 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.479 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 2.1 m -84.84 115.61 22.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.886 0.374 . . . . 0.0 110.835 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 39.2 p 44.36 40.62 3.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -68.97 154.34 53.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.498 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.843 HD12 ' CE1' ' A' ' 277' ' ' PHE . 33.4 mt -133.83 144.07 48.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.508 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.0 OUTLIER -113.08 139.1 48.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.903 -179.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.449 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.9 p -127.42 134.69 65.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.106 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.39 166.02 27.33 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.501 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 73.71 46.15 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.896 0.379 . . . . 0.0 110.842 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 233' ' ' VAL . 65.2 mt -108.5 174.55 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.945 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.426 ' CE1' ' CZ ' ' A' ' 238' ' ' PHE . 4.5 t-80 -94.66 126.42 39.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.825 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.426 ' CZ ' ' CE1' ' A' ' 237' ' ' HIS . 5.8 p90 -39.35 -50.28 2.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.864 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -43.53 -49.42 7.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.872 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 45.1 mm -38.73 139.59 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.119 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 30.8 p -120.09 175.15 6.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.156 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -61.12 -31.01 70.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . 0.454 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 2.2 m-20 -63.37 -35.84 81.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 8.2 mmt -72.08 -39.28 69.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.59 ' CD1' HD21 ' A' ' 260' ' ' LEU . 54.6 mt -68.23 -39.87 82.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.92 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.487 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 3.8 ptm180 -70.48 -37.31 74.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.487 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -68.45 -35.35 81.52 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.492 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.428 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 93.7 mt -77.5 -42.41 29.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.899 0.381 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.602 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -83.86 -4.12 58.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.869 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.8 OUTLIER -69.7 -58.29 5.76 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.637 0.732 . . . . 0.0 110.897 -179.901 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.3 Cg_endo -69.8 2.78 3.24 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.671 2.247 . . . . 0.0 112.34 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.78 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.96 -35.55 8.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -177.57 159.84 26.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.514 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 16.6 ttmt -60.24 120.15 9.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.732 HG21 HD11 ' A' ' 258' ' ' ILE . 64.5 mt -90.74 113.78 27.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.117 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' A' ' 256' ' ' ASP . 31.1 t0 -77.2 -40.61 44.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.826 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 25.8 t30 -168.33 147.76 4.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.89 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.732 HD11 HG21 ' A' ' 255' ' ' ILE . 53.3 mt -129.36 132.83 66.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.09 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.485 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.5 m -134.07 138.43 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.164 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.59 HD21 ' CD1' ' A' ' 245' ' ' LEU . 20.2 mt -104.16 132.6 50.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 272' ' ' TYR . 26.3 mmt -90.8 121.08 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.901 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.27 142.44 51.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -68.2 179.03 1.68 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.842 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 30.4 t -112.82 -53.33 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.832 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -61.94 -41.6 98.16 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.915 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 76.3 p -94.34 -42.07 9.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 67.47 24.15 73.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.445 ' O ' ' C ' ' A' ' 269' ' ' SER . 57.7 mtp180 -115.17 103.49 10.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.861 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.7 OUTLIER -34.62 108.93 0.07 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.773 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 22.6 mmtp -53.52 -42.39 67.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.901 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 130.99 35.93 0.37 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.481 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 261' ' ' MET . 2.6 p90 -145.06 161.8 38.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.936 0.398 . . . . 0.0 110.907 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.72 171.55 37.7 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.477 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.485 ' HB2' HG23 ' A' ' 259' ' ' VAL . 16.2 m-85 -118.86 136.76 53.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.859 0.362 . . . . 0.0 110.873 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.421 HG12 HG23 ' A' ' 258' ' ' ILE . 89.3 mt -135.73 138.7 47.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.134 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 61.0 m -113.03 128.77 56.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.843 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.1 m-85 -101.98 170.45 8.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.93 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 14.6 t -115.79 33.15 5.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -172.58 124.97 0.48 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 23.0 t -62.74 -40.52 97.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -66.8 -43.71 83.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.86 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 51.9 m -64.36 -42.58 96.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.913 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -62.74 -44.03 97.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.165 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -59.31 -48.56 81.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.87 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -57.96 -51.17 70.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.78 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -54.96 -39.62 69.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.098 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.645 HD22 ' CE1' ' A' ' 304' ' ' HIS . 11.7 tp -63.33 -39.99 96.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -68.49 -34.95 76.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 49.4 mm-40 -83.97 -26.77 28.96 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.771 ' HB3' HG21 ' A' ' 302' ' ' VAL . 62.2 mt -81.4 -47.02 13.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.897 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . 0.456 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.7 OUTLIER -53.07 114.71 1.54 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 78.18 34.99 35.39 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.488 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 17.4 t80 -105.04 122.53 46.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.861 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -77.17 112.02 13.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 40.7 tp -93.99 -60.47 1.74 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.964 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -102.93 -21.81 13.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.088 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 169.95 -33.94 0.17 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.79 152.5 45.63 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.67 0.747 . . . . 0.0 110.859 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 120.43 7.21 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.668 2.246 . . . . 0.0 112.344 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . 0.643 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.8 ptt? -72.41 168.54 18.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 41.7 mmt-85 -111.91 125.0 53.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 290' ' ' LEU . 57.8 t -131.37 129.62 62.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.63 163.01 26.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.645 ' CE1' HD22 ' A' ' 287' ' ' LEU . 20.3 m170 -75.21 98.38 3.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 0.0 110.857 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 5.8 p -40.18 -28.87 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.147 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 49.8 p -77.24 120.36 22.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -104.29 140.57 37.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 56.5 mtt180 -113.79 132.23 55.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 7.0 mp -123.51 121.55 35.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.913 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.66 141.25 37.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -132.92 104.79 0.56 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.494 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 176.69 120.65 0.63 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.491 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.0 t -83.12 160.96 21.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.911 0.386 . . . . 0.0 110.859 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -143.59 78.46 0.26 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.494 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.71 127.5 14.73 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.8 t -98.31 136.8 37.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.838 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 23.5 m -88.51 156.73 18.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.834 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.462 -179.984 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 N-CA-C 112.45 -0.26 . . . . 0.0 112.45 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 3.2 m -41.71 108.6 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.927 0.394 . . . . 0.0 110.857 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 36.6 t -115.05 127.96 55.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 61.6 -106.73 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 73.0 m -142.52 -179.77 6.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.898 0.38 . . . . 0.0 110.841 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 95.8 p -107.16 85.49 2.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.817 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -104.9 143.24 15.62 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.466 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.539 HD12 ' CE2' ' A' ' 277' ' ' PHE . 20.6 mt -128.29 146.97 50.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.92 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.683 ' HB2' HG12 ' A' ' 305' ' ' VAL . 1.7 t80 -114.39 136.53 52.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.604 ' CG2' HD11 ' A' ' 236' ' ' LEU . 7.4 p -121.12 134.53 64.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.099 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.47 165.05 27.97 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 3.8 t 74.58 46.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.933 0.397 . . . . 0.0 110.875 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.604 HD11 ' CG2' ' A' ' 233' ' ' VAL . 85.8 mt -111.49 170.69 7.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.934 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 18.4 t-80 -88.82 147.28 24.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.412 ' O ' ' C ' ' A' ' 239' ' ' ASN . 2.9 m-85 -52.91 -59.76 4.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.412 ' C ' ' O ' ' A' ' 238' ' ' PHE . 1.0 OUTLIER -36.17 -47.32 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 23.5 mm -38.42 136.7 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 7.8 t -123.03 179.55 4.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.158 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 45.7 mp0 -63.05 -35.23 79.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -58.78 -38.51 78.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.4 mmt -64.68 -45.98 84.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.529 ' HB3' HD11 ' A' ' 275' ' ' ILE . 56.0 mt -59.98 -39.24 85.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.536 ' HA ' HD13 ' A' ' 255' ' ' ILE . 0.0 OUTLIER -72.05 -40.8 68.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.46 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.91 -29.6 74.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.519 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.42 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 79.0 mt -87.51 -43.53 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.869 0.366 . . . . 0.0 111.096 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.557 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 2.7 m-85 -85.17 -0.11 53.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.502 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 4.0 tt0 -68.99 -59.88 4.87 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.652 0.739 . . . . 0.0 110.917 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.502 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.4 Cg_endo -69.7 -9.45 26.15 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.256 . . . . 0.0 112.388 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 248' ' ' ILE . 9.7 m-85 -88.78 -24.8 22.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.01 164.43 25.72 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.514 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -68.3 108.84 3.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.857 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.74 HG21 HD11 ' A' ' 258' ' ' ILE . 19.4 mt -77.23 113.63 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.094 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.5 t0 -72.19 -45.2 61.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.921 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -163.32 157.68 20.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.74 HD11 HG21 ' A' ' 255' ' ' ILE . 71.6 mt -138.6 131.85 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.129 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.771 HG23 ' HB2' ' A' ' 274' ' ' PHE . 3.8 m -134.79 126.6 47.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.486 HD21 HD11 ' A' ' 245' ' ' LEU . 20.7 mt -93.58 129.33 39.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.936 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.574 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 17.8 mmm -89.85 128.49 36.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.85 165.42 18.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -85.57 170.21 12.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 27.4 p -106.54 -42.63 4.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.872 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.9 -46.62 71.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 36.3 p -93.95 -41.73 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.164 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 74.58 24.83 71.61 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.513 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 61.0 mtp180 -119.95 114.23 21.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.787 0.327 . . . . 0.0 110.927 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 24.9 m -38.94 112.06 0.22 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.86 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -58.91 -50.3 74.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.888 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 145.72 40.32 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.506 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.574 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.3 p90 -150.36 162.21 40.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.951 0.405 . . . . 0.0 110.944 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -161.59 177.32 37.92 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.5 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.771 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.1 m-85 -120.1 133.99 55.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.774 0.321 . . . . 0.0 110.925 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.529 HD11 ' HB3' ' A' ' 245' ' ' LEU . 67.9 mt -133.08 135.93 56.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.144 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 64.5 m -117.51 129.3 55.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.539 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.6 m-85 -100.68 178.74 4.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.843 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.6 t -114.98 12.84 16.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.858 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -155.66 128.5 8.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.851 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.4 t -64.0 -40.98 97.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 35.6 mm-40 -62.26 -43.93 97.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.897 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 98.7 m -64.51 -36.19 83.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.832 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -65.53 -43.7 89.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.087 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -61.11 -49.09 78.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 71.5 mtt180 -59.49 -44.32 93.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.407 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -62.61 -35.06 78.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.126 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.607 HD12 HG12 ' A' ' 302' ' ' VAL . 17.6 tp -64.74 -44.66 89.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.894 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -69.18 -35.02 75.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -73.59 -42.0 62.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.926 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.823 ' HB3' HG21 ' A' ' 302' ' ' VAL . 42.0 mt -75.25 -47.04 29.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.876 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t30 -42.14 106.25 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.917 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.65 34.59 31.05 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -96.07 102.02 13.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.821 0.344 . . . . 0.0 110.891 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 79.1 mt-10 -56.22 90.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.909 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 25.6 tp -80.18 -58.53 3.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.76 40.34 2.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.53 -26.98 21.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 3.5 ptp85 -120.08 147.34 44.4 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.859 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 122.33 9.01 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.674 2.249 . . . . 0.0 112.328 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -75.36 177.31 6.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 11.5 mmm-85 -110.85 122.68 48.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.823 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.0 t -128.99 123.51 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.113 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -156.47 161.25 30.78 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.444 ' CD2' HD22 ' A' ' 287' ' ' LEU . 90.4 m-70 -72.68 128.27 35.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.855 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 232' ' ' TYR . 21.5 m -59.5 -43.33 90.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . 0.436 ' N ' HG23 ' A' ' 305' ' ' VAL . 10.5 t -78.52 131.18 36.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -52.29 125.66 16.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.405 ' HD2' ' C ' ' A' ' 308' ' ' ARG . 3.4 ppt_? -91.33 1.07 57.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.899 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 29.7 tp -57.76 -58.81 6.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.907 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.6 p30 -94.11 137.73 32.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.892 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 115.93 88.87 1.5 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.468 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 116.66 163.28 13.2 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.476 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 88.7 p -147.5 157.21 43.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.93 0.395 . . . . 0.0 110.864 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -116.45 179.53 17.73 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.468 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 172.94 11.68 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.652 2.235 . . . . 0.0 112.38 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 6.6 t -119.23 135.79 54.52 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.837 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 87.9 p -131.23 152.74 50.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.881 -179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.986 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 49.3 m -116.88 102.88 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 110.851 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 32.2 m -127.51 163.65 23.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.868 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -47.58 114.32 1.68 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.501 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 21.3 t -86.09 60.62 6.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 110.889 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 4.8 t -72.41 121.48 19.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -168.41 131.19 2.25 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.456 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.97 HD12 ' CE1' ' A' ' 277' ' ' PHE . 34.3 mt -118.6 146.83 44.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.806 0.336 . . . . 0.0 110.929 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.581 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.4 OUTLIER -118.6 141.3 48.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.915 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.64 ' CG2' HD11 ' A' ' 236' ' ' LEU . 12.0 p -123.08 131.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.14 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -136.91 165.9 25.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 58.5 m 62.54 49.87 3.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.884 0.373 . . . . 0.0 110.822 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.64 HD11 ' CG2' ' A' ' 233' ' ' VAL . 61.8 mt -103.67 -175.13 2.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.88 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 16.8 t-80 -110.39 142.31 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.836 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.474 ' CD1' ' HD2' ' A' ' 268' ' ' ARG . 3.2 t80 -49.47 -44.31 45.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.85 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -52.44 -33.74 45.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 10.5 mm -57.21 125.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.144 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.1 p -117.28 178.64 4.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.162 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -60.83 -36.67 79.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . 0.443 ' HA ' ' CD ' ' A' ' 246' ' ' ARG . 6.9 t0 -60.88 -34.37 74.53 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.807 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 21.6 mtt -72.05 -42.71 65.97 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.878 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 63.1 mt -66.8 -42.97 85.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.939 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.448 ' HG2' ' N ' ' A' ' 247' ' ' GLY . 4.0 ptm180 -66.38 -38.74 88.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.866 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.448 ' N ' ' HG2' ' A' ' 246' ' ' ARG . . . -66.45 -36.82 92.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.498 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 86.8 mt -78.56 -43.91 26.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.912 0.387 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.4 m-85 -81.75 -4.72 57.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.924 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.501 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.5 OUTLIER -66.55 -60.13 7.06 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.677 0.751 . . . . 0.0 110.897 -179.908 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.8 Cg_endo -69.73 2.34 3.61 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.706 2.271 . . . . 0.0 112.321 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.824 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.3 m-85 -103.39 -23.33 13.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.881 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 168.35 158.98 13.02 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.466 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.47 117.58 7.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.768 0.318 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.68 HD13 HD11 ' A' ' 258' ' ' ILE . 45.4 mt -86.33 120.89 36.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.103 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -79.51 -41.23 27.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.851 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 38.4 t30 -167.7 145.78 4.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.852 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.68 HD11 HD13 ' A' ' 255' ' ' ILE . 93.9 mt -128.44 127.88 67.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.105 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.635 HG23 ' HB2' ' A' ' 274' ' ' PHE . 18.3 m -129.51 139.15 52.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.096 179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 28.9 mt -111.41 139.49 46.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.572 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 29.8 mmt -97.78 120.34 37.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.91 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.53 131.06 39.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.926 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -51.5 -175.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.881 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 31.0 t -114.81 -66.12 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 -179.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -49.55 -40.84 39.63 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.893 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 18.1 p -91.62 -44.81 8.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 77.47 8.44 87.1 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.474 ' HD2' ' CD1' ' A' ' 238' ' ' PHE . 3.0 tpt180 -103.61 112.75 25.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.344 . . . . 0.0 110.877 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.403 ' C ' ' O ' ' A' ' 268' ' ' ARG . 0.7 OUTLIER -37.37 132.31 0.8 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.88 -179.856 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.09 -36.07 82.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.858 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 127.92 29.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.506 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.572 ' CE1' ' HB2' ' A' ' 261' ' ' MET . 2.1 p90 -151.01 165.18 34.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.926 0.393 . . . . 0.0 110.94 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -157.89 168.01 34.37 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.492 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.635 ' HB2' HG23 ' A' ' 259' ' ' VAL . 29.0 m-85 -114.44 137.79 51.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.864 0.364 . . . . 0.0 110.872 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 85.1 mt -137.24 134.45 47.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.6 m -117.76 129.18 55.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.191 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.97 ' CE1' HD12 ' A' ' 231' ' ' LEU . 45.4 m-85 -99.28 177.97 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.859 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 62.6 p -98.8 -36.28 9.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.819 -179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -115.97 129.19 56.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 32.8 p -57.48 -37.98 73.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.419 ' HG3' ' N ' ' A' ' 282' ' ' CYS . 11.1 pt-20 -62.32 -43.35 99.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.904 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . 0.419 ' N ' ' HG3' ' A' ' 281' ' ' GLU . 68.1 m -62.25 -37.49 85.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -66.02 -40.17 90.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 47.6 ttt85 -62.08 -48.94 77.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.862 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 25.8 mmt180 -58.66 -51.02 71.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.57 -35.07 69.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.7 HD12 HG12 ' A' ' 302' ' ' VAL . 10.7 tp -65.06 -41.96 94.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -68.99 -42.91 75.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.943 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 10.0 mm100 -71.98 -36.03 69.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.664 ' HB3' HG21 ' A' ' 302' ' ' VAL . 54.9 mt -75.3 -46.95 30.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.892 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -42.0 112.41 0.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.905 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 73.96 40.16 44.45 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 23.9 t80 -100.93 98.05 8.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.824 0.345 . . . . 0.0 110.861 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.19 105.83 0.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 5.7 tt -94.82 -53.68 3.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.926 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -112.14 40.64 2.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.2 -35.21 4.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.491 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 -110.23 149.1 39.66 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.576 0.703 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 119.16 6.15 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.724 2.283 . . . . 0.0 112.325 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.1 ptm -71.07 171.55 10.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -106.92 125.17 50.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.913 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.7 HG12 HD12 ' A' ' 287' ' ' LEU . 7.0 t -128.5 121.5 55.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.097 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.69 163.49 28.54 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.503 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.478 ' CE1' HD22 ' A' ' 287' ' ' LEU . 18.5 m170 -79.24 130.37 35.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.885 0.374 . . . . 0.0 110.82 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 83.9 t -53.4 -63.4 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.134 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 12.4 t -46.0 151.68 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -122.71 112.93 18.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.858 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.417 ' HD3' ' C ' ' A' ' 308' ' ' ARG . 0.4 OUTLIER -95.23 173.07 7.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.893 -179.957 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 1.7 tt -128.43 121.67 29.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.889 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -54.22 179.78 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.854 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 148.0 150.56 5.23 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -162.13 41.96 0.37 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.504 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 14.7 m -79.76 158.34 26.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.957 0.408 . . . . 0.0 110.819 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -147.27 -100.88 0.26 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 108.56 2.1 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.697 2.265 . . . . 0.0 112.313 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 5.2 m -73.2 -50.56 21.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.895 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 2.1 m -75.63 91.59 2.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.812 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.488 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 51.8 p -103.12 155.83 18.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.872 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 59.7 p -90.52 -45.89 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.853 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -66.96 133.41 31.55 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.471 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 19.8 m -126.34 120.57 30.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.932 0.396 . . . . 0.0 110.795 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 23.1 t -132.1 -178.77 5.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 140.08 131.25 2.75 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.514 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.465 HD11 ' O ' ' A' ' 283' ' ' ALA . 37.0 mt -129.96 147.04 51.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.834 0.349 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.492 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.4 t80 -110.13 131.81 54.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.74 136.46 55.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.18 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.56 165.47 27.53 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.448 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.5 t 74.28 46.81 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.9 0.381 . . . . 0.0 110.85 -179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.37 170.7 7.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 238' ' ' PHE . 31.4 t-80 -98.65 132.16 44.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.437 ' C ' ' O ' ' A' ' 237' ' ' HIS . 0.9 OUTLIER -34.46 -61.07 0.4 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.878 -179.91 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.533 ' ND2' ' N ' ' A' ' 240' ' ' ILE . 0.3 OUTLIER -36.95 -47.27 0.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.941 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.533 ' N ' ' ND2' ' A' ' 239' ' ' ASN . 40.3 mm -36.74 128.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.181 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 38.0 p -118.44 175.57 5.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -60.61 -31.07 70.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.844 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -64.89 -32.45 74.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.834 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 13.5 mmt -71.74 -40.88 69.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.476 ' CD1' HD21 ' A' ' 260' ' ' LEU . 45.1 mt -69.35 -43.0 74.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.956 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.436 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 6.2 ptm180 -66.02 -40.11 90.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.859 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -66.48 -38.25 93.32 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.507 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.422 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 95.0 mt -77.27 -41.84 30.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.902 0.382 . . . . 0.0 111.131 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.591 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.1 m-85 -83.74 -3.88 58.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.847 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.535 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.94 -58.34 5.42 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.654 0.74 . . . . 0.0 110.853 -179.932 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.7 Cg_endo -69.74 2.74 3.25 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.734 2.289 . . . . 0.0 112.347 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.816 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.1 m-85 -103.62 -33.11 9.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.931 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 175.67 138.66 2.88 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.449 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -45.64 116.64 1.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.769 0.319 . . . . 0.0 110.924 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 246' ' ' ARG . 55.5 mt -85.3 134.7 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.12 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -91.38 -46.47 8.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.874 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 33.8 t30 -160.92 145.82 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.863 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 63.1 mt -124.14 133.1 70.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.151 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 89.4 t -131.86 125.78 55.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.13 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.476 HD21 ' CD1' ' A' ' 245' ' ' LEU . 26.2 mt -96.93 131.32 43.83 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.53 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.7 mmt -90.54 140.92 29.28 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.894 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . 0.432 ' HD2' ' C ' ' A' ' 261' ' ' MET . 0.0 OUTLIER -140.44 135.13 31.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.946 179.939 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -51.6 176.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 37.5 p -106.42 -58.8 1.88 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.899 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -55.79 -58.81 6.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.865 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 63.1 p -78.78 -39.69 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.131 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 71.77 14.7 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -100.95 134.56 43.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.859 0.361 . . . . 0.0 110.869 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 1.5 p -50.18 111.59 0.55 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.85 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.49 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 1.1 mmmp? -69.34 -28.54 66.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.905 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 114.4 40.5 0.94 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.497 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.53 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 1.1 p90 -151.0 153.72 35.7 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 0.0 110.934 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.01 175.36 40.15 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -117.79 140.29 49.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.939 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.437 HD11 ' HB3' ' A' ' 245' ' ' LEU . 90.6 mt -138.25 128.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 83.5 m -110.02 130.0 55.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.158 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.444 ' CE1' HD12 ' A' ' 231' ' ' LEU . 32.7 m-85 -96.37 179.51 5.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.894 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 27.8 t -92.03 -42.73 9.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.83 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.41 ' CG ' ' HG2' ' A' ' 281' ' ' GLU . 10.9 t0 -114.1 139.35 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 3.7 m -60.75 -39.74 89.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.41 ' HG2' ' CG ' ' A' ' 279' ' ' ASP . 11.6 pt-20 -61.62 -43.73 98.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.868 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 87.9 m -60.13 -38.93 84.55 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.465 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -65.37 -40.93 94.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -60.1 -48.31 82.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 47.7 mmt-85 -58.25 -51.01 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.816 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.24 -35.54 69.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.593 HD12 HG12 ' A' ' 302' ' ' VAL . 12.4 tp -65.01 -40.55 95.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.902 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -68.41 -42.63 78.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.855 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 24.7 mm-40 -71.88 -38.99 69.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.997 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.8 mt -72.62 -45.87 56.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.924 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -47.81 108.07 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.833 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.46 36.11 27.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.474 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 48.7 t80 -100.45 121.64 41.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.832 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -73.68 96.64 2.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 42.5 tp -88.52 -47.83 8.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.927 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -121.9 43.57 2.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.133 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 93.78 -25.17 22.73 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.507 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 55.2 mtp180 -122.94 148.69 54.75 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.605 0.717 . . . . 0.0 110.844 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 121.17 7.85 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.635 2.223 . . . . 0.0 112.357 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.0 ptp -74.46 171.8 13.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.88 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.2 mmm180 -108.8 123.51 49.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.997 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.4 t -129.46 126.6 63.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.126 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -147.78 158.97 27.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . . . . . . . . . 6.3 m170 -71.65 120.58 17.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.812 0.339 . . . . 0.0 110.873 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . . . . . . . . . 96.4 t -42.87 -55.59 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 90.3 m -140.77 115.7 9.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . 0.608 ' OE2' HD23 ' A' ' 309' ' ' LEU . 0.0 OUTLIER -101.17 79.62 2.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.835 -179.95 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.428 ' HB2' ' NH1' ' A' ' 308' ' ' ARG . 0.5 OUTLIER -100.13 100.88 11.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.944 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.615 ' C ' HD12 ' A' ' 309' ' ' LEU . 1.4 pp -119.93 140.3 51.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -128.97 98.39 4.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . 58.73 -113.07 4.6 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.516 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -84.91 113.02 3.72 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . 0.414 ' HB2' ' CB ' ' A' ' 317' ' ' SER . 3.9 m -47.37 -64.75 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.889 0.376 . . . . 0.0 110.877 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -164.24 -162.89 16.04 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.488 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -0.02 6.27 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.736 2.291 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 4.0 t -118.37 -43.93 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 -179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . 0.414 ' CB ' ' HB2' ' A' ' 313' ' ' SER . 2.6 m -102.57 108.37 19.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.898 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.999 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 83.7 p -162.28 153.81 18.31 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.86 0.362 . . . . 0.0 110.853 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.5 p -66.11 95.48 0.28 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.889 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -74.84 -98.31 0.11 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 10.3 t -130.44 161.41 31.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 110.864 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 76.7 p -96.64 79.6 3.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -126.21 144.59 15.2 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.694 HD12 ' CE1' ' A' ' 277' ' ' PHE . 40.2 mt -122.18 144.82 48.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.358 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -109.52 141.97 41.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.948 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.92 135.75 63.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -142.59 166.06 26.61 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.8 m 64.03 49.82 2.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.892 0.377 . . . . 0.0 110.878 -179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . . . . . . . . . 96.4 mt -103.06 -179.02 3.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.417 ' O ' ' C ' ' A' ' 238' ' ' PHE . 11.2 t-80 -109.85 133.11 53.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.883 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.528 ' CD1' ' O ' ' A' ' 269' ' ' SER . 71.7 m-85 -37.38 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.86 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.448 ' ND2' ' C ' ' A' ' 239' ' ' ASN . 0.2 OUTLIER -35.8 -40.86 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.908 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 37.4 mm -49.07 146.11 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 239' ' ' ASN . 12.6 p -143.2 -179.86 6.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.171 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -60.52 -35.82 76.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.882 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.23 -41.23 88.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 19.3 mtt -69.28 -44.92 70.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.883 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.464 HD22 HD11 ' A' ' 275' ' ' ILE . 47.4 mt -60.25 -36.38 77.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.486 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.05 -39.73 68.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.953 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.482 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -62.65 -36.34 93.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.438 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.612 ' CG2' HD21 ' A' ' 290' ' ' LEU . 95.4 mt -81.78 -44.1 20.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.871 0.367 . . . . 0.0 111.103 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.628 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.3 m-85 -79.07 -8.08 58.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.525 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.1 tp10 -67.96 -58.78 7.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.68 0.752 . . . . 0.0 110.91 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.525 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.78 1.88 4.05 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.779 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.9 m-85 -103.0 -34.45 8.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -179.41 158.03 21.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 2.4 ttmp? -64.73 101.53 0.48 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.745 0.307 . . . . 0.0 110.932 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 38.4 mt -69.36 125.65 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.162 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -83.03 -42.53 17.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.823 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -168.82 146.77 3.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . . . . . . . . . 95.9 mt -123.08 133.79 68.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.144 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.517 HG23 ' HB2' ' A' ' 274' ' ' PHE . 7.1 m -133.92 124.59 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 29.5 mt -92.04 138.05 31.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.562 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 10.5 mmm -102.63 122.36 44.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 262' ' ' LYS . 1.0 OUTLIER -131.88 150.9 52.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.886 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 13.1 t0 -69.54 169.31 12.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.846 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 31.0 t -105.2 -31.76 8.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.905 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -65.94 -63.13 1.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.825 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 15.4 p -86.42 -39.6 16.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.098 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 76.89 28.15 59.34 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 31.8 mmt180 -110.26 132.27 54.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 0.0 110.897 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.528 ' O ' ' CD1' ' A' ' 238' ' ' PHE . 1.6 m -61.26 92.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.885 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 24.0 mttm -46.14 -42.17 13.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 131.81 39.34 0.24 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.526 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.562 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -146.89 153.29 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.926 0.393 . . . . 0.0 110.927 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -159.66 -178.15 33.4 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.517 ' HB2' HG23 ' A' ' 259' ' ' VAL . 32.7 m-85 -129.71 140.11 51.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 249' ' ' PHE . 62.5 mt -136.64 137.27 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.137 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 87.5 m -116.13 127.25 54.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.125 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.694 ' CE1' HD12 ' A' ' 231' ' ' LEU . 48.9 m-85 -96.92 -179.27 4.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 12.2 t -96.93 -41.85 8.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.863 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -112.52 138.12 49.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 88.1 p -61.51 -39.74 92.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.847 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -61.91 -44.04 97.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 72.2 m -60.4 -37.31 80.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.904 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.05 -41.44 86.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 14.4 ttt180 -59.96 -48.78 80.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.86 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -58.41 -51.02 71.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.779 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.15 -35.02 69.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.105 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.664 HD12 HG12 ' A' ' 302' ' ' VAL . 10.8 tp -63.88 -45.3 90.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.922 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -69.08 -39.01 79.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -69.46 -42.11 75.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.91 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.727 ' HB3' HG21 ' A' ' 302' ' ' VAL . 56.7 mt -74.45 -47.03 35.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -43.59 114.53 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 71.22 38.2 63.17 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -104.57 109.57 21.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.84 0.352 . . . . 0.0 110.923 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -55.29 95.05 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.913 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.454 ' C ' HD13 ' A' ' 295' ' ' LEU . 0.5 OUTLIER -76.25 -64.78 1.02 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -114.6 37.41 3.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.62 -40.2 2.46 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 62.1 mtp180 -115.95 157.58 44.5 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.659 0.742 . . . . 0.0 110.835 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 127.82 15.16 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.716 2.277 . . . . 0.0 112.356 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . 0.41 ' HE2' HD23 ' A' ' 295' ' ' LEU . 2.1 ptp -79.51 179.53 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.875 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 15.4 mmt180 -110.73 123.36 49.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.89 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.727 HG21 ' HB3' ' A' ' 290' ' ' LEU . 14.8 t -132.75 125.35 52.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -146.56 160.83 28.3 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.436 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.534 ' CE1' HD22 ' A' ' 287' ' ' LEU . 9.6 m170 -75.55 111.6 11.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.834 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' A' ' 304' ' ' HIS . 98.5 t -35.59 133.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.174 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 10.2 t -59.22 137.73 57.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.178 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -116.66 99.81 7.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.882 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 26.9 ttt85 -89.96 91.59 8.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.859 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 5.8 tp -148.76 125.5 11.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -94.27 157.31 16.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.873 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -156.72 129.45 2.42 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.454 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -116.5 173.43 14.71 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.456 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.2 t -127.73 -59.72 1.19 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.894 0.378 . . . . 0.0 110.827 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 148.81 -159.1 27.91 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.501 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 173.34 11.13 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.631 2.221 . . . . 0.0 112.332 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 7.4 t -97.63 138.61 34.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 8.0 t -45.32 -47.18 13.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.46 -179.951 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 16.5 t -163.39 157.19 19.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.873 0.368 . . . . 0.0 110.817 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 2.3 t -89.94 168.01 12.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.879 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 157.64 -112.25 0.52 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.478 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 5.2 t 41.69 40.21 1.38 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.91 0.385 . . . . 0.0 110.851 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 14.8 m -93.8 -41.14 9.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.888 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -51.17 138.52 26.97 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.488 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.611 HD11 ' O ' ' A' ' 283' ' ' ALA . 44.6 mt -116.85 144.66 44.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.847 0.356 . . . . 0.0 110.935 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.475 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 1.7 t80 -106.73 129.53 54.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 236' ' ' LEU . 8.7 p -114.81 132.54 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.179 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.12 163.85 28.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.479 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.4 t 74.64 43.01 0.27 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.928 0.394 . . . . 0.0 110.881 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.428 HD11 ' CG2' ' A' ' 233' ' ' VAL . 23.1 mt -101.88 -177.41 3.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' A' ' 240' ' ' ILE . 6.6 t-80 -103.75 126.77 51.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.865 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.49 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 4.2 p90 -35.89 -44.69 0.37 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.859 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.49 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 39.5 t30 -51.7 -46.15 63.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.919 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.44 ' N ' ' O ' ' A' ' 237' ' ' HIS . 40.3 mm -40.19 147.87 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.127 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 10.0 t -136.98 174.51 10.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.099 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 38.0 mp0 -56.89 -34.96 68.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -58.33 -44.18 88.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 3.4 mmt -65.08 -42.23 94.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.694 HD11 HD21 ' A' ' 260' ' ' LEU . 41.7 mt -61.19 -39.62 90.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.894 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.01 -37.97 69.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.454 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -63.37 -34.61 90.42 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.511 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . 0.437 ' O ' ' CD2' ' A' ' 252' ' ' PHE . 68.1 mt -83.55 -44.81 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.618 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.7 m-85 -78.94 -5.97 55.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.536 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.58 -58.28 5.9 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 0.0 110.909 -179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.9 Cg_endo -69.78 -0.95 7.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.63 2.22 . . . . 0.0 112.388 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.793 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 11.7 m-85 -100.05 -23.87 14.76 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 167.57 167.33 28.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm -68.43 115.09 7.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.71 0.29 . . . . 0.0 110.872 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.441 HG21 HD11 ' A' ' 258' ' ' ILE . 27.3 mt -83.41 120.65 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.126 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -77.63 -49.37 14.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -163.25 145.64 10.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.911 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.441 HD11 HG21 ' A' ' 255' ' ' ILE . 84.8 mt -124.42 129.6 73.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.142 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 51.8 t -131.03 131.94 63.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.165 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.694 HD21 HD11 ' A' ' 245' ' ' LEU . 30.0 mt -101.08 133.7 45.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.473 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 57.6 mmm -94.62 125.97 39.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.888 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.67 157.91 40.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.868 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -65.53 172.67 3.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.854 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 19.1 t -106.85 -41.8 5.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.844 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -75.5 -54.42 7.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.895 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 72.2 p -78.04 -41.2 36.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.177 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 72.53 21.05 79.72 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.458 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 23.2 mmm-85 -109.89 131.2 55.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.813 0.339 . . . . 0.0 110.874 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 14.9 m -61.18 125.97 25.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.846 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 52.4 mmtt -77.32 -39.5 47.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 131.25 37.92 0.29 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.481 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.473 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 1.5 p90 -148.19 159.09 44.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.904 0.383 . . . . 0.0 110.962 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -166.1 176.3 41.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -119.74 135.9 54.65 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.339 . . . . 0.0 110.886 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.428 HD12 ' CE2' ' A' ' 249' ' ' PHE . 75.8 mt -131.89 140.11 48.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 69.5 m -120.97 128.23 52.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.181 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -96.8 -175.34 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.841 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 5.4 t -105.23 -28.79 10.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.893 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.66 135.56 55.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.845 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 77.3 p -63.54 -40.52 97.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -61.68 -43.63 98.49 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.861 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.9 m -62.5 -38.81 91.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.905 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.611 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -63.92 -43.17 96.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.128 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -61.65 -47.58 84.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.3 mmt180 -57.98 -49.8 75.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.793 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.25 -39.47 75.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.106 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.683 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -61.68 -40.71 95.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -68.24 -35.04 77.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -82.58 -26.5 32.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.952 ' HB3' HG21 ' A' ' 302' ' ' VAL . 71.3 mt -81.71 -47.06 13.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . 0.444 ' O ' ' CG ' ' A' ' 291' ' ' ASN . 0.5 OUTLIER -51.36 117.17 2.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 75.25 32.45 55.73 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.446 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -97.49 106.89 19.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -59.73 102.53 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 39.7 tp -92.79 -63.36 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -107.88 39.79 1.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.109 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.88 -25.81 26.67 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 64.1 mtt180 -120.68 154.53 57.22 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.601 0.715 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.85 128.93 16.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.683 2.255 . . . . 0.0 112.333 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . 0.605 ' CE ' HD22 ' A' ' 290' ' ' LEU . 1.9 ptt? -82.43 164.35 21.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 66.6 mmt-85 -102.28 121.19 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.916 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.952 HG21 ' HB3' ' A' ' 290' ' ' LEU . 15.9 t -130.28 121.32 51.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.15 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -140.78 163.98 26.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.514 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.437 ' O ' ' C ' ' A' ' 305' ' ' VAL . 7.0 m170 -73.02 112.49 9.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 110.833 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' A' ' 304' ' ' HIS . 74.4 t -34.27 136.1 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.134 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 9.8 t -102.41 142.44 33.61 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.174 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.15 -175.49 2.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.29 153.55 46.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.894 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.47 99.23 5.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.944 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -108.61 108.66 19.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -159.82 130.09 2.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . -161.31 111.86 0.5 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.464 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 6.9 t -70.83 -41.01 72.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.918 0.39 . . . . 0.0 110.891 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 113.19 145.55 9.38 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 126.2 13.07 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.719 2.279 . . . . 0.0 112.373 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 1.1 t -172.46 159.33 4.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.86 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 26.4 t -110.75 -54.76 2.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.824 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.493 -179.986 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 24.6 m -139.06 166.49 24.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 96.4 p -57.29 -46.92 82.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 103.98 164.55 24.93 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.48 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 47.7 t -68.06 139.72 56.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.882 0.373 . . . . 0.0 110.874 -179.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 36.9 p -69.05 101.54 1.43 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.874 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -128.34 149.97 18.39 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.444 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . . . . . . . . . 63.5 mt -129.03 145.7 51.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.942 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.498 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 2.0 t80 -105.54 135.0 47.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.597 ' CG2' HD11 ' A' ' 236' ' ' LEU . 9.6 p -121.73 129.39 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.125 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -138.65 162.55 25.84 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.514 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 73.47 46.73 0.2 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.891 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.597 HD11 ' CG2' ' A' ' 233' ' ' VAL . 64.2 mt -106.73 -176.14 2.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.959 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -113.6 130.26 56.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.418 ' O ' ' C ' ' A' ' 239' ' ' ASN . 1.2 m-85 -38.12 -58.29 0.98 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 238' ' ' PHE . 18.3 m-20 -36.19 -46.1 0.49 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . . . . . . . . . 47.0 mm -47.43 128.92 3.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.103 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . . . . . . . . . 73.7 p -113.1 174.88 5.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -58.53 -33.86 70.35 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.876 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -61.58 -46.02 91.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.901 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 30.6 mtt -60.23 -42.49 95.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.735 HD11 HD21 ' A' ' 260' ' ' LEU . 42.4 mt -60.42 -40.5 91.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.498 ' O ' ' N ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -63.51 -43.98 95.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.966 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.467 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -64.87 -32.01 82.8 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.485 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 87.0 mt -78.4 -40.99 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.881 0.372 . . . . 0.0 111.175 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.701 ' CE2' HD12 ' A' ' 275' ' ' ILE . 3.2 m-85 -90.91 -8.65 48.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.886 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.515 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 3.6 tp10 -59.0 -59.28 14.36 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.636 0.731 . . . . 0.0 110.88 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.515 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.82 2.75 3.28 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.268 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.725 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 9.6 m-85 -106.41 -9.67 16.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 152.7 168.25 16.5 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.45 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 31.6 tttp -72.46 122.03 20.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.75 0.309 . . . . 0.0 110.932 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.468 HG21 HD11 ' A' ' 258' ' ' ILE . 33.4 mt -93.8 111.65 25.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.106 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -70.14 -39.34 75.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.883 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -167.66 155.05 8.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.468 HD11 HG21 ' A' ' 255' ' ' ILE . 49.0 mt -131.57 131.99 62.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 8.1 t -128.4 137.8 56.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.161 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.735 HD21 HD11 ' A' ' 245' ' ' LEU . 48.3 mt -110.07 132.81 53.83 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.525 ' HB3' ' CZ ' ' A' ' 272' ' ' TYR . 13.3 mmt -84.34 141.82 30.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . 0.416 ' HD2' ' C ' ' A' ' 261' ' ' MET . 0.0 OUTLIER -140.85 151.79 44.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -61.92 -176.97 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.903 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 3.2 m -124.83 -11.25 7.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.834 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . 0.482 ' CG ' HG23 ' A' ' 266' ' ' THR . 32.8 p-10 -87.4 -41.3 13.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.88 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . 0.482 HG23 ' CG ' ' A' ' 265' ' ' ASP . 1.3 p -119.67 -53.6 2.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 116.74 14.07 7.58 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -89.93 123.04 33.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.76 143.89 1.29 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.831 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.461 ' HB2' ' CD1' ' A' ' 272' ' ' TYR . 6.5 mmmm -91.02 -8.2 49.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.897 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 96.98 27.81 9.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.496 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.525 ' CZ ' ' HB3' ' A' ' 261' ' ' MET . 0.5 OUTLIER -150.42 161.95 41.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.931 0.396 . . . . 0.0 110.879 -179.832 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -167.9 -173.17 35.69 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.62 148.5 46.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.815 0.34 . . . . 0.0 110.912 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.701 HD12 ' CE2' ' A' ' 249' ' ' PHE . 82.1 mt -138.58 139.66 40.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 56.4 m -118.21 129.98 55.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.16 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -103.48 -175.11 2.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 22.8 t -100.15 -41.76 6.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -113.93 139.94 48.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.852 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 60.9 p -63.14 -40.16 96.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.847 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.15 -42.77 99.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.904 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 92.2 m -60.7 -35.98 77.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . . . . . . . . . . . -68.07 -41.98 81.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.081 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 19.6 ttm180 -59.23 -49.11 79.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 28.4 mmt180 -58.91 -50.93 72.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.885 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.725 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -57.41 -34.9 69.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.09 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.759 HD12 HG12 ' A' ' 302' ' ' VAL . 15.0 tp -64.09 -45.29 89.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -69.01 -42.03 76.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 17.6 mm100 -67.81 -42.02 82.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.916 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.675 HD13 ' CZ ' ' A' ' 249' ' ' PHE . 65.2 mt -73.72 -46.82 43.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' A' ' 290' ' ' LEU . 0.7 OUTLIER -37.19 103.6 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 179.909 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 79.58 33.86 33.39 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 290' ' ' LEU . 22.6 t80 -87.42 105.48 17.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -57.67 96.75 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.864 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.404 HD23 ' C ' ' A' ' 295' ' ' LEU . 8.5 tt -89.72 -69.54 0.71 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.946 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -99.3 32.05 2.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.106 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 107.68 -36.86 4.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.512 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -108.94 148.01 37.03 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.58 0.705 . . . . 0.0 110.885 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.03 7.73 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.716 2.277 . . . . 0.0 112.325 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptm -74.02 171.96 12.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 7.0 mmt85 -111.73 122.95 49.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.759 HG12 HD12 ' A' ' 287' ' ' LEU . 4.2 t -124.17 122.32 64.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.49 162.54 26.92 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.449 ' O ' ' C ' ' A' ' 305' ' ' VAL . 5.0 m170 -71.4 127.27 32.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.812 0.339 . . . . 0.0 110.826 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 304' ' ' HIS . 54.0 t -34.17 123.35 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . . . . . . . . . 38.7 p -79.2 -51.96 8.79 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.146 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -41.69 133.45 2.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -53.91 133.84 42.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.884 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 32.5 mt -115.09 44.96 1.71 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.927 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -165.32 166.73 18.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.905 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -164.82 -100.34 0.15 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.47 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 44.93 66.38 1.48 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.507 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 69.2 m -41.55 123.91 2.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 0.0 110.877 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -160.65 82.9 0.13 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.483 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 128.42 16.0 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.64 2.227 . . . . 0.0 112.334 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.3 t -135.57 145.6 47.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 60.8 p -93.62 142.82 26.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.89 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.496 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 1.8 m -169.19 134.77 1.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 110.88 -179.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 34.3 p -108.06 176.05 5.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . 134.29 -167.01 23.97 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.523 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 10.6 t -72.79 127.99 34.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 0.0 110.853 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . 0.496 ' O ' HG23 ' A' ' 276' ' ' THR . 20.7 m -52.73 109.03 0.36 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.851 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -138.87 134.37 6.74 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.482 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.752 HD12 ' CE2' ' A' ' 277' ' ' PHE . 51.8 mt -123.94 145.22 49.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.545 ' C ' ' CD1' ' A' ' 232' ' ' TYR . 0.7 OUTLIER -112.51 133.79 54.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.946 -179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.415 ' CG2' HD11 ' A' ' 236' ' ' LEU . 14.7 p -122.07 132.85 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.113 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -144.76 165.78 27.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.474 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.3 m 74.03 47.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.937 0.399 . . . . 0.0 110.823 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.415 HD11 ' CG2' ' A' ' 233' ' ' VAL . 74.7 mt -110.03 178.78 4.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.919 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -97.53 132.08 43.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.859 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.468 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.1 t80 -42.62 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.85 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 238' ' ' PHE . 59.4 t-20 -34.62 -33.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.911 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.468 ' N ' ' O ' ' A' ' 238' ' ' PHE . 21.8 mm -54.85 147.98 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.109 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.407 HG23 ' HB3' ' A' ' 243' ' ' ASP . 8.9 t -134.98 175.8 9.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.137 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . 0.431 ' HG3' ' CD1' ' A' ' 260' ' ' LEU . 11.8 mt-10 -57.82 -32.65 67.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . 0.407 ' HB3' HG23 ' A' ' 241' ' ' THR . 4.1 t70 -60.26 -33.83 72.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.89 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 5.4 mmt -71.98 -37.87 69.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . 0.666 ' HB3' HD11 ' A' ' 275' ' ' ILE . 39.1 mt -69.54 -42.89 74.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.959 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.489 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 14.9 ptt85 -67.53 -39.46 85.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.462 ' O ' ' CD ' ' A' ' 251' ' ' PRO . . . -67.6 -35.63 86.58 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.492 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 73.3 mt -79.1 -45.19 24.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.815 0.341 . . . . 0.0 111.101 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 255' ' ' ILE . 3.1 m-85 -80.6 -4.9 55.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.537 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 0.6 OUTLIER -69.89 -58.19 5.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.69 0.757 . . . . 0.0 110.875 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.537 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 53.4 Cg_endo -69.77 2.81 3.2 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.651 2.234 . . . . 0.0 112.353 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.479 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.6 m-85 -103.91 -25.84 12.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.841 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 170.93 166.14 29.33 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.464 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 15.2 ttmt -67.4 109.54 3.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 249' ' ' PHE . 33.6 mt -81.06 123.68 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.141 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -79.31 -44.53 21.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.837 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 42.4 t30 -168.33 151.16 5.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.865 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.513 HG23 HG12 ' A' ' 275' ' ' ILE . 36.7 mt -128.19 134.02 65.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.16 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . . . . . . . . . 1.7 m -134.51 134.76 54.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.143 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . 0.431 ' CD1' ' HG3' ' A' ' 242' ' ' GLU . 32.3 mt -97.48 134.62 40.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.934 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.571 ' HB2' ' CE2' ' A' ' 272' ' ' TYR . 26.9 mmm -98.16 129.31 44.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.33 146.34 51.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.883 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 11.4 t0 -61.4 -176.69 0.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.868 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 72.6 m -118.35 -47.81 2.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -57.93 -38.33 75.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.825 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 5.4 p -107.31 -54.5 2.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.106 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 93.13 15.84 49.91 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.474 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . . . . . . . . . 84.8 mtt-85 -105.88 117.55 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.854 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . . . . . . . . . 6.5 t -43.81 128.83 5.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.569 ' HB2' ' CE1' ' A' ' 272' ' ' TYR . 32.5 mttm -86.89 8.87 21.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 83.12 40.28 9.38 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.477 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.571 ' CE2' ' HB2' ' A' ' 261' ' ' MET . 3.7 p90 -148.69 155.92 41.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.931 0.396 . . . . 0.0 110.861 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -164.5 177.89 39.95 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.553 ' HE1' HG22 ' A' ' 305' ' ' VAL . 18.1 m-85 -117.56 139.43 50.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.866 0.365 . . . . 0.0 110.92 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . 0.666 HD11 ' HB3' ' A' ' 245' ' ' LEU . 71.0 mt -136.02 138.55 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.132 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . 0.496 HG23 ' O ' ' A' ' 229' ' ' SER . 92.9 m -117.47 123.94 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.752 ' CE2' HD12 ' A' ' 231' ' ' LEU . 41.4 m-85 -91.24 -175.69 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.857 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 38.9 t -100.02 -34.3 10.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.867 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -122.94 138.27 54.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.903 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 43.8 p -61.72 -35.88 79.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -63.66 -44.11 94.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.879 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 74.0 m -62.42 -37.8 87.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.588 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -67.22 -36.94 82.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.073 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . 0.42 ' NH1' ' HB2' ' A' ' 284' ' ' ARG . 0.1 OUTLIER -64.13 -48.98 73.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.864 -179.891 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -59.83 -43.22 94.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.83 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.479 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -63.15 -35.23 79.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.138 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.816 HD12 HG12 ' A' ' 302' ' ' VAL . 11.6 tp -65.07 -44.65 88.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.923 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -69.39 -38.98 78.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.856 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -71.5 -41.12 69.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.895 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.565 ' HB3' HG21 ' A' ' 302' ' ' VAL . 74.8 mt -74.29 -46.93 37.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -45.22 107.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 81.5 38.66 13.89 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.449 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -105.54 100.27 9.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.874 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -50.82 103.47 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.861 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . . . . . . . . . 15.9 tp -94.67 -55.82 3.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -120.42 45.55 2.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.145 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 99.82 -37.19 3.65 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.491 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -117.03 150.45 46.01 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 123.36 10.01 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.64 2.226 . . . . 0.0 112.381 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 2.2 ptp -69.45 170.68 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.847 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 6.1 mmm180 -108.76 124.21 50.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.816 HG12 HD12 ' A' ' 287' ' ' LEU . 17.3 t -129.38 125.41 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.126 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -145.74 162.63 28.29 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.442 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.483 ' NE2' HD22 ' A' ' 287' ' ' LEU . 39.9 m-70 -76.92 126.88 31.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.861 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.553 HG22 ' HE1' ' A' ' 274' ' ' PHE . 82.5 t -45.1 94.44 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 304' ' ' HIS . 15.2 t -116.7 134.8 54.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -92.65 147.82 22.56 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.874 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.93 -2.08 53.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . 0.46 ' HA ' HD22 ' A' ' 309' ' ' LEU . 0.7 OUTLIER -74.67 -67.03 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.974 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -81.13 93.02 6.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.848 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -102.28 -78.81 1.34 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.431 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 142.64 179.35 19.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.531 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 91.9 p -170.6 121.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.901 0.382 . . . . 0.0 110.939 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . -135.38 92.63 0.23 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 153.6 68.92 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.708 2.272 . . . . 0.0 112.345 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 26.3 m -121.92 179.1 4.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 35.5 t -88.11 135.09 33.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.519 179.987 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' SER . . . . . . . . . . . . . 68.9 m -101.58 43.58 1.06 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.851 0.358 . . . . 0.0 110.861 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 3.1 m -71.68 90.14 1.04 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.856 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' GLY . . . . . . . . . . . . . . . -168.57 158.24 30.81 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' SER . . . . . . . . . . . . . 15.9 t -157.85 162.26 38.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.893 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' SER . . . . . . . . . . . . . 13.3 p -89.26 90.57 8.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.865 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.413 ' O ' HG22 ' A' ' 305' ' ' VAL . . . -150.86 147.34 17.25 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.493 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' LEU . . . . . 0.639 HD11 ' O ' ' A' ' 283' ' ' ALA . 30.0 mt -121.78 139.12 53.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.948 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' TYR . . . . . 0.948 ' HB2' HG12 ' A' ' 305' ' ' VAL . 0.9 OUTLIER -106.47 137.79 43.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' VAL . . . . . 0.4 HG21 HD11 ' A' ' 236' ' ' LEU . 7.4 p -122.56 136.91 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' GLY . . . . . . . . . . . . . . . -145.95 163.95 28.27 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.468 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' SER . . . . . . . . . . . . . 1.1 t 74.16 45.25 0.21 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.891 0.377 . . . . 0.0 110.902 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' LEU . . . . . 0.4 HD11 HG21 ' A' ' 233' ' ' VAL . 96.7 mt -104.9 -176.29 3.03 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' HIS . . . . . 0.438 ' O ' ' N ' ' A' ' 240' ' ' ILE . 9.2 t-80 -109.29 135.06 50.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.84 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 239' ' ' ASN . 1.9 p90 -38.7 -44.14 0.97 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' ASN . . . . . 0.479 ' N ' ' CG ' ' A' ' 238' ' ' PHE . 36.4 t30 -54.02 -42.18 68.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.923 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' ILE . . . . . 0.503 ' CD1' HD21 ' A' ' 295' ' ' LEU . 15.5 mm -50.63 106.25 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.152 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 243' ' ' ASP . 10.9 t -95.25 179.49 5.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.096 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -61.16 -30.83 70.63 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' ASP . . . . . 0.447 ' H ' HG23 ' A' ' 241' ' ' THR . 5.1 m-20 -61.11 -43.55 98.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' MET . . . . . . . . . . . . . 7.8 mtt -62.68 -46.03 90.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' LEU . . . . . . . . . . . . . 31.9 mt -60.07 -38.75 83.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.497 ' O ' ' CB ' ' A' ' 250' ' ' GLU . 0.0 OUTLIER -72.02 -42.4 66.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.877 -179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . 0.435 ' N ' ' HD3' ' A' ' 246' ' ' ARG . . . -61.48 -30.61 74.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.468 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 248' ' ' ILE . . . . . . . . . . . . . 88.4 mt -88.33 -43.59 15.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 111.171 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' PHE . . . . . 0.534 ' CZ ' HD13 ' A' ' 290' ' ' LEU . 3.2 m-85 -82.23 -2.64 53.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.886 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' GLU . . . . . 0.528 ' N ' ' HD2' ' A' ' 251' ' ' PRO . 2.1 tt0 -70.34 -58.56 4.77 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.594 0.711 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' PRO . . . . . 0.528 ' HD2' ' N ' ' A' ' 250' ' ' GLU . 54.1 Cg_endo -69.72 2.03 3.88 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' PHE . . . . . 0.496 ' HB3' ' HB2' ' A' ' 286' ' ' ALA . 10.5 m-85 -103.27 -11.12 18.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 154.23 177.34 27.54 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.51 131.13 41.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.762 0.315 . . . . 0.0 110.921 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.641 HG21 HD11 ' A' ' 258' ' ' ILE . 94.6 mt -98.76 98.7 7.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -59.43 -44.72 92.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.825 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -167.2 153.55 8.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.938 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' ILE . . . . . 0.641 HD11 HG21 ' A' ' 255' ' ' ILE . 78.3 mt -130.27 133.01 64.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' VAL . . . . . 0.476 HG23 ' HB2' ' A' ' 274' ' ' PHE . 1.6 m -134.41 134.28 54.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' LEU . . . . . . . . . . . . . 21.6 mt -103.35 128.81 50.35 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' MET . . . . . 0.563 ' CB ' ' CZ ' ' A' ' 272' ' ' TYR . 12.1 mmt -86.04 135.59 33.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.831 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.52 154.64 51.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.931 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -67.13 177.58 1.73 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.0 m -110.93 -35.15 6.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.845 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -67.62 -45.71 74.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.866 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' THR . . . . . . . . . . . . . 1.3 p -105.51 -54.63 2.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.094 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' GLY . . . . . . . . . . . . . . . 96.18 26.67 10.93 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.531 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 269' ' ' SER . 6.5 ttm105 -110.2 124.17 51.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 0.0 110.846 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' SER . . . . . 0.402 ' C ' ' O ' ' A' ' 268' ' ' ARG . 6.4 m -38.06 124.79 1.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.888 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.34 -29.3 31.09 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . 124.87 31.43 0.87 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.501 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' TYR . . . . . 0.563 ' CZ ' ' CB ' ' A' ' 261' ' ' MET . 1.0 OUTLIER -146.96 154.86 41.76 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.934 0.397 . . . . 0.0 110.929 -179.827 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' GLY . . . . . . . . . . . . . . . -162.21 172.89 38.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' PHE . . . . . 0.476 ' HB2' HG23 ' A' ' 259' ' ' VAL . 33.1 m-85 -119.8 134.39 55.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.824 0.345 . . . . 0.0 110.848 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.74 137.4 56.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' THR . . . . . . . . . . . . . 90.9 m -110.42 129.77 55.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' PHE . . . . . 0.499 ' CE2' HD12 ' A' ' 231' ' ' LEU . 43.3 m-85 -103.68 170.83 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.845 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' SER . . . . . . . . . . . . . 1.1 t -115.38 24.79 11.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.843 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -162.59 113.09 1.49 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' SER . . . . . . . . . . . . . 95.2 p -53.12 -40.47 64.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 -179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -62.02 -43.99 97.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' CYS . . . . . . . . . . . . . 85.6 m -64.56 -40.91 96.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' ALA . . . . . 0.639 ' O ' HD11 ' A' ' 231' ' ' LEU . . . -58.08 -46.35 85.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 284' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -61.91 -47.4 85.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -59.15 -50.93 72.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.87 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 286' ' ' ALA . . . . . 0.496 ' HB2' ' HB3' ' A' ' 252' ' ' PHE . . . -56.71 -35.2 68.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.076 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.437 HD22 ' CD2' ' A' ' 304' ' ' HIS . 7.6 tp -64.59 -44.66 89.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 288' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -69.14 -42.5 75.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.895 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 68.2 mm-40 -67.44 -41.95 83.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 290' ' ' LEU . . . . . 0.881 ' HB3' HG21 ' A' ' 302' ' ' VAL . 73.9 mt -73.73 -46.95 42.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 291' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -41.5 104.93 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . 84.43 34.8 15.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.522 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -100.84 99.76 10.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -61.08 118.22 6.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.893 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' LEU . . . . . 0.503 HD21 ' CD1' ' A' ' 240' ' ' ILE . 10.0 tp -108.1 -50.26 3.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.883 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' ALA . . . . . . . . . . . . . . . -113.11 42.81 1.83 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.082 179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 98.33 -35.53 4.54 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.479 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -115.92 152.51 47.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.885 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 130.47 19.36 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.697 2.265 . . . . 0.0 112.357 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' MET . . . . . . . . . . . . . 1.6 ptp -78.24 174.78 10.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' ARG . . . . . . . . . . . . . 16.6 mmt180 -111.38 120.6 42.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' VAL . . . . . 0.881 HG21 ' HB3' ' A' ' 290' ' ' LEU . 13.0 t -123.43 131.44 73.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.123 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -155.2 161.8 30.62 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.546 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' HIS . . . . . 0.442 ' HB3' HG22 ' A' ' 306' ' ' THR . 34.2 m-70 -70.12 121.94 18.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.865 0.364 . . . . 0.0 110.864 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' VAL . . . . . 0.948 HG12 ' HB2' ' A' ' 232' ' ' TYR . 17.2 m -63.11 -32.17 55.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.099 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' THR . . . . . 0.442 HG22 ' HB3' ' A' ' 304' ' ' HIS . 7.0 t -60.0 147.65 38.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.154 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 308' ' ' ARG . 6.7 tt0 67.48 40.24 2.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.87 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' ARG . . . . . 0.422 ' C ' ' O ' ' A' ' 307' ' ' GLU . 22.8 mtp180 -35.81 -62.38 0.42 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' LEU . . . . . . . . . . . . . 7.6 mp -85.99 103.87 15.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.901 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -123.12 127.88 49.31 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' GLY . . . . . . . . . . . . . . . -74.91 -66.81 1.85 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.503 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' GLY . . . . . . . . . . . . . . . 124.52 78.94 0.37 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.48 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 34.2 p -104.49 86.24 2.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.89 0.376 . . . . 0.0 110.844 -179.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 314' ' ' GLY . . . . . . . . . . . . . . . 60.03 68.56 1.62 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 315' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 123.36 10.02 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.363 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 27.7 p -57.75 169.96 0.65 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 317' ' ' SER . . . . . . . . . . . . . 7.3 t -113.32 167.05 10.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.848 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 318' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.53 -179.983 . . . . . . . . 0 0 . 1 stop_ save_